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The paucity of well validated preclinical models is frequently cited as a contributing factor to 
the high attrition rates seen in clinical oncological trials. There remains a critical need to 
develop models which are accurately able to recapitulate the features of human disease. 
The aims of this study were to use genetically engineered mouse models (GEMMs) to 
explore the efficacy of novel treatment strategies in HER2 positive breast cancer and to 







 model, we demonstrated that Src plays an important role in 
the early stages of tumour development. Chemopreventative treatment with dasatinib 
delayed tumour inititation (p= 0.046, Wilcoxon signed rank test) and prolonged overall 
survival (OS) (p=0.06, Wilcoxon signed rank test). Dasatinib treatment also induced 
squamous metaplasia in 66% of drug treated tumours.  We used 2 cell lines derived from 
this model to further explore dasatinib’s mechanism of action and demonstrated reduced 
proliferation, migration and invasion following in vitro treatment. 
 
Due to the prolonged tumour latency and the low metastatic rate seen in this model, further 
studies were     undertaken with the MMTV-NIC model. This model also allowed us to study 
the impact of PTEN loss on therapeutic response. We validated this model by treating a 
cohort of MMTV-NIC PTEN
+/-
 mice with paclitaxel and demonstrated prolonged OS 
(p=0.035, Gehan Breslow Wilcoxon test). AZD8931 is an equipotent signalling inhibitor of 
HER2, HER3 and EGFR. We observed heterogeneity in tumour response but overall 





models. PTEN loss was associated with reduced sensitivity to AZD8931 and failure to 
suppress Src activity, suggesting these may be suitable predictive biomarkers of AZD8931 
response. To facilitate further studies exploring resistance, we transplanted MMTV-NIC 
PTEN
+/-
 fragments into syngeneic mice and generated 3 tumours with acquired resistance to 
AZD8931. These tumours displayed differing resistance strategies; 1 tumour continued to 
express HER2 whilst the remaining 2 underwent EMT and lost HER2 expression reflecting to 
a very limited degree some of the heterogeneity of resistance strategies seen in human 
disease.  
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To further explore resistance to HER2 targeting tyrosine kinase inhibitors, we generated a 
panel of human cell lines with acquired resistance to AZD8931 and lapatinib. Western 
blotting demonstrated loss of HER2, HER3 and PTEN in all resistant lines. Acquisition of 
resistance was associated with a marked change in phenotype and western blotting 
confirmed all lines had undergone EMT. We used a combination of RPPA and mass 
spectrometry to further characterise the AZD8931 resistant lines and identified multiple 
potential novel proteins involved in the resistant phenotype, including several implicated in 
EMT. 
 
In conclusion, when coupled with appropriate in vitro techniques, the MMTV-NIC model is a 
valuable tool for selection of emerging drugs to carry forward into clinical trials of HER2 
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Chapter 1: Introduction 
 
Traditionally, the systemic treatment of cancer has relied on the use of non-specific, highly 
toxic chemotherapeutics. However, significant progress in the field of molecular biology has 
led to a dramatic increase in our understanding of some of the complex processes 
underpinning the development of cancer. This in turn has led to the identification of multiple 
signalling molecules with altered expression or aberrant activity in cancer, which are 
potentially amenable to exploitation by modern anti-cancer therapies. The introduction of 
iconic drugs such as imatinib and trastuzumab has revolutionised the management of 
Chronic Myeloid Leukaemia (CML) [1] and HER2 positive breast cancer [2]  respectively. 
However, after this initial success, numerous potential agents have been investigated in 
clinical trials yet relatively few have successfully been incorporated into mainstream clinical 
practice. Oncological drug development has historically been plagued by low success rates 
with less than 10%of drugs tested in phase 1 trials successfully making it to market [3] and 
studies suggest these rates have not improved in the last 2 decades [4], implying that recent 
biomedical innovations have not impacted on our ability to successfully identify active 
candidates.  Most drugs fail late in the development process at a cost in excess of $400 
million [5] placing a huge economic strain on the pharmaceutical industry and crucially 
resulting in exposure of potentially hundreds of patients to toxic, yet ineffective treatments.  
Traditional drug development programmes are not ideally suited to testing drug efficacy of 
more modern molecularly targeted agents, yet current programmes have largely failed to 
adapt to the vast numbers of these agents currently under investigation.  
 
1.1 Conventional oncological drug development 
programmes 
 
Drug development programmes consist of a preclinical and subsequent clinical phase.  
Generally, the mechanism of action of most conventional chemotherapeutics is unknown at 
the start of the drug development process and therefore potential compounds of interest are 
identified by empiric screening normally involving a panel of human cell lines aiming to 
encompass the major tumour types. Once in vitro efficacy has been established, 
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demonstration of activity using in vivo models remains a critical step providing the earliest 
evidence of drug efficacy within an animal as a whole and potentially allowing for the 
contribution of systemic factors, such as tumour-stromal cell interactions. In vivo studies also 
provide essential pharmacokinetic (PK) and pharmacodynamic (PD) data. PK data, including 
measurements of drug absorption, distribution and metabolism, are used to inform initial 
dosing levels in subsequent clinical trials whilst elimination data may be used to optimise the 
dosing schedule. The importance of the data generated during these studies has been 
highlighted by previous experiences where drugs have entered into late phase clinical trials 
despite the active murine dose being substantially above the human maximum tolerated 
dose (MTD) (see below) [6]. This has led to late stage and high profile, yet predictable, drug 
failures. A variety of different in vivo models are used in drug efficacy studies, including 
spontaneous murine models, hollow fibre assays and genetically engineered mouse models 
(GEMM) but xenografts remain the most commonly used. For further discussion on the 
different in vivo models in these studies see section 2.1.      
 
On completion of preclinical testing, new agents must then pass through a series of clinical 
studies referred to as phase 1, 2 and 3 trials. Traditionally, phase 1 trials include a relatively 
small number of patients with advanced disease, often with mixed tumour types, for whom 
no standard treatment options exist. The main aims of phase 1 trials are to determine a 
novel drug’s safety and tolerability either when given alone or in combination with the main 
outcome being determination of a recommended dose for further study [7]. It is assumed that 
for traditional chemotherapeutics, a common mechanism of action results in both tumour 
efficacy and drug induced side effects and therefore higher doses resulting in greater 
treatment toxicities will be more efficacious. The recommended dose for further study in 
these drugs generally equates to the MTD [8]. Phase 1 trials also frequently generate 
important PK and PD data and whilst preliminary evidence of efficacy may also be reported, 
these trials are generally not sufficiently powered to detect clinical activity [9]. 
 
Phase 2 trials may be designed as either single arm or randomized studies which aim to 
demonstrate either preliminary activity or to guide selection of specific tumour types for 
further study [10]. The main aim of most phase 3 trials is to compare the activity of a novel 
compound either alone or in combination with that of the gold-standard treatment within a 
well-defined disease population [11].  Both phase 2 and 3 clinical trials aim to give a 
measure of disease response and a range of endpoints are used including overall response 
rate (ORR), time to progression (TTP), progression free survival (PFS), overall survival (OS), 
time to treatment failure (TTF) and clinical benefit ratio (CBR).  
Chapter 1: Introduction     3 
 
 
Although drug development programmes can be described as a streamlined passage 
through from in vitro studies to in vivo and on through the various stages of clinical trial 
development, at present there is little in the way of consensus about key criteria that a drug 
must reach in order to successfully move from one phase into the next [4]. The decision to 
halt the progression of a drug after development of intolerable toxicity during a phase 1 trial 
at a lower dose than would be predicted to be efficacious is relatively straightforward. 
However, deciding whether there is sufficient evidence of drug activity to progress from pre-
clinical to clinical studies or from phase 2 to phase 3 clinical trials may be much more 
complex and is likely to be influenced by a host of other non-scientific factors, including 
societal and economic pressures.     
 
1.2 Developing appropriate drug development 
programmes for molecularly targeted agents 
 
This schema for drug development is still generally applied to the development of 
molecularly targeted agents, despite several critical differences between these agents and 
traditional chemotherapeutics. The most fundamental of these differences is that, unlike 
during the process of generating a novel chemotherapeutic, the mechanism of action of 
molecularly-targeted agents is known at the start of the drug development process. 
Molecularly targeted therapies exploit differences in either the expression or activity of 
disease targets (primarily receptors or enzymes) between normal healthy cells and cancer 
cells. These targets therefore represent potential susceptibilities within the cancer cell, which 
when inhibited will negatively impact on the progression of the tumour [12]. Cancer is a 
highly heterogeneous condition with high levels of both intra- and inter-patient variability 
observed. Therefore, similarly to chemotherapeutics, molecularly targeted therapies are 
unlikely to be ubiquitously efficacious but instead activity is restricted to patient subgroups, 
defined on the basis of their genotype or proteomic phenotype. Extensive preclinical work up 
is required even prior to the generation of drug candidates to generate detailed information 
on both the potential positive and negative consequences of target inhibition and the level 
and timing (continuous versus intermittent) of target inhibition required to meaningfully 
moderate tumour behaviour. Following validation of the target, a variety of different 
approaches can be used to generate potential drugs, including high throughput screening of 
chemical libraries, screening of low molecular weight fragments, virtual screening or where 
the structure of the target is already known a custom-designed drug can be generated. 
Potential candidates are prioritised on the basis of their physiochemical, PK and toxicity 
profiles demonstrated using a range of in silico techniques. The most promising of these 
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candidates then undergo repeated cycles of production, testing and further modification to 
optimise their efficiency, physiochemical, PK and toxicity profiles during in vitro testing [13]. 
In vivo testing exploits the same range of models used during the testing of 
chemotherapeutics. In addition to demonstrating evidence of in vivo efficacy, these models 
ideally need to provide evidence of a direct relationship between the drug levels achieved, 
target inhibition and modulation of tumour behaviour [4].       
 
Clinical trials using molecularly targeted agents also frequently follow the same programme 
as outlined above for chemotherapeutics. This includes the use of MTD as the main outcome 
for phase 1 trials. As many potential targets are differentially expressed or activated in 
cancer cells compared to healthy cells, it may be possible to inhibit cancer progression with 
minimal toxicity to healthy cells [4]. The mechanism of any observed treatment related 
toxicities may therefore be distinct from the drug’s mechanism of action making the MTD an 
inappropriate end point. Determination of the ‘biologically optimal dose’ may be a more 
relevant endpoint. In view of the vast range of drugs now available, Hunsberger proposed 
that identification of the ‘biologically adequate dose’, which can be achieved with as little as 3 
or 4 patients at each dose level, may be sufficient prior to commencing drug efficacy studies 
[14]. However, both these approaches require the development of appropriate biomarkers, 
which is an extremely complex and time-consuming process. The lack of such biomarkers 
may account, at least in part, for the results of a recent study which showed that toxicity was 
still used to define the dose recommended for phase 2 study in the majority of 60 phase 1 
clinical trials involving targeted, non-cytotoxic drugs [15]. Incorporation of biomarkers into 
study end points would also likely require paired pre- and post-treatment biopsies.  At 
present, there is still considerable reluctance to make repeat biopsies mandatory at the time 
of entry into clinical trials due to concerns that it might adversely impact on patient accrual 
and therefore the current feasibility of using biologically relevant doses as an endpoint in 
clinical trials is challenging. Alternative solutions that could avoid the need to perform repeat 
biopsies might include the use of a surrogate marker, such as target inhibition in peripheral 
blood mononuclear cells (PBMC) or the use of modern functional imaging techniques, such 
as digital contrast enhanced MRI, which has been used to measure tumour vascularity and 
permeability in dose finding studies of angiogenesis inhibitors. However, prior to adoption of 
these techniques, it would be essential to demonstrate that changes in the readout from 
such surrogates accurately reflect target inhibition within the tumour and modulation of 
tumour behaviour [4]. 
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A further important difference between the design of clinical trials for chemotherapeutics and 
molecularly targeted agents is the use of therapeutic combinations. Before 
chemotherapeutics are trialled in combination, all individual agents must show evidence of 
disease activity. Considering the highly specific mechanism of action of targeted agents, this 
may not be appropriate and failure to account for this may result in rejection of a potentially 
active drug. For example, there is considerable preclinical evidence that Src activity 
moderates the behaviour of HER2 positive breast cancer [16]. However, a phase 2 trial of 
single agent dasatinib failed to show any single agent efficacy in HER2 positive breast 
cancer [17]. Arguably, the expectation that Src inhibitors alone would inhibit tumour growth 
might be considered optimistic whilst combining these drugs with HER2 directed therapies, 
such as trastuzumab, may have proved more fruitful. 
 
When designing phase 2 and 3 trials for molecularly targeted agents, consideration needs to 
be given to appropriate patient recruitment. Traditionally trials have focussed on examining 
drug activity within a single condition assuming this represents a single entity, yet there is 
increasing recognition of the heterogeneity within given cancer subtypes and failure to 
account for this may lead to premature rejection of a potentially active drug. For example 
only 8% of patients with non-small cell lung cancer (NSCLC) possess a mutation in exons 19 
and 21 of the epidermal growth factor receptor (EGFR), which predicts for response to the 
tyrosine kinase inhibitor (TKI) gefitinib [18]. As these mutations are relatively rare, the 
inclusion of all other NSCLC patients in these trials could easily mask the efficacy of this 
drug within this patient subgroup.  
 
Selection of appropriate endpoints is a further important consideration when designing phase 
2 and 3 trials with these agents. Whilst these agents may be cytotoxic, many are cytostatic in 
nature or have anti-metastatic properties and therefore slow tumour growth rather than 
causing tumour shrinkage. Traditional trial endpoints which rely on tumour shrinkage, such 
as ORR (defined as the proportion of patients with a tumour reduction of a predetermined 
amount within a specified time period), are therefore not suitable for use in these studies. OS 
unarguably remains the most meaningful end point in all clinical trials, irrespective of the 
nature of the drug being investigated. However, these trials are generally lengthy to conduct 
and the outcomes are susceptible to bias by cross over to other arms within the trial or by 
initiation of other treatments at the time of disease progression. Neither PFS nor TTF are 
dependent on tumour shrinkage and therefore represent meaningful endpoints for cytostatic 
drugs in phase 2 and 3 trials, although results can be influenced by the frequency of clinical 
and radiological follow up [4] [9].    




In summary, there are numerous factors which contribute to the high attrition rates, which 
continue to be seen during oncological drug development. In the following experiments, we 
have elected to focus predominantly on the development of models, which might further 
improve selection of agents to take forward into clinical trials as appropriate selection of 
active agents and rejection of unsuitable agents at this stage of development would produce 
huge time and economic savings as well as minimising the numbers of patients exposed to 
ineffective treatments. There remains an urgent unmet need to develop in vivo models which 
are better able to recapitulate the key features of human cancer as highlighted by the finding 
that at present only 4% of patients participating in phase 1 clinical trials actually benefit from 
the treatment they receive [19]. 
 
1.3 Use of in vivo models in preclinical drug 
development 
 
1.3.1 Hollow fibre assay (HFA) 
 
The HFA consists of human tumour cells grown in bio-compatible hollow fibres and then 
transplanted into either subcutaneous or intraperitoneal sites of immune-deficient mice. The 
fibres contain narrow pores, enabling exposure of transplanted cells to anti-cancer drugs but 
preventing their escape into subcutaneous or intraperitonal locations. The NCI developed 
this technique to try and further refine selection of drugs with proven efficacy in the in vitro 
setting prior to commencing relatively costly and lengthy traditional in vivo studies [20]. 
Studies exploring the efficacy of this technique have shown that response in the HFA is 
predictive of response in subsequent xenograft studies and this predictive capability can be 
further enhanced by implantation of the fibres at intra-peritoneal locations. More recently, the 
HFA has been used to confirm drug-target interactions using a variety of PD end points, 
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1.3.2 Early in vivo models 
 
The earliest animal studies used either chemical or radiation-induced murine leukaemias. 
However, activity in these models was not predictive of clinical activity [22] and they were 
superseded by mouse cell line allografts. The P388 and L1210 leukaemia cell lines were the 
earliest murine cell lines used to screen novel compounds for potential therapeutic activity 
[23]. These cell lines were used in the development process of several drugs which are still 
in use today for rapidly growing malignancies, such as haematological cancers. However, 
they were less suitable for use in predicting activity within solid tumours leading to the 
introduction of the B16 melanoma and Lewis lung carcinoma cell lines in the 1970s. These 
cell lines also benefited from the ability to generate lung metastases allowing novel 
compounds to be tested for efficacy against both the primary tumour and the development of 
metastases [24].     
 
1.3.3 Xenograft based models 
 
1.3.3.1 Subcutaneously implanted human tumour xenografts 
 
Tumour xenografts remain the most frequently used in vivo models and have played a role in 
the development of most anti-cancer treatments in mainstream clinical practice today. 
However, the high attrition rates seen during the clinical phase of drug development suggest 
that these models are far from perfect and have a tendency to over-estimate the sensitivity of 
human tumours to novel therapeutic compounds. Indeed, when the efficacy of 39 drugs in a 
panel of xenografts was retrospectively compared to data from phase 2 clinical trials, it was 
found that drugs needed to be active in at least a third of tested xenografts to be predictive of 
efficacy in at least some clinical trials. Furthermore, the correlation between activity in 
tumour type specific xenografts and matched human tumours was low with only NSCLC 
xenografts correctly identifying drugs with activity in NSCLC clinical trials [25].          
 
Traditionally, xenografts are established by subcutaneous inoculation of human tumour cells 
into the flanks of immunocompromised mice. This is technically straightforward and results in 
the timely generation of a single tumour; the growth of which can be followed using simple 
calliper measurements. The resulting tumour retains the histomorphology of the parental cell 
line from which it was derived, although after decades of in vitro culture this is unlikely to still 
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be representative of the tumour from which the cell line originated [26]. Furthermore, due to 
the limited treatment options at the time when many of these cell lines were generated, the 
resulting tumours are relatively treatment naive in comparison to the advanced disease 
states against which they will be tested in early phase clinical trials. Cancer is also a highly 
heterogeneous condition with high levels of variation observed both within and between 
individual tumours from the same cancer subtype. Use of well-established highly 
homogeneous immortalized cell lines to generate xenografts therefore fails to recapitulate 
the huge complexity seen in human disease. In addition, individual studies typically only use 
relatively few cell lines to generate xenografts and therefore these models represent only a 
very limited snap shot of the enormous diversity of genetic and epigenetic mutations that 
may be found within any given clinical tumour subtype. Some tumour types are also not 
amenable to current tissue culture techniques and therefore will inevitably be under-
represented in xenograft studies.   
 
Another critical limitation of xenografts is their dependency on immune compromised hosts, 
which prevents the exploration of any modulating effect the immune system might have on 
drug efficacy. The role of the immune system in moderating tumour behaviour is now well-
established [27] and the inability of these models to explore this is likely to become an 
increasing issue due to the development of a growing number of immune modulatory drugs, 
including the CTLA4 inhibitor, ipilumumab, and the PD1 inhibitor, nivolumab, which have 
both recently been approved for use in malignant melanoma. The lack of a fully functioning 
immune system also doubtless contributes to the general frailty seen in host mice which may 
limit their ability to tolerate certain drugs. Furthermore, SCID mice possess significant DNA 
repair defects which may also affect response to drugs [5].  
 
Whilst traditionally research has focused predominantly on the behaviour of epithelial cells 
within cancers, the importance of non-epithelial tumour components, such as stromal tissue, 
in moderating tumour behaviour is increasingly recognised [28]. Xenografts contain only 
limited amounts of stromal tissue and the epithelial-stromal cell interactions found in these 
tumours are unlikely to be reflective of those in human cancers as firstly the stromal tissue is 
host derived (i.e. mouse in origin) and secondly it originates from a non-native tumour site 
[29]. Studies comparing the response of xenografts to drugs have shown variable tumour 
responses depending on the xenograft location [30]. Undoubtedly, the development of 
tumours at non-native sites also contributes to the low rates of metastases seen with these 
models. Therefore, whilst these models can be used to explore drug efficacy in primary 
tumours, they are not suited to exploring the effect of drugs on processes such as local 
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invasion and the development of metastases. Given that the vast majority of patients with 
cancer die as a result of their metastatic disease rather than their primary tumours, this is 
clearly a fundamental issue and limits the degree to which drug testing in these models can 
accurately reflect clinical testing. 
 
A final factor to consider when examining the differential activity of drugs during preclinical in 
vivo experiments and clinical studies is the use of dramatically differing trial endpoints [31]. 
Agents which slow the rate of tumour growth are generally considered active in xenograft 
studies, whilst more robust criteria must be met during clinical trials for a tumour to be 
classified responsive, including tumour shrinkage of at least 30% [32]. 
 
Despite these limitations, there are numerous examples of the successful use of xenografts 
in drug development, for example well characterised ovarian xenografts were initially used to 
demonstrate the activity of trabectedin in this tumour group [33]. This activity was later 
confirmed in phase 2 clinical trials [34] [35] and promising activity has also recently been 
identified in a phase 3 trial [36]. However, as already alluded to there are also numerous 
examples of xenograft studies which have supported the transition of drugs into early phase 
clinical trials only to result in disappointment. Worse still there have been cases where drugs, 
despite appearing efficacious in preclinical models, have subsequently been suggested to 
promote tumour progression in clinical trials. Thiazolidinediones (TZDs) are agonists of 
peroxisome proliferator-activated receptor ɣ (PPAR ɣ) and are widely used in the 
management of type 2 diabetes. They were shown to be active against colon cancer 
xenografts [37] but when troglitazone was trialled in a cohort of patients with colon cancer, all 
patients experienced disease progression within a matter of months of starting treatment 
[38]. This led some people to suggest that TZD treatment expedited disease progression, 
although subsequent epidemiological studies exploring the risk of cancer in diabetic patients 
treated with these drugs would not support this [39]. Xenograft studies alone are insufficient 
to accurately determine the in vivo efficacy of novel compounds. The tendency of these 
models to over-estimate tumour response to new drugs suggests they may be useful as 
initial screening tools as any drug which fails to display activity in xenografts is unlikely to be 
efficacious in later studies using more refined, potentially less sensitive and more specific 
models. However, as we begin to develop a greater understanding of the many complex 
factors acting together to influence a tumour’s response to a drug, this assumption appears 
less robust and we must recognise the possibility that current models are equally capable of 
failing to identify active drugs. Xenografts are unlikely to disappear altogether from drug 
development programmes and it is increasingly clear in order to optimise the quality of the 
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data generated, efforts currently underway to genetically characterise the human cell lines 
used must continue. This will facilitate selection of appropriate models in which to test 
molecularly targeted agents but may also provide greater information on the potential 
mechanism of action of emerging chemotherapeutics [40]. 
 
1.3.3.2 Orthotopically implanted human tumour xenografts 
 
Orthotopic transplantation involves the transplantation of donor tumour material into the 
appropriate anatomical location within the host, for example inoculation of the mouse 
mammary fat pad (MFP) with a human breast cancer cell line. This technique was developed 
to overcome 2 major limitations of subcutaneous xenografts; firstly that the subcutaneous 
location fails to accurately model the role of the local microenvironment in tumour 
development and secondly that the rate and sites of metastases seen in these more 
traditional models are not characteristic of those seen in human cancers. The earliest 
experiments using this approach involved syngeneic transplantation of a murine colon 
adenocarcinoma cell line into various sites within the gastrointestinal tract and resulted in 
high rates of mesenteric lymph node and hepatic metastases [41], consistent with the most 
common pattern of spread seen in human colorectal cancer [42]. Today, there are numerous 
reports describing the successful implantation of tumour material into most sites where 
human cancers commonly arise [30] although clearly certain tumour types are more 
amenable to this type of transplantation; for example implantation of human breast cancer 
cell lines into the mouse MFP is relatively straight forward, whilst transplantation of tumour 
material into the murine prostate gland or to deep sites within the brain is considerably more 
challenging.  
 
In addition to the development of a metastatic pattern more in keeping with that observed in 
human disease, orthotopic transplantation is widely acknowledged as offering two other main 
advantages. Orthotopic transplantation allows the exploration of processes involved in local 
invasion at a clinically relevant site, for example angiogenesis. This is particularly relevant 
given that endothelial cells in different tissues have been shown to express different 
receptors [43]. Orthotopic models of colon cancer have been used to demonstrate the 
activity of the anti-angiogenic drug combretastatin A-4 phosphate both at primary and 
secondary tumour sites, although its activity in clinical disease has yet to be shown [30]. 
Several studies have suggested that orthotopic xenografts may also be more predictive of 
response to cytotoxics. For example, Kuo et al showed that an orthotopic SCLC xenograft 
Chapter 1: Introduction     11 
 
 
was sensitive to cisplatin, which constitutes the backbone of treatment for human SCLC, but 
when the same xenograft was transplanted subcutaneously, its sensitivity to the drug was 
lost [44]. However, the response of orthotopic xenografts is not universally predictive of 
human response; the matrix metalloprotease inhibitor baltimastat was found to be active in 
an orthotopic model of colon cancer yet unfortunately the results from a subsequent clinical 
trial were disappointing [30].   
 
In addition to issues relating to the technical feasibility of transplanting tumour material into 
particular anatomical locations, other challenges associated with this approach include 
difficulty in monitoring tumour progression and response. Depending on the site of the 
transplant, costly, specialist imaging techniques may be required to facilitate this potentially 
limiting the widespread adoption of this technique. In addition, although these models result 
in more efficient development of metastases, most animals still die from their primary 
tumour. For example Bibby et al found that most mice with orthotopic colorectal implants 
died from their primary tumour whilst their metastatic burden was relatively low. However, 
resection of the primary tumour did permit the development of more extensive liver 
metastases thereby enhancing the ability of this model to reproduce the features of human 
disease [30]. Finally, orthotopic transplantation is still not able to overcome some major 
limitations associated with the use of traditional xenografts, such as the lack of a functioning 
immune system. Many studies continue to use established human cell lines to generate 
xenografts and therefore, similarly to traditional xenograft studies, are also limited by a lack 
of tumour heterogeneity. However, more recently this approach has been exploited in 
studies using GEMMs and patient derived xenografts (PDXs) in an attempt to overcome this 
(see below).   
 
1.3.3.3 Patient derived xenografts (PDXs) 
 
Recognising the issues relating to the generation of xenografts from homogeneous cell lines, 
many of which bear little resemblance to the original tumour from which they were derived, 
there has been a recent surge in the popularity of using fresh human material to generate 
xenografts. During these experiments, sections of fresh human tumour samples are 
transplanted either subcutaneously or orthotopically into immune-compromised mice. Once 
the xenograft is established, it can be propagated over successive generations (without any 
intervening period of in vitro culture) to generate a cohort of mice with tumours all derived 
from the same host material. Previous studies using comprehensive genome wide analysis 
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has shown retention of activity of the majority of key genes and signalling pathways in 
xenografts derived from a variety of tumour types, including small cell lung [45] [46] and 
pancreatic [47] cancers. Key benefits of PDXs include the preservation of molecular tumour 
heterogeneity and through co-transplantation of human stromal tissue along with tumour 
material the accurate recapitulation of the tumour microenvironment. One of the biggest 
collections of PDXs has been generated by Fiebig and colleagues, who subcutaneously 
transplanted material from 1600 tumours resulting in the successful generation of over 300 
different xenografts representing all the major tumour types [48] [49]. Specifically, within the 
field of breast cancer, DeRose transplanted material from 49 primary or metastatic tumours 
following which 37% successfully engrafted and 24% resulted in the development of 
established xenografts which were successfully maintained over several passages. These 
xenografts resulted in the development of metastases in sites similar to those seen within the 
corresponding patient. The rate of tumour engraftment was not predicted by either hormone 
receptor or HER2 status although the rate of engraftment was predictive of patient survival 
[50].   
 
Once generated the models can be used to explore a range of different scientific questions; 
for example transplantation into multiple different recipients could be used to facilitate the 
collection of tumour tissue at a variety of different time points and therefore enhance our 
understanding of molecular changes which accrue over time in evolving tumours and 
promote processes such as metastasis. This would be extremely valuable as at present 
tumour characterisation in humans is performed at a limited number of time points, for 
example at the time of diagnosis. However, it remains critical to compare the changes in 
molecular signature seen within the model with those observed in the corresponding human 
tumour to ensure that the model continues to reflect the original tumour from which it was 
derived. These xenografts have also been used in the successful development of 
biomarkers, for example studies in K-RAS mutant colorectal cancer PDXs and human 
colorectal cancer cell lines identified Wnt pathway activation as being predictive of resistance 
to the MEK1/2 inhibitor AZD6244 [51]. However, undoubtedly the most excitement surrounds 
their potential use in predicting therapeutic response in human disease. In one study, 15 
colorectal PDXs were treated with 5-fluorouracil (5-FU) and oxaliplatin or irinotecan and 
when the response was compared to that of the corresponding human tumour a reasonable 
degree of concordance was observed [52]. This has led some to speculate that in the future 
PDXs may play a central role in determining an individuals’ treatment through establishment 
of personalised, real-time clinical trials prior to initiation of any treatment. In reality the 
development of such trials is unlikely to be feasible on a mass basis (see below), however 
these models are valuable resources for identifying new therapeutic targets and for testing 
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the therapeutic response to novel agents within molecularly defined subtypes of cancer. For 
example, PDXs have been used to demonstrate the activity of a pan-aurora kinase inhibitor 
within triple negative breast cancer [53].  
 
1.3.4 Genetically engineered mouse models (GEMMs) 
 
Since the initial development of gene targeting technology, GEMMs have undergone 
numerous refinements to facilitate the more accurate modelling of human cancers. The 
earliest GEMMs were generated through manipulation of embryonic stem cells (ESCs) 
resulting in the ubiquitous over-expression of an oncogene or loss of a tumour suppressor 
gene at all stages of prenatal and postnatal development. Examples of models generated in 
this way include models with loss of p53 expression or expression of a mutant 
retinoblastoma (Rb) allele [5]. These models have improved our understanding of the role 
played by individual genes in tumourigenesis and have contributed to our greater 
understanding of the co-operation seen between different gene mutations during tumour 
evolution. However, the range of genes which can be studied using these models is 
restricted as where the gene has an essential, non-redundant function in prenatal 
development embryonic lethality is inevitable. In addition whilst these models accurately 
recapitulate the features of rare inheritable cancer susceptibility syndromes, they fail to 
model the sporadic onset of most human tumours. Furthermore, the ubiquitous expression or 
knockout of the gene of interest means these models frequently develop multiple tumours at 
different anatomical sites and have a high incidence of haematological malignancies. This 
results in a relatively short life-span, which largely prohibits their use in preclinical drug 
testing.  
 
These limitations led to the development of the next generation of GEMMs, in which there is 
conditional expression of the gene of interest in a tissue-specific and/or time dependent 
manner. Several different approaches have been used to achieve this including the use of 
chemically induced transcription factors, such as the tetracycline-dependent system and 
somatic gene transfer. This later approach most commonly uses avian retroviruses and 
involves the manipulation of cells in the target tissue to express the retroviral receptor. The 
corresponding retroviral vector is then used to deliver the gene, which can only be taken up 
by cells expressing the receptor thereby restricting the expression/loss of expression of the 
gene in a tissue-specific manner [57]. However, the cre-lox P system is the most commonly 
used system to facilitate conditional expression/inactivation of an individual gene and relies 
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on the use of lox P recognition sites to guide cre-recombinase mediated recombination. In 
order to inactivate a gene, it must be flanked by lox P sites, which when placed in direct 
orientation, do not interfere with the gene’s function in the absence of the enzyme cre-
recombinase. Introduction of the enzyme, either by somatic delivery or by crossing with a 
cre-recombinase bearing mice results in recombination between the 2 recognition sites and 
deletion of the gene. This system can also be used to activate an oncogene; in the absence 
of cre-recombinase, a transcription terminator, flanked by 2 lox P sites, is used to separate 
the oncogene from its promoter. Introduction of cre recombinase triggers recombination and 
excision of the transcription terminator placing the oncogene under the control of its 
promoter resulting in gene transcription. An additional mechanism for regulating gene 
expression in a time-specific manner involves the CreERT2 transgene, which is created by 
fusing cre recombinase to the ligand binding domain of the oestrogen receptor (ER). When 
treated with the oestrogen analogue tamoxifen, ERT2 translocates to the nucleus allowing 
cre-mediated recombination to occur [58].  
An alternative approach involves the stochastic activation of oncogenes and has recently 
been used to generate a KRAS2 model of spontaneous cancers. This is achieved by 
generating a silent mutant allele in which 2 exons of the gene (the second of which contains 
an activating mutation) are separated by a transcription terminator, such as a neomycin 
resistant gene. Genetic recombination is a low incidence, spontaneous event that occurs 
during mitosis and occasionally may occur in a random fashion to trigger excision of the 
transcription terminator resulting in concomitant expression of both the wild-type and mutant 
alleles. Whilst this is not the most efficient way to trigger oncogene activation and lacks the 
control seen with the previously described methods, it results in mosaic expression of the 
mutant allele under physiological conditions making this a potentially powerful method of 
modelling sporadically occurring cancers [59]. 
 
A further alternative approach is the use of chimeric models. Initial experiments involved the 
transplantation of ESCs, which had been manipulated ex vivo to ensure they contained all 
the required mutations, prior to transplantation into the mature tissue of the recipient animal. 
This allows the modified ESCs to proliferate in the context of a normally functioning organ 
and avoids the need for complex breeding schemes to generate the required genotype, 
although the initial manipulation of the ESCs is still time consuming. To try and overcome 
this, more recently techniques have been developed to extract progenitor cells from 
previously validated GEMMs for direct transplant into recipient animals, thereby avoiding the 
complex process of modifying the cells prior to transplantation [60]. 
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Although potentially costly and time consuming to develop, once generated GEMMs are 
useful tools in a wide range of oncological experiments. To date, their major use has been in 
the fields of target validation and testing of novel and established therapeutic agents [5]. 
GEMMs are well characterised at the molecular level and allow us to explore the 
consequences of relevant gene mutations as well as providing a suitable model to test the 
efficacy of drugs which act against them. For example, combined treatment with the EGFR 
inhibitor erlotinib and gemcitabine resulted in a slight improvement in survival in Kras mutant 
model of pancreatic cancer compared to gemcitabine alone, reflecting the results of an 
earlier phase 3 clinical trial [61]. GEMMs also have a valuable role to play in determining the 
efficacy of more traditional cytotoxics. One of the earliest examples of the successful use of 
these models in the development of novel treatment strategies was in the management of 
acute promyelocytic leukaemia, which is caused by translocations involving chromosome 17. 
Using 2 different GEMMs, Pandolfi and colleagues demonstrated that the combination of 
arsenic trioxide with retinoic acid was an efficacious treatment for promyelocytic leukaemias 
caused by a PML-RARα translocation whilst an HDAC inhibitor and retinoic acid was suitable 
treatment for disease caused by a PLZF- RARα translocation. When these treatments were 
taken into the clinic they resulted in a high complete remission rate, reflecting the fact that 
the translocations used to drive tumorigenesis in the models recapitulated the driving 
mutations in human disease [56].  
 
As already alluded to in the previous study, GEMMs have the potential to be powerful 
models in the development of biomarkers, both in facilitating early cancer diagnosis and in 
enabling prediction of therapeutic response. It is well established that early detection of 
cancer results in higher cure rates but at present this is largely dependent on the use of 
costly and specialist imaging techniques. Hung and colleagues used the Apcδ580 colorectal 
GEMM to demonstrate increased expression of the cysteine proteases cathepsin B and D in 
the plasma of tumour bearing mice [62]. Testing of human tumour colorectal cancers 
demonstrated up-regulation of cathepsin B expression in 82% of colorectal tumour samples 
and expression correlated with poor prognosis [63]. Should the increase in plasma 
concentration of cathepsin B and D be translated into the clinic, it may lead to development 
of the first blood test capable of diagnosing cancer at an early stage. GEMMs also have the 
potential to be valuable tools in the development of biomarkers which are able to identify 
patients who are likely to respond to specific therapeutic agents. For example, much 
controversy has surrounded the ability of PTEN status to predict response to trastuzumab. 
Although there is compelling in vitro preclinical evidence to support this, when tested in 
several large clinical trials the results have been mixed [64]. This is likely to be due at least in 
part due to the vast array of genetic and epigenetic permutations in human cancers, which 
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are also likely to impact on treatment response and may have obscured any predictive role 
of PTEN. Using a GEMM of HER2 positive breast cancer, Wang and colleagues 
demonstrated that loss of PTEN was associated with resistance to a HER2 targeting 
antibody [65].      
A further important use of GEMMs is the identification of resistance mechanisms. Rottenberg 




model of BRCA1 deficient breast cancer to 
identify up-regulation of the efflux transporter P glycoprotein in tumours with acquired 
resistance to a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor [66], although to date, 
there is no evidence that this mechanism of resistance is clinically relevant. The only 
mechanism of resistance which has been identified in clinical populations is genetic 
reversion of the original BRCA1 mutation through the acquisition of secondary mutations, 
which either correct or bypass the original mutation [67]. However, more global analysis of 
resistant tumours in the future is likely to provide further data on clinically relevant resistance 
mechanisms and potential resistance biomarkers.   
  
GEMMS offer a number of advantages over more traditional xenograft based models. One of 
the major advantages is that spontaneous tumours develop within the appropriate organ and 
in the context of a fully functioning immune system. Furthermore, these models are highly 
molecularly characterised and the initiating genetic lesion underpinning tumour development 
is known making these models well suited to testing the efficacy of molecularly targeted 
agents. Importantly, models can be developed to ensure the driving genetic mutation has a 
correlate within human disease. In addition, the rate of metastases seen with these models 
tends to be more reflective of those observed in clinical disease and therefore they provide 
us with a greater opportunity to study some of the molecular processes underpinning this 
process. For example studies using the Rip1Tag2 model of pancreatic cancer showed that 
reduced neural cell adhesion molecules promoted the metastatic dissemination of pancreatic 
beta tumour cells [68]. However, most animals with metastatic disease still succumb as a 
result of the rapid growth of their primary tumour whilst their metastatic burden is relatively 
low, which is not reflective of the course of human disease. Where feasible, resection of the 
primary tumour prolongs animal survival allowing the development of more substantial 
secondary deposits [69], which could be exploited in the future to test the efficacy of novel 
agents in the metastatic setting. Finally, GEMMs, through the random acquisition of 
secondary mutations, are more able to recapitulate the heterogeneity of human cancer than 
xenografts and how this impacts on drug efficacy. In a Kras mutant model of pancreatic 
cancer, the combination of gemcitabine with an anti-VEGF monoclonal antibody improved 
OS in 50% of animals compared to gemcitabine alone but in the remaining 50% resulted in 
no survival advantage [61]. This difference in survival was seen despite the fact that 
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laboratory mouse strains are relatively inbred and cancer development occurs on a relatively 
homogeneous background.  
GEMMs also have a number of limitations. Firstly, although significant overlap exists in the 
genes and pathways activated in human and murine cancers [70], some important 
differences have been identified. Inter-species variation in the distribution of genes between 
different chromosomes is seen, for example p53 and BRCA1 are found on the same 
chromosome in mice so co-deletion is more common than in human tumours [5]. 
Furthermore, fewer mutations are required to transform murine cells than human cells [71] 
and unlike tumours which develop in humans, those which develop in mice are generally 
chromosomally stable and contain fewer somatic structural rearrangements [72]. Additionally 
whilst telomerase dysfunction is frequently seen in human tumours, it is rare in cancers 
which develop in mice [73]. Secondly, despite the use of tissue-specific promoters, there 
may be some limited Cre expression in other tissues resulting in tumour development in non-
target tissues. Thirdly, depending on the model used, lengthy and complex breeding 
programmes may be required to generate animals with the required genotype. Tumour 
penetrance rates can also be unpredictable and coupled with potentially lengthy tumour 
latency intervals (defined as the age of the mouse at the onset of tumour development), 
these experiments can be very protracted. Attempts to streamline these experiments have 
led to some groups performing othotopic transplants with either fragments from mature 
tumours or cell lines derived from the parental model. Whilst this may reduce the length of 
experiments, it also prevents the study of the stepwise development of tumour progression 
making it inappropriate for some experiments. Fourthly, similarly to orthotopic xenografts, 
depending on the model used, monitoring disease progression may be more complicated 
than when using subcutaneous xenografts and may require the use of specialist, complex 
imaging techniques. Fifthly, the development of new GEMMs is extremely time consuming 
and the number of models in existence is still relatively low. To try and develop sufficient 
models to reflect even a proportion of the diverse range of tumour initiating lesions seen in 
clinical practice would require an immense effort.  
 
In summary, a range of different in vivo models are now available. All of these different 
models have their own relative strengths and weaknesses and in reality they are all likely to 
have a role to play in future oncological studies. 
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1.4 Breast cancer and its classification 
 
It is a sobering thought that 1 in 8 women in the UK will develop breast cancer during their 
life time making it the most prevalent form of invasive cancer (excluding non-melanoma skin 
cancer) in the UK. Despite dramatic improvements in disease outcomes, 12 000 women and 
80 men die each year from breast cancer (http://www.breastcancercampaign.org).  
 
Breast cancer is no longer considered to be a single disease entity but is recognised to 
consist of several different pathological subtypes, which have distinctive histomorphologies 
and different clinical pictures [74]. Until recently, breast cancer was primarily classified 
according to the presence or absence of oestrogen receptor (ER), progesterone receptor 
(PR) and the HER2 receptor. Although, this is still the dominant mechanism of disease 
classification used clinically, gene expression studies using DNA micro-arrays have allowed 
breast cancers to be further classified into 5 groups on the basis of gene-expression 
pathways; luminal A and B, HER2 positive, normal-type and basal-like. Luminal tumours 
display similar features as those of luminal epithelial cells and tend to be hormone receptor 
(HR) positive whilst HER2 positive tumours are identified by the over-expression of the 
HER2 receptor. Normal-type tumours are characterised by high expression of basal 
epithelial-cell genes and low expression of luminal epithelial-cell genes. Basal-like tumours 
are identified by the absence of ER, PR and HER2 expression [75]. Several studies have 
shown that HER2 positive and basal-like tumours have worse outcomes than either luminal 
or normal-like tumours [76].  
 
 
1.5 HER2    
 
The human epidermal receptor (HER) family, comprising HER1 (EGFR), HER2, HER3 and 
HER4 is a family of structurally related transmembrane tyrosine kinase receptors, which are 
implicated in normal cell growth and development [77]. The receptors comprise an 
extracellular binding domain, an α helical transmembrane domain and an intracellular 
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1.5.1 The role of HER2 in normal development 
 
The HER family of receptors are expressed in a wide range of tissues. HER2 in particular 
plays an important role in the development of both cardiac myocytes and the peripheral 
nervous system [79]. Ubiquitous loss of HER2 expression in the developing embryo results 
in embryonic lethality at 10.5 days of gestation, most likely due to defective cardiac function 
as a result of absent trabeculae [79]. However, animals with a ventricular-restricted absence 
of HER2 expression were viable but develop cardiomyopathy, suggesting that HER2 plays 
an essential role in the prevention of this condition [80] [81].  
 
HER2 is also expressed in the developing nervous system [82]. When mice with germline 
loss of HER2 were genetically rescued by myocardial expression of a HER2 transgene, the 
resulting animals died at birth due to severe defects affecting both motor nerves and 
Schwann cells.  
 
1.5.2 The role of HER2 in breast cancer 
 
HER2 gene amplification or protein over-expression is found in approximately 15 to 20% of 
all breast cancer cases [83]. Tumours are classified as HER2 positive if on 
immunohistochemistry (IHC) they demonstrate uniform, intense membranous staining of at 
least 30% of invasive cells (scored as 3+) or if using fluorescent in situ hybridization (FISH) 
they have at least 6 copies of the HER2 gene per nucleus or a FISH ratio (defined as HER2 
gene signal to chromosome 17 signal) of more than 2.2 [83]. In breast cancer, HER2 status 
is positively correlated with tumour size, grade, proliferation index, lymph node status, DNA 
aneuploidy, p53 mutations and high urokinase-type plasminogen activator expression [84] 
[85]. Despite this, HER2 gene amplification is an independent predictor of poor clinical 
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1.5.3 HER family signaling 
 
1.5.3.1 HER receptor activation 
 
Under normal physiological conditions, HER receptor signaling is regulated by the 
expression of their ligands. There are 6 HER receptor ligands, or EGF-related growth factors 
[87]; EGF, transforming growth factor α, amphiregulin, heparin-binding EGF, betacellulin, 
epiregulin and heregulin [78]. These ligands are initially produced as transmembrane 
proteins and are subsequently cleaved by cell surface proteases to release the mature 
ligand ready for signaling [87] [78].  
 
Receptor homo- or hetero-dimerization is essential for HER receptor signaling. With the 
exception of HER2 (which has no known ligand and relies on cross-activation by other HER 
family receptors), HER receptors normally exist as inactive monomers. Binding of the 
respective ligands to the receptor induces conformational change leading to receptor 
dimerization [88]. Following receptor dimerization, there is asymmetric dimerization of the 
kinase domains resulting in sequential allosteric activation of one kinase domain by the other 
[89]. Activation of the kinase domains, results in phosphorylation of specific residues within 
the receptor’s cytoplasmic tail, which then act as docking sites for a number of proteins 
leading to activation of downstream intracellular signaling pathways [78]. EGFR and HER4 
both have recognized ligands and active kinase domains [78] and are therefore capable of 
forming both hetero- and homodimers. Heterodimers are more potent activators of 
downstream signaling pathways than homodimers and HER2-HER3 is widely acknowledged 
as being the most potent HER dimer in terms of strength of receptor interaction, ligand 
induced tyrosine phosphorylation and signaling pathway activation [90] [91]. HER3 is able to 
bind several ligands (including neuregulin 1 and 2 [77]) but is generally considered not to 
have an active kinase domain and is therefore considered incapable of binding ATP [92]. 
Therefore, it is dependent upon forming heterodimers with other receptors to activate 
intracellular signaling pathways. More recent experiments have shown that HER3 is locked 
in an inactive conformation and although it is able to bind ATP it remains catalytically inactive 
suggesting that it may function as a specialized allosteric activator of other HER receptors 
[93]. Conversely, whilst HER2 has no known ligand, it has an active catalytic domain and 
has the strongest kinase activity of all the HER receptors [94]. The ligand binding site of 
HER2 also differs from that of other receptors as it is in a conformationally active 
conformation making it the preferred heterodimerization partner for other HER family 
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receptors [95]. HER2-containing dimers are also slower to dissociate but undergo 
endocytosis and receptor recycling to the cell surface more frequently resulting in prolonged 
activation of intracellular signaling pathways [96]. When over-expressed, HER2 is able to 
signal in a ligand-independent fashion forming homo- and/or heterodimers resulting in 
uncontrolled cell growth, division and avoidance of apoptosis [77].    
 
1.5.3.2 Intracellular signaling pathway activation 
 
Phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) 
signalling are the major biological readouts of ligand-dependent and -independent HER 
receptor activation (Figure 1.1).  
 
1.5.3.2.1 MAPK signalling 
 
 
Src homology 2-containing proto-oncogene (Shc) docking sites are found in numerous 
proteins and the cytoplasmic tails of all HER receptors contain at least 1 Shc docking site. 
This includes HER2 which contains 5 such docking sites making Shc the most common 
HER2 interacting protein [97]. Following phosphorylation, Shc associates with Growth Factor 
Receptor Bound 2 (Grb2), although Grb2 can also bind directly to HER2 at tyrosine residue 
1139 [98]. In the cytosol, Grb2 is bound to the guanine nucleotide exchange factor Son-of 
Sevenless (Sos) and this complex binds to the membrane bound protein Ras catalysing the 
conversion of GDP to GTP with subsequent Ras activation [99]. Ras activates several 
effector proteins, including B-Raf, which in turn phosphorylates and activates MAPK (or 
MEK1). In turn, MAPK activates p44/42 MAPK (also referred to as ERK-1 and ERK-2) 
resulting in activation of members of the activator protein 1 (AP-1) family, including jun and 
fos. Following activation, jun and fos translocate to the nucleus, form a complex and bind to 
the AP-1 domain of DNA resulting in the transcription of genes involved in a range of 
different cellular processes, including proliferation, differentiation and cell survival. 
 
 
1.5.3.2.2 PI3 Kinase (PI3K)/Akt signalling 
 
PI3Ks are a family of lipid kinases characterised by their ability to phosphorylate inositol ring 
3’ groups within inositol phospholipids [100]. Three distinct classes of PI3Ks exist with class I 
being the most heavily implicated in the pathogenesis of cancer [101]. PI3K gene mutations 
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are frequently identified in human cancers and are observed in between 20 and 25% of 
breast cancers [102]. Class 1 PI3Ks are heterodimers containing a catalytic subunit (p110) 
and an adaptor/regulatory subunit (p85). They can be further subdivided into class IA, which 
are activated by RTKs, and class Ib, which are activated by G protein coupled receptors 
[100]. 
 
There are 3 main mechanisms of PI3K activation. Firstly, binding of PI3K’s adaptor subunit 
to a phospho-YXXM motif (where X represents any amino acid) on a RTK triggers the 
activation of PI3K’s catalytic subunit (HER2 does not contain a PI3K docking site, although 6 
such sites are found in the intracellular domain of HER3 [97]). Secondly, indirect binding of 
PI3K can occur to the RTK via GRB2 and its scaffold protein GAB, which in turn is capable 
of binding to the PI3Ks adaptor subunit triggering activation of the catalytic subunit. Finally, 
the GRB2-Sos complex can activate RAS, which can activate the catalytic subunit of PI3K 
independently of its adaptor subunit [103].         
 
Once activated, the p110 subunit of PI3K binds to phosphatidylinositol-4,5-biphosphate 
(PIP2) in the lipid bilayer of the cell membrane and phosphorylates it to form 
phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 activates a number of intracellular 
signalling pathways implicated in numerous cell functions including those involved in tumour 
initiation and progression. The tumour suppressor gene phosphatase and tensin homologue 
(PTEN) dephosphorylates PIP3 back to PIP2 thereby terminating PI3K signalling. Loss of 
PTEN is seen in approximately 50% of human tumours [104] resulting in hyperactivation of 
this signalling pathway. PIP3 contains a pleckstrin homology (PH) binding site to which both 
the protein serine/threonine kinases 3’-phosphoinositide-dependent kinase-1 (PDK1) and 
Akt/PKB are able to bind [103]. When brought into close proximity, PDK1 activates Akt by 
phosphorylation at its threonine 308 residue [105]. For full activation, Akt must also be 
phosphorylated at its serine 473 residue. Initial studies identified multiple potential 
candidates capable of performing this second phosphorylation but more recent studies have 
suggested that mammalian target of rapamycin complex 2 (mTORC2) is the only kinase 
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1.5.3.2.3 Effects of activated Akt on cell behaviour 
 
1.5.3.2.3.1 Inhibition of apoptosis 
 
Activated Akt inhibits apoptosis through a number of different mechanisms. Firstly, it inhibits 
the activity of the pro-apoptotic proteins BAD and BAX [107]. It also negatively regulates the 
activity of the pro-apoptotic protein p53 through phosphorylation and activation of mouse 
double minute 2 homolog (Mdm2). Furthermore, activated Akt negatively regulates the 
transcription factor NFKβ resulting in an increase in the transcription of pro-survival and anti-
apoptotic genes. It also negatively regulates the transcription of forkhead transcription 
factors, which reduces the production of cell-death promoting proteins such as Fas-ligand 
[108].   
 
1.5.3.2.3.2 Cell cycle progression and proliferation 
 
 
Akt inhibits glycogen synthase kinase 3 (GSK3) mediated phosphorylation of β catenin 
thereby increasing β catenin’s stability. Unphosphorylated β catenin translocates to the 
nucleus, where it induces the expression of cyclin D and cell cycle progression [109]. 
Furthermore, Akt phosphorylates and enhances the stability of p21, a positive regulator of 
cell cycle progression [110]. Finally, it phosphorylates p27 preventing its translocation to the 
nucleus and inhibition of cyclin E/CDK2 [111].   
 
1.5.3.2.3.3 Protein synthesis   
 
Akt plays a critical role in protein synthesis through activation of the mammalian target of 
rapamycin (mTOR) pathway. mTOR forms 2 complexes; mTORC1 and mTORC2. Activated 
mTORC1 phosphorylates and activates p70 S6 kinase and eukaryotic initiation factor 4E 
binding protein 1, which increase mRNA translation [112]. mTORC2 is responsible for 
phosphorylation of Akt on serine residue 473, which is essential for full Akt activation [106]. 
In addition, mTORC is involved in regulation of cell morphology and the cytoskeleton [113]. 
 
 






Figure 1.1: HER family signalling and site of action of targeted therapies in HER2 
positive breast cancer (see section 1.5). HER family receptors are capable of forming 
either homo- or hetero-dimers at the cell surface in a ligand-dependent or 
independent fashion. Dimerization triggers transphosphorylation of tyrosine residues 
(P) and downstream signalling. Trastuzumab and pertuzumab are anti-HER2 
monoclonal antibodies which target the extracellular domain of the HER2 receptor 
and inhibit receptor dimerization. T-DM1 is an antibody dependent conjugate of 
trastuzumab and maytansine. Binding of trastuzumab to the HER2 receptor results in 
internalization of the conjugate where subsequent lysosomal degredation results in 
intracellular release of DM-1 enabling it to bind to tubulin and inhibit microtubule 
polymerization. Lapatinib, neratinib and AZD8931 are TKIs with in vitro activity against 
EGFR and HER2. ERK, extracellular-signal-regulated kinase; FOXO, forkhead box O; 
GSK3, glycogen synthase kinase 3; MDM2, murine double minute 2; MEK, MAPK/ERK 
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1.6 Treatment of HER2 positive breast cancer 
 
The management of HER2 positive breast cancer is multi-modal. Surgery is currently the 
mainstay of treatment for early breast cancer and where appropriate is supplemented with 
radiotherapy, chemotherapy and targeted agents. The current guidelines used to guide 
management are discussed below, although in practice all treatment decisions must be 




Mastectomy is the traditional management of early breast cancer although more recently 
breast conserving surgery (BCS) has become increasingly popular. This involves removal of 
the breast tumour without the need to remove the entire breast. Randomised trials 
comparing treatment outcomes following mastectomy and BCS have shown comparable 
survival rates but an increase in local recurrence rates following BCS, which can be 
abrogated by use of breast radiotherapy [115]. The more widespread use of neoadjuvant 
systemic therapy (see section 1.5.3), which involves the upfront administration of systemic 
treatment prior to surgical management, has led to greater use of BCS as tumours requiring 
mastectomy at diagnosis can often be down-staged to permit a more conservative surgical 
approach. In fact, in some cases neoadjuvant systemic therapy has been so successful that 
no viable tumour cells are found at the time of surgery (defined as a pathological complete 
response (PCR)) and this has led some to question whether surgery is still warranted. 
However, at present no data exists to support the omission of surgery in this context. A 
further area of contention is the role of surgery in the management of primary metastatic 
disease (defined as patients with metastatic disease at the time of presentation). Again, 
there is a lack of data from prospective randomized trials and what data is available has 
been drawn from retrospective studies which provide conflicting results [116] [117].             
 
Appropriate management of the axillary lymph nodes is a further important surgical 
consideration. Treatment of the lymph nodes serves 2 main purposes; firstly it reduces the 
risk of local recurrence in the axilla and secondly as lymph node metastases are an 
important negative prognostic marker, it facilitates rationale decision making regarding 
further treatment. Axillary lymph node clearance remains the gold standard treatment for 
patients with evidence of lymph node involvement on ultrasound or ultrasound guided needle 
biopsy. In patients with no pre-operative evidence of axillary lymph node metastases at the 
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time of surgery, sentinel lymph node biopsy (which involves the identification of the lymph 
node most likely to be positive in the presence of axillary metastases) is now the standard of 
care. Only those with pathological evidence of lymph node metastases following biopsy are 
offered axillary clearance or radiotherapy [118]. In cases in which patients will receive 
adjuvant chemotherapy, endocrine therapy or targeted therapy some have questioned 
whether further treatment for a positive lymph node biopsy is still necessary. 
   
1.6.2 Radiotherapy 
 
Radiotherapy is aimed at further improving local control rates and is routinely used following 
BCS and in selected cases following mastectomy. Traditional treatment following BCS has 
involved whole breast irradiation (WBI) coupled with a boost in patients under the age of 50. 
A boost increases the delivery of radiotherapy to the tumour bed and the surrounding breast 
parenchyma (the areas at highest risk of harbouring residual microscopic disease) and 
reduces the risk of local recurrence. The lengthy duration of traditional WBI schedules and 
the potential for longstanding cosmetic changes has a detrimental effect on patients’ quality 
of life. In efforts to overcome this, accelerated partial breast irradiation (ABPI) is becoming 
increasingly popular. ABPI involves delivering larger doses per radiotherapy fraction than 
standard regimes and focusing treatment on the tumour bed alone, giving an improved 
cosmetic outcome. It is currently considered in patients under the age of 50, with node 
negative tumours which are under 3cm in diameter. Ideally these patients should be treated 
within the context of a clinical trial as long term follow up data for ABPI versus WBI is still 
lacking.          
 
Post mastectomy and axillary nodal surgery, the decision whether to proceed with chest wall 
radiotherapy or radiotherapy to the un-dissected regions of the axilla (upper axilla, internal 
mammary nodes and infra-clavicular and supra-clavicular nodes) is based on the risk of 
loco-regional recurrence. Features indicative of a high risk of recurrence and therefore 
mandating the use of radiotherapy include a substantial metastatic lymph node burden and a 
locally advanced tumour. Where neoadjuvant systemic therapy has been delivered, this 
decision is based on the disease stage prior to the delivery of any treatment, although in light 
of increasingly efficacious systemic options, there is a risk that patients are being over-
treated. Reviewed in [119].  
 





Unlike surgery and radiotherapy, chemotherapy aims to improve distant disease control (i.e 
control within organs other than the breast). It is used in the management of both early and 
metastatic breast cancer (MBC).  
 
1.6.3.1 Use of chemotherapy in early breast cancer 
 
In early breast cancer, the primary aim of chemotherapy is to eradicate micrometastatic 
disease thereby reducing recurrence rates and improving long-term OS. It can be delivered 
either post-operatively (adjuvant treatment) or pre-operatively (neo-adjuvantly). Neoadjuvant 
and adjuvant chemotherapy offer equivalent treatment outcomes [120] but neo-adjuvant 
therapy offers further advantages in terms of increasing BCS rates and providing an in vivo 
assay of chemotherapy efficacy within an individual tumour. The more wide-spread use of 
chemotherapy in early breast cancer has undoubtedly contributed to the reduction in 
disease-specific mortality observed in developed countries [121]. Current recommendations 
for adjuvant chemotherapy are based on evidence drawn from numerous clinical trials 
conducted over the past 30 years.  
 
Combinational chemotherapy regimes, which contain an anthracycline (e.g. epirubicin and 
adriamycin), now form the cornerstone of adjuvant chemotherapy. Frequently used 
combinations include 5-FU and cyclophosphamide given either with epirubicin (FEC) or 
adriamycin (FAC). Comparison of anthracycline and non-anthracycline regimes 
demonstrated a 4% survival advantage at 10 years in favour of anthracyclines [122]. 
Anthracycline use is associated with significant acute treatment-related toxicities (e.g. 
alopecia, nausea, vomiting and mucositis). However, as treatment outcomes have improved, 
what has become increasingly evident is the significant longer-term complications associated 
with these drugs, including cardiotoxicity and the excess risk of secondary haematological 
malignancies [123].      
 
Taxanes are used in addition to anthracyclines in patients with high risk early breast cancer. 
A systematic review comparing outcomes of taxane containing and non-containing regimes 
demonstrated an increase in the PCR rate following taxane treatment in 4 out of 5 neo-
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adjuvant studies, although this failed to reach statistical significance. Furthermore, all 5 
adjuvant studies included in the review demonstrated an increase in disease free survival 
(DFS) and 2 studies, which contained only patients with node positive disease, showed an 
improvement in OS following taxanes [124]. 
 
1.6.3.2 Use of chemotherapy in metastatic breast cancer 
 
Although secondary breast cancer is incurable, a high proportion of metastatic tumours 
continue to respond to chemotherapy. When given in the metastatic setting, chemotherapy 
aims to palliate symptoms and improve OS, although the duration of treatment response is 
frequently disappointingly short.  
 
Anthracyclines remain an important therapeutic option in patients who have not received 
adjuvant treatment or who were treated more than 1 year prior to the onset of metastatic 
disease. This latter group of patients who have received prior anthracyline treatment may 
require a dose reduction due to the greater risk of toxicity, particularly bone marrow 
suppression and cardiotoxicity. ORRs of approximately 30% have been observed following 
anthracycline treatment in patients with anthracycline naive disease [125]. 
 
Taxanes also remain an important option and are considered first line treatment for patients 
who have received adjuvant anthracyclines or progressed following anthracycline treatment 
in the metastatic setting. When used in metastatic disease ORRs of up to 50% have been 
seen [126].  
 
Other treatment options include capecitabine and vinorelbine. Capecitabine (an oral 
fluoropyridimine prodrug) is widely used in metastatic disease. Major advantages of this 
treatment include its oral route of administration and that due to its well tolerated side-effect 
profile if disease responds, it can often be given long term as a maintenance treatment. 
ORRs of 20% have been seen with median survival in excess of 1 year even in patients with 
anthracycline and taxane resistant disease [127]. Vinorelbine is a vinka alkaloid which 
results in ORRs of up to 50% [128] although it is frequently poorly tolerated.         
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1.6.4 Endocrine therapy 
 
Approximately 50% of HER2 positive breast cancers are also HR positive [129]. In the 
adjuvant setting, pre-menopausal patients with HR positive breast cancer receive between 5 
and 10 years of tamoxifen treatment. In high risk cancers, anti-oestrogen therapy can be 
enhanced by the addition of GnRH analogues, or depending on patient preference, 
oophorectomy. Post-menopausal women with HR positive early breast cancer are either 
treated upfront with an aromatase inhibitor (AI) or with tamoxifen for 2 to 3 years before 
switching to an AI. These drugs are also active in the metastatic setting.    
 
In the context of HER2 positive disease, preclinical data suggests that HER2 positivity 
confers intrinsic resistance to hormonal therapy [130] and that HER2 directed therapy may 
re-sensitize HER2 and HR positive cells to hormonal therapy [131]. This has been explored 
as part of two prospective, randomized clinical trials. Patients with newly diagnosed 
metastatic HER2 positive cancer were randomized to treatment with either the AI 
anastrozole or anastrozole plus trastuzumab as part of the Trastuzumab and Anastrozole 
Directed against Estrogen and HER2 Positive Carcinoma (TAnDEM) trial [132]. The 
EGF30008 trial also randomized patients with HR receptor positive breast cancer to 
treatment with the AI letrozole or letrozole and lapatinib [133]. In both TAnDEM and the 
HER2 positive subgroup of the EGF30008 trial, combinational therapy led to statistically 
significant increases in PFS, ORR and CBR. Neither trial demonstrated a statistically 
significant increase in OS, although survival was increased in TAnDEM despite a 70% cross-
over from the single to the combined treatment arms. Together these trials support the 
combined use of hormonal and HER2 directed therapy, which is particularly relevant to 
patients with less aggressive metastatic disease or those who are too frail to receive 
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1.6.5 Targeted therapy 
 
The introduction of HER2 targeting agents has revolutionized the management of HER2 
positive breast cancer. Chemotherapy demonstrates a lack of cell specificity and kills both 
healthy and cancerous cells. These agents, however, exploit the increased reliance of HER2 
positive cancer cells on the HER2 signaling pathway and therefore exhibit more selective 
cytotoxicity and a reduced side-effect profile. Currently licensed therapies include 
monoclonal antibodies, tyrosine kinase inhibitors and most recently antibody dependent 
conjugates (Figure 1.1). 
 
1.6.5.1 Currently licensed targeted therapies 
 




Trastuzumab was the first of the HER2 targeted agents to enter mainstream clinical practice 
and is approved for use in both early and metastatic HER2 positive breast cancer. It binds to 
subdomain IV of HER2’s extracellular domain but despite its widespread use, its mechanism 
of action remains to be fully elucidated. Its mechanism of action is likely multimodal and 
thought to involve inhibition of ligand-independent receptor dimerization and downstream 
signalling, induction of cell-cycle arrest and apoptosis, interference with DNA repair, 
inhibition of angiogenesis, antibody-dependent cell-mediated cytotoxicity (ADCC) and 
inhibition of the cleavage of the HER2 extracellular domain preventing generation of the 
truncated constitutively active p95HER2 [2]. Although the efficacy of single agent 
trastuzumab is low, when given in combination with standard adjuvant chemotherapy it 
further reduces the risk of death by 33% [134]. The addition of trastuzumab to neoadjuvant 
chemotherapy also results in a significant increase in the PCR rate [135]. When given in 
combination with chemotherapy in metastatic disease, trastuzumab increases the rate and 
duration of responses and results in an approximate 4 month increase in OS [136]. This 
additional efficacy comes at the cost of little in terms of toxicity. The most common treatment 
related adverse event is asymptomatic reduction in left ventricular ejection fraction (LVEF), 
which is both generally treatable and reversible. 
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1.6.5.1.1.2 Pertuzumab 
 
Pertuzumab binds to subdomain II of HER2’s extracellular domain thereby inhibiting ligand-
induced heterodimerization. Preclinical studies have suggested that when combined, 
trastuzumab and pertuzumab provided a more complete blockade of HER signalling than 
either drug alone (91). This is currently being tested in several ongoing clinical trials but 
following promising results in the NEOSPHERE trial [135] the combination of pertuzumab 
plus trastuzumab and docetaxel has already been granted accelerated approval by the FDA 
and European Medicines Agency for use in the neoadjuvant setting. Preliminary data from 
the CLEOPATRA study in which this same combination was tested in metastatic disease 
suggest that these findings from NEOSPHERE may be validated in larger, more definitive 
trials. 
 
1.6.5.1.2 Tyrosine kinase inhibitors: Lapatinib 
 
TKIs differ from monoclonal antibodies in several important ways. Firstly, they can be 
administered orally rather than intravenously, which is required for monoclonal antibodies. 
Secondly, as monoclonal antibodies bind irreversibly to the protein of interest whilst TKIs 
frequently bind reversibly, monoclonal antibodies tend to have a longer half-life. Thirdly, TKIs 
are generally considered to be less specific than monoclonal antibodies as they often target 
more than 1 kinase [137]. Lapatinib is currently the only TKI approved for use in trastuzumab 
refractory, metastatic HER2 positive breast cancer and it is given in combination with 
capecitabine [138]. Although classified as an ATP-dependent reversible TKI of HER2 and 
EGFR, it is a much more potent inhibitor of HER2 and it is questionable whether it inhibits 
EGFR signalling to any significant degree in vivo. It is active against ligand-dependent and 
independent signalling as well as p95HER2 receptors and thereby effectively inhibits 
downstream signalling [2]. 
 
 Data from the Neo-ALLTO trial suggests that lapatinib given in combination with 
trastuzumab and chemotherapy is more effective than the combination of either drug alone 
with chemotherapy [139]. Lapatinib is also postulated to have better central nervous system 
penetration than trastuzumab and may therefore reduce the risk of brain metastases [140], 
although the results of a head to head comparison is awaited.  




1.6.5.1.3 Antibody dependent conjugates: Trastuzumab-DM1 
 
The most recent drug to gain approval for use in metastatic HER2 breast cancer is the 
antibody dependent conjugate Trastuzumab-DM1 (T-DM1). This is a conjugate of 
trastuzumab and the microtubule polymerization inhibitor DM1 (a derivative of mytansine). 
When used in heavily pre-treated trastuzumab and lapatinib resistant HER2 positive MBC 
RR of approximately 40% have been seen [141]. Furthermore, when compared with 
docetaxel and trastuzumab in the management of previously untreated metastatic disease, 
T-DM1 resulted in higher RR and an improved toxicity profile [2].      
 
1.6.5.2 Targeted therapies currently in clinical trials 
 
A number of therapies which specifically target HER family signalling are currently in clinical 
development and in addition to the drugs discussed below many others are in preclinical 
development. Furthermore, several drugs which target signalling pathways downstream of 
the HER receptors (e.g. PI3K, mTOR, IGF1R and heat shock protein 90 inhibitors) have 
been developed. 
1.6.5.2.1 Monoclonal antibodies-MM-111 
 
Multiple HER3 targeting antibodies have been developed. The most advanced of these is 
MM-111, a bispecific monoclonal antibody which is believed to inhibit HER3 ligand binding 
and thereby HER3 heterodimerization [142]. The activity of MM-111 is currently being 
explored in HER2 positive, heregulin-positive metastatic cancer (including patients with 
trastuzumab and lapatinib resistant disease). A further study is focussing on its efficacy in 
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Irreversible TKIs result in longer target inhibition than their reversible counterparts. Neratinib 
is an irreversible inhibitor of HER2 and EGFR. When tested in HER2 positive metastatic 
disease, RR of 24% were seen in trastuzumab resistant disease and 56% in trastuzumab 
naive disease. A subsequent phase 1/2 trial of trastuzumab plus neratinib in trastuzumab 
resistant metastatic disease demonstrated a RR of 27% and a median PFS of 19 weeks. 
However, when tested head to head with lapatinib and capecitabine, neratinib and 
capecitabine offered equivocal OS. Phase 3 evaluation of neratinib in trastuzumab pre-
treated early breast cancer is currently underway [143].  
    
1.6.5.2.2.2 Afatinib 
  
Afatinib is a further irreversible inhibitor of HER2 and wild type and mutant EGFR. During a 
phase 2 trial of afatinib in patients with trastuzumab refractory disease, 4 partial responses 
were identified in a cohort of 35 patients. Its activity is currently being explored in phase 2 




AZD8931 is a reversible inhibitor of EGFR, HER2 and HER3 signalling that is believed to be 
preferentially active in ligand-dependent signalling. However, its efficacy in combination with 
either paclitaxel [144] or anastrozole [145] was disappointing. 
 
1.6.5.2.3 HER2 vaccination 
 
Several studies have shown that some patients develop spontaneous anti-HER2 specific 
immunity triggering efforts to develop anti-HER2 vaccinations. Amongst vaccines currently in 
development, peptide-based vaccines, particularly E75 (derived from the extracellular 
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domain of HER2), are the best studied. A recent retrospective analysis of patients with MBC 
treated with E75 demonstrated that 40% were still alive at a median follow up of 112 months 
and 75% exhibited persistent T cell immunity. Furthermore, the combined analysis of 2 
phase 2 trials, which collectively contained 195 patients with either node positive or node 
negative early breast cancer, reported a recurrence rate of 5.6% in patients receiving the 
vaccine following standard treatment compared to 14.2% in the observation arm at a median 
follow up of 18 months. However, this difference was no longer significant at 24 months. 
Major draw backs of peptide-based vaccines include the requirement for HLA restriction (i.e. 
a T cell is only able to recognise a peptide antigen when it is bound to the host body’s own 
HLA molecule) which limits the number of patients that may be potentially treatable with such 
an approach as if the peptide is unable to bind to an HLA molecule no immune response will 
be generated. Secondly, as the immune response is triggered by a limited number of 
epitopes, the magnitude of immune response is limited. Finally, peptide vaccines 
predominantly stimulate a CD8+ T-cell response and are therefore not able to generate a 
strong, sustained immunological memory in the absence of repeated antigen exposure and 
stimulation by antigen-presenting cells. To try and overcome these shortcomings, several 
other approaches are being used to generate vaccines, including protein-based, DNA, whole 
tumour cell and dendritic cell vaccines (Reviewed in [146]).   
 
1.7 Mechanisms of resistance to HER2 targeted 
therapies   
 
The development of resistance to HER2 targeted therapies has been the focus of numerous 
pre-clinical studies, although far fewer of these have been clinically validated (Table 1.1). 
Mechanisms of resistance can be broadly classified as involving: structural alterations in the 
HER2 receptor, development of HER2-independent strategies for activating intracellular 
signalling and defects in cell-cycle control or apoptosis [147]. More recently, several studies 
have identified changes in metabolic pathways, which are responsible for driving resistance 
to HER2 targeted agents. Patient specific factors, for example genetic polymorphisms have 
also been linked to inherent trastuzumab resistance. Several preclinical and clinical studies 
have demonstrated lapatinib efficacy in trastuzumab resistant cells suggesting in some 
circumstances discrete mechanisms of resistance exist. However, other studies have shown 
a degree of overlap in resistance mechanisms between the 2 drugs despite their different 
mechanisms of action, highlighting the multi-factorial nature of resistance to these drugs.       




 Preclinical Data Clinical Validation 
Alterations in HER2 expression 
Loss of HER2 expression  Loss of HER2 during/after tx associated with reduced OS [148] 
p95 HER2 expression Stable transfection of HER2/p95 HER2 renders 
cells resistant to T but not L [149]. 
Conflicting data [64] 
Bypass signalling/activation of alternative survival pathways 
Transactivation of 
HER2/HER3 by EGFR 
T resistant cell lines show increased EGFR & 
pEGFR. EGFR TKIs inhibited HER2 activation. 
[147].  
No consistent relationship between EGFR expression & outcome. No 
additional efficacy from combined tx with gefitinib & T [150]. Increased 
PCR rate observed with combined NAC+ T+L [139] 
Increased heregulin 
expression &HER3 activity 
Tx of HER2+ve lines with HER TKIs results HER3 
re-activation & activation of PI3K pathway [147]. 
Inconsistent relationship between HER3 expression & tx outcomes 
[64]. Increased PCR rate with NAC+ T+ P tx [135] 
Loss of PTEN PTEN loss assoc with T resistance in HER2+ve 
cells [147] & GEMM [151]. PTEN knockdown in L 
tx cells has variable effect [152]. 
No consistent relationship between PTEN status & T sensitivity. PTEN 
loss not associated L resistance [153]. 
Activating p110α PI3K 
mutations 
Over-expression of mutant PI3K confers T [147] & 
L [154] resistance. 
Variable reports of impact of mutations on T sensitivity [64]. PI3 kinase 
mutations not associated L resistance [152]. 
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Src hyperactivation Increased Src activity in T& L resistant lines. 
Inhibition of Src restored sensitivity [155] [147]. 
High pTyr
416
 Src expression associated reduced OS following T [155]. 
Increased Met/HGF 
expression 
Knock down of MET increases T sensitivity [156]. 
HGF tx rescues L tx cells [157]. 
Increased MET and HGF expression in non-responders to T + 
chemotherapy [147]. 
HER2-IGF1R cross talk Inhibition of IGF1R in T resistant cells inhibits 
HER2 phosphorylation & restores T sensitivity 
[147]. 
Conflicting reports on the impact of IGF1R expression on response to 
T [147] [150]. 
EphA2 expression Overexpression of EphA2 by T resistant cells. 
EphA2 inhibition restored T sensitivity [158]. 
Elevated EphA2 gene expression associated with poor prognosis 
[158]. 
Increased TGFα expression L sensitivity of HER2 +ve cells reduced by TGFα 
tx  [159]. 
Low serum TGFα levels predictive of response to L + chemotherapy 
[159]. No correlation between tumour TGFα expression & response to 
T [64].              
Elevated (1) integrin 
expression 
Transfection of (1) integrin conferred T 
resistance [64].              
High expression associated reduced TTP post T tx [64].              
Erythropoetin receptor 
(EpoR) activation 
Epo tx reduces sensitivity of HER2 +ve cells to T 
[147]. 
Concomitant tx with T & Epo associated with reduced OS [147]. 
p70 S6 kinase 
hyperphosphorylation 
Increased p70 S6 kinase phosphorylation seen in 
L resistant HER2 transfected cells. Tx with 
rapamycin restored L sensitivity [160]. 
Elevated p70 S6 kinase expression associated with clinical response 
[161]. 
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Up-regulation of ER 
signalling 
Increased FOXO3A expression & ER & PR 
signalling in L resistant cells [162] [163]. 
Concomitant treatment with L & aromatase inhibitors associated with 
increased PFS in HER2 +ve/ER +ve tumours [132] [133]. 
Defects in cell-cycle control/ apoptosis 
Cyclin E gene amplification Increased cyclin E & CDK2 activity observed in T 
resistant cell lines. CDK2 inhibition reduced 
growth of T resistant xenografts [147]. 
Gene amplification/protein over-expression associated with reduced 
CBR & PFS [147]. 
Elevated survivin expression Increased expression seen in T & L resistant cell 
lines. Survivin knock down restored drug 
sensitivity [164] [165]. 
High pre-tx survivin RNA levels associated poor response to T + 
chemotherapy  [164]. 
 Elevated RelA activity L resistant cell lines expressed increased RelA. 
Knockdown of RelA restored L sensitivity [153]. 
Trend towards reduced RelA expression in L responders [153]. 
Alterations in metabolic pathways 
Enhanced glucose 
deprivation response  (GDR) 
Network analysis showed increased expression of 
genes involved in GDR in L resistant cell line 
[166]. 
Over-expression of genes associated GDR associated with high 
relapse rate in HER2 +ve breast cancer [166]. 
 
Table 1.1-Clinically validated mechanisms of acquired to resistance to trastuzumab (T) and lapatinib (L). Tx, treatment. Adapted from [114]
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The majority of published studies which have developed models of resistance to either 
trastuzumab or lapatinib have shown persistent HER2 expression. However, Lesniack 
described spontaneous loss of HER2 expression in SKBR3 cells associated with induction of 
an epithelial-to-mesenchymal transition (EMT) programme [167]. Whilst EMT has not been 
linked to clinical resistance, loss of HER2 expression has been identified in up to a third of 
metastatic tumours previously treated with trastuzumab ± lapatinib [168]. This suggests that 
loss of HER2 is a clinically relevant mechanism of resistance.    
 
Mutations in the HER2 receptor itself are rare. In his seminal paper, Bose identified 25 
mutations within the HER2 gene from a total population of 1499 patients. These mutations 
were all detected in tumours without HER2 gene amplification and as 50% of them were 
capable of driving tumourigenesis, these mutations identify a small additional subset of 
patients with the potential to benefit from trastuzumab treatment [169]. The majority of gene 
sequencing studies have focussed on tumours without HER2 gene amplification. However, 
in a small study of HER2 positive MBC (n=14) all 3 patients who developed metastases after 
more than a year of trastuzumab treatment had acquired a point mutation in exon 21 of the 
HER2 gene at the new metastatic site. These findings require further validation [64]. 
 
Increased expression of p95, a naturally occurring truncated form of HER2 which lacks the 
antibody binding domain, has been linked in preclinical studies to trastuzumab resistance 
[149] but not lapatinib resistance. Initial phase 2 clinical studies supported p95 as a potential 
biomarker of trastuzumab resistance. However, analysis of samples collected as part of 2 
major neoadjuvant phase 3 trials failed to identify any association between p95 expression 
and PCR rate. Furthermore, in the GeparQuattro trial p95 positivity was actually predictive 
for a statistically significant increase in PCR rate [64]. Preclinical studies have identified a 
second naturally occurring HER2 receptor splice variant (HER2Δ16), which eliminates exon 
16 in the receptor’s extracellular domain, and represents approximately 9% of total HER2 
expression. This does not prevent antibody binding but promotes the formation of intra-
molecular disulphide bonds stabilizing HER2 homodimers and preventing their disruption by 
antibody binding [170]. The clinical significance of this variant remains to be determined.   




Finally, whilst not an intrinsic alteration in the structure or expression of HER2, production of 
proteins which are capable of binding to HER2, such as mucin-4 (MUC-4), are able to 
abrogate trastuzumab-HER2 interaction. MUC-4 is a membrane associated glycoprotein, 
which when over-expressed can co-localize with HER2 and mask the antibody binding 
domain [171]. MUC-1 has also been reported to co-localize with the HER2 receptor in this 
/manner but other studies have shown that it can also homodimerize and initiate intracellular 
signalling independently of HER2 [147].      
 
1.7.2  Resistance associated with strategies for enhancing 
PI3K and p44/42 MAPK signaling 
 
Studies have identified several different strategies for enhancing PI3K/Akt and/or p44/42 
MAPK pathway activity.  These include up-regulation of HER family ligands or activation of 
other HER family receptors, acquisition of PI3K mutations/PTEN loss and activation by HER 
family independent signalling pathways.  
 
1.7.2.1 Activation of PI3K/Akt signalling via HER family/PI3K/PTEN 
activity 
   
1.7.2.1.1 The role of increased HER family ligands or alternate HER receptor 
activation in resistance 
 
The disintegrin and metalloproteinase-17 (ADAM17) is involved in the proteolytic shedding of 
the membrane bound HER family ligands resulting in increased bioavailability of active, 
soluble HER family ligands and subsequently increased downstream HER family signalling. 
Studies have implicated 2 methods of ADAM17 activation in trastuzumab resistance; firstly 
enhanced TGFβ signalling [139] and secondly a trastuzumab induced reduction in Akt 
activity, which initiates a negative feedback loop enhancing ADAM17 activity and the 
availability of HER family ligands [172]. Increased expression of the ligand TGFα has also 
been linked to resistance to lapatinib. Time to progression was shorter in patients treated 
with lapatinib and capecitabine with elevated levels of TGFα than in those with lower 
concentrations of the ligand [159].  Finally, other studies have shown increased heregulin 
expression is predictive of poor treatment outcomes in patients with HER2 positive breast 
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cancer [173] although combining pertuzumab (which is most active in the presence of 
heregulin) with trastuzumab (which is most active in the absence if heregulin) appears to 
overcome this [174] [135].  
 
Activation of other HER family receptors has also been linked to resistance. Ritter and 
colleagues generated trastuzumab resistant BT474 xenografts, which in addition to 
increased HER ligands, expressed elevated levels of EGFR and increased numbers of 
EGFR/HER2 heterodimers. Treatment with the EGFR TKI gefitinib, reduced HER2 
phosphorylation and disrupted the interaction between HER3-PI3K suggesting that in this 
model, ligand mediated induction of EGFR led to transactivation of HER2 and HER3 and 
continued downstream signalling [175]. More recently, Xia postulated an alternative 
mechanism by which autocrine induction of heregulin in lapatinib resistant cells activated 
HER3. Activated HER3 dimerized with EGFR which had not been completely inactivated by 
lapatinib treatment, resulting in persistent PI3K/AKT signalling[173]. The clinical significance 
of this remains uncertain as the addition of gefitinib to trastuzumab did not improve treatment 
outcomes. However, only low number of tumours that over-expressed EGFR were included 
in this study leading to it being underpowered [64]. As previously discussed, promising 
clinical data has been obtained with the combination of lapatinib and trastuzumab [139] 
although the extent of in vivo EGFR inhibition obtained with lapatinib is debatable. 
 
1.7.2.1.2 The role of PI3K mutations and loss of PTEN in resistance 
 
PI3K is a positive regulator of Akt activity and activating ‘hotspot’ mutations within its 
catalytic domain have been linked to both trastuzumab and lapatinib resistance in preclinical 
models [147]. PI3K activity is antagonised by PTEN and compelling preclinical data also 
supports the role of PTEN in moderating trastuzumab sensitivity [147] [65]. However, the 
impact of PTEN loss on lapatinib sensitivity is less well defined [154] [152]. The use of these 
biomarkers to predict trastuzumab sensitivity has been the focus of multiple clinical studies. 
Several retrospective studies demonstrated that individually the predictive power of PTEN 
and PI3K mutational status was limited, although combining biomarkers indicative of 
PI3K/PTEN/Akt pathway hyperactivation improved the predictive capability. However, data 
from prospective studies trials did not provide any conclusive evidence that trastuzumab 
efficacy was restricted to patients with PI3K/PTEN/Akt pathway hyperactivation [64]. 
Furthermore, data from the phase 3 EMILIA trial suggested that T-DM1 sensitivity was 
independent of PI3K mutational status [176]. Clinically, considerable controversy also 
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surrounds the impact of PI3K status on lapatinib sensitivity [176] [152]. One explanation for 
this lack of consistency may be the combined analysis of all PI3K mutations as a single 
group, when their individual impact on treatment outcomes may be very different. 
Prospective analysis of samples collected as part of the Neosphere trial showed that overall 
PI3K mutational status was not predictive of treatment outcomes. However, on an individual 
basis, certain mutations were predictive of poor outcomes [135]. Downstream of PI3K/Akt, 
mTOR 1 and 2 have both also been implicated in lapatinib resistance [177, 178]. 
 




Src inhibition appears a promising approach to tackling drug resistance as elevated Src 
activity is a common downstream consequence in resistant cell lines generated using 
several different approaches, including PTEN loss and over-expression of either EGFR or 
IGF1R [155]. Clinical resistance is multi-factorial in nature and therefore targeting features 
common to multiple resistance strategies is likely to provide the greatest therapeutic benefit. 
However, although high Src activity was correlated with reduced survival following 
trastuzumab treatment in MBC [155], response rates to single agent dasatinib were 
disappointing [179].       
    
1.7.2.2.2 EphA2 
The receptor tyrosine kinase, EphA2, is over-expressed in 92% of breast cancers and in 
patients with HER2 positive breast cancer, elevated gene expression is associated with 
reduced survival [180]. In vitro, trastuzumab induced Src activation led to increased EphA2 
activity culminating in persistent PI3K/Akt and MAPK signalling. Inhibition of EphA2 restored 
trastuzumab sensitivity, suggesting that elevated EphA2 activity was capable of driving the 
resistant phenotype and was not simply a downstream consequence of Src activation [158].  
   
1.7.2.2.3 Erythropoetin receptor 
The addition of erythropoietin to standard therapy in HER2 positive MBC had a detrimental 
impact on treatment outcomes. A significant percentage of cells co-express HER2 and the 
erythropoietin receptor. It is believed that whilst trastuzumab binds to the HER2 receptor and 
abrogates its signalling, erythropoetin binds to its own receptor and activates Jak. This 
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subsequently results in the activation of Src and PTEN inactivation, thereby amplifying any 
residual PI3K/Akt signal [181].    
 
1.7.2.2.4 IGF1R 
IGF1R is able to activate both Akt and p44/42 MAPK signalling by forming complexes with 
HER2 and/or HER3 and is therefore able to induce trastuzumab resistance in both a HER2-
dependent and –independent manner [147]. Furthermore, compelling in vitro evidence exists 
supporting the role of IGF1R in mediating resistance to HER2 targeted therapies; the 
sensitivity of HER2 positive cell lines to trastuzumab was enhanced by the addition of an 
IGF1R monoclonal antibody or IGF1R targeting TKI and lapatinib has been shown to reverse 
IGF1R mediated resistance [147]. Despite this, IGF1R has not readily translated into the 
clinic as a biomarker of resistance. Several studies have failed to demonstrate an 
association between IGF1R expression and treatment outcomes in either the adjuvant or 
metastatic setting, although its use in the neoadjuvant setting appears more promising. In a 
small phase 2 trial, membranous IGF1R expression was associated with reduced response 
rates to pre-operative vinorelbine and trastuzumab, although this is not standard treatment. 
Genetic profiling of samples collected in the phase 3 NOAH trial, which compared 
neoadjuvant/adjuvant trastuzumab plus chemotherapy with chemotherapy alone, 
demonstrated a correlation between low IGF metagene expression (defined as insulin 
receptor plus IGF1R expression [182]) and increased PCR rates amongst ER negative 
tumours in the combined treatment arm. Furthermore, low IGF1R expression was predictive 
of increased PCR rates amongst patients with ER negative tumours who received docetaxel 
with trastuzumab and pertuzumab in the Neosphere trial, although this finding was not 
replicated in other treatment arms [64]. Together, these results suggest that IGF1R signalling 
may be a clinically relevant resistant mechanism within ER negative tumours. Given the 
importance of ER signalling pathways in driving alternative survival pathways in HER2 
positive/ER positive tumours [183], it is possibly unsurprising that these effects are most 
apparent in ER negative disease. A randomised phase 2 trial comparing the efficacy of 
capecitabine and lapatinib with and without cixutumumab, an IGF1R targeted monoclonal 
antibody, has finished accrual but has yet to be reported. 
 
1.7.2.2.5 MET 
The proto-oncogene MET is also capable of activating PI3K/Akt signalling. It is frequently co-
expressed with HER2 in breast cancer and promotes trastuzumab resistance through 
sustained Akt activity. In vitro, loss of MET function, either through siRNA mediated 
knockdown or through TKI mediated inhibition, increased cell line sensitivity to trastuzumab 
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whilst MET activation reduced drug sensitivity. Interestingly, in HER2 positive breast cancer 
cells, MET expression was rapidly up-regulated in response to trastuzumab treatment 
thereby promoting its own resistance [156]. MET amplification has also been implicated in 
resistance to the EGFR targeting TKI, gefitinib, where it dimerized with HER3 causing 
downstream activation of PI3K/Akt [184]. In a separate study, RON, which is another 
member of the MET family, has also been linked to persistent PI3K/Akt activity and lapatinib 
resistance [185].   
 
1.7.2.2.6 Axl 
Over-expression of the receptor tyrosine kinase Axl has been linked both directly and 
indirectly to lapatinib resistance. In vitro, Axl and HER3 associate with the p85 subunit of 
PI3K and inhibition of both Axl and HER family receptors is required to fully inhibit PI3K/Akt 
activity. Unopposed Axl activity has been demonstrated to lead to lapatinib resistance [186]. 
Axl is also a common downstream effector of the epithelial-to-mesenchymal transition (EMT) 
programme [187], which has recently been linked to lapatinib resistance [167]. Furthermore, 
a recent study has shown that EMT is able to rewire the signalling pathways leading to 
PI3K/Akt activation demonstrating the complexities associated with effectively inhibiting this 
pathway in the context of drug resistance [188].     
 
1.7.2.2.7 β1 integrin 
β1 integrin is able to activate both the PI3K/Akt and p44/42 MAPK pathways. Using IHC, β1 
integrin over-expression was found to be an independent negative prognostic marker for 
TTP in a cohort of women with HER2 positive MBC treated with trastuzumab [189]. 
 
1.7.2.2.8 FGFR2 
The FGFR2 gene has been shown to be amplified in a model of lapatinib resistance in which 
both HER2 and EGFR expression were down-regulated. Activation of FGFR2 was 
demonstrated to contribute to persistent Akt and p44/42 MAPK activity culminating in 
lapatinib resistance [190]. 
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1.7.3 Activation of PI3K and p44/42 independent cell survival 
signaling pathways 
 
Two studies have implicated up-regulation of ER signaling in lapatinib resistance. In 
untreated HER2 positive breast cancer, increased Akt activity represses FOXO3A activity 
and ER expression. Therefore, HER2 signaling dominates in the control of cell survival. 
However, the reduction in Akt signaling associated with lapatinib treatment abrogates Akt’s 
inhibitory effects on FOXO3A and increases expression of ER and caveolin 1 (which further 
enhances ER activity). Comparison of lapatinib sensitive and resistant cell lines revealed 
increased FOXO3A expression and induction of ER and PR signaling pathways in the 
resistant cell line. This increase in ER signaling switched the dominant control of cell survival 
from HER2 to ER regulated, although HER2 expression persisted and continued to be 
inhibited by lapatinib [183]. Similarly, Wang and colleagues reported increased ER signaling 
in cells with acquired resistance to lapatinib or lapatinib plus trastuzumab. However, in 
resistant cells prolonged culture with lapatinib (>6 months) resulted in a switch back from 
endocrine to HER2 driven signaling. Interestingly, trastuzumab resistance was not 
associated with enhanced ER signaling [191]. This mechanism of resistance may only be 
relevant in ER positive tumours and both these studies relied heavily on the ER positive 
BT474 cell line. However, at least within ER positive tumours, this resistance mechanism is 
likely to be more generalisable as comparison of pre- and post-lapatinib treatment biopsies 
in ER positive tumours demonstrated increased HR pathway signaling [183]. Furthermore, 
results from the phase 3 clinical trials TAnDEM and EGF30008 clearly illustrated the 
importance of dual HER2 and ER signaling pathway blockade in tumours co-expressing the 
2 receptors [132] [133] .  
 
1.7.4 Resistance associated with induction of apoptosis and 
defects in cell cycle control  
 
Several studies have linked resistance to HER2 directed therapies to changes in the 
expression of proteins involved in apoptosis. Elevated basal expression of survivin (an 
inhibitor of apoptosis) has been linked to primary [165] [192] and acquired [192] [183] 
resistance to both trastuzumab and lapatinib. This was tested clinically using microarray data 
derived from patients treated with neoadjuvant trastuzumab and docetaxel and it was 
confirmed that higher baseline survivin expression was predictive of lack of response to 
systemic therapy [164].  




In a separate series of experiments, elevated NIBP expression, which potentiates NFkappa-
β activity, was found in 11.1% of HER2 positive breast cancers [193]. Furthermore, Xia et al 
demonstrated that increased expression of RelA, the pro-survival subunit of NFkappa-β, was 
associated with acquired lapatinib resistance in vitro. Changes in phosphoRelA expression 
beween pre- and post-lapatinib treatment biopsies were of borderline significance for 
predicting therapeutic response [153].  
 
Expression of Notch 1 and its ligand, Jagged 1, are believed to contribute to the 
pathogenesis of breast tumours by inhibiting cell differentiation and promoting cell survival 
and/or proliferation. Notch 1 expression is associated with poor OS in breast cancer although 
interestingly its expression is suppressed by HER2. Treatment with trastuzumab and an 
EGFR/HER targeting TKI abrogated HER2’s suppressive effects on Notch 1 expression 
thereby driving the resistant phenotype. [194].  
 
Other studies have detected differences in apoptosis regulating proteins in resistant cell lines 
including increased expression of X-linked inhibitor of apoptosis (XIAP) [195], an increase in 
the ratio of Bcl:Bax [196], up-regulation of MCL1 and down regulation of BAX [197] [198], 
although these have not been clinically validated. Finally, baseline levels of the pro-apoptotic 
protein Bim have been found to be predictive of in vitro lapatinib sensitivity in treatment naive 
cells [199]. 
 
Changes in the expression of proteins involved in the G1/S cell cycle checkpoint have also 
been implicated in trastuzumab resistance. The cyclin E/CDK2 complex plays a critical role 
in the G1/S cell cycle check point by inducing phosphorylation of the CDK inhibitor p27 
marking it for ubiquitin mediated degradation and enabling cells to transit from the G1 to the 
S phase [200]. Trastuzumab is believed to act at least in part by inhibiting cyclin E/CDK2 
mediated phosphorylation of p27 thereby inducing a G1/S phase arrest [201]. Scaltiti found 
that cells rendered resistant to trastuzumab displayed amplification of the cyclin E gene 
[202]. Furthermore, cyclin E gene amplification in a cohort of patients treated with 
trastuzumab was associated with reduced response rates [147]. Consistent with these 
findings, Nahta observed an increase in CDK2 activity and reduced p27 expression in 
resistant SKBR3 cells, which was reversed by exogenous p27 expression [201].     




1.7.5 Resistance associated with defects in metabolic 
pathways 
 
Oncometabolics is a rapidly evolving field and further experiments are likely to demonstrate 
a huge range of changes in metabolic pathways associated with resistance. Using global 
gene expression from matched lapatinib sensitive and resistant SKBR3 cell lines, Komurov 
identified an enhanced glucose deprivation response (GDR) in the resistant cell line. In the 
drug sensitive cell line, treatment resulted in reduced glucose metabolism and impaired 
glycolysis culminating in glucose deprivation induced cytotoxicity. Resistant cells adapted to 
a chronic state of hypoglycaemia by increasing the rate of glycolysis, up-regulating the 
expression of glucose transporters, increasing amino acid and fatty acid break down and 
enhancing glycogen breakdown. Analysis of microarray data showed that markers of GDR 
correlated with a higher risk of relapse in HER2 positive breast cancer [166]. 
 
 Consistent with the increased rate of fatty acid break down seen as part of the GDR in the 
previous report, lapatinib and trastuzumab resistant BT474 xenografts exhibited greater 
sensitivity to G28UCM, a fatty acid synthase inhibitor, than their sensitive counterparts [203]. 
Finally, Griner noted that incubation of BT474 cells in adipocyte conditioned media increased 
Akt phosphorylation. The adipocytokines leptin and growth differentiating factor 15 (GDF15) 
were isolated from the conditioned media and resulted in lapatinib and trastuzumab 
resistance respectively.       
 
1.7.6 Patient specific factors associated with inherent 
trastuzumab resistance 
 
Antibody dependent cell cytotoxicity (ADCC) is well established as a major determinant of 
trastuzumab efficacy and therefore patient factors which affect this immune response have 
the potential to contribute to inherent trastuzumab resistance. Genetic polymorphisms in the 
gene encoding the FcgRIII receptor have been linked to trastuzumab efficacy [204]. 
Furthermore, leucocytes derived from patients who responded to trastuzumab demonstrated 
a higher level of in vitro ADCC than those from patients who did not respond [205]. A 
Chapter 1: Introduction     47 
 
 
subsequent study confirmed that it was the quantity and lytic efficiency of the CD16 (+) 
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1.8 Project aims 
 
The high drug attrition rates seen in late phase oncological trials are partially attributable to 
the inability of traditional preclinical models to detect ineffective agents. Even if novel agents 
are successfully adopted into clinical practice, their efficacy is usually limited as when used 
in metastatic disease, resistance is almost universally inevitable. This thesis has focused on 
the use of preclinical models, particularly GEMMs, to predict response in HER2 positive 
breast cancer. 
 
The aims of this study were: 




model of HER2 positive breast cancer. 




model to explore the potential role of dasatinib in 
the management of HER2 positive breast cancer.    
3. To characterize the MMTV-NIC model of HER2 positive breast cancer. 
4. To use the MMTV-NIC model to explore the role of PTEN in tumour growth, 
intracellular signaling and response to AZD8931. 
5. To further develop the MMTV-NIC model for use in studies exploring mechanisms of 
acquired drug resistance. 
6. To generate MMTV-NIC tumours with acquired resistance to AZD8931. 
7. To generate a panel of cell lines with acquired resistance to either AZD8391 or 
lapatinib to facilitate further study of the drug resistance mechanisms using a 
proteomic approach, incorporating western blotting, reverse phase protein array 
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2.1.1 Buffers and solutions 
 
The composition of buffers and solutions used in this study are described in table 2.1.
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PBS 1 PBS tablet, 100mL dH20. 
Trypsin 1mM EDTA, 0.25%(v:v) Trypsin (Gibco). Made up in PBS. 
Freezing medium (for 
tissue culture) 
90% (v:v) media containing 10% FBS, 10% (v:v) DMSO. 
Cryopreservation medium 
(for tumour fragments) 
50% DMEM, 50% freezing mix (90% FBS, 10% DMSO) 
Wash buffer (for 
harvesting in vivo 
tumours) 
7.5mL PBS, 2.5mL ammonium chloride solution (Stem Cell Technologies), 1 x 
Complete mini protease inhibitor tablet (Roche), 1 x Phos-stop inhibitor tablet 
(Roche). 
Digestion buffer 4mg/mL collagenase, 4mg/mL dispase, 0.25mg/mL hyaluronidase made up in 
DMEM supplemented with 1% L-glutamine but no FBS. 
0.4% SRB solution in 1% 
acetic acid  
2g SRB, 500mL acetic acid.  
10 mM Tris solution (pH 
10.5) 
1.21g Tris base, 1L dH20. Adjust to pH 10.5.  
RIPA buffer 50mM Tris pH8.0 with HCl (Melfords), 150mM NaCl, 1% (v/v) NP40 (Calbiochem), 
0.5% (w:v) Sodium Deoxycholate, 0.1% (v/v) SDS. Made up in dH20. 
Lysis buffer (for western 
blots) 
1 Complete ultra mini tablet (Roche), 1 Phos-stop tablet (Roche),10mL RIPA buffer. 
 Lysis buffer (RPPA) 1%Triton X-100, 50mM HEPES (pH 7.4), 150mM sodium chloride, 1.5mM 
magnesium chloride, 1mM EGTA, 100mM sodium fluoride, 10mM sodium 
pyrophosphate, 1mM sodium vanadate, 10% glycerol, 1x Complete ultra mini tablet 
(Roche), 1 x Phos-stop inhibitor tablet (Roche). 
6x sample buffer  2.4mL 2-mercaptoethanol, 1.3 mL 1M Tris pH6.8 with HCl (Melfords), 2.5mL 20% 
SDS,1.8mL dH20, 2mL Glycerol. 
4x RPPA sample buffer 40% glycerol, 8% SDS, 0.25M Tris HCl, (pH 6.8), 2-mercaptoethanol (1:10, v:v), 
added just before use of buffer. 
Running buffer  10x Tris-Glycine-SDS running buffer. Made in dH2O. 
TBST 6.05g Tris, 8.76g NaCl,1mL Tween 20. Make up to 1L dH20 Adjust to pH 7.6.  
TBST with 5% BSA 12.5g BSA, 250mL TBST. 
Sodium citrate retrieval 
buffer pH6 
82mL 0.1M Sodium citrate, 18mL 0.1M Citric acid. Made up in 900mL dH20 and 
adjusted to pH 6.0. 
EDTA retrieval buffer, PH8 0.372g EDTA. Made up in 1L dH20. Adjusted to pH8.0. 
Scott’s tap water 3.5g Sodium Bicarbonate, 20g Magnesium sulphate. Made up in 1L dH20. 
Mass spectrometry buffer 2.5% (v/v) acetonitrile, 0.1% (v/v) formic acid made up in dH20. 
 
Table 2.1- Composition of buffers and solutions used in this study. All reagents from 
sigma unless otherwise stated.
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2.1.2 Primary antibodies 
 
A list of the antibodies used in this research together with their dilutions for each assay can 
be found in table 2.2.
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ANTIBODY COMPANY CATALOGUE 
NUMBER 
SOURCE APPLICATION AND 
DILUTION 
ER Abcam ab16660 Rabbit IHC: 1:100,CB*
* 
PR Abcam ab62621 Rabbit IHC: 1:100,CB 
Ki-67 Vector VP-RM04 Rabbit IHC:1:500, CB 
pTyr 1248/1173 HER2/EGFR  Cell Signaling 2240 Rabbit WB 1:1000 
RPPA: 1:250 
HER2/EGFR DAKO A0485 Rabbit RPPA: 1: 500 
pTyr 992 EGFR Cell Signaling 2235 Rabbit WB: 1:1000 
IHC:1:50, EDTA**
* 
pTyr 1173 EGRF Cell Signaling 4407 Rabbit RPPA:1:1000 
EGFR Cell Signaling 4405 Rabbit WB: 1:1000 
IHC: 1:50,EDTA 
EGFR Cell Signaling 2232 Rabbit RPPA: 1:1000 
pTyr 1221/1222 HER2  
 
Cell Signaling 2243 Rabbit WB: 1:1000 
IHC: 1:400,CB 
HER2 Cell Signaling 2248 Mouse WB:1:1000 
HER2 Invitrogen AH01011 Mouse IHC:1:1000,CB 
pTyr 1289 HER3  Cell Signaling 4791 Rabbit WB: 1:1000 
IHC: 1:100,EDTA 
RPPA: 1:500 
HER3 Cell Signaling 4754 Rabbit WB:1:1000 
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Cell Signaling 9554 Rabbit RPPA: 1:250 
PTEN Cell Signaling 9188 Rabbit WB:1:1000 
IHC:1:200, CB 
PTEN Cell Signaling 9552 Rabbit RPPA: 1:500 
PI3K p110α Cell Signaling  Rabbit RPPA: 1:500 
pSer 473 Akt  Cell Signaling 4060 Rabbit WB: 1:1000 
RPPA: 1:500 
pThr 308 Akt Cell Signaling 2965 Rabbit RPPA: 1:500 
Akt Cell Signaling 9272 Rabbit WB: 1:1000 
RPPA: 1:500 
pSer2448 mTOR Cell Signaling 2971 Rabbit RPPA:1:250 
pSer2481 mTOR Millipore 09-343SP Rabbit RPPA: 1:1000 
p70 S6 kinase Cell Signaling 9202 Rabbit RPPA: 1:500 
pThr 389 p70 S6 kinase Epitomics 1175-1 Rabbit RPPA: 1:500 
pSer235,Ser236 S6  Ribosomal protein  
 
Cell Signaling 2211 Rabbit RPPA:1:1000 
pSer240,Ser244 S6 Ribosomal protein Cell Signaling 2215 Rabbit RPPA:1:250 
S6 ribosomal protein Cell Signaling 2217 Rabbit RPPA: 1:250 
GSK-3β Cell Signaling 9315 Rabbit RPPA:1:500 
pSer 21/9GSK-3 α/β Cell Signaling 9331 Rabbit RPPA: 1: 500 
pSer 9GSK-3-β 
 
Cell Signaling 9336 Rabbit RPPA: 1: 500 
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Phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr 204) 
Cell Signaling 4370 Rabbit WB:1:1000 
RPPA:1:500 
P44/42 MAPK (ERK 1/2)   
 
Cell Signaling 9102 Rabbit WB:1:1000 
RPPA:1:500 
SAPK/JNK Cell Signaling 9258 Rabbit RPPA: 1:500 
MEK1/2 Cell Signaling 9122 Rabbit RPPA: 1:1000 
pTyr 416 Src Cell Signaling 2101 Rabbit WB: 1:1000 
IHC:1:500,CB 
RPPA:1:500 
Src Cell Signaling 36D10 Rabbit WB:1:1000 
IHC: 1:500,CB 
RPPA:1:500 
FAK Cell Signaling 3285 Rabbit WB:1:1000 
pTyr397 FAK Life 
Technologies 
446246 Rabbit WB:1:1000 
pTyr 1162/1163 IGF1R-β Cell Signaling 44-804G Rabbit WB:1:10000 
RPPA: 1:500 
EphA2 Cell Signaling 6997 Rabbit  WB:10000 
pSer 897 EphA2 Cell Signaling 6347 Rabbit  WB:10000 
Ezrin Abcam  Ab50433 Rabbit WB:10000 
Stat 3 Cell Signaling 9132 Rabbit RPPA:1:500 
pTyr 694 Stat 5 Cell Signaling 9351 
 
Rabbit RPPA: 1:500 
Stat 5 Invitrogen 44-368G Rabbit RPPA:1:5000 
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c-jun, N-term  Epitomics 1254-1 Rabbit RPPA: 1:250 
pThr58,Ser62 c-myc 
 
Epitomics 1203-1 Rabbit RPPA:1:250 
c-myc Cell Signaling 5605 Rabbit RPPA: 1:250 
pSer 660 pan-PKC Cell Signaling 9371 Rabbit RPPA:1:1000 
pTyr 783 PLC-gamma1  
 
Cell Signaling 2821 Rabbit RPPA:1:250 
PLCɣ Cell Signaling 2822 Rabbit RPPA: 1:500 
pTyr 207 Crkl Cell Signaling 3181 Rabbit RPPA:1:500 
pSer465/Ser423,Ser467/Ser425 Smad 
2/3 
Cell Signaling 9501 Rabbit RPPA:1:500 
E Cadherin Cell Signaling 3195 Rabbit WB:1:1000 
IHC: 1:5000,CB 
RPPA:1:250 
Vimentin Cell Signaling 5741 Rabbit WB:1:1000 
IHC: 1:100,CB 
N Cadherin BD Bioscience 610920 Mouse WB: 1:1000 
 
Vinculin Sigma 4139 Rabbit WB:1:1000 
Fibronectin Abcam ab2413 Rabbit WB: 1:1000 
BAG3 Abcam ab7124 Rabbit WB:1:1000 
Valosin containing protein Cell Signaling 2648 Rabbit WB:1:1000 
Profilin Cell Signaling 3237 Rabbit WB:1:1000 
CDK2 Epitomics 1134-1 Rabbit RPPA: 1:250 
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pSer 216  cdc25c Cell Signaling 4901 Rabbit RPPA:1:250 
Bim Epitomics 1036 Rabbit RPPA: 1:250 
pSer69 Bim 
 
Cell Signaling 4585 Rabbit RPPA: 1:500 
Survivin Cell Signaling 2808 Rabbit RPPA: 1:250 
Cleaved caspase 3 Cell Signaling 9664 Rabbit IHC:1:200,CB 
CD31 Santa Cruz sc 1506-R Rabbit IHC: 1:10000,CB 
HIF-1α Abcam ab659791 Rabbit IHC: 1:100,CB 
GAPDH Life 
Technologies 
1209025 Rabbit WB: 1: 2500 
ɣ tubulin Sigma T-3559 Rabbit WB: 1:3000 
 tubulin Abcam ab6046 Rabbit RPPA:1:5000 
 actin Cell Signaling 4970 Rabbit RPPA: 1:1000 
 
 
Table 2.2- Antibodies and their applications. List of antibodies and the conditions for 
performing western blotting (WB), immunohistochemistry (IHC) and reverse phase 
protein array (RPPA). 
*
CB- citrate buffer, PH6, 
**
EDTA- EDTA buffer, pH8 refers to 
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2.1.3 Cell Lines 
 
Fourteen different cell lines were used in this study. The HER2 positive breast cancer cell 
lines SKBR3 and BT474 were also used to generate a further 7 cell lines, with acquired 
resistance to either lapatinib or AZD8931. A further 5 mouse cell lines were used; BLG 5957 




 model by Dr. S. Karim. MNP 
129 RM, MNP 135 RM and MNP 145 LU were generated from the MMTV-NIC PTEN
+/-
 
model by L. Balderstone. The growth conditions for all cell lines are summarised in table 2.3. 
Cell lines were maintained in tissue culture flasks, dishes and plates in a humidified 
atmosphere at 37
0
C and 5% CO2. All cell lines were routinely tested for mycoplasma and 
were negative.  
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CELL LINE SOURCE CELL TYPE MAINTENANCE MEDIA ROUTINE SUBCULTURE 
BLG-6222 S. Karim 
(Beatson Institute) 
Murine mammary carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep
1
. 
1:20 twice weekly 
BLG-5957 S.Karim 
 
Murine mammary carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep. 
1:20 twice weekly 
WGH 145LU L. Balderstone Murine mammary carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep. 
1:20 twice weekly 
WGH 135RM L. Balderstone 
 
Murine mammary carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep. 
1:20 twice weekly 
WGH 129 RM L. Balderstone Murine mammary carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep. 
1:20 twice weekly 
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SKBR3 ATCC Human breast carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep. 
1:5 twice weekly 
BT474 ATCC Human breast carcinoma RPMI (Gibco), 10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep. 
1:3 once weekly 
8931 R-SKBR3a H. Creedon Human breast carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep, AZD8931
2
. 
1:20 twice weekly 
8931 R-SKBR3b H.Creedon Human breast carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep, AZD8931. 
1:20 twice weekly 
8931 R-SKBR3c H.Creedon Human breast carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep, AZD8931. 
1:20 twice weekly 
Lap. R-SKBR3a H. Creedon Human breast carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco) pen/strep, lapatinib
3
. 
1:20 twice weekly 
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Lap. R-SKBR3b H. Creedon Human breast carcinoma DMEM (Gibco),10% FCS (Gibco), 
2mM L-glutamine (Gibco), pen/strep, lapatinib. 
1:20 twice weekly 
Lap. R-BT474a H. Creedon Human breast carcinoma RPMI (Gibco), 20% FCS (Gibco), 2mM L-glutamine (Gibco), 
pen/strep, lapatinib. 
1:20 twice weekly 
Lap. R- bt474b H. Creedon Human breast carcinoma RPMI (Gibco), 20% FCS (Gibco), 
2mM L-glutamine( Gibco), pen/strep, lapatinib. 
1:20 twice weekly 
 
1
1% Penicillin-Streptomycin combined antibiotic      
2




Table 2.3- Details of cell lines used in this study and their culture conditions.  
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2.2.1 Cell culture 
 
2.2.1.1 Cell harvesting and counting 
 
Cells were harvested when they reached 80% confluency. Adherent cells were harvested by 
aspirating off the media before washing the plate with Phosphate buffered saline (PBS), pH 
7.3. Each plate was incubated with 1mL of 0.25% trypsin in sterile 1mM EDTA for between 1 
and 5 minutes. The disaggregated cells were re-suspended in the appropriate complete 
media to give a final volume of ≥ 10mL to ensure complete inactivation of the trypsin. The 
cell suspension was aspirated several times to ensure complete cell disaggregation and 
generation of a single cell suspension. A proportion of the resulting suspension was 
transferred to appropriate tissue culture plates and dishes (Greiner bio-one) and maintained 
in complete media in a humidified atmosphere at 37
0
C and 5% CO2.  
 
Where experiments required a fixed number of cells, 10µL of the above cell suspension was 
transferred to a haemocytometer. The cell count was obtained by manually counting the 




2.2.1.2 Cryopreservation and liquid nitrogen recovery 
 
Cells to be stored in liquid nitrogen were harvested as described in section 2.2.1.1.  The cell 
suspension was centrifuged at 1300rpm for 3 minutes to generate a cell pellet. The pellet 
was re-suspended in freezing medium and on average for every 75cm
2 
of monolayer cells 
harvested, 3 liquid nitrogen stocks were generated by re-suspension of the cells in 3mL of 
freezing medium. The resulting suspension was then transferred to cryovials (Thermo 
Scientific) and placed in the -80
0
C freezer for 24 hours before being transferred to the liquid 
nitrogen tank for long term storage.   
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Cells to be recovered from liquid nitrogen were defrosted and re-suspended in 10mL of 
complete media. The resulting suspension was pelleted by centrifugation at 1300rpm for 3 
minutes. The supernatant was aspirated off and the pellet re-suspended in complete media 
before being transferred to appropriate tissue culture plates and dishes. 
 
2.2.1.3 Images of cell culture 
 
The Leica DM IL LED microscope in conjunction with the Q Imaging Retiga Exi Fast 1394 
camera was used to capture phase contrast images of cells. 
 
2.2.2 Animal husbandry and in vivo assays 
 
2.2.2.1 Breeding, genotyping and monitoring of transgenic 
mouse lines 
 





 model was carried out by staff at the animal unit of the Beatson 
Institute. BLG-Cre, HER2
KI
 and PTEN floxed mice were interbred to generate progeny with a 
knocked in HER2 transgene and loss of a single PTEN allele. These mice were crossed with 
the Z/EGFP mouse allowing the use of fluorescent imaging to follow tumour development 
[233]. This model was bred on a mixed strain background. 
 
For the MMTV-NIC model, animal husbandry, including breeding, was carried out by staff at 
the Biomedical Research Facility, University of Edinburgh.  Mice harbouring a bicistronic 
transcript expressing a constitutively activated HER2 transgene followed by an internal 
ribosome entry sequence (IRES) element and Cre recombinase under the control of the 
MMTV promoter were a gift from Prof. W. Muller (Goodman Cancer Centre, McGill 
University). These mice were cross-bred with a strain in which PTEN was floxed or not with 
loxP recognition sequences (129/J The Jackson Laboratory) to generate either MMTV-NIC 
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progeny. This model was bred on an FVB background as 
this strain is associated with high penetrance of mammary tumours. Genotyping was 
performed by Transnetyx on ear notch material from at least 14 day old mice. Any mice with 
unwanted genotypes were sacrificed using cervical dislocation. All experiments were 
conducted in compliance with UK Home Office guidelines. 
 
Nulliparous females were monitored twice weekly, using manual palpation, for tumour 
formation. The greatest tumour dimension and its perpendicular measurement were 
recorded. Once tumours had reached their maximum size (17mm in the earliest experiments 
and 15 mm in subsequent experiments as determined by Home Office regulations), mice 
were sacrificed using schedule 1 cervical dislocation. Mammary tumours and lungs were 
collected as detailed in section 2.2.2.3. 
 
2.2.2.2 Establishment of orthotopic mammary tumours 
 
Three different techniques were used to generate single mammary tumours; mammary fat 
pad (MFP) inoculation with an established murine cell line, inoculation of the MFP with 
freshly harvested disassociated mammary tumours and orthotopic transplantation of mature 
tumour fragments.   
 
2.2.2.2.1 Orthotopic implantation with established MMTV-NIC cell line (WGH 
145 LU) 
 
WGH 145LU cells were grown in T150 culture flasks before being harvested and counted as 
described in section 2.2.1.1. The resulting cell suspension was centrifuged at 1300 rpm for 3 
minutes to generate a cell pellet, which was washed twice in PBS before being re-





Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
 
Chapter 2: Materials and Methods      64 
 
 
Eight week old female athymic mice were injected in their left flank subcutaneously with 
0.05mg/kg of the analgesic buprenorphine (Henry Schein Animal Health). Isofluorane (Henry 
Schein Animal Health) at a flow rate of 5% was used to induce anaesthetization, which was 
then maintained at a flow rate of 2% throughout the procedure. The surgical field was 
cleaned with 70% ethanol and a plastic steri-drape (Millpledge Veterinary) was used to 
maintain an aseptic field. Sterile forceps were used to separate the skin from the underlying 
musculature at the level of the pubis before sterile blunt ended scissors were used to make a 
2cm longitudinal incision in the skin to the left of the midline.  The resulting skin flap was 
peeled back and pinned to a cork support to expose the underlying fourth left MFP. The MFP 
was inoculated with 50µL of the cell containing HBSS suspension (containing a total of 1*10
6
 
cells) causing the MFP to visibly engorge. Following this procedure, the skin was returned to 
its original position and secured in place using 4-5 clay adams clips applied with the EZ clip 
applier (VetTech Solutions Ltd).      
 
Post-surgery, mice were fed a diet of SDS RM1 (E) (DBM Food Hygiene) soaked in water 
and 2.5mg/kg of the anti-inflammatory carprofen (Henry Schein Animal Health) was added to 
their drinking water for 48 hours. Animals were checked and weighed daily for the first 7 
days following surgery. Tumours were subsequently measured twice weekly (section 2.2.2.1) 
and tumours and lungs collected as described below (section 2.2.2.3). 
 
2.2.2.2.2 Orthotopic transplantation with freshly harvested disassociated 
MMTV-NIC tumours  
 
Tumours for disassociation were washed in room temperature PBS and finely chopped using 
a mechanical tissue chopper (Mickle Laboratory Engineering). The minced tumour was 
suspended in digestion buffer (containing 4mg/mL collagenase, 4mg/mL dispase and 
0.25mg/mL hyaluronidase) and incubated on a shaking platform at 37
0
C for 1 hour. The 
suspension was centrifuged at 1300rpm for 3 minutes to generate a cell pellet. The 
supernatant was removed and the pellet re-suspended in 0.25% trypsin (made up in EDTA) 
and incubated at 37
0
C for 4 minutes. The trypsin was inactivated by the addition of 2% FBS 
(made up in PBS) to which 4µL of DNAase was added and incubated at room temperature 
for 2 minutes. A cell pellet was formed by centrifuging the suspension at 1300rpm for 3 
minutes. The resulting pellet was then re-suspended in and incubated with an ammonium 
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chloride containing solution (125mM ammonium chloride made up in a 1:1 PBS: FBS 
solution) for 2 minutes on ice to lyse any residual red blood cells.  After this, the cells were 
pelleted by centrifuging at 1300rpm for 3 minutes, the supernatant aspirated off and the 
pellet re-suspended in a PBS: FBS (1:1) mixture. Finally, the suspension was passed 
through a single cell filter (Stem Cell Technologies) and a cell count performed as described 
in section 2.2.1.1. The appropriate number of cells were pelleted and re-suspended in HBSS 






Disassociated tumour cells were used to inoculate the fourth left MFP of 9 to 14 week old 
virgin FVB mice. The left flank of recipient mice was shaved and injected subcutaneously 
with 0.05 mg/kg of the analgesic buprenorphine. Induction and maintenance of anaesthesia 
and exposure of the MFP was performed as described in section 2.2.2.2.1. The MFP was 




cells in 50µL HBSS before the skin flap was replaced 
and secured in place using 4-5 clay adams clips applied with the EZ clip applier. Post-
operative care was provided as described in section 2.2.2.2.1.  
 
2.2.2.2.3 Orthotopic transplantation with MMTV-NIC tumour fragments   
 
Tumours used for the generation of fragments were washed in ice cold PBS and cut into 
1mm
3 
fragments and any macroscopic necrotic areas removed. The fragments generated 
and the PBS they were suspended in were transferred to an eppendorf and centrifuged at 
450g for 1 minute. The supernatant, containing fibrous and necrotic material, was removed 
and the remaining fragments suspended in ice cold DMEM. An equal volume of freezing 
medium was then added a drop at a time before the fragments and the cryopreservation 
buffer in which they were suspended were placed in cryovials and stored at -80
0
C. 
    
At the time of transplantation, fragments were defrosted at room temperature and washed in 
PBS. The fourth left MFP was prepared and exposed as described in section 2.2.2.2.2. A 
17Fg trocar was used to insert the tumour fragment into the MFP before the surgical wound 
was closed as described above. Post-operative care was provided as described in section 
2.2.2.2.1.  
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2.2.2.3 Collection of mouse tissue 
 
Once tumours had reached their maximum permitted size, mice were culled by cervical 
dislocation. The mouse was then placed on a wooden board in a supine position with the 
limbs spread and fixed firmly in place at an angle of 45
0
 to the body. A pair of forceps was 
used to separate the skin from the underlying musculature and a pair of blunt ended scissors 
then used to make a midline incision along the length of the pelvic, abdominal and thoracic 
cavities. The resulting skin flaps were then folded back on themselves and pinned in place to 
allow direct visualisation of the mammary tumours. Prior to collection, callipers were used to 
record the longest tumour dimension and its perpendicular measurement. Tumours were 
then excised by using the scissors to carefully separate them from the surrounding tissue.  
Following excision, the weight of all tumours was recorded.  
 
Tumours for analysis by IHC were fixed in formalin (Fisher Scientific) and stained as 
described below (section 2.2.4.2). Tumours to be dissociated for generation of single 
mammary tumours were processed as described in section 2.2.2.2.2. Tumours to generate 
tumour fragments for orthotopic transplantation were processed as described in section 
2.2.2.2.3. Tumours for analysis by western blotting and RPPA were cut into fragments 
approximately 5mm
3
 in size, which were rinsed twice in ice cold wash buffer before being 
incubated for 5 minutes in fresh wash buffer to lyse red blood cells. The wash buffer was 
removed and tumours washed a further 2 times in PBS before being patted dry with tissue 
and transferred to cryovials for storage in liquid nitrogen. 
 
The lungs were harvested by cutting along the length of the sternum to open the thoracic 
cavity.  A pair of forceps was used to separate the 2 halves of the rib cage and the heart and 
lungs liberated by dissecting the main vessels. After removal from the thoracic cavity, the 
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2.2.3 Cell culture assays 
 
2.2.3.1 Cell counting experiments  
 
The effect of various conditions on cell proliferation was measured by cell counting. At the 
start of the experiment, a single cell suspension was generated and using the 
haemocytometer, as described in section 2.2.1.1, a predetermined number of cells were 
seeded into duplicate wells of a 6 or 12 well dish (termed c1). After a specified time interval 
(termed h), cells were trypsinized, a single cell suspension generated, and a further cell 
count performed (termed c2).  
 
When required, an online calculator (http://www.doubling-time.com) was used to calculate 
the cell doubling time using the formula: h*ln(2)/ln (c2/c1). 
 
2.2.3.2 Sulphorhodamine B (SRB) assay 
 
SRB assays were used to measure cell growth. Cells were seeded at a density of 1250-5000 
cells/well in 96 well plates (Greiner bio-one) and allowed to attach for 24 hours, at which 
point day 0 plates were fixed. In the remaining plates, the media was replaced with 200µL 
fresh media containing escalating doses of dasatinib (provided by Bristol Myers Squib, 
Princeton), lapatinib (SelleckChem) or AZD8931 (provided by AstraZeneca, Alderley Park) 
prepared in DMSO. All plates contained a DMSO control comprising 6 wells to which DMSO 
alone was added at an equivalent concentration to that used in the maximum drug treated 
cells to ensure that any observed cytotoxic effects were as a result of drug treatment rather 
than the cytotoxic effect of DMSO. The maximum concentration of DMSO used in any 
experiment was 1:1000. The remaining plates were fixed at allotted time points. Cells were 
fixed by the addition of 50µL of 25% cold trichloracetic acid and incubated at 4
0
C for 1 hour 
before being washed 10 times under running water and dried overnight at room temperature. 
Plates were then stained by the addition of 50µL SRB dye (0.4% w:v SRB in 1% v/v acetic 
acid) to each well and incubated at room temperature for 30 minutes. The plates were then 
washed four times in 1% acetic acid to remove any excess, non-protein bound SRB dye. The 
SRB stain was solubilised by the addition of 150µL 10mM Tris solution (pH 10.5) and 
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incubated at room temperature for 1 hour under agitation. The optical density was then 
measured at 540nm on a plate reader (Biohit). Cell numbers at each drug concentration 
were calculated as an average of 6 wells and normalized against the average value of the 
untreated control wells at the same time point.          
 
2.2.3.3 Migration assays 
 
2.2.3.3.1 Wound healing assay 
 
BLG-6222 and BLG-5957 cells were grown to confluence in a 12 well dish (Greiner bio-one). 
The monolayer was wounded using 10µL pipette tip and any detached cells removed by 
washing the plate gently 3 times with media. Cells were treated with escalating doses of 
dasatinib (ranging from 0 to 200nM) and serial images recorded every 15 minutes for 18 
hours using the automated Olympus ScanR-screening station. The cell velocity was 
calculated from the distance advanced into the wound over time using Cell R software.       
 
2.2.3.3.2 Random migration assay 
 
To determine the effects of AZD8931 resistance on random migration, parental SKBR3 and 
AZD8931 resistant cells were seeded in duplicate wells of a 12 well dish at a density of 3000 
cells/well. Cells were cultured in complete media supplemented with 10mM HEPES buffer 
(Gibco) for 16 hours and serial images recorded every 15 minutes using the automated 
Olympus ScanR-screening station. Image J software was used to calculate both the total 
distance and vectorial distance travelled by representative cells in each well during this time 
interval. Persistence was calculated using the formula: vectorial distance/ cumulative 




Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
 
Chapter 2: Materials and Methods      69 
 
 
2.2.3.4 Matrigel inverse invasion assays  
 
Transwell inserts (Corning, Fisher Scientific) containing matrigel (Becton Dickinson) were 
seeded with 400 cells in 100µL of media and incubated at 37
0
C for 4 hours. The inserts were 
then placed in 1mL of serum-free medium. Media supplemented with 10% FBS (containing 
when appropriate escalating doses of drug) was placed on top of the matrix. Seventy-two 
hours after seeding, invading cells were stained with Calcein-AM (Invitrogen) and visualized 
by confocal microscopy (Olympus FV1000). Serial optical sections were captured and 
quantified using ImageJ software using the area analysis module.     
 
2.2.3.5 Generation of AZD8931 and lapatinib resistant cell lines 
 
For a detailed description of the methods used to generate lapatinib and AZD8931 resistant 
cell lines please refer to chapter 7 sections 7.3 and 7.6 respectively. 
 
2.2.4 Methods for protein analysis 
 
2.2.4.1 Western blotting 
 
2.2.4.1.1 Sample preparation 
 
2.2.4.1.1.1 Generation of lysate and protein quantification for samples derived from 
cultured cells 
 
Cells to be analysed by western blotting were cultured in 150mm dishes. Where the effects 
of a short term drug treatment on protein expression were to be studied, the appropriate drug 
treatment was applied once the cells reached 80% confluency and cells continued to be 
cultured in the presence of the drug for a further 12 hours. Cells which had developed 
resistance to a drug were maintained in the presence of the drug until they reached a 
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confluency of 80%. The media containing the drug was aspirated off and replaced with fresh 
media containing no drug in which the cells continued to be cultured for a further 12 hours. 
For all samples, at the end of the culture period, the media was removed and the plate 
washed 3 times in ice cold PBS before being snap frozen using dry ice. Plates were stored 
at -80
0
C until an appropriate time for lysate generation. 
 
Prior to generation of lysate, the plates were defrosted on ice. The cells were lysed by the 
addition of 300µL of lysis buffer and adherent cells scraped from the surface of the dish into 
the lysis buffer and transferred into an eppendorf. The resulting cell suspension was 
incubated on ice for 15 minutes prior to centrifugation at 13200rpm for 15 minutes at 4
0
C. 
The supernatant was transferred to a fresh eppendorf and stored at -20
0
C whilst the cell 




 protein assay kit (Thermo Scientific) was used to determine the protein 
concentration of individual samples.  BCA reagent solution was prepared according to the 
manufacturers’ instructions (50% reagent A, 48% reagent B and 2% reagent C). To generate 
standard BSA samples, 800µL of BCA reagent solution was added to 1µL lysis buffer and 
escalating concentrations of BSA (ranging from 0 to 10µg/mL). To analyse the protein 
concentration of protein lysates, 1µL of an individual lysate was added to 800µL of BCA 
reagent solution. All samples were then incubated at 60
0
C for 45 minutes.  
 
To measure absorbance, 100µL of each of the above solutions was transferred to individual 
wells in a 96 well plate and absorbance read using a plate reader set at 570 nm. To generate 
a standard BSA curve, the absorbance value of each BSA standard was plotted against the 
BSA concentration. The absorbance of each protein lysate sample was then plotted on the 
standard curve and its protein concentration obtained.     
 
For each western blot, aliquots of lysate containing the same amount of total protein were 
prepared for each sample. Samples contained either 20µg or 40µg of protein depending on 
the abundance of the protein of interest and the affinity of the primary antibody. Sample 
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volumes were equalized using lysis buffer and 6x sample buffer added. Samples were 
denatured at 95 
0
C for 5 minutes and then briefly centrifuged. 
 
2.2.4.1.1.2 Generation of lysate and protein quantification for samples derived from 
tumours 
 
At the time of lysate preparation, a piece of each tumour, approximately 8mm in length, was 
placed in a pre-cooled matrix A-tube (MP biomedicals). These tubes contained a garnet 
matrix and a ceramic sphere and using the FastPrep 24 system, the tumour sample was 
ground down to a fine powder. Following the addition of RPPA lysis buffer, the mixture was 
incubated for 30 minutes at room temperature on a shaking platform and then centrifuged for 
10 minutes at 13200 rpm at 4 
0
C.  The supernatant was collected into micro-centrifuge tubes 
and its protein content determined using a Bradford assay. Standard BSA samples were 
generated as part of the Bradford assay by adding 5µL of RPPA lysis buffer to PBS and 
escalating concentrations of BSA (ranging from 0 to 0.6mg/mL) to give a final combined total 
volume of 100µL. The samples were diluted 1:20 with PBS and 10µL transferred to duplicate 
wells in a 96 well plate. For each sample to be analysed, 10 µL of the lysate was transferred   
to duplicate wells of a 96 well plate. 240µL of Coomassie Plus Protein Assay (Thermo 
Scientific) was then added to each well and the plate incubated at room temperature for 10 
minutes. Absorbance was read using the plate reader set at 570nm. A standard BSA curve 
was generated by plotting the absorbance value of each BSA standard against its BSA 
concentration. The absorbance of each protein lysate sample was then plotted on the 
standard curve and its protein concentration obtained. 
 
The protein concentration of each sample was adjusted to 2mg/ml by the addition of extra 
lysate buffer. 4xSDS (RPPA) sample buffer was then added and samples boiled for 5 




2.2.4.1.2 Protein electrophoresis 
 
Proteins were electrophoretically resolved using a precast 4-15% mini protean TGX precast 
gel (Biorad Life Science) and running buffer (Biorad Life Science). 5µL precision plus protein 
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dual colour standard marker (Biorad Life Science) was run on all gels to facilitate 
identification of the band of interest. Gels were run at 240V for 40 minutes. 
 
2.2.4.1.3 Western blot transfer 
 
Proteins were transferred to a nitrocellulose membrane using the trans-blot turbo transfer 




After transfer, the membrane was blocked with TBST-BSA (5%) for 1 hour at room 
temperature whilst constantly being agitated. The primary antibody in TBST-BSA (5%) was 
then added and the membrane incubated overnight at 4
0
C with constant agitation.  
 
The membrane was then washed 4 times in TBST, each for a period of 5 minutes, and then 
incubated with horseradish peroxidase conjugated secondary antibodies (New England 
Biolabs) in TBST-5% BSA for 45 minutes. HRP anti-mouse antibody was used at a 
concentration of 1:5000 and HRP anti-rabbit antibody was used at a 1:3000 concentration. 
The membrane was then washed a further 4 times in TBST and ECL (Biorad Life Sciences) 
reagent added for 2 minutes. The proteins were visualized using the Biorad Chemi Doc MP 




Bands on western blots were quantified using Image J software. Briefly, the corrected 
intensity of the band of interest was calculated by subtracting the background intensity from 
the intensity of the band of interest. This process was repeated for the tubulin loading control 
band and used to calculate the normalized intensity of the band of interest by dividing the 
corrected intensity of the band of interest by the corrected intensity of the tubulin loading 
control.  
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2.2.4.2 Immunohistochemistry (IHC) 
 
Formalin fixed specimens were paraffin embedded, cut at 4µm sections and stained with 
haematoxylin and eosin (University of Edinburgh Histology Services). Additional blank 
sections were requested for IHC.  
 
Unstained sections were dewaxed by washing twice in xylene (Fisher Scientific) for 5 
minutes each. They were then rehydrated by 2 minute washes in a series of reducing 
concentrations of ethanol (99%, 99%, 80% and 50%) and then washed briefly in tap water.  
Antigen retrieval was performed by microwaving sections under pressure for 5 minutes in 
either pH 6 citrate buffer or pH8 EDTA buffer (for a full list of antigen retrieval buffers used 
with individual antibodies see table 2.2).  Once cool, sections were washed briefly in tap 
water and outlined using an ImmEdge Hydrophobic barrier pen (Vector Laboratories). 
Sections were then incubated with peroxidase block (DAKO) for 10 minutes to quench 
peroxidase activity. The peroxidase block was then removed and sections were incubated 
with serum free protein block (DAKO) for 30 minutes to eliminate non-specific background 
staining, except for when the primary antibody being used was PTEN. When PTEN was the 
primary antibody, 5% FBS (made up in PBS) was used as the secondary block. Sections 
were then incubated with the primary antibody overnight at 4
0
C at concentrations optimized 
for each antibody and tumour type (see table 2.2). All experiments included a negative 
control section, comprising a tumour section incubated in the absence of primary antibody to 
confirm the specificity of any staining observed.  
 
After incubation with the primary antibody, sections were washed twice in TBST, each for a 
period of 5 minutes, and incubated with mouse/rabbit Envision (DAKO) for 30 minutes at 
room temperature to amplify the signal. Sections were then washed a further 2 times in 
TBST before incubation with 3,3’ diaminobenzidine solution (DAB, DAKO) to enable 
detection of positive staining. Slides were then washed in water and counterstained in 
haematoxylin (Sigma) and Scott’s tap water. Finally, the sections were dehydrated with 2 
minute washes in a series of increasingly concentrated ethanol solutions (50%, 80%, 99% 
and 99%) and washed twice for 5 minutes each in xylene before being mounted with 
coverslips (Thermo Scientific) using di-n-butyl phthalate in xylene (DPX) mounting medium 
(Fisher Scientific). 
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The slides were viewed by light microscopy using an Olympus BX51 microscope and 
pictures captured using a DP73 camera with cellware software (Olympus).      
  
2.2.4.3 Reverse Phase Protein Array (RPPA) 
 
2.2.4.3.1 Preparation of samples 
 
2.2.4.3.1 .1 Preparation of cell lysate from frozen tumour samples for RPPA 
  
See section 2.2.4.1.2. 
2.2.4.3.1.2 Preparation of cell lysate from cultured cell lines for RPPA 
 
Cells were cultured in vitro and at approximately 80% confluence, snap frozen. The plates 
were subsequently defrosted on ice and washed twice in PBS prior to incubation with ice 
cold RPPA lysis buffer for 20 minutes. Adherent cells were scraped off into lysis buffer and 
then transferred into microcentrifuge tubes (Greiner Bio-One). The lysate was centrifuged at 
1400 rpm for 10 minutes at 4
0
C. The resulting lysate was transferred to a fresh eppendorf 
and the cell pellet was discarded. The protein concentration of the lysate was determined 
using a Bradford assay (see section 2.2.3.2.1.2). The concentration of the lysate was then 
adjusted to 1mg/ml by the addition of additional lysate buffer as required. Aliquots of each 
sample containing a fixed amount of total protein were transferred to eppendorfs and 4x SDS 
(RPPA) sample buffer added to the lysate. The samples were boiled at 95
0
C for 5 minutes to 
denature the proteins.  
 
2.2.4.3.2  RPPA 
 
Samples were analyzed by K. Macleod. To facilitate quantification, lysates were serially 
diluted to produce a dose curve comprising 4 2-fold dilutions of each sample (1.5, 0.75, 
0.375 and 0.1875 mg/ml). The diluted concentration series of each sample was then spotted 
onto nitrocellulose slides (Grace bio) in triplicate under conditions of constant 70% humidity 
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using the Ausha 2470 array platform. The slides were hydrated in blocking buffer (Thermo 
Fisher Scientific) for 1 hour at room temperature and then incubated for 18-24 hours with 
primary antibodies, which had previously been validated for use in RPPA (for a full list of 
primary antibodies used see table 2.2). 
 
Slides were subsequently incubated with anti-Rabbit Dy light-800 conjugated secondary 
antibody (New England Biolabs) for 1 hour and then washed 3 times in TBST. The slides 
were read on the Innopsys 7101R scanner and images acquired at the highest gain without 
saturation of the fluorescent signal.  
 
Mapix software was used to analyse RPPA data and to calculate the Relative Fluorescent 
Intensity (RFI) each sample replicate and to calculate the linear fit through each sample’s 
dose curve.  Where possible, the ratio of the signal from phosphorylated to 
unphosphorylated antibodies was calculated to give a measure of the activation of a specific 
protein across all samples [206]. All other signal intensities were normalized using the global 
normalization technique [40].   
 
2.2.4.4 Mass spectrometry 
 
2.2.4.4.1 Sample preparation 
 
Parental SKBR3 and AZ8931 R-SKBR3c cells were cultured (in the absence of drug) in 
triplicate in 150mm tissue culture plates. When cells reached confluence, the medium was 
removed, the plates washed 3 times in PBS and adherent cells scraped into 1mL of PBS. 
The cells were pelleted by centrifugation at 13200rpm for 15 minutes. The supernatant was 
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2.2.4.4.2 Sample digestion 
 
Samples were processed and analyzed by Dr. T. Le Bihan. Cell pellets were reconstituted in 
250µL of 8M urea, 25 µL of 1M ammonium chloride and 25 µL of 200mM dithiothreitol (DTT) 
to denature and reduce the samples. Samples were incubated at room temperature for 30 
minutes before cysteine alkylation was performed by the addition of 25 µL of 500mM 
iodoacetamide for 1 hour. Samples were incubated overnight at room temperature in the 
presence of 10µg of trypsin to allow sample digestion. The resulting peptide extracts were 
then cleaned on an SPE reverse-phase Bond Elut LMS cartridge (Agilent) and an aliquot of 
10 µg of digest was dried under low pressure (SpeedVac; Thermo Jouan) and stored at -
20
0
C. The aliquots were subsequently re-suspended in 5 µL of 2.5% (v/v) acetonitrile, 0.1% 
(v/v) formic acid in water to give a final concentration of 1 µg/µL. The samples were then 
filtered using a Millex filter (Millipore) before being subjected to high-performance liquid 




Nano-HPLC-MS was performed using an on-line system consisting of a nano-pump (Dionex 
Ultimate 3000; Thermo Fisher Scientific) coupled to a Q Exactive instrument (Thermo Fisher 
Scientific) with a 300µm x 5mm pre-column (5µm particle size, Acclaim PepMap; Thermo 
Fisher Scientific) connected to a 75 µm x 50cm column (3µm particle size, Acclaim PepMap; 
Thermo Fisher Scientific). Samples were analyzed on a 2-hour gradient using data-
dependent analysis with one 70k-resolution survey scan followed by the top five MS/MS 
scans at 17.5k resolution.     
 
2.2.4.4.4 Label-free quantification 
 
Progenesis (version 4.1; Nonlinear Dynamics) was used for HPLC-MS label-free 
quantification. Only MS peaks with a charge of 2+, 3+ or 4+ were included in the total 
number of features (defined as the signal at a given retention time and mass:charge ratio) 
and only the 5 most intense spectra within each feature were included in the analysis. 
Normalization was performed based on the sum of the ion intensities of these sets of multi-
charged ions (i.e. 2+, 3+ and 4+) and an abundance value for an individual protein was 
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subsequently calculated by addition of the unique peptide ion intensities for the given 
protein. As this method detects a substantial number of low-abundance peptides, which 
generate near-zero intensities, log transformation was unsuitable for this dataset. Therefore, 
abundance values were transformed using an ArcSinH function. Transformed abundance 
values were used to calculate mean values for the parental SKBR3 and AZD8931R-SKBR3c 
cell lines and from this the fold change for expression of individual proteins within the 
AZD8931R-SKBR3c cell line relative to the parental SKBR3 cell line was calculated. P 
values were calculated using one-way ANOVAs based on the transformed values. Proteins 
were defined as demonstrating significant differences in expression when the following 
conditions were met: i) the number of detected peptides which were used in quantification 
was ≥ 2, ii) absolute fold change was ≥ 2, iii) calculated pair-wise p value was < 0.05. 
 
2.2.4.4.5 Protein identification 
 
MS data were searched using MASCOT software (version 2.4; Matrix Science) against both 
the Homo sapiens and Mus musculus subsets of the NCBI protein database to identify the 
proteins from which the identified peptide sequences were most likely to be derived. 
Features included in all searches were: i) variable methionine oxidation, ii) fixed cysteine 
carbamidomethylation, iii) precursor ion mass tolerance of 10 ppm, iv) product ion mass 
tolerance of 0.05 amu, v) significance threshold (p) below 0.05 (MudPIT scoring), vi) final 
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Chapter 3: The effect of dasatinib on tumour 










The non-receptor tyrosine kinase Src has attracted considerable attention as a potential 
therapeutic target in the management of solid cancers. However, despite compelling 
evidence for its role in the regulation of several critical processes in tumour development and 
the availability of dasatinib, a Src family kinase (SFK) inhibitor with proven efficacy in 
haematological malignancies, the results of clinical trials in solid tumours to date have been 
disappointing.    
 
Src is involved in integrating signals from growth factor receptors and integrins and has been 
implicated in several fundamental processes involved in the malignant phenotype, including 
cell proliferation, invasion, migration and angiogenesis [207] [208]. Increased Src expression 
and activity has been observed in numerous different tumour types [209], including breast 
cancer, where it has been linked to reduced OS [210] [211]and shown to play a central role 
in multiple intracellular signalling pathways associated with breast cancer development. For 
example, Src and ER reciprocally moderate each other’s activity [212]and several preclinical 
studies have shown that combining Src inhibitors with anti-hormonal treatment resulted in 
greater inhibition of cell proliferation and delayed the onset of drug resistance [213] [214]. 
Src has also been implicated in signalling downstream of HER family receptors [215] and 
was recently identified as a common factor in a number of independent signalling pathways 
leading to trastuzumab resistance [155].   
 
 
The data in this chapter has been previously been published in: 
Karim S, Creedon H, Patel H, Carragher N, Morton JP,Muller WJ et al. Dasatinib 
inhibits mammary tumour development in a genetically engineered mouse model. J. 
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Dasatinib is a small molecule inhibitor, which in addition to inhibiting SFK, inhibits several 
other kinases including BCR-ABL, c-Kit and platelet-derived growth factor receptor (PDGFR) 
[217]. It is licensed for use in imatinib-resistant chronic myeloid leukaemia (CML) and 
Philapdelphia chromosome positive acute lymphoblastic leukaemia (ALL), and has 
transformed both the management and outlook of these conditions. Looking at dasatinib’s 
activity in solid tumours, results from both in vitro [218], [219] [220] and in vivo studies [220], 
[88], [221] suggest that inhibition of invasion and migration is its dominant mechanism of 
action in most tumour types, whilst inhibition of proliferation was observed in a more 
restricted subset of tumours. However, clinical trials using any one of several SFKs in breast 
cancer have yielded disappointing results [222] [17]. Several studies did describe isolated 
cases of prolonged disease stabilization or partial responses suggesting that whilst there 
may well be a role for SFK inhibitors in the management of breast cancer, when and in which 
patients to use them remains to be determined.  
 
 One potential explanation for SFKs apparent lack of clinical activity may be that to date 
clinical trials have focussed exclusively on their use in metastatic cancer whilst preclinical 
data suggests they may be more efficacious in early disease. We therefore decided to 
explore dasatinib’s activity in a GEMM of breast cancer, focussing predominantly on its use 




 model for these experiments as 
not only is Src implicated in HER2 signalling but patients with early HER2 positive breast 
cancer remain at increased risk of local [223] and distant, particularly central nervous system 
[224], recurrences despite the introduction of adjuvant trastuzumab. There is therefore an 
urgent need to develop new therapies in this field.  
 
Specific aims of this section of the project included: 





2. Determining the impact of single agent dasatinib on mammary tumour development 





3. Exploring the mechanism of action of dasatinib on HER2 positive cancer cells both 
in vitro and in vivo. 
4.  Describing the effect of dasatinib on intracellular signalling pathways in HER2 
positive breast cancer cells.  
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3.1 Model background 
 
In this model, tumourigenesis is driven by a HER2 transgene (herein referred to as HER2
KI
), 
which has been rendered constitutively active by a valine to glutamine substitution at position 
664 in the transmembrane domain [225]. The exact details of how this substitution results in 
a persistently activated receptor is not yet fully understood, although it is thought to alter the 
relative orientation of HER2 monomers in a predimerized state favouring the development of 
an activated receptor homodimer complex [226]. When this transgene was coupled to the 
MMTV promoter and injected into 1 cell mouse embryos, the resulting progeny demonstrated 
mammary specific expression of the transgene with subsequent development of multiple 
synchronous mammary tumours [225]. HER2 transgene expression was critical for 
mammary transformation but concern that the use of the viral MMTV promoter might 
compromise the model’s physiological relevance drove the development of an alternative 
model in which the trangenes expression remained under the control of the endogenous 
HER2 promoter. Analysis of the resulting tumours confirmed that this model recapitulated 
many of the molecular features seen in human HER2 positive disease with a strong 
correlation between genomic amplification of the HER2 transgene and HER2 expression and 
co-amplification of many of the same genes as is seen in human disease. However, the 
prolonged tumour latency and poorly-invasive nature of these tumours limited the utility of 
this model [227].   
 
Loss of the tumour suppressor gene PTEN is a common event in all cancers and is observed 
in up to 50% of cases of breast cancer, where it is considered a marker of poor prognosis 
[104] [228]. Specifically within HER2 breast cancer, loss of PTEN expression is seen in 
between 25% [229] and 50% [104] of cases. Although preclinical studies have linked its loss 
to trastuzumab resistance [230] this has yet to be confirmed clinically [150]. PTEN acts as a 
negative regulator of the Akt pathway and therefore its loss affects a range of processes 
including cell proliferation, survival, motility and stem cell self-renewal [231]. When mice 
bearing the HER2 transgene under the control of the HER2 promoter were crossed with a 
strain containing a floxed PTEN allele, the resulting mammary specific PTEN loss resulted in 
accelerated tumour development and progression and higher incidence of metastases [231].  
Our lab has experience of using the Cre-recombinase system under the control of the β-
lactoglobulin enhancer (BLG-Cre) to trigger mammary specific Cre-mediated recombination 
Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
 
Chapter 3: The effect of dasatinib on tumour development in the BLG-HER2KI PTEN+/- model      81 
 
 
resulting in knock down of adenomatous polyposis coli (APC) [232]. We therefore elected to 
cross-breed transgenic mice harbouring the HER2
KI
 transgene and Cre-recombinase under 
the control of the BLG-promoter with a strain containing a floxed PTEN allele. The progeny 
which had mammary specific expression of the HER2 transgene and a floxed PTEN allele, 
were crossed with the Z-EGFP model enabling mammary tumour development to be 
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genotype. A: Transgenic mice bearing the 
constitutively activated HER2 transgene (under the control of the HER2 promoter) and 
BLG-targeted Cre-recombinase were crossed with mice containing a floxed PTEN 
allele. B: The resulting progeny were crossed with the Z-EGFP model to enable 
tumour development to be followed by fluorescent imaging.   
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3.2 Model characterisation 
 
3.2.1 Tumour development and growth in the BLG-






 mice were monitored twice weekly for tumour development and 
progression by palpation. Tumour onset was defined as the presence of a palpable tumour. 
Once tumours reached a diameter ≥ 1.7 cm in any direction, the animal was sacrificed. 
 
All animals (n=24) developed unifocal mammary tumours with a median age of onset of 473 
days (Figure 3.2A). Following tumour development, the median duration of survival was 42 
days (Figure 3.2B) (S. Karim). We observed considerable variability in the timing of both 
tumour onset and survival following tumour development, which is reflective of the highly 
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 mice were monitored for tumour development and 
progression. A: Age at onset of palpable disease.  B: Duration of survival following 
development of palpable disease.  
 
 
Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
 
Chapter 3: The effect of dasatinib on tumour development in the BLG-HER2KI PTEN+/- model      85 
 
 
3.2.2 Characterization of BLG-HER2KI PTEN+/- tumours 
 
3.2.2.1Histology of BLG-HER2KI PTEN+/- tumours 
 
Histological review of this tumour series (n=11) confirmed that they were comprised of 
moderately to poorly differentiated adenocarcinomas (Prof. B. Gusterson, pathologist). 
Lung metastases were identified in 18% (n=2) of animals when non-serial lung sections were 
examined. In both animals with evidence of metastatic disease, the metastases had the 
same histomorphology as the matched primary tumour (Figure 3.3) (Prof B. Gusterson). 
 
3.2.2.2 IHC characterization of BLG-HER2KI PTEN+/- tumours 
 
We used IHC to further characterize these tumours. Using a HER2 antibody at a 





tumours. However, expression was substantially reduced compared to expression in the 
MMTV-NIC PTEN
+/-
 model, an alternative model of HER2 positive breast cancer (see 
chapter 4), which showed strong staining at an antibody concentration of 1:1000 (Figure 
3.4). Tumours were negative for both oestrogen receptor (ER) and progesterone receptor 
(PR).  
 
We also performed IHC using a Ki67 antibody (S. Karim), an established marker of cell 
proliferation [234]. When sections were manually scored for Ki67 expression, we observed 
considerable variation in the percentage of Ki 67 positive nuclei within individual tumours 
with actively proliferating cells found predominantly at the periphery of tumours and 
quiescent cells located more centrally (Figure 3.5). The mean percentage of Ki67 positive 
nuclei was 24.10%.  The peripheral distribution of actively proliferating cells may reflect 
vascular insufficiency with more centrally located cells reliant on diffusion from peripherally 
located blood vessels and the resulting paucity of nutrients forcing cells into a quiescent 
state. 
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Figure 3.3- Matched mammary tumours and lung metastases displayed the same 
histomorphology. Representative H and E sections of a mammary tumour and its 
corresponding lung metastases. Mag x40, scale bar represents 100μM. 
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 tumours were HER2 positive but hormone receptor 
negative. IHC was performed with HER2, ER and PR antibodies on paraffin embedded 




 tumours (n=3). Positive control for HER2 comprises 
section of MMTV-NIC PTEN
+/- 
tumour incubated with HER2 antibody at concentration 




 tumours).    
Positive controls for ER and PR comprise sections of human hormone receptor 
positive breast cancer stained with the appropriate antibody. Mag x40. Scale bar 
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 tumours. IHC was 




 tumours with a Ki67 
antibody. Images were manually analysed to calculate the percentage of Ki67 positive 
nuclei in three low power fields (mag x20) per tumour. A: Box and whiskers plot of 
percentage Ki67 positive nuclei (n=4). B: Representative images of IHC staining for 
Ki67 showing regions of low (i) and higher (ii) proliferation. Mag x20. Scale bar 
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3.3 Effect of dasatinib treatment on tumour initiation and 
progression in the BLG-HER2KI PTEN+/- model 
 
We randomized cohorts of mice at the age of 8 weeks, prior to mammary tumour 
development, to either dasatinib (n=9) or vehicle (n=11) treatment. Mice received daily 
treatment with dasatinib (100mg/kg) suspended in citrate buffer or vehicle. Animals were 
monitored twice weekly for tumour development and progression and sacrificed once the 
maximum tumour diameter had reached 1.7cm, in accordance with the project license (S. 
Karim).   
 
We observed a statistically significant delay in tumour initiation in dasatinib treated animals 
(Figure 3.6A). The median age of tumour onset in drug treated mice was 585 days compared 
to 467 days in the vehicle treated cohort (p=0.046, Wilcoxon signed rank test). OS, 
measured from the date of birth until the date of death, was also increased in drug treated 
animals, although this did not reach statistical significance (Figure 3.6B). The median OS 
was 692 days in the dasatinib treated cohort and 624 days in the vehicle treated cohort 
(p=0.06, Wilcoxon signed rank test). This increase in OS was attributable to the delay in 
tumour onset as there was no difference in the survival following tumour development in the 
2 cohorts (Figure 3.6c). Median survival following tumour development was 39 days in drug 
treated animals and 42 days in vehicle treated animals (p=0.284, Wilcoxon signed rank test).  
The majority of mice (85%) developed a single tumour whilst the remainder developed a 
small secondary tumour in a separate mammary fat pad (MFP).     
 
Dasatinib did not appear to influence the incidence of lung metastases. In vehicle treated 
animals 18% (n=2) developed lung metastases compared to 22% (n=2) in the dasatinib 
treated arm. Although the low number of animals with metastatic deposits limited our ability 
to draw any conclusions from this experiment, the difference in the number of metastases 
found in the dasatinib and vehicle treated animals was striking. Vehicle treated animals with 
metastases had multiple lesions (23 and 35) whilst considerably fewer lesions were 
observed in the dasatinib treated animals (2 and 4). This could suggest that although 
dasatinib did not appear to influence tumour cell invasion and migration, it might influence 
the ability of cells to colonize secondary tumour sites. 
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 mice but did 




 mice were randomised to 
treatment with daily dasatinib or vehicle and tumour response monitored. A: Age of 
tumour onset in vehicle (n=11) and dasatinib (n=9) treated mice. p=0.046, Wilcoxon 
signed rank test. B: Overall survival in vehicle and dasatinib treated mice. p= 0.06, 
Wilcoxon signed rank test. C: Survival from time of tumour onset in vehicle and 
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3.4 Effect of dasatinib on tumour differentiation 
 
Histological examination of tumour sections revealed that dasatinib had a marked impact on 
tumour differentiation. In addition to the moderately to poorly differentiated adenocarcinoma 
found in vehicle treated tumours, 66% (n=6) of dasatinib treated tumours also contained 
prominent squamous metaplastic elements. In 5 of these tumours, squamous metaplasia 
occupied over 80% of the section and in one tumour both epidermal elements, consisting of 
keratin whorls and stratified squamous epithelium, and sebaceous elements were present 
(Figure 3.7). Again, examination of both matched primary tumours and their metastases 
revealed preserved tumour histomorphology, irrespective of the treatment group (Prof. 
Gusterson) (Figure 3.8). 
 
To confirm the squamous nature of the metaplastic regions, we performed IHC with a CK5 
antibody, a marker of stratified squamous epithelia [235]. Little or no CK5 expression was 
observed in vehicle treated tumours whilst dasatinib treated tumours exhibited prominent 
expression in the basal layer of the glandular tumour (S.Karim) (Figure 3.9). Squamous 
metaplasia has previously been linked to mammary-specific activation of Wnt, specifically β-
catenin stabilization [236], [237]. Using IHC, we demonstrated low level β-catenin expression 
in vehicle treated tumours. Within the dasatinib-treated tumours, we observed increased 
expression in both the nuclei and at cell-cell junctions within regions of squamous 
metaplasia. In particular nuclear expression of β-catenin was observed in regions 
surrounding keratinized zones suggesting that increased β-catenin activity may have driven 
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Figure 3.7- Representative H&E sections of vehicle and dasatinib treated tumours. i: 
low powered view of vehicle and dasatinib treated tumours (mag x20). The vehicle- 
treated tumour comprised poorly differentiated (asterix) and glandular (arrowhead) 
elements. The dasatinib-treated tumour contained glandular elements (arrowheads), 
sebaceous elements (red asterix) and keratin whorls (arrow). Scale bar represents 100 
μm. ii: high powered view of vehicle and dasatinib treated tumours. Mag x40. Scale 
bar represents 100 μm (Prof. Gusterson). 
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Figure 3.8- Representative H & E sections of matched primary and secondary tumours 
from vehicle and dasatinib-treated animals. Lung metastases demonstrated the same 
histomorphology as the corresponding primary tumour in both vehicle and dasatinib-
treated animals. Mag x40. Scale bar represents 100 μm (Prof. Gusterson). 
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Figure 3.9- Representative images of IHC sections demonstrating increased CK5 
expression in dasatinib treated tumours. IHC was performed on paraffin embedded 
sections of vehicle and dasatinib treated tumours with a CK5 antibody. Mag x40. Scale 
bar represents 100 μm (S. Karim). 
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Figure 3.10-Representative images of IHC sections demonstrating increased β –
catenin expression in dasatinib treated tumours. IHC was performed on paraffin 
embedded sections of vehicle and dasatinib treated tumours with a β –catenin  
antibody. β –catenin expression was expressed at cell-cell junctions (arrows) and in 
the nucleus (arrowhead) in dasatinib treated tumours.  Mag x40. Scale bar represents 
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3.5 Effect of dasatinib on Src kinase activity 
 
As well as inhibiting Src, dasatinib inhibits several other kinases, including BCR-ABL, c-Kit 
and PDGFR [217]. We therefore performed IHC with a pTyr416 Src antibody, a frequently 
used biomarker of Src activation, to confirm that the effects we observed in vivo reflected 
reduced Src activity. Quantification of pTyr416 Src expression was complicated by both 
considerable inter- and intra-tumoural variability in expression. However, we did observe a 
reduction in p Tyr 416 Src expression in dasatinib treated tumours although this did not 
reach statistical significance (Figure 3.11). The median p Tyr416 Src histoscore in dasatinib-
treated tumours was 7.5 compared to 190 in vehicle-treated tumours   (p= 0.103, Mann 
Whitney U test). Total Src expression was increased in dasatinib-treated tumours, although 
again this failed to reach statistical significance. The median Src histoscore in dasatinib-
treated tumours was 285 and 140 in vehicle-treated tumours (p=0.110, Mann Whitney U 
test). Although we cannot be certain that the inhibition of other kinases did not contribute to 
dasatinib’s effects on mammary tumour initiation, this data suggests that Src inhibition is at 
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Figure3.11- Dasatinib treatment resulted in reduced Src activity. IHC was performed 
on paraffin embedded sections of dasatinib and vehicle treated tumours with p Tyr 
416 Src (n=5 in each treatment group) and total Src antibodies (n=4 in each treatment 
group). The histoscore was calculated as the sum of the product of percentage cells 
stained by the intensity graded from 0-3, where 1=weak, 2=moderate and 3=strong 
staining (histoscore = (% *1) + (% *2) + (% *3)). A: IHC analysis of pTyr 416 Src 
(p=0.103, Mann Whitney U test) and Src (p=0.110, Mann Whitney U test) in dasatinib 
and vehicle treated tumours. B: Representative IHC images of vehicle and dasatinib 
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3.6 Effect of dasatinib on tumour cell proliferation and 
apoptosis 
 
Ki67 is a frequently used marker of cell proliferation [234] and has been validated as 
prognostic marker in breast cancer with high scores (>20%) associated with reduced 
disease free and overall survival [238]. To further explore dasatinib’s mechanism of action, 
we performed IHC with a Ki67 antibody (S. Karim). We found that the majority of cells with 
Ki67 positive nuclei were found at the periphery of both dasatinib and vehicle treated 
tumours, whilst few actively proliferating cells were seen more centrally. Comparison of the 
percentage of Ki67 positive nuclei found within 3 peripheral regions of both dasatinib and 
vehicle treated tumours showed no significant difference in the proliferative capacity of the 2 
cohorts (Figure 3.12).The median percentage Ki67 positive nuclei was 20.8% in vehicle 
treated tumours and 20.05% in dasatinib treated tumours (p=0.736, Mann Whitney U test).   
 
We also performed IHC with an antibody to cleaved caspase 3, a frequently used biomarker 
of apoptosis [239]. There was no evidence of significant apoptosis in either dasatinib or 
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Figure 3.12- Dasatinib treatment did not inhibit tumour cell proliferation. IHC was 
performed on paraffin embedded sections of dasatinib (n=6) and vehicle treated (n=4) 
tumours with a Ki67 antibody. Images analysed manually to calculate percentage 
nuclei positive for Ki67 in 3 randomly selected low power fields (mag x20) per tumour. 
A: Box–whisker plot analysis of percentage of nuclei positive for Ki67 (p=0.736, Mann 
Whitney U test). B: Representative IHC images of vehicle and dasatinib treated 
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Figure 3.13- Dasatinib treatment did not result in apoptosis. IHC was performed on 
paraffin embedded sections of dasatinib (n=4) and vehicle (n=2) treated tumours. 
Positive control consists of 4T1 cells subcutaneously implanted in an FVB mouse and 
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tumours (S. Karim). Although both cell lines were 
derived from vehicle treated tumours, they exhibited heterogeneity in expression of some 
key receptors and signalling molecule (Figure 3.14). For example, expression of pTyr 416 
Src expression was substantially increased in the first of these cell lines (BLG-6222) 
compared to expression in the second cell line (BLG-5957). We also observed greater Akt 
activity in the BLG-6222 cell line than in the BLG-5957 cell line. However, neither cell line 
expressed EGFR and unlike other mouse models of HER2 positive breast cancer (see 
chapter 4), both cell lines retained PTEN, which may have contributed to the long tumour 
latency observed during the in vivo study.  
 
3.8 Effect of dasatinib on cell proliferation in vitro 
 
As both cell lines continued to express Src, we decided to explore their sensitivity to 
dasatinib. Interestingly, in marked contrast to our observations in vivo, both BLG-6222 and 
BLG-5957 cell lines demonstrated dose-dependent inhibition of proliferation in response to 
dasatinib treatment with an IC50 of 85.9 nmol and 75.0 nmol respectively (Figure 3.15A). 
Using western blotting, we demonstrated a reduction in Src phosphorylation at 
concentrations which inhibited cell proliferation, despite an increase in total Src expression 
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 derived cell lines by western 
blotting demonstrating heterogeneity in expression of key receptors and signalling 
molecules between the 2 cell lines derived from vehicle treated tumours. 20μg protein 
loaded in each lane. A431 used as positive control for EGFR. MDA-MB 231 used as a 
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 cell lines resulted in dose 
dependent inhibition of proliferation and reduced Src activity. A. 2000 cells were 
plated out in each well of a 96 well plate and treated with escalating doses of 
dasatinib. After 72 hours an SRB assay was performed. Data was analysed using 
GraphPad Prism 6 software. Error bars represent SEM across 6 wells treated at the 
same drug dose within 1 experiment. IC50 85.9 nmol in BLG-6222 and 75.0 nmol in 
BLG-5957. B: BLG-6222 and BLG-5957 cells were incubated overnight with escalating 
doses of dasatinib before being used to generate cell lysate for western blotting. 20μg 
protein loaded in each lane. Actin used as loading control. 
Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
 
Chapter 3: The effect of dasatinib on tumour development in the BLG-HER2KI PTEN+/- model      104 
 
 
3.9 Effect of dasatinib on in vitro cell migration  
   
Previous studies have shown that dasatinib is capable of inhibiting cell migration in a number 
of different tumour types [219], [218]. Using wound healing assays, we demonstrated that 
dasatinib treatment resulted in a dose dependent inhibition of migration in both BLG-6222 
and BLG-5957 cell lines with significant reductions in the velocity of migration (BLG-6222 
p<0.001, one way ANOVA, BLG-5957 p<0.001, one way ANOVA, Figure 3.16). The IC50 for 
dasatinib’s effect on migration was 0.12nM in BLG-6222 and 0.14nM in BLG-5957. To 
ensure that impaired wound closure was due to dasatinib’s effects on migration and not as a 
result of reduced proliferation, 2500 cells were treated with escalating doses of dasatinib for 
24 hours before being trypsinized and re-counted (Figure 3.17). No effect on proliferation 
was observed at any concentration of dasatinib in the BLG-6222 cell line (p=0.105, one way 
ANOVA). There was a statistically significant reduction in proliferation of the BLG-5957 cell 
line but only at dasatinib concentrations of 100nM and 200nM (p=0.018, one way ANOVA 
with Tukey’s test), which is considerably greater than the concentrations required to inhibit 
migration. Taken together these results suggest that in both BLG-6222 and BLG-5957 lower 
concentrations of dasatinib were required to inhibit cell migration than were required to inhibit 
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Figure 3.16- Dasatinib treatment resulted in dose dependent inhibition of cell 
migration. Cells were plated out in 12- well cell culture plate and grown to confluency. 
The monolayer was scratched with a pipette tip, washed with media to remove any 
floating cells and treated with either DMSO or escalating doses of dasatinib. The plate 
was placed in a microscope humidity chamber, which was maintained at 37
0
C and 
supplemented with CO2. Wound closure was monitored overnight with an Olympus 
scan R microscope and sequential images recorded at 15 minute intervals. A: Effect 
of dasatinib on rate of migration. Mean value ± SEM (n= 3) displayed. B Representative 
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Figure 3.17- Dasatinib did not inhibit proliferation at concentrations required to inhibit 
migration. 2500 cells were seeded into a 12 well dish and treated with escalating 
doses of dasatinib. After 24 hours, cells were trypsinized and resuspended in media 
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3.10 Effect of dasatinib on invasion 
 
Previous studies have also established dasatinib’s ability to inhibit invasion in several 
different cell lines [218] [219] [220]. When BLG-6222 cells were treated with dasatinib for 72 
hours, we observed a dose dependent reduction in their invasion into Matrigel (Figure 3.18). 
Further cell counting experiments were performed to ensure that the observed effect was 
due to inhibition of invasion rather than impaired cell proliferation. After 72 hours of dasatinib 
treatment, proliferation was only significantly inhibited at a concentration of 10nM (p=0.021, 
one way ANOVA with Tukey’s test, Figure 3.19), whilst invasion was significantly inhibited at 
dasatinib concentrations of 1nM onwards (p ≤0.001, one way ANOVA with Tukey’s test). 
BLG-5957 cells did not invade into Matrigel. Interestingly, on western blot this cell line was 
shown to express more E-cadherin than BLG-6222 and this may have accounted for its less 
invasive phenotype (Figure 3. 14).  
 
Previous studies have shown that dasatinib inhibits tumour cell invasion by stabilization of E-
cadherin –mediated cell-cell junctions. Using IHC, we demonstrated cytoplasmic and 
membranous E-cadherin expression in all tumours (Figure 3.20). However, whilst there was 
little membranous expression in the vehicle-treated cohort, both cytoplasmic and 
membranous expression was dramatically upregulated in dasatinib-treated tumours 
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Figure 3.18- Dasatinib treatment resulted in dose dependent inhibition of invasion in 
BLG-6222. Cells were seeded on Transwell filters and allowed to invade into Matrigel. 
After 72 hours, cells were labelled with calcein AM and visualized in the Matrigel at 
15μM increments (n=3). A:  Percentage cell invasion into Matrigel at depth of 45μM. B: 
Representative composite images of invading cells at increasing doses of dasatinib.  
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Figure 3.19- Dasatinib does not inhibit proliferation of BLG-6222 cells at 
concentrations required to inhibit invasion. 2500 cells were seeded into a 12 well dish 
and treated with escalating doses of dasatinib. After 72 hours, cells were trypsinized 
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Figure 3.20-  Dasatinib treatment resulted in increased cytoplasmic and membranous 
expression of E-cadherin. A. IHC was performed on paraffin embedded sections of 
dasatinib and vehicle treated tumours. i-Mag x20. ii- Mag x40. Scale bars represents 
100µM. Bi: Western blot performed on tumour lysate confirmed increased expression 
of E-cadherin in dasatinib treated tumours. ii: Quantification of E cadherin expression 
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3.11 The effect of dasatinib on downstream signalling 
 
We next looked at the effect of dasatinib on HER2 expression and its downstream signalling 
activity. We used IHC to examine HER2 expression in both dasatinib and vehicle treated 
tumours. Whilst moderate HER2 expression was seen in vehicle treated tumours, HER2 was 
barely detectable in any of the dasatinib treated tumours (Figure 3.21) irrespective of the 
tumour’s phenotype. Unfortunately, we were unable to detect HER2 expression by western 
blot on tumour lysates. We were also unable to detect HER2 activity using antibodies to key 
autophosphorylation residues, including pTyr 1221/1222 HER2 on IHC and pTyr 1248 HER2 
on western blot. However, looking at signalling downstream of HER2, we observed reduced 
Akt activity following dasatinib treatment on western blot (Figure 3.22, S.Karim). The tumour 
suppressor gene PTEN is a negative regulator of the Akt pathway and it was therefore 
intriguing to note that this reduction in Akt activity was seen despite a reduction in PTEN 
expression in the dasatinib treated tumours (S.Karim). 
 
As the amount of tissue from the original GEMM tumours was limited, we used the BLG-
6222 cell line to generate further tumours for analysis of downstream signalling pathways.  
We inoculated the fourth left mammary fat pad (MFP) of CD1 nude mice with 1*10
6
 BLG-
6222 cells. All recipients subsequently developed a single mammary tumour and once these 
had reached a volume of 0.2cm
3
, animals were randomized to receive either a single dose of 
dasatinib (10mg/kg) or vehicle. Mice were sacrificed 2 hours later and the tumours used to 
generate further lysate for reverse phase protein microarray (RPPA) analysis. We did not 
observe any statistical differences in the activity of any of the signalling pathways examined 
during this experiment but this is most likely due to the low number of tumours used in each 
experimental arm. We did, however, observe a strong trend towards reduced Src activity on 
RPPA (Figure 3.23). We also observed a reduction in autophosphosphorylation of HER2 on 
Tyr 1248. Although the antibody used on this platform was also capable of detecting pTyr 
1173 EGFR, no change in signal was observed when a pTyr 1173 EGFR specific antibody 
was used suggesting the change in signal associated with the combined antibody was a 
reflection of reduced HER2 activity alone. Hence, short-term dasatinib treatment was 
associated with both reduced HER2 and Src activity. Consistent with our previous findings, 
we also observed reduced Akt activity as demonstrated by reduced phosphorylation on both 
Thr 308 and Ser 473. For a full set of results see appendix 1.   
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Figure 3.21- Dasatinib treatment inhibited HER2 expression. Representative images of 
IHC of HER 2 in vehicle (n=3) and dasatinib (n=3) treated tumours. Magnification x 40, 
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Figure 3.22- Dasatinib treatment led to reduced Akt activity and PTEN expression. 
Dasatinib (n=4) and vehicle (n=4) treated tumours were used to generate lysate for 
western blotting. A: Western blot demonstrating reduced Akt activity and PTEN 
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Figure 3.23- Dasatinib treatment led to reduced Src, HER2 and Akt activity. Animals 
bearing a BLG-6222 tumour were randomized to treatment with either a single dose of 
dasatinib (10mg/kg) or vehicle and sacrificed 2 hours later. Tumour lysate (n=3 in each 
arm) was analysed using reverse-phase protein array platform.  Where ever possible 
ratio of phospho: total protein has been expressed to give a measure of signalling 
activity within specific pathways. All other values have been corrected using the 
global normalisation technique [40]. Red data points represent dasatinib treated 
tumours and black data points represent vehicle treated tumours. P values generated 
using Mann Whitney U test. 
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Pre-clinical data demonstrating Src’s fundamental role in a number of processes 
underpinning the malignant phenotype coupled with evidence of increased Src activity in 
numerous tumour types has generated much interest in the potential use of Src inhibitors as 
therapies in solid tumours. However, despite isolated responses, overall results of clinical 
trials have been disappointing suggesting that there is a need to better understand which 
patients and at what stage of their disease Src inhibitors are most likely to be efficacious. In 




model, a GEMM of HER2 positive breast cancer, and to determine the response of the 
model to the Src inhibitor dasatinib.   
 
3.12.1 Characterization of the BLG-HER2KI PTEN+/- model 
 




 model is driven by an activated HER2 transgene   
under the control of the BLG promoter which when combined with Cre-recombinase 
mediated  loss of a PTEN allele results in the stochastic development of mammary tumours. 
Although tumorigenesis in all animals was driven by the same driver mutations, we observed 
considerable heterogeneity in both the age of tumour onset and duration of survival following 
tumour development. This most likely reflects the random accumulation of secondary 
mutations within the tumour and suggests that this model is better able to model the diverse 
range of tumour behaviours seen within human HER2 positive breast cancer than more 
traditional xenograft based models. Both the tumour microenvironment [28]and the immune 
system [27] are increasingly recognised to play pivitol roles in tumour development and 
therefore the development of these tumours within the appropriate organ in the context of a 
functioning immune system are further important benefits of this model over xenografts. 
However, the median age of tumour onset in vehicle treated animals was 467 days and this 
long interval is not fully reflective of the frequently aggressive nature of human HER2 
positive disease. Previously published work using this HER2 transgene coupled with Cre-
recombinase mediated PTEN loss under the control of the MMTV promoter enhancer 
described a much shorter tumour latency interval of 6.5 months [231]. There are several 
possible explanations for the vastly different latency intervals between these 2 models. 
Firstly, low levels of Cre mediated recombination have been described in cohorts of virgin 
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mice when under the control of the BLG promoter [240] whilst the MMTV promoter enhancer 
is well recognised as an efficient driver of cre mediated recombination [241]. Low rates of 
recombination in our model are likely to have resulted in retention of both PTEN alleles in 
many tumour cells and this is likely to have contributed to the prolonged tumour latency. 
Furthermore, loss of heterozygosity (LOH) for PTEN was described in 50% of tumours in the 





 tumours and this is again likely to have contributed to the lengthy tumour 
latency interval. The efficiency of BLG-Cre mediated recombination is greatly enhanced in 
lactating mice [240] and therefore we could improve the efficiency of future experiments by 
allowing all mice to undergo 1 breeding cycle. We also noted that the level of HER2 
expression in our model was substantially lower than in the MMTV-driven model and as 
HER2 has previously been shown to play a critical role in mammary epithelial cell 
transformation [225], this is also likely to have contributed to the longer tumour latency 
interval. Finally, these 2 models used different background mouse strains. The MMTV-driven 
model was bred on an FVB background whilst our model used a mixed background and it 
may be that these animals were not as susceptible to mammary tumour development. 
 
In summary, despite the long tumour latency interval, this model is capable of               
recapitulating some of the key pathological features of human HER2 positive breast cancer 
and may therefore be a useful tool in the development of novel therapeutic strategies.   
 
3.12.2 The effect of dasatinib on tumour initiation and   
progression 
 
We found that tumour development was significantly delayed by dasatinib treatment. 
However, continued treatment following tumour initiation did not inhibit progression 
suggesting that whilst Src is important in the initial stages of tumour development, it may 
have a less significant role in the latter stages of disease. This is consistent with data from 
several other previously published studies; Webster et al reported that mammary-specific 
expression of activated Src resulted in the development of hyperplastic lesions but these 
rarely progressed to tumours [242]. Mammary-specific deletion of Src in the MMTV-polyoma 
middle T(PyMT) model reduced the proliferation of hyperplastic lesions and prevented the 
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development of tumours [243]. In addition, similar results were obtained following treatment 
with the Src inhibitor bosutinib in this model [244]. The importance of Src in early tumour 
development does not appear to be restricted to breast tumour development as Src inhibition 
in a model of skin carcinogenesis reduced the incidence of papillomas but did not prevent 
their conversion to squamous cell carcinomas [245]. In humans, increased Src activity has 
also been associated with the development of the pre-malignant hyper-proliferative skin 
lesions, human actinic keratoses [245].  
 
Whilst dasatinib treatment delayed disease onset, all animals ultimately developed tumours 
due to the onset of acquired drug resistance. Using IHC we demonstrated that the onset of 
resistance was not associated with loss of Src inhibition. However, we did observe a 
significant reduction in the HER2 expression in dasatinib-treated tumours and this is likely to 
be a reflection of compensatory signaling changes associated with the development of 




tumour cell lines with dasatinib resulted in dose dependent inhibition of proliferation, no such 
effect was observed in our in vivo model. This was most likely due to the acquisition of other 
genetic changes which were responsible for the ongoing proliferation despite Src inhibition. 
Src’s effects on cell proliferation appear to vary according to the model in which it is 
assessed. In previous studies using a HER2 driven mouse model of breast cancer, Src and 
HER2 were found to interact via their SH2 domains [246] [247] [248] resulting in enhanced 
Src activity and changes in breast cancer cell growth, survival and polarity [249] [250] [251]. 
In contrast, mammary-specific expression of CSK, a negative regulator of Src, did not alter 
the growth of HER2  positive mammary tumours in mice [252] and in studies using human 
HER2 positive breast cancer cell lines, no consistent relationship between HER2 activation 
and dasatinib was identified [253] [254] . Furthermore, in a GEMM of pancreatic cancer, 
dasatinib had no effect on proliferation in the primary tumour but did inhibit the development 
of metastases [220]. Src’s variable impact on primary tumour cell proliferation highlights the 
critical need to develop biomarkers which are capable of predicting which patients are likely 
to benefit from dasatinib treatment. 
It is also well established that dasatinib is capable of potently inhibiting tumour cell invasion 
and migration both in vitro and in vivo and in several models, including breast cancer derived 
cell lines, these are its dominant mechanisms of action [220] [88] [255] [256]. Whilst our in 





cells, we found that similar numbers of dasatinib and vehicle-treated 
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animals developed metastatic disease. Although the numbers of animals developing 
metastases were too low to permit statistical analysis, amongst animals with evidence of 
metastatic disease, we observed a striking reduction in the number of metastases in 
dasatinib-treated animals compared to vehicle-treated animals. These results are consistent 
with previously published data showing that dasatinib reduced the metastatic burden in both 
mouse models of pancreatic and prostate cancer [220] [88]. We also observed a substantial 
increase in E-cadherin expression in dasatinib treated tumours suggesting that dasatinib 
may inhibit E-cadherin endocytosis and enhance the protein’s stability thereby preventing 
tumour dissemination [257] [258].         
 




 model dasatinib inhibited 
tumour initiation but had no effect on tumour cell proliferation or tumour progression. It also 
provides preliminary evidence that dasatinib was able to inhibit the development of 
metastases in this model. 
  
 
3.12.3 Effect of dasatinib on tumour differentiation  
 
The effect of dasatinib on tumour differentiation was one of our most striking observations 
with the presence of prominent squamous elements in dasatinib treated tumours. Squamous 
metaplasia has been linked to mammary-specific activation of the Wnt pathway in previous 
studies [236]. Consistent with these findings, we observed increased β-catenin expression in 
regions adjacent to the keratinized zones of dasatinib treated tumours suggesting that β 
catenin mediated signaling was responsible for driving the squamous differentiation. Our 
data is consistent with that of Hebbard et al who also observed squamous differentiation in 
the MMTV-PyMT mouse model following treatment with the Src inhibitor bosutinib [244]  and 
taken together the data suggests that Src and Wnt are capable of co-operating to regulate 
mammary epithelial cell differentiation. Src and Wnt have also been shown to co-operate in 
regulating the differentiation of other cell types, including osteoblasts [162] [259].   
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3.12.4 Clinical relevance of these findings in the management 
of human HER2 positive breast cancer 
 
Clinical trials to date have focused on the use of Src inhibitors in metastatic disease. 
However, increased Src activity is frequently observed in DCIS, where it is associated with 
factors predictive of high recurrence risk, including HER2 positivity [260]. Increased Src 
activity is frequently observed in invasive breast cancers but different studies have yielded 
conflicting results about the relationship between tumour stage and the level of Src activity 
[261] [262] [263]. Ito et al reported increased Src activity was more commonly observed in 
early rather than advanced disease [262] and taken together with the established anti-
migratory roles of Src inhibitors this further supports the argument for their use in early or 
even pre-invasive disease. DCIS is not associated with mortality but current treatment 
strategies, which include mastectomy and breast conserving surgery (BCS) ± radiotherapy, 
result in significant morbidity. Recurrence rates after BCS in high risk subgroups, such as 
HER2 positive disease, can be as high as 40% [264] and as 50% of these patients will have 
developed invasive disease at the time of relapse [265], aggressive upfront surgical 
management of high risk DCIS is mandatory. Together with other previously published 





In conclusion, our results provide further evidence that GEMMs can be useful tools in the 
development of novel therapeutic strategies for the management of solid tumours. We have 
also confirmed that Src plays important roles in the early stages of tumour development and 
in the development of metastases in our model providing a strong rationale for future clinical 
trials looking at the use of Src inhibitors in early and pre-invasive disease. However, the 
development of predictive biomarkers is essential if these drugs are to be successfully 
adopted into mainstream clinical practice.
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Chapter 4: Validation and Characterisation of 
MMTV-NIC Model 
 




 model for use in preclinical drug studies 
include the development of primary tumours within the mammary fat pad, in the context of a 
functioning immune system and with a high penetrance rate. However, neither the long and 
varying latency period prior to the development of palpable disease or the low metastatic 
rate (8% of animals) is reflective of the frequently aggressive nature of HER2 positive 
disease in humans. Therefore an alternative model, the MMTV-Neu Internal Ribosome Entry 
Site (IRES)-Cre (NIC) model was selected for use in further experiments. From here on this 
model will be referred to as MMTV-NIC.   
 
4.1 Model Background 
 




 model, tumourigenesis in the MMTV-NIC model is 
driven by a constitutively activated HER2 transgene. However, in this model the constitutive 
activity of the transgene is conferred by a 16 amino acid deletion in the extracellular domain 
of the HER2 receptor referred to as Neu in Frame Deletion (NDL) mutation. This promotes 
the formation of intermolecular disulphide bonds which results in persistently activated HER2 
dimers. In comparison with wild type HER2, the NDL mutation has greater transforming 
capacity although its presence alone is insufficient to result in tumourigenesis.  A 10 fold 
increase in activated HER3 is also observed in this model and it is likely the co-expression of 
both HER2 and HER3 together play a critical role in tumourigenesis [266].  A similar naturally 
occurring splice variant is observed in human breast cancers (HER2 Δ16), which also 
contains an extracellular domain deletion promoting the formation of stable disulphide bonds 
and enhanced transforming capacity. This alternative HER2 protein is found in approximately 
50% of cases of human HER2 breast cancer and 90% of cases with lymph node involvement  
[267] making this model highly clinically relevant.   
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 model, in its use of th 
strong Mouse Mammary Tumour Virus (MMTV) promoter to regulate expression of the 
transgene.  MMTV is a naturally occurring milk transmitted retrovirus that causes mammary 
tumour development by integration of the virus adjacent to proto-oncogenes such as Wnt-1, 
Fibroblast Growth Factor 3 (FGF3) and Notch [268].  Transgenic mouse models exploit a 
recombinant MMTV promoter, which is expressed from birth [241], and models in which this 
promoter is fused to oncogenes, such as c-myc, Wnt-1 and RET, have been widely used 
[268]. Previous studies using MMTV-driven activated HER2  expression have described 
development of multiple poorly differentiated mammary adenocarcinomas although 
discrepancy exists between whether these develop in a synchronous [225] or stochastic 
[269] manner. MMTV- driven expression of activated HER2 is largely confined to mammary 
tissue but limited expression is also observed in the adrenal glands, lung, pancreas, ovaries 






 model, the MMTV-NIC model employs a bicistronic 
transcript to co-express HER2
NDL
 with Cre-recombinase. Therefore, when crossed with a 
strain containing a floxed allele, the model can be used to explore the effect of conditional 
knockout of a tumour suppressor gene, such as PTEN (Figure 4.1). Whilst MMTV is an 
efficient promoter and is expressed in the majority of mammary epithelial cells, mosaicism 
has been observed with some cells ‘escaping’ from Cre-expression and subsequent genetic 
recombination [241]. The use of a bicistronic transcript couples HER2
NDL
 expression to the 
loss of a PTEN allele ensuring every HER2
NDL 
expressing cell has also lost a PTEN allele 
[270]. This alleviates problems associated with tumours containing mixed cell populations 
with combinations of HER2
NDL 
expressing and/or Cre positive PTEN
+/-
 cells. As previously 
discussed, loss of PTEN is a common genetic event in breast cancer. It has been linked with 
resistance to trastuzumab but despite compelling in vitro evidence [271], analysis from 
various clinical trials have given conflicting results [150]. This model is therefore a useful tool 
to further explore this contentious area. 
 




 model making 
it better suited to use in preclinical studies. Firstly, the greater efficiency of the MMTV 
promoter results in Cre-mediated recombination in the majority of luminal epithelial and 
myoepithelial cells [241] whilst only low level recombination is observed in the non-lactating 
gland when the BLG-promoter is used [240]. This results in a shorter latency period before 
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the onset of palpable disease and more rapid tumour progression (see below). Furthermore, 
loss of PTEN in the MMTV-NIC model has previously been demonstrated to accelerate 
tumourigenesis [272]. In this model, over 50% of mice with heterozygous loss of PTEN 
(PTEN
+/-
) develop loss of heterozygosity (LOH) resulting in the loss of the second PTEN 
allele and further accelerating tumourigenesis [272].  Thirdly, as already described this 
model can be used to explore the role of PTEN in moderating drug sensitivity. Whilst the 




 model mean this is also technically possible, the long 
tumour latency and slow progression rate in this model means it is not logistically feasible to 
develop HER2
KI
 expressing tumours with wild type PTEN (PTEN 
FL/+
) within the average life 
expectancy of a mouse. Finally, the considerably higher rates of lung metastases observed 
in the MMTV-NIC PTEN
+/- 
model are more reflective of the virulent nature of human HER2 
positive breast cancer. 
 
Initial work focussed on characterising and validating the model as a preclinical tool for 
predicting response to drugs in human HER2 positive breast cancer. Subsequently, its 
response to AZD8931, a novel equipotent inhibitor of HER2 and EGFR was explored [273].  
 
Specific aims of this section of the project included: 





2. Comparing signalling pathway activity in MMTV-NIC PTEN 
FL/+




3. Describing MMTV-NIC PTEN
+/-
 tumours in terms of histology, hormone receptor 
(HR) status, HER2 expression and Ki67 expression.  
4. Exploring the response of MMTV-NIC PTEN
+/-
 model to paclitaxel, an active drug in 
the management of human breast cancer. 
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Figure 4.1- MMTV-NIC Genotype.  Tumourigenesis in the MMTV-NIC model is driven by 
expression of a constitutively activated HER2 transgene under the control of the 
MMTV promoter. Use of a bicistronic transcript couples HER2 and Cre recombinase 
expression to facilitate study of HER2 over-expression in conjunction with loss of a 
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4.2 Model Characterisation and Validation 
 
4.2.1 Growth of MMTV-NIC PTEN FL/+ and MMTV-NIC PTEN+/- 
tumours   
 
Both MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/- 
mice were monitored twice weekly for 
the development of tumour formation by palpation. Tumour onset was defined as the 
presence of a palpable tumour. Animals were sacrificed once their tumour burden reached ≥ 
1.7 cm in any direction.  
 
In both MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/- 
cohorts, 100% of mice developed 
multiple tumours in a stochastic manner. Loss of PTEN significantly accelerated tumour 
onset (Figure 4.2). The median age of tumour onset was 81 days in the MMTV-NIC PTEN
+/-
 
cohort compared to 138 days in the MMTV-NIC PTEN 
FL/+ 
cohort (p=0.0001, Gehan-Breslow-
Wilcoxon test). Following tumour onset, loss of PTEN also accelerated tumour progression. 
The median survival after tumour onset was 21 days in the MMTV-NIC PTEN
+/-
 cohort 





Wilcoxon test) (L. Balderstone).   
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Figure 4.2- Loss of PTEN accelerated tumour onset and progression. Cohorts of 
MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/-
 mice were monitored for tumour 
development and progression. A: Age at onset of palpable disease. p=0.0001, Gehan-
Breslow-Wilcoxon test.  B: Duration of survival following onset of palpable disease. 
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4.2.2 Comparison of signaling pathways between MMTV-NIC 
PTEN FL/+ and MMTV-NIC PTEN+/- models 
 
To explore the consequences of PTEN loss on downstream signaling pathways, we 
performed RPPA analysis on lysate from MMTV-NIC PTEN 
FL/+
 (n= 4) and MMTV-NIC 
PTEN
+/-
 (n=3) tumours (K. Macleod). The full set of results is presented in Appendix 2.  
 
We observed striking heterogeneity in the expression of both cell surface and downstream 
signaling molecules, even between tumours of the same genotype (Appendix 2). Overall, a 
significant difference in expression was detected in only 2 of the proteins assayed. Whilst the 
total PTEN antibody signal was too weak to accurately quantify, the pSer380, Thr382, 
Thr383 PTEN expression was reduced in MMTV-NIC PTEN
+/-
 tumours. Phosphorylation of 
these carboxy-terminal residues results in increased enzyme stability [2] suggesting the 
amount of functional enzyme present at the cell membrane was reduced in MMTV-NIC 
PTEN
+/- 
tumours (Figure 4.3). This was consistent with previous data from our group as 
using western blotting a non-statistically significant reduction in total PTEN expression had 
been demonstrated in an independent panel of MMTV-NIC PTEN
+/- 
tumours compared to 
MMTV-NIC PTEN 
FL/+ 
tumours (L. Balderstone, Figure 4.4).  
 
Consistent with reduced PTEN expression, we observed increased Akt pathway activity in 
MMTV-NIC PTEN
+/- 
tumours compared to MMTV-NIC PTEN 
FL/+ 
tumours. A statistically 
significant increase in median pSer473 Akt: Akt ratio was observed on both RPPA analysis 
(p=0.01, Mann Whitney U test, Figure 4.3) and on western blot (p= 0.01, Mann Whitney U 
test, Figure 4.4). Median pThr308 Akt: Akt was also increased in MMTV-NIC PTEN
+/-
 
tumours on RPPA analysis although this did not reach statistical significance (p= 0.33, Mann 
Whitney U test). We also observed changes in the activity of several other signaling 
pathways using RPPA, including signaling molecules downstream of Akt, although none of 
these reached statistical significance. 
 
 
Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
 





Figure 4.2- RPPA analysis demonstrated reduced pSer 380, Thr 382, Thr 383 PTEN 
expression and increased Akt activity in MMTV-NIC PTEN
+/- 
tumours. RPPA analysis 
was performed on lysate from MMTV-NIC PTEN
+/- 
(red data points) and MMTV-NIC 
PTEN 
FL/+ 
(black data points) tumours. Bar represents mean value for each data series. 
Asterix denotes statistically significant result. P values calculated using Mann 
Whitney U test.  
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Figure 4.4- A. Western blot confirmed reduced PTEN expression and increased Akt 
activity in a panel of MMTV-NIC PTEN
+/-
 tumours. 40 µg protein loaded in each lane. 
Actin used as loading control (L.Balderstone). B. Quantification of PTEN expression. 
Blots analysed using Image J. P=0.38, Mann Whitney U test. C. Quantification of Akt 
activity. Blots analysed using Image J. P=0.05, Mann Whitney U test. 
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4.2.3 Characterization of MMTV-NIC PTEN+/- tumours 
 
4.2.3.1 Histology of MMTV-NIC PTEN+/- tumours 
 
Histologically, these tumours were comprised of multiple highly cellular nodules (Figure 
4.5A). Review of a series of mammary tumours by an experienced breast pathologist (Dr. J. 
Loane, consultant pathologist) confirmed the presence of highly mitotic (Figure 4.5B), 
grade 3 invasive carcinoma in all specimens (n=32). Extensive necrosis was observed in 
71.8% (n=23) of samples and focal necrosis observed in a further 18.8% (n=6) (Figure 
4.5C). There was no evidence of necrosis in 9.4% (n=3) of samples.  
 
Using a single section of lung per mouse, we observed evidence of lung metastases in 25% 
(n=3) of 12 samples (Figure 4.5D). However, we only detected frank pulmonary metastases 
in one sample with disease being limited to micro-foci in the remaining two. The true rate of 
metastases is likely to be greater than that observed as we have inspected only one section 
per animal and it is likely that if the whole lungs were sectioned further metastases would be 
identified. Therefore, these findings suggest a significant proportion of tumour cells have the 
capacity to invade and metastasize even though the metastatic burden is low.  
 
4.2.3.2 IHC characterization of MMTV-NIC PTEN+/- tumours 
 
We used IHC to further characterize these tumours. Tumours were negative for both ER and 
PR (Figure 4.6). Using Ki67 to assess proliferation, we found that all tumours were highly 
proliferative (Figure 4.7). We also used IHC to assess HER2 expression in tumours (n=8) 
and found considerable variation in HER2 expression both within and between tumours 
(Figure 4.8B). According to the joint American Society of Clinical Oncology (ASCO) and 
College of American Pathologists (CAP) guidelines a human breast cancer must 
demonstrate uniform, intense (3+) membranous staining in over 30% of all tumour cells to be 
classified as HER2 over-expressing by IHC alone. According to these guidelines only 25% of 
tumours examined in this series were classifiable as HER2 over-expressing on the basis of 
their IHC result and a further 50% had an equivocal result (Figure 4.8).  Despite this, the 
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majority of tumours still expressed high levels of HER2 and we therefore felt further 
characterization of this model in terms of response to cytotoxics and HER2 directed 
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Figure 4.5- Representative H & E image of MMTV-NIC PTEN
+/-
 mammary tumour and 
lung metastases. A: Mammary tumour (mag x20) showing the typical highly cellular 
nodules within the tumour. Scale bar represents 100 µm. B: Highly mitotic region of 
mammary tumour (mag x40). Scale bar represents 100 µm. C: Extensive necrosis 
within mammary tumour (mag x40). D: Section of lung demonstrating isolated lung 
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Figure 4.6- MMTV-NIC PTEN
+/-
 tumours were hormone receptor negative.  IHC was 
performed with ER and PR antibodies on paraffin embedded sections of MMTV-NIC 
PTEN
+/- 
tumours (n=3). Positive controls comprise sections of human hormone 
receptor positive breast cancer stained with the appropriate antibody. Mag x40. Scale 
bar represents 100 μm.
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Figure 4.7- MMTV-NIC PTEN
+/-
 tumours were highly proliferative. IHC was performed 
on paraffin embedded sections of MMTV-NIC PTEN
+/- 
tumours with a Ki67 antibody. 
Images analysed using Immunoratio software to calculate percentage of Ki67 positive 
nuclei in six low power fields (mag x20) per tumour. A: Box and whiskers plot of 
percentage Ki67 positive nuclei (n=7). B: Representative images of IHC staining for 
Ki67 in negative control (i) and MMTV-NIC PTEN
+/- 
tumour. Negative control consists 
of tumour section incubated in the absence of primary antibody. Mag x20. Scale bar 
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Figure 4.8- HER2 expression varied across a panel of MMTV-NIC PTEN
+/-
 tumours. IHC 
was performed with a HER2 antibody on paraffin embedded sections of MMTV-NIC 
PTEN
+/- 
tumours (n=8).  Membranous histoscore determined using 6 representative 
high powered fields (x40 mag) and calculating the sum of the product of percentage 
cells stained by the intensity graded from 0-3, where 1=weak, 2=moderate and 
3=strong staining (histoscore = (% *1) + (% *2) + (% *3)). A: Membranous HER2 
histoscore in MMTV-NIC PTEN
+/-
 tumours. Red data points represent tumours 
classified as over-expressing HER2 by IHC or with an equivocal result. Black data 
points represent tumours classified as not over-expressing HER2 by IHC. B: 
Representative images of HER2 IHC demonstrating negative control (i), limited 
membranous HER2 expression (ii), extensive membranous expression (iii) and 
cytoplasmic staining (iv). Negative control consists of tumour section incubated in the 
absence of primary antibody.  Mag x40. Scale bar represents 100 μm.  
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4.2.4 Response of MMTV-NIC PTEN+/- tumours to Paclitaxel 
 
The role of the taxanes in the management of both early [274] and metastatic breast cancer 
[275] is well established. In order to assess the response of the model to paclitaxel, we 





tumour) to treatment with paclitaxel (n=5) or vehicle (n=4) once weekly for a maximum of 4 
doses. Animals were monitored twice weekly for tumour progression and sacrificed once any 
tumour had reached 1.5 cm (in any direction). All vehicle-treated animals were sacrificed 
before the final dose. However, 2 out 5 drug-treated animals completed the full treatment 
schedule and were sacrificed 72 hours after the final dose. In 1 of these animals the longest 
dimension of the index tumour was greater than 1.5 cm at the time of sacrifice. In the second 
animal, the longest dimension of all tumours was less than 1.5 cm at the time of sacrifice.   
 
Despite small cohort sizes, paclitaxel treatment statistically significantly prolonged OS from a 
median of 13.5 days (range 7-18 days) in the control animals to 21 days (range 17-24 days) 
in drug treated animals (p=0.035, Gehan-Breslow-Wilcoxon test, Figure 4.9A). One third of 
animals (n=3) were sacrificed due to a non-index lesion and therefore to compare growth of 
vehicle and paclitaxel treated tumours, the growth rates of the largest tumours at the time of 
sacrifice were plotted (Figure 4.9B). This graph suggests that paclitaxel slowed tumour 
progression but did not cause tumour shrinkage. It is important to note that the timing of 
animal sacrifice was dictated by a single 2D measurement. Significant heterogeneity in 
tumour shape was observed and therefore variation in the tumour burden at the experiment’s 
end point was considerable. Despite this, a non-statistically significant trend towards a 
reduction in total tumour mass (defined as sum of the mass of all individual tumours) at the 
time of sacrifice in the paclitaxel treated cohort was observed (p=0.17, Mann Whitney U test, 
Figure 4.9C).      
 
Whilst paclitaxel delayed tumour progression, it did not prevent new tumour development. 
Paclitaxel-treated animals developed a median of 3 additional non-index tumours during the 
study compared to 2.5 in the vehicle-treated arm (p=0.60, Mann Whitney U test). 
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Figure 4.9- Paclitaxel slowed tumour growth and prolonged OS in MMTV-NIC PTEN
+/-
 
mice. A: Overall survival in vehicle (n=4) and paclitaxel (n=5) treated mice, p=0.035, 
Gehan-Breslow Wilcoxon test.  B: Growth rate of largest (at the time of sacrifice) 
vehicle and paclitaxel treated tumours. C: Sum of all individual tumour weights at time 
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Paclitaxel impairs microtubule depolymerisation and results in apoptosis [276]. Therefore, we 
performed IHC with an antibody to cleaved caspase 3, a frequently used biomarker of 
apoptosis [239], to try and confirm successful drug uptake by the tumours. Six representative 
low power fields (20x) were selected at random throughout each tumour and Image J was 
used to calculate the percentage of each field positively stained for cleaved caspase 3.  
Discrete foci of cells stained intensely for cleaved caspase 3 but the majority of tumours in 
both the drug and vehicle treated arms showed no staining (Figure 4.9). Despite this, 
paclitaxel treatment resulted in a significant increase in cleaved caspase 3 expression and 
apoptosis (p= 0.02, Mann Whitney U test).  
 
In summary, this experiment provided limited evidence that the MMTV-NIC model responds 
to paclitaxel, one of the first line chemotherapeutic agents used in the management of breast 
cancer, suggesting the model may be a useful tool in predicting response to novel therapies 
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Figure 4.10- Paclitaxel resulted in apoptosis. IHC was performed on paraffin 
embedded sections of MMTV-NIC PTEN
+/- 
paclitaxel and vehicle treated tumours with a 
cleaved caspase 3 antibody. Images analysed using Image J software to calculate 
percentage area staining positive for cleaved caspase 3 in six low power fields (mag 
x20) per tumour. A: Box–whisker plot analysis of percentage area positive for cleaved 
caspase 3 in vehicle (n=4) and paclitaxel (n=5) treated tumours. p=0.02, Mann Whitney 
U test. B: representative images of IHC; negative control (i), vehicle (ii) and paclitaxel 
(iii) treated tumours. Negative control consists of tumour section incubated in the 
absence of primary antibody.  Scale bar 100 μm. Mag x20.    
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4.2.5 Response of MMTV-NIC PTEN FL/+ and MMTV-NIC 
PTEN+/- tumours to AZD8931 
 
The introduction of HER2 directed therapies has revolutionised the management of both 
early and advanced HER2 positive breast cancer. However, despite significant 
improvements in treatment outcomes, both inherent and acquired resistance are frequently 
encountered problems [277]. Emerging evidence from neo-adjuvant clinical trials suggests 
that use of different strategies to target multiple members of the HER family is more 
efficacious than single target inhibition alone. The Neo-ALTTO study reported that combined 
inhibition of EGFR and HER2 using lapatinib and trastuzumab was more efficacious than 
use of either single agent [139]. In the Neo-sphere trial, Gianni and colleagues reported that 
the combined use of pertuzumab and trastuzumab to inhibit HER2 and HER2/HER3 
dimerization, was more active than either drug alone [2]. Currently there are no drugs in 
mainstream clinical practice which are able to directly target HER3 although HER3 
expression has an independent negative impact on prognosis [141]. Furthermore, it has 
been postulated that following treatment with TKIs such as gefitinib and erlotinib, incomplete 
Akt inhibition triggers a shift in the steady-state phosphorylation equilibrium of HER3, 
favouring the active conformation, and enabling ‘escape’ from the growth-inhibitory effects of 
TKIs [279] [280]. Whilst lapatinib is classified as an reversible TKI of HER2 and HER3, the 
extent of EGFR inhibition in vivo is questionable. AZD8931 is a novel equipotent reversible 
tyrosine kinase inhibitor (TKI) of HER2 and EGFR, which through its robust inhibition of both 
these receptors is also capable of inhibiting HER3 signalling. Preclinical studies have 
previously shown it to be active in breast, head and neck and non-small cell lung cancer 
[273]. 
 
To assess the efficacy of AZD8931 in the MMTV-NIC model, we randomized cohorts of 
MMTV-NIC PTEN 
FL/+




to treatment with either AZD8931 (n=5 
for each genotype) or vehicle (n=5 for each genotype). Treatment was commenced when 
mice had at least 1 tumour ≥ 0.1 cm
3 
(index tumour) and continued until complete resolution 
of the index tumour or until the animal was sacrificed due to tumour size ≥ 1.5 cm (in any 
direction).  Mice were dosed daily with AZD8931 (100 mg/kg) suspended in 1% Tween 80 (in 
PBS) by oral gavage.   
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AZD8931 treatment prolonged overall survival in both the MMTV-NIC PTEN 
FL/+
 (Figure 
4.11A) and MMTV-NIC PTEN
+/-
 mice (Figure 4.11B). Median overall survival in the vehicle 
arm of the MMTV-NIC PTEN 
FL/+ 
cohort was 35 days (range 10- 39 days). AZD8931 
treatment was stopped at day 40 in the MMTV-NIC PTEN 
FL/+ 
drug-treated animals and the 
experiment terminated without further ageing of the mice. It is therefore not possible to 
define median OS in the AZD8931 treated arm more specifically than > 40 days (p=0.004, 
Gehan Breslow Wilcoxon test).  In the AZD8931 group of the MMTV-NIC PTEN
+/-
 cohort, 1 
mouse was sacrificed after only 11 days of treatment due to respiratory compromise and on 
pathological review of a single section of lung, small foci of metastatic cells were identified 
(Dr. J. Loane). Despite this, median survival was prolonged to 45 days (range 11-124 days) 
in AZD8931 treated animals compared to 20 days (range 18-35 days) in vehicle treated 
mice, although this did not reach statistical significance (p= 0.1658, Gehan Breslow 
Wilcoxon  test). The early loss of 1 animal in a study with a small sample size had a 
profound impact when calculating p values. If this experiment was repeated with a larger 
sample size, it is possible that AZD8931 treatment would have resulted in a statistically 
prolonged overall survival in the MMTV-NIC PTEN
+/-
 cohort. Indeed, when this animal was 
excluded from analysis a highly significant difference in overall survival was observed 
(p=0.023, Gehan Breslow Wilcoxon test). 
 
This experiment illustrates the significant heterogeneity in tumour behaviour and response to 
treatment seen with this model. When we looked at the growth of the individual tumours in 
the different cohorts we saw that all AZD8931 treated MMTV-NIC PTEN 
FL/+
 tumours initially 
responded to treatment and after 40 days of drug treatment 2 out of 5 tumours had fully 
resolved. A further 2 tumours displayed a downwards trend in volume and had achieved a 
reduction in volume of 29.8% and 76.4% compared to pre-treatment volumes. The final 
tumour initially responded but after 17 days of drug treatment became insensitive and began 
to increase in volume again. After 40 days of treatment, its volume had increased by 34.2% 
compared to its pre-treatment volume. Therefore the median reduction in tumour volume in 
the AZD8931 arm was 76.4% (range -34.2%-100%). In comparison, the tumours in the 
vehicle treated arm continued to grow throughout the experiment and when each animal was 
sacrificed due to tumour burden, the volume of all tumours had increased in volume by at 
least 60% (Figure 4.12 A). The difference in percentage change of tumour volume between 
drug and vehicle treated MMTV-NIC PTEN 
FL/+
 animals was highly statistically significant 
(p=0.012, Mann Whitney U test). In contrast, only 4 out of 5 AZD8931 treated MMTV-NIC 
PTEN
+/-
 tumours initially responded to treatment with a median reduction in tumour volume 
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of 44.1% (range 6.9-74.3%). However, all 4 of these tumours rapidly became insensitive to 
AZD8931 and after a median of 12 days (range 7-17 days) of treatment, tumours had grown 
beyond their initial starting volume. Interestingly, the mammary tumour from the animal 
which was sacrificed due to symptoms of metastatic disease, did not respond to AZD8931 
suggesting inherent resistance. As expected, all vehicle treated tumours continued to grow 
steadily throughout the experiment. All MMTV-NIC PTEN
+/- 
mice were sacrificed due to 
tumour burden and at the time of sacrifice both drug and vehicle treated tumours had 
increased in volume by at least 60% (Figure 4.12B). The difference in percentage change of 
tumour volume between drug and vehicle treated MMTV-NIC PTEN
+/-
 animals was not 
significant (p=0.531, Mann Whitney U test). In summary, AZD8931 resulted in tumour 
shrinkage in the majority of MMTV-NIC PTEN 
FL/+
 animals but whilst it slowed tumour growth 
in MMTV-NIC PTEN
+/-
 animals it did not cause tumour resolution. 
 
In addition to targeting established tumours, AZD8931 treatment also inhibited tumour 
initiation in both the MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/- 
models. In the MMTV-
NIC PTEN 
FL/+
 model statistically fewer additional tumours developed during the study in the 
AZD8931 arm (median-0) compared to in the vehicle arm (median-3) (p=0.048, Mann 
Whitney U test). There was also a reduction in the median number of additional tumours 
which developed in the MMTV-NIC PTEN
+/- 
cohort from 2 in the vehicle treated arm to 0 in 
the drug treated arm but this failed to reach statistical significance (p=0.087, Mann Whitney 
U test).
   
 
  
As there was little residual tissue from the AZD8931 treated MMTV-NIC PTEN 
FL/+
 tumours, 
histological examination was limited to the MMTV-NIC PTEN
+/- 
tumours. Histological review 
of MMTV-NIC PTEN
+/- 
tumours suggested that AZD8931 can cause a reduction in tumour 
grade (Dr. J. Loane). All vehicle treated index samples contained grade 3 carcinoma whilst 
only 60% (n=3) of AZD8931 index tumours were classified as grade 3. The remaining 40% 
(n=2) of AZD8931 index lesions consisted of grade 2 carcinoma. Interestingly, the rate of 
lung metastases was higher in the AZD8931 treated cohort (60%, n=3) than in the vehicle 
treated cohort (20%, n=1) and both animals with evidence of drug efficacy in the primary 
tumour, in terms of reduced tumour grade, had lung metastases at the time of sacrifice. 
Although the small size of cohorts in this study make it difficult to draw conclusions regarding 
the differential rate of lung metastases, it is feasible that the increased rate of metastases 
seen in the drug-treated cohort reflects their prolonged overall survival allowing sufficient 
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time for cells which had metastasised prior to the commencement of AZD8931 treatment to 
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randomized to treatment with daily AZD8931 or vehicle and tumour response 
monitored. A: Overall survival in vehicle (n=5) and AZD8931 (n=5) treated MMTV-NIC 
PTEN 
FL/+
 mice. p=0.004, Gehan-Breslow Wilcoxon test.  B: Overall survival in vehicle 
(n=5) and AZD8931 (n=5) treated MMTV-NIC PTEN
+/-
 mice. p=0.1658, Gehan-Breslow 
Wilcoxon test. 
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Figure 4.12- PTEN status determined sensitivity to AZD8931. A: Waterfall plot of 
percentage tumour volume change over duration of experiment in MMTV-NIC PTEN 
FL/+ 
vehicle and AZD8931 treated animals. p=0.012, Mann Whitney U test. B: Waterfall 
plot of percentage tumour volume change over duration of experiment in MMTV-NIC 
PTEN
+/-
 vehicle and AZD8931 treated animals. p=0.531, Mann Whitney U test.  
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4.3 Exploring the Mechanism of Action of AZD8931 in vivo  
 
4.3.1 Inhibition of signaling via EFGR, HER2 and HER3  
 
In order to investigate the effects of AZD8931 on signaling, we conducted a short term 
treatment study to ensure at completion of the experiment tumours were responsive to 





mice were randomized to treatment with either AZD8931 (n=4 for each genotype) or 
vehicle (n=4 for each genotype) for 3 days. Treatment was commenced when animals had at 
least 1 tumour ≥ 0.3 cm
3
. Mice were dosed daily with AZD8931 (100 mg/kg) suspended in 
1% Tween 80 (in PBS) by oral gavage.  Animals were sacrificed 2 hours after the final dose.  
 
We used IHC to explore expression of HER family proteins in vehicle and drug treated 
tumours. Reduced expression of total HER2 was observed following AZD8931 treatment in 
MMTV-NIC PTEN 
FL/+
 tumours. The median HER2 histoscore was 120.0 in drug treated 
tumours compared to 225.0 in vehicle treated tumours (p= 0.05, Mann Whitney U test). 
Expression in MMTV-NIC PTEN
+/-
 tumours was unaffected by AZD8931 treatment with a 
median histoscore of 90.0 in vehicle treated tumours compared to 80.0 in AZD8931 treated 
tumours (p=1.0, Mann Whitney U test) (Figure 4.13).  
  
The activity of HER2 in tumours was assessed by measuring the phosphorylation of 2 key 
tyrosine autophosphorylation residues, Tyr 1221 and 1222 [97]. Expression of pTyr 





tumours, although this reduction failed to reach statistical significance in either 
model (Figure 4.14). In the MMTV-NIC PTEN 
FL/+
 cohort median pTyr 1221/1222 HER2 
histoscore was reduced from 225.0 in the vehicle arm to 135.0 in the drug treated arm 
(p=0.48, Mann Whitney U test). In the MMTV-NIC PTEN
+/-
 cohort, median histoscores were 
120.0 and 82.5 in
 
vehicle and drug treated tumours respectively (p=1.0, Mann Whitney U 
test).  
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We also performed IHC using a pTyr 1289 HER3 antibody. This residue participates in PI3 
kinase (PI3K) signaling [97] and therefore gives an accurate readout of HER3 activity. Again, 
in both the MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/-
 models, AZD8931 treatment 
resulted in a reduction in HER3 activity, although this also did not reach statistical 
significance (Figure 4.15). In the MMTV-NIC PTEN 
FL/+ 
model, median pTyr 1289 HER3 
histoscore was reduced from 57 in the vehicle treated cohort to 0 in the AZD8931 treated 
arm (p=0.2, Mann Whitney U test). In the MMTV-NIC PTEN
+/- 
cohort, median pTyr 1289 
HER3 histoscore was reduced from 80 in vehicle treated tumours  to 31 in  AZD8931 treated 
tumours (p= 0.07, Mann Whitney U test). IHC was used to explore the expression of total 
HER3 but we were not satisfied with the quality of the staining and therefore this data has 
not been included. 
 
Expression of total EGFR (Figure 4.16) and p Tyr 992 EGFR, an autophosphorylation 
residue [281], (Figure 4.17) was determined. However, expression of both was too low to 
permit further quantification.  
 




models, although this failed to reach statistical significance. 
Significant intra-tumoural heterogeneity was observed in terms of receptor expression, with 
staining predominantly focused at the periphery of the tumours. This coupled with the small 
sample sizes used in this study is likely to account for the lack of observed statistical 
reduction in HER2 and HER3 activity. AZD8931 treatment also reduced total HER2 
expression in the MMTV-NIC PTEN 
FL/+ 
cohort but not in the MMTV-NIC PTEN
+/- 
cohort. 
Further experiments are currently underway to explore the impact of AZD8931 treatment on 
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Figure 4.13- AZD8931 reduced HER2 expression in MMTV-NIC PTEN 
FL/+
 but not MMTV-
NIC PTEN
+/- 
tumours. IHC was performed on paraffin embedded sections of AZD8931 
and vehicle treated tumours with a total HER2 antibody. Membranous histoscore 
calculated as the sum of the product of percentage cells stained by the intensity 
graded from 0-3, where 1=weak, 2=moderate and 3=strong staining (histoscore = (% 
*1) + (% *2) + (% *3)). A: IHC analysis of HER2 in AZD8931 and vehicle treated tumours. 
MMTV-NIC PTEN 
FL/+
: p=0.05, MMTV-NIC PTEN
+/-
: p=1.0 (Mann-Whitney U test). Black 
data points represent vehicle treated tumours. Red data points represent AZD8931 
treated tumours. Bar represent mean value for each genotype.  B: Representative IHC 
images of vehicle and AZD8931 treated MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/-
 
tumours. Negative control consists of tumour section incubated in the absence of 
primary antibody. Mag x40. Scale bar represents 100 μm. 
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Figure 4.14- AZD8931 treatment reduced HER2 phosphorylation although this did not 
reach statistical significance. IHC was performed on paraffin embedded sections of 
AZD8931 and vehicle treated tumours with a pTyr 1221/1222 HER2 antibody. 
Membranous histoscore calculated as the sum of the product of percentage cells 
stained by the intensity graded from 0-3, where 1=weak, 2=moderate and 3=strong 
staining (histoscore = (% *1) + (% *2) + (% *3)). A: IHC analysis of pTyr 1221/1222 HER2 
in AZD8931 and vehicle treated tumours. MMTV-NIC PTEN 
FL/+
: p=0.48, MMTV-NIC 
PTEN
+/-
: p=1.0 (Mann-Whitney U test). Black data points represent vehicle treated 
tumours. Red data points represent AZD8931 treated tumours. Bar represent mean 
value for each genotype. B: Representative IHC images of vehicle and AZD8931 
treated MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/-
 tumours. Negative control 
consists of tumour section incubated in the absence of primary antibody.  Mag x40. 
Scale bar represents 100 μm. 
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Figure 4.15- AZD8931 reduced HER3 activity, although this did not reach statistical 
significance. IHC was performed on paraffin embedded sections of AZD8931 and 
vehicle treated tumours with a pTyr 1289 HER3 antibody. Membranous histoscore 
calculated as the sum of the product of percentage cells stained by the intensity 
graded from 0-3,where 1=weak, 2=moderate and 3=strong staining (histoscore = (% *1) 
+ (% *2) + (% *3)).  A: IHC analysis of pTyr 1289 HER3 in AZD8931 and vehicle treated 
tumours. Black data points represent vehicle treated tumours. Red data points 
represent AZD8931 treated tumours. Bar represent mean value for each genotype. 
MMTV-NIC PTEN 
FL/+
: p=0.20, MMTV-NIC PTEN
+/-
: p=0.07 (Mann-Whitney U test).  B: 





 tumours. Negative control consists of tumour section incubated in 
the absence of primary antibody.  Mag x40. Scale bar represents 100 μm. 
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Figure 4.16- Limited expression of EGFR in MMTV-NIC PTEN 
FL/+
 and MMTV-NIC 
PTEN
+/-
 tumours. IHC was performed on paraffin embedded sections of AZD8931 and 
vehicle treated tumours with an EGFR antibody. Representative IHC images of vehicle 
and AZD8931 treated MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/-
 tumours. Positive 
control consists of section of A431 derived xenograft stained with EGFR antibody. 
Negative control consists of tumour section incubated in the absence of primary 
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 tumours. IHC was performed on paraffin embedded sections of 
AZD8931 and vehicle treated tumours with a pTyr 992 EGFR antibody. Representative 
IHC images of vehicle and AZD8931 treated MMTV-NIC PTEN 
FL/+
 and MMTV-NIC 
PTEN
+/-
 tumours. Positive control comprises section of A431 xenograft stained with 
pTyr 992 EGFR antibody. Negative control consists of tumour section incubated in the 
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4.3.2 RPPA analysis of AZD8931 treatment in MMTV-NIC PTEN FL/+ and 
MMTV-NIC PTEN+/- tumours. 
 
In order to provide more definitive evidence of signaling changes, we carried out RPPA 
analysis on vehicle and drug treated tumours (K. Macleod), enabling us to look at changes 
in a range of signaling molecules (for full set of results see Appendix 3). Wherever possible 
the ratio of the phosphorylated protein to corresponding total protein was calculated to give a 
measure of the signaling pathway activity. Where this was not possible, data was corrected 
using the global normalization technique [282].   
 
We wanted to use this platform to further assess changes in the activity of HER family 
proteins in response to AZD8931. Two antibodies were used to assess changes in total 
HER2 expression with differing results. One antibody from CST detected an increase in 
HER2 expression following AZD8931 treatment in both MMTV-NIC PTEN
+/-
 (p=0.01, Mann 
Whitney U test) and MMTV-NIC PTEN 
FL/+ 
(p=0.07, Mann Whitney U test) tumours (Appendix 
3). However, the second antibody from DAKO did not detect any difference in HER2 
expression between vehicle and AZD8931 treated tumours. When tested on western blot 
using a third total HER2 antibody and quantified using Image J, we observed a non-
statistical increase in the median intensity of the HER2 band (corrected for loading using 
GAPDH) from 1.03 in vehicle treated tumours to 3.25 in drug treated MMTV-NIC PTEN 
FL/+
 
tumours (p= 0.10, Mann Whitney test). Similarly, the HER2 band intensity was increased 
from 1.64 in vehicle treated tumours to 3.35 in drug treated MMTV-NIC PTEN
+/-
 tumours (p= 
0.11, Mann Whitney U test) (Figure 4.20). 
 
Using RPPA, we initially explored HER2 activity using a pTyr 2243 HER2 antibody, which is 
validated for use on this platform. However, the antibody signal was too low in all samples to 
enable further quantification. The signal from an alternative HER2/EGFR pTyr1248/Tyr1173 
antibody was more robust and as we have previously demonstrated, using IHC, that EGFR 
expression was low in these tumours, the signal from this antibody likely predominantly 
reflected HER2 activity alone. Our RPPA data identified a trend towards reduced 
pTyr1248/Tyr1173 HER2/EGFR expression in the MMTV-NIC PTEN
+/-
 model, which did not 
reach statistical significance (p=0.30, Mann Whitney U test) (Figure 4.18B). Unexpectedly, 
RPPA did not demonstrate a reduction in HER2 activity in the MMTV-NIC PTEN 
FL/+
 model 
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(Figure 4.18A). However, when western blot was used to measure HER2 activity in these 
samples using a pTyr 1221/1222 HER2 antibody and quantified using Image J, a non-
statistically significant reduction in HER2 activity was seen in both models. P Tyr1221/1222 
HER2: HER2 (both corrected for variations in loading using GAPDH) was reduced from 0.94 
in vehicle treated MMTV-NIC PTEN 
FL/+
 tumours to 0.34 in drug treated tumours (p=0.11, 
Mann Whitney U test, Figure 4.20A). Similarly, in MMTV-NIC PTEN
+/-
 tumours, HER2 
pTyr1221/1222: HER2 was reduced from 0.81 in vehicle treated tumours to 0.11 in drug 
treated tumours (p=0.11, Mann Whitney U test, figure 4.20B). The most likely explanation for 
the lack of concordance between our RPPA and western data is the heterogeneous nature 
of these tumours which were comprised of multiple different cell clones which were also 
likely to have varying sensitivity to AZD8931.    
 
RPPA analysis also did not identify any convincing evidence of reduced HER3 or EGFR 
activity in either model although it is important to note that the antibody signal from all 
samples was extremely low. It is therefore impossible to confidently differentiate changes in 
signalling pathway activity from background ‘noise’. We were unable to validate these 
changes using western blotting due to poor antibody signal.  
 
Crucially, RPPA identified a statistically significant reduction in both Akt and MAPK activity in 
AZD8931 treated tumours in both models (Figure 4. 19). PTEN negatively regulates Akt 
activity. Consistent with this, Akt activity in vehicle treated MMTV-NIC PTEN 
FL/+ 
tumours was 
lower than in MMTV-NIC PTEN
+/- 
tumours (Appendix 3). However, AZD8931 treatment 
inhibited Akt activity (measured in terms of p Ser 473 Akt) in both models (Figure 4.19). 
MAPK activity was also suppressed to a similar extent in both models (Appendix 3).  The 
reduction in Akt and MAPK activity in both models was corroborated using western blot 
(Figure 4.19). Furthermore, a statistically significant reduction in S6 ribosomal protein 
activity, which is downstream of Akt, was observed in both models on RPPA analysis (Figure 
4.19). However, there was no reduction in other signalling pathways downstream of Akt, 
such as mTOR and GSK-3-beta (Appendix 3).  
 
Our initial in vivo data demonstrated that the MMTV-NIC PTEN 
FL/+ 
model was inherently 
more sensitive to AZD8931 than the MMTV-NIC PTEN
+/- 
model. We therefore hoped that by 
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looking for differences in the AZD8931 triggered signalling response between the 2 models, 
we may be able to identify potential biomarkers capable of identifying patients with AZD8931 
sensitive disease. In addition to the above changes, RPPA identified a statistically significant 
reduction in PI3K p110-alpha expression following AZD8931 treatment but only in the 
MMTV-NIC PTEN 
FL/+ 
model (p=0.05, Mann Whitney U test). Although baseline Src 
expression was similar between both models, a significant reduction in Src activity (p=0.03, 
Mann Whitney U test) was seen in the MMTV-NIC PTEN 
FL/+ 





In conclusion, the reduced HER2 activity coupled with the profound inhibition of both Akt and 
MAPK activity provides compelling evidence that the drug response seen in these models is 
both real and due to on-target effects. Reduced PI3K  p110-alpha expression and inhibition 
of Src activity following AZD8931 treatment may act as early positive predictive biomarkers 





Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
 




Figure 4.18- AZD8931 did not result in demonstrable target inhibition. RPPA analysis 
was performed on lysate from AZD8931 (red data points) and vehicle (black data 
points) treated MMTV-NIC PTEN 
FL/+ 
(A) and MMTV-NIC PTEN
+/-
 (B) tumours.  The ratio 
of pTyr 1289 HER3 to total HER3 is presented. The RFI for all other antibodies are 
corrected using global normalization technique [40]. Each data series is normalised to 
its maximum value.  Asterix denotes statistically significant result. P values calculated 
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Figure 4.19- RPPA analysis demonstrated reduced Akt and p44/42 MAPK pathway 
activity. RPPA analysis was performed on lysate from AZD8931 (red data points) and 
vehicle (black data points) treated MMTV-NIC PTEN 
FL/+ 
(A) and MMTV-NIC PTEN
+/-
 (B) 
tumours.  The ratio of phospho:corresponding total protein is presented [206], 
normalized to the maximum value in each data set. Asterix denotes statistically 
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Figure 4.20- Western blot confirmed RPPA findings that AZD8931 inhibited AKT and 
p44/42 MAPK (ERK1/2) activity in MMTV-NIC PTEN 
FL/+
 (A) and MMTV-NIC PTEN
+/-  
(B) 
tumours. Representative blots shown from a series of 2. 40 µg protein loaded in each 
lane. GAPDH used as loading control. Image J used to quantify western blots and 
results shown in right panel. P values calculated according to Mann Whitney U test. 
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4.3.3 Effect of AZD8931 on tumour proliferation 
 
We assessed proliferation of both MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/- 
tumours by 
performing IHC with a Ki67 antibody and used ImmunoRatio software to quantify the 
percentage of Ki67 positive nuclei [283]. MMTV-NIC PTEN
+/- 
tumours grew more rapidly than 
MMTV-NIC PTEN 
FL/+ 
tumours. It was therefore surprising that the median percentage Ki67 
positive nuclei was higher in the vehicle treated MMTV-NIC PTEN 
FL/+ 
tumours than in the 
vehicle treated MMTV-NIC PTEN
+/- 
(p=0.004, Mann Whitney U test, Figure 4.21). However, 
AZD8931 reduced proliferation in both MMTV-NIC PTEN 
FL/+
 (n=3 for each treatment group) 
and MMTV-NIC PTEN
+/- 
tumours (n=4 for each treatment group) (Figure 4.21). In the MMTV-
NIC PTEN 
FL/+
 cohort median percentage Ki67 positive nuclei was reduced from 70.0% in 
vehicle to 32.2% in AZD8931 treated tumours (p=0.010, Mann Whitney U test). The median 
percentage Ki67positive nuclei was 54.6% in vehicle treated MMTV-NIC PTEN
+/-
 tumours 
compared to 35.0% in AZD8931 treated tumours (p=0.005, Mann Whitney U test). There 
was no statistical difference in percentage of Ki67 positive nuclei in AZD8931 treated MMTV-
NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/- 
tumours (p= 0.766, Mann Whitney U test).    
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Figure 4.21- AZD8931 inhibited tumour proliferation.  IHC was performed on paraffin 
embedded sections of AZD8931 and vehicle treated tumours with a Ki67 antibody. 
Images analysed using ImmunoRatio software to calculate percentage nuclei positive 
for Ki67 in six randomly selected low power fields (mag x20) per tumour. A: Box–
whisker plot analysis of percentage of nuclei positive for Ki67. MMTV-NIC PTEN 
FL/+
 
(n=3 in each treatment group, p= 0.010, Mann Whitney U test). MMTV-NIC PTEN
+/-
 (n=4 
in each treatment group, p=0.005).  B: Representative IHC images of vehicle and 
AZD8931 treated MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/-
 tumours. Negative 
control consists of tumour section incubated in the absence of primary antibody.  
Scale bar represents 100 μm. Mag x20.    
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4.3.4 Effect of AZD8931 on apoptosis 
 
AZD8931 treatment resulted in a minimal increase in apoptosis as evidenced by the 
presence of cleaved caspase 3 (Figure 4.22B). However, expression was low in all groups 
with 0.1% tumour area staining positively for cleaved caspase 3 in AZD8931 treated tumours 
in both MMTV-NIC PTEN 
FL/+ 
(p=0.05) and MMTV-NIC PTEN
+/- 
(p=0.04) cohorts (Figure 
4.22A). Whilst this represents a statistically significant increase in expression compared to 
vehicle treated tumours, such low expression is likely to be of minimal biological relevance. 
 
4.3.5 Effect of AZD8931 on tumour vascularization 
 
Tumour progression is dependent on efficient tumour vascularization. Inhibition of 
angiogenesis is one of the proposed mechanisms of action of trastuzumab [284]. Therefore, 
we stained sections of vehicle and AZD8931 treated MMTV-NIC PTEN
+/- 
tumours with a 
CD31 antibody, a marker of endothelial cells and vasculature [285]. To maximize the 
potential of identifying any impact on vascularization, only tumours from the long term 
treatment study were stained and analyzed. As long term AZD8931 treatment resulted in 
complete or near complete resolution of the majority of MMTV-NIC PTEN 
FL/+
 tumours, this 
analysis was restricted to MMTV-NIC PTEN
+/- 
tumours. Vascularization was expressed in 
terms of the mean percentage area contained within a CD31 positive region in 6 
representative low-powered fields (mag x20) per tumour. Prolonged AZD8931 treatment did 
not alter either vessel morphology or the extent of tumour vascularization (p= 0.53, Mann 
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Figure 4.22- AZD8931 did not cause significant levels of apoptosis. IHC was 
performed on paraffin embedded sections of AZD8931 and vehicle treated tumours 
with a cleaved caspase 3 antibody. Images analysed using Image J software to 
calculate percentage area staining positive for cleaved caspase 3 in six randomly 
selected low power fields (mag x20) per tumour. A: Box-whisker plot analysis of 
percentage area positive for cleaved caspase 3 in MMTV-NIC PTEN 
FL/+
 (n=3 in each 
treatment group, p= 0.053, Mann Whitney U test) and MMTV-NIC PTEN
+/-
 (n=4 in each 
treatment group, p=0.042). B: Representative IHC images of vehicle and AZD8931 
treated MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/-
 tumours. Positive control consists 
of section of 4T1 tumour treated with doxorubicin.  Scale bar represents 100 μm. Mag 
x20.    
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Figure 4.23- AZD8931 did not inhibit angiogenesis in MMTV-NIC PTEN
+/-
 tumours.  IHC 
was performed on paraffin embedded sections of AZD8931 (n=3) and vehicle (n=2) 
treated tumours with a CD31 antibody. Images analysed using Image J software to 
calculate percentage area within a CD31 positive region in six low power fields (mag 
x20) per tumour. A: Box–whisker plot analysis of extent of vascularization in vehicle 
and AZD8931 treated tumours (p=0.53, Mann Whitney U test). B: Representative IHC 
images of vehicle (i) and AZD8931 (ii) treated tumours. Arrowheads denote 
representative blood vessels. Negative control consists of tumour section incubated 
in the absence of primary antibody (iii).  Scale bar represents 100 μm. Mag x20. High 
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 model to assess response to 
dasatinib in HER2 positive breast cancer. However, due to concerns that the slow tumour 
growth in this model was not reflective of the aggressive course of human HER2 positive 
disease, we opted to use the MMTV-NIC model for further experiments. In this current series 
of experiments, we aimed to describe MMTV-NIC tumour development and to assess tumour 
response to drugs with known efficacy in HER2 positive breast cancer thereby determining 
whether this is an appropriate model of human disease. PTEN loss is a common genetic 
event occurring in between 25% [229] and 50% [104] of HER2 positive breast cancer cases. 
By crossing the model with a strain containing a floxed PTEN allele, we aimed to explore the 
role of PTEN status in determining sensitivity to HER2 directed therapies using AZD8931, a 
novel pan-HER inhibitor, as an example.  
 
4.4.1 Characterisation of MMTV-NIC PTEN model 
 
We used IHC to explore HER2 protein expression in MMTV-NIC PTEN
+/- 
tumours. Although 
most tumours expressed large amounts of HER2, only 25% were classified as HER2 over-
expressing on the basis of their IHC result alone according to the ASCO/CAP guidelines. A 
further 50% had an equivocal result (2+) and require further assessment using Fluorescent 
In Situ Hybridisation (FISH) to determine their HER2 status [83]. The ASCO/CAP guidelines 
were devised for use in human breast cancer and their relevance for determining thresholds 
of HER2 expression in transgenic mouse models is questionable. Tumourigenesis in human 
HER2 positive breast cancer is driven by genetic amplification and/or over-expression of 
wild-type HER2 [277]. Although spontaneous HER2 mutations have been identified, these 
have been in the context of tumours without HER2 gene amplification or protein over-
expression [169]. In contrast, wild-type HER2 over-expression in mouse models only 
resulted in tumour development after the acquisition of secondary mutations [286] [287]. In 
the MMTV-NIC model, tumourigenesis is driven by a mutated and constitutively activated 
HER2 transgene, which shares similarities with the naturally occurring HER2Δ16 protein 
seen in human breast cancer. In this mutated transgene,  a 16 amino acid deletion in the 
extracellular domain promotes the formation of inter-molecular disulphide bonds which 
stabilize HER2 homodimers and gives the transgene a 10-fold greater transforming capacity 
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than wild-type HER2 [266]. Given this enhanced transforming ability, lower expression of the 
mutant transgene may be required to generate the HER2 phenotype. This hypothesis is 
supported by previously published data showing that treatment with a HER2 directed 
antibody inhibited tumour growth in MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/-
 models 
[40]. Furthermore, in our own experiments we saw a marked response to treatment with 
single agent AZD8931. Despite the dependence of human HER2 positive breast cancer on 
the HER2/PI3K/Akt pathway, response rates to both single agent trastuzumab (15-26%) and 
lapatinib (24%) are modest [137]. Although there is no clinical data for AZD8931 efficacy in 
human HER2 positive disease, the response to drug in our experiments, particularly in the 
MMTV-NIC PTEN 
FL/+
 model, was more dramatic than anticipated. This may suggest that, 
despite reduced HER2 expression, the MMTV-NIC model is actually more dependent on 
HER2 signalling for growth than human disease and inhibition of this signalling pathway 
results in profound tumour responses. 
 
The apparent discrepancy between lower than predicted HER2 expression and reliance on 
HER2 signalling may also be due to a variety of technical issues. Variations in tumour 
fixation and section storage have been reported to have a significant impact on HER2 
staining in sections collected as part of large phase 3 clinical trials. The choice of primary 
antibody also impacts on the staining pattern and intensity [288] and in these experiments 
we did not use the FDA-approved Hercep Test (® DAKO), which is standard in clinical trials. 
Finally, histoscoring is a highly skilled technique and tumour sections in these experiments 
were scored by a single observer. Ideally tumours should be independently scored by at 
least 2 observers, although considerable inter-observer scoring variation is often seen. In 
fact, when a series of experienced scorers were assessed using the Hercep Test (® DAKO) 
only 57-65% demonstrated an acceptable standard of performance [288].  
 
The localization of HER2 detected by IHC is also intriguing. As predicted, membranous 
staining predominated throughout most tumours. However, multiple tumours contained 
regions with extensive cytoplasmic staining but weak/little membranous staining. There are 2 
main explanations for this. Firstly, it may be a result of the extracellular domain NDL deletion, 
which confers constitutive activity to the receptor but may also affect receptor targeting to the 
membrane. Secondly, following receptor activation and downstream signaling, the HER2 
receptor complex is internalized and either degraded or recycled and returned to the 
receptor membrane [77]. Constitutive activation of HER2 may result in rapid receptor 
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signaling and subsequent internalization resulting in significant pools of the receptor within 
the cytoplasm.  
 
Using IHC we also determined that MMTV-NIC PTEN
+/-
 tumours did not express ER or PR. 
In a recent case series of over 3000 patients with HER2 positive breast cancer, 49% were 
classified as HR negative [129]. These patients tended to present with more advanced 
disease and had an increased risk of death in the 5 years following diagnosis [129]. This 
model is therefore not only clinically relevant but representative of a high risk patient group 
who require additional therapeutic options. 
 
Using a single lung section, we identified evidence of metastatic spread in 25% of MMTV-
NIC PTEN
+/-
 mice and previously published data using a higher number of lung sections per 
mouse suggests this is likely to be an under-estimate [272]. The development of 
spontaneous metastases is frequently cited as a major advantage of GEMMs making them 
valuable tools for assessing drug efficacy in the metastatic setting. This is potentially a major 
advance as whilst many patients with early breast cancer are successfully treated, there are 
currently no curative treatments for metastatic disease and it is no longer possible to assume 
that drugs which are active in primary tumours will be active in metastases as subsets of 
genes have been shown to be differentially expressed between primary and metastatic 
tumours [168]. Furthermore, preclinical studies have shown that the normal tissue 
surrounding a tumour is also capable of influencing its response to treatment [289]. There 
therefore remains a major unmet need to develop preclinical models of metastatic disease. 
However, in this study the burden of metastatic disease was too low in all animals to permit 
further quantification. Although metastatic spread is now considered to be an early event in 
tumour progression [290], the rapid growth of mammary tumours in this model is likely to 
have resulted in the sacrifice of animals before the development of established metastatic 
deposits. Removal of multiple mammary tumours to enable to further growth of metastatic 
deposits in this model is not feasible and therefore in the following studies we have focused 
on drug efficacy in the primary tumours.  
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4.4.2 Predictive value of the MMTV-NIC PTEN+/- model for assessing 
drug response  
 
We used paclitaxel, a drug with known efficacy in HER2 positive breast cancer, to determine 
the MMTV-NIC PTEN
+/-
 model’s appropriateness for predicting drug response in human 
HER2 positive disease. Four weekly doses of paclitaxel prolonged OS in MMTV-NIC
+/-
 mice 
and resulted in a statistically significant increase in apoptosis, although the biological 
relevance of such a small increase is questionable. However, it did not cause tumour 
shrinkage instead resulting in slowed yet continual growth, which in the context of a clinical 
trial would be classified as progressive disease. This universal lack of tumour shrinkage 
stands in marked contrast to paclitaxel’s activity in human disease, where response rates of 
between 22% and 78% have been described in metastatic disease [291]. This data precedes 
the introduction of routine HER2 testing and is therefore likely to reflect paclitaxel’s efficacy 
in a mixed cohort of both HER2 positive and HER2 negative breast cancers. However, 
taxane sensitivity is generally believed to be independent of HER2 status [292] [293] and 
therefore similar response rates would be expected amongst an exclusively HER2 positive 
population. There is little available data for the use of single agent paclitaxel in the 
neoadjuvant setting in human HER2 positive breast cancer as it is generally given 
sequentially with an anthracycline and concomitantly with trastuzumab, which increases the 
pathological complete response rates (PCR) [294]. However, 25% of patients treated with 
neoadjuvant paclitaxel and 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in the 
absence of trastuzumab achieved a PCR [294].  
 
There are several possible explanations for the discrepancy between paclitaxel activity in 
humans and in the MMTV-NIC
+/-
 model. Firstly, the polyclonal nature of these tumours 
coupled with their extremely rapid growth rate makes these tumours a greater therapeutic 
challenge than human breast cancer and the rapid development of resistant clones may be 
inevitable. Secondly, the limited efficacy of paclitaxel may be attributable to inefficient drug 
delivery as suggested by the focal nature of apoptosis within tumours. Extensive areas of 
necrosis are observed throughout many of these tumours, suggesting they outgrow their 
blood supply and therefore drug delivery to large regions of actively growing tumour may be 
compromised. Finally, in this study mice were treated at only 50% of the maximum tolerated 
dose (MTD) of paclitaxel. Interestingly, unlike in humans, the MTD in mice is dictated by the 
toxicity of the cremaphor vehicle rather than the active drug [295]. Therefore, the lack of 
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tumour shrinkage in response to paclitaxel may in part be related to the use of a suboptimal 
drug dose and future experiments should use the MTD of cremaphor.   
 





mice, single agent AZD8931 increased OS, although 
the degree of tumour sensitivity was dependent on PTEN status (see section 4.7.2.4 for 
further discussion). Comparison of tumours with the same genotype demonstrated 
heterogeneity in the rate and extent of response to AZD8931, despite the use of predefined 
genetic mutations to drive tumour development. This variation in therapeutic response has 
been previously described in other GEMMs [296] and contrasts with the more uniform 
response seen in xenograft studies [26]. This is an important advance as it enables us to 
more accurately recapitulate the behaviour of human tumours and is most likely due to the 
random acquisition of secondary mutations during tumour development and progression. 
Consistent with this, human tumours have been shown to have more somatically acquired 
structural rearrangements than GEMM tumours [72] and display greater variation in 
therapeutic response than we have seen in our model. 
 
As we have previously discussed, this model is not suitable to explore drug response in 
metastatic disease. However, the increased rate of metastases seen in the AZD8931 treated 
MMTV-NIC PTEN
+/-
 cohort is an intriguing observation, although the use of small cohorts 
makes it impossible to draw any firm conclusions. The increased rate of detectable 
metastases is likely to reflect the increased OS of this cohort due to AZD8931’s efficacy in 
reducing mammary tumour progression. However, this also suggests that AZD8931 is more 
efficacious in treating primary tumours than metastatic lesions, although further experiments 
are required to confirm this. If this is subsequently confirmed, it raises the possibility of using 
AZD8931 to control local disease facilitating the development of a greater metastatic burden, 
which could be therapeutically targeted with other novel agents.   
 
The exact mechanism, by which AZD8931 inhibits mammary tumour progression remains to 
be fully determined. A robust reduction in the percentage of cells staining positively for Ki67 
was seen in both the MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/- 
models following 3 days 
of treatment with AZD8931. Whilst this reduction in cell proliferation undoubtedly makes an 
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important contribution to AZD8931’s efficacy in vivo, alone it is unable to account for the 
difference in sensitivity seen between the 2 models. Furthermore, given that MMTV-NIC 
PTEN
+/- 
tumours grow more rapidly than MMTV-NIC PTEN 
FL/+
, the higher percentage of 
Ki67 positive nuclei seen in vehicle treated MMTV-NIC PTEN
+/- 
tumours was also surprising. 
The choice of method used to quantify the percentage of Ki67 nuclei may account in part for 
these results. Currently, there are no standardized guidelines for quantification of Ki67 
staining and we scored randomly selected tumour regions to give a measure of cell 
proliferation within the whole tumour. It may have been more appropriate to compare 
proliferation in the most mitotically active tumour regions, which are likely to contain most 
aggressive clones capable of dominating tumour behaviour [234].  
 
A reduction in cell proliferation also does not explain the marked tumour shrinkage seen in 
the MMTV-NIC PTEN 
FL/+ 
cohort. We therefore went on to look for changes in apoptosis 
following drug treatment. AZD8931 resulted in a minor yet statistically significant increase in 
apoptosis in both models. Whilst our GEMM tumours had a much more profound response 
to AZD8391 than predicted from the response of human tumours to trastuzumab or lapatinib, 
the percentage of cells undergoing apoptosis remained equally low [297]. The ability of IHC 
to quantify apoptosis is limited as it is only captures cells which are undergoing apoptosis at 
the time of sacrifice. Apoptosis is a transient event with a limited time between induction of 
apoptosis and removal of cell debris [298] and therefore in future experiments, use of 
modern intravital imaging techniques such as FRET-based probes may be give a more 
dynamic and informative estimate of drug-induced apoptosis [299]. Paclitaxel also results in 
necrotic cell death [300] and this may be the dominant mechanism of cell death in this 
model. We also used IHC to explore the impact of long term AZD8931 treatment on 
angiogenesis but did not detect any effect of treatment on either blood vessel structure or 




Together, these experiments provide preliminary evidence that the MMTV-NIC model is a 
useful tool for predicting activity of therapeutic agents, particularly HER2 directed therapies, 
in human HER2 positive breast cancer. However, considerable inter-species variation in the 
magnitude of response may be observed due to the greater reliance of MMTV-NIC tumours 
on the HER2/PI3K/Akt pathway than their human counterparts. The heterogeneity of 
response to AZD8931 suggests that despite its limitations, this model is better suited for 
preclinical testing of targeted agents than traditional xenografts. Finally, although the exact 
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mechanism of AZD8931’s actions remains to be determined, our data suggests that trials of 
AZD8931 in human HER2 positive breast cancer may be merited. 
 
4.4.3 Analysing Target Pathway Inhibition in Response to AZD8931 
 
One of the main problems with using the MMTV-NIC model to assess response to AZD8931 
has been assessing target inhibition. RPPA and IHC analysis gave conflicting results 
regarding the effects of AZD8931 treatment on HER2 expression. With IHC, a borderline 
statistical reduction in HER2 expression was seen in AZD8931 treated MMTV-NIC PTEN 
FL/+ 
tumours but not in MMTV-NIC PTEN
+/- 
tumours. Two separate antibodies were used to 
assess HER2 expression on the RPPA platform, which again gave conflicting results. Data 
with the first antibody suggested that AZD8931 treatment had no effect on HER2 expression, 
whilst the second showed an increase in HER2 expression associated with drug treatment. 
This drug induced increase in HER2 expression was subsequently confirmed on western blot 
using a third independent HER2 antibody. Whilst an increase in total HER2 expression has 
been described following lapatinib treatment in vitro [301], the lack of consistency between 
antibodies on the RPPA platform and with our IHC result means this result must be 
interpreted with a degree of skepticism. 
 
We then went on to examine the effects of AZD8931 on the activity of HER family receptors. 
Using a combination of IHC, RPPA and western blotting, we demonstrated a non-statistical 
reduction in HER2 activity following AZD8931 treatment. A non-statistical reduction in pTyr 
1289 HER3 expression was also observed using IHC but this was not replicated using 
RPPA. The signal obtained on the RPPA platform with both the total HER3 and pTyr 1289 
HER3 antibodies was weak and it is likely that the system lacked sufficient sensitivity to 
determine changes in this pathway’s activity on these tumours. EGFR expression was too 
low for activity to be quantified using either RPPA or IHC.  
 
Several factors are likely to have contributed to the difficulties in obtaining conclusive 
evidence of target receptor inhibition. Firstly, using both RPPA and IHC we found that 
expression of key signaling molecules was extremely heterogeneous, even amongst 
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tumours of the same genotype. This is likely due in part to the random acquisition of 
secondary mutations, which underpins the observed heterogeneity in tumour response to 
AZD8931. With such heterogeneity, further studies using larger cohorts are needed to fully 
explore the range of signaling responses to AZD8931 treatment and these experiments are 
currently underway. Furthermore, considerable heterogeneity in target receptor expression is 
observed even within individual tumours. This intra-tumoural variation is readily 
demonstrable using IHC, although scoring these samples is complex and ideally needs to be 
undertaken by skilled and experienced observers [288]. Whilst RPPA provides a quantitative 
readout, the small protein concentrations required make it particularly vulnerable to intra-
tumoural sampling bias. Tumour lysate was prepared from whole tumours and therefore in 
addition to epithelial tumour cells is likely to include non-epithelial components, such as 
stromal tissue and macrophages, which are likely to add to the observed signaling pathway 
heterogeneity. As previously described, these tumours also contained large necrotic regions 
and whilst macroscopically necrotic areas were not used to prepare lysate, inclusion of 
microscopic regions may also have potentially obscured significant changes in signaling 
pathway activity. Use of H & E stained slides to guide selection of viable and tumour-rich 
regions for lysate preparation may help to overcome some of these issues in future 
experiments [302] as it has previously been shown that RPPA analysis of laser 
microdissected and non-microdissected samples from the same tumour show considerable 
differences in reported signaling pathway activity [303].  
 
Despite lacking direct conclusive evidence of target receptor inhibition, we believe the robust 
reduction in both Akt and MAPK activity coupled with the marked in vivo response following 
AZD8931 treatment is compelling evidence that the drug’s efficacy is due to on-target 
effects.  
 
4.4.4 Understanding Mechanisms of Resistance to AZD8931 
 
Whilst the introduction of HER2 targeted therapies such as trastuzumab and lapatinib has 
revolutionized the outlook for patients with HER2 positive breast cancer, inherent and 
acquired resistance are frequently encountered problems. Although,  in vitro studies have 
identified numerous different mechanisms of resistance [147], to date none of these 
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resistance pathways or their associated biomarkers have transferred into standard clinical 
practice, reflecting the huge obstacles which need to be overcome during the transition from 
bench to bedside.  The impact of PTEN loss on the sensitivity to HER2 targeted therapies is 
an example of a one such potential mechanism of resistance. Several preclinical studies 
have produced compelling evidence that PTEN loss is associated with trastuzumab 
resistance [271]. The effect of PTEN loss on lapatinib sensitivity has been explored in 2 
preclinical studies with conflicting results [154] [254]. However, despite being the focus of 
several trials, no consensus has been reached on whether clinically PTEN expression 
determines sensitivity to either trastuzumab [150] or lapatinib [254] [304] [176]. The lack of 
concordance between preclinical and clinical data may be due to several factors. Firstly, the 
limited numbers of cell lines used in preclinical studies may fail to recapitulate the complex 
situation seen in a heterogenous disease population. Secondly, within clinical studies, 
analysis of specimens is complicated by the lack of a standardized, validated assay with 
variations in antibody and scoring techniques used. It may also reflect in part the restricted 
capabilities of the most widely used techniques to look at more than a limited range of 
resistance mechanisms. Several small retrospective studies suggested that combining 
markers suggestive of PTEN/PI3K/Akt hyperactivation may be more predictive of response 
to trastuzumab than PTEN alone, although prospective studies failed to conclusively 
demonstrate that benefit from trastuzumab was confined to patients with evidence of 
PTEN/PI3K/Akt pathway hyperactivation [150]. However, the major complication in 
interpreting data from clinical studies is the reliance on biopsies collected at the time of 
diagnosis although many of these trials are conducted in the metastatic setting. A 26% 
disconcordance rate for PTEN status between matched primary and secondary samples has 
been reported [182] and therefore it is likely that any impact PTEN loss has on trastuzumab 
resistance would be obscured by incorrect classification on the basis of PTEN status. As a 
more physiologically relevant preclinical model, the MTMV-NIC model therefore has the 
ability to provide a unique insight into this highly contentious issue. We found that single 
agent AZD8931 prolonged OS in both MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/-
 
models. However, AZD8931 was more effective in the MMTV-NIC PTEN 
FL/+
 model, where it 
caused tumour eradication compared to slowed tumour progression in the MMTV-NIC 
PTEN
+/-
 model. This is consistent with previously published data in this model showing that 
sensitivity to a HER2 targeted antibody was dependent on PTEN status [40]. Further studies 
to explore the activity of AZD8931 in MMTV-NIC PTEN
-/-
 mice are currently underway. 
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Previous data from our laboratory showed a non-statistical reduction in PTEN expression in 
MMTV-NIC PTEN
+/-
 tumours compared to MMTV-NIC PTEN 
FL/+ 
tumours. However, whilst 
Schade et al reported that over 50% of MMTV-NIC PTEN
+/-
 tumours had evidence of LOH 
with loss of the second PTEN allele [272], all 4 of the tumours in our panel retained low level 
PTEN expression. Whole tumours were used to prepare lysate for both western blotting and 
RPPA and therefore the most likely explanation for residual PTEN expression is the inclusion 
of non-epithelial tumour components in the lysate. In future experiments, macrodisection, to 
remove non-epithelial elements, could be used to overcome this issue [302]. Alternatively, 
IHC could be used to explore PTEN expression on an individual cell basis. There is also 
considerable heterogeneity in PTEN expression between the different tumours, especially 
amongst the MMTV-NIC PTEN 
FL/+ 
tumours. Therefore, the use of a small tumour panel size 
may have failed to accurately capture the range of PTEN expression in the full cohorts and 
therefore repeating this experiment with a greater sample size may be beneficial.  
 
Having identified PTEN loss as a key determinant of AZD8931 resistance, we sought to 
identify other, potentially drugable, downstream targets involved in the resistance pathway. 
PTEN is an important negative regulator of the PI3K/Akt pathway [305] and consistent with 
previously published data in this model [272] [40], we found baseline Akt activity was 
increased in MMTV-NIC PTEN
+/-
 tumours compared to MMTV-NIC PTEN 
FL/+
 tumours. Both 
MMTV-NIC PTEN 
FL/+
 and MMTV-NIC PTEN
+/- 
tumours displayed reduced Akt activity 
following treatment with AZD8931, although in both models there was still evidence of 
residual activity following AZD8931 treatment. Incomplete inhibition of Akt signaling is a well-
established mechanism of resistance to HER2 targeted therapies [147] and is likely to 
contribute to the continued tumour progression in the MMTV-NIC PTEN
+/- 
model. Consistent 
with this, Wang and colleagues found that combination therapy with a HER2 monoclonal 
antibody and an Akt inhibitor inhibited growth of MMTV-NIC PTEN
-/-
 tumours, which were 
resistant to treatment with either drug alone [65].  
 
By dephosphorylating PTEN, Src is able to amplify PI3K/Akt activity [216], [306]. AZD8931 
treatment suppressed Src activity but only in the more sensitive MMTV-NIC PTEN 
FL/+
 
model, suggesting that incomplete Src inhibition may also contribute to AZD8931 resistance. 
It is likely that in the MMTV-NIC PTEN 
FL/+ 
model, AZD8931 prevents Src’s inhibition of 
PTEN and therefore downregulates Akt signaling. Experiments are currently in progress to 
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try and determine whether combined treatment with AZD8931 and a Src inhibitor in the less 
sensitive MMTV-NIC PTEN
+/- 
model will result in tumour shrinkage. Targeting Src as a 
means of overcoming resistance is a particularly promising approach as increased Src 
activity has been identified as a common event in cell lines rendered resistant to HER2 
directed therapies using several approaches, such as PTEN loss and over-expression of the 
receptor tyrosine kinases EGFR and IGF1R [216]. As clinical resistance is multi-factorial, 
targeting features common to multiple different resistance pathways is likely to yield the 
greatest therapeutic benefits and high Src activity has been correlated with reduced OS 
following treatment with trastuzumab in metastatic breast cancer [216]. However, response 
rates to single agent dasatinib were disappointing in trastuzumab resistant HER2 positive 
breast cancer [50], although combined treatment with HER2 directed therapy and Src 
inhibitors may be more successful. 
 
In conclusion, GEMMs are useful tools in ongoing efforts to validate putative biomarkers and 
potentially to identify and test therapeutic combinations aimed at overcoming resistance. The 
characteristics of GEMMs uniquely place them to overcome some of the issues seen with 
other preclinical and clinical approaches. They provide a more physiologically relevant model 
than in vitro cell line based assays and despite tumour progression occurring within the 
context of predefined genetic lesions, the stochastic accumulation of secondary mutations 
results in tumour heterogeneity so that results are more generalizable to the disease 
population. Although the degree of tumour heterogeneity seen between GEMMs is clearly 
less than that seen in the clinical HER2 positive population as a whole, the potential for 
GEMM tumours to develop different resistance strategies, which might mask the effect of the 
biomarker in question, is also less. Furthermore, the ability to genetically control expression 
of the biomarker under investigation overcomes the problem of defining high and low 
biomarker expression, which is encountered in clinical trials. Whilst the use of GEMMs alone 
is not sufficient for biomarker validation, they are clearly a useful addition to other existing 
strategies. At present, HER2 status is the only available predictive biomarker of response to 
both trastuzumab and lapatinib but it is unable to predict which patients with HER2 positive 
disease will benefit from treatment. There is a real need to develop better biomarkers for 
disease response and this is likely to become increasingly relevant with the advent of multi-
agent HER2 directed therapy. Development of better biomarkers has the potential to spare 
patients with a good prognosis the additional toxicity and cost associated with these more 
complex treatment strategies.  
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In this series of experiments we have focussed on methods associated with inherent 
resistance. Studying acquired drug resistance involves generating a tumour which is initially 
sensitive to drug treatment but loses this sensitivity following prolonged drug exposure. 
Development of acquired resistance in these models is complicated by the generation of 
multiple tumours with differing inherent sensitivities as the presence of a tumour with de 
novo resistance will necessitate the premature termination of the experiment prior to 
sensitive tumours developing resistance. GEMMs have been used to explore acquired 
resistance [296], although this requires the use of techniques to generate a single tumour 
(see Chapter 5).  
      
4.5 Summary 
    
In conclusion, we have obtained preliminary evidence that the MMTV-NIC model is a useful 
tool for predicting response to drugs in human HER2 positive breast cancer, particularly 
HER2 targeted agents. However, the increased reliance of MMTV-NIC tumours on the 
HER2/PI3K/Akt pathway is likely to result in a greater response to HER2 targeted agents 
than may be expected in human disease. Finally, we have used the model to demonstrate 
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Chapter 5: Development of a model amenable 
to drug studies  
 
Despite the improvements in outcomes seen since the introduction of trastuzumab and 
lapatinib to routine clinical care [307] approximately 5000 patients still die every year of 
HER2 positive metastatic breast cancer in the United States alone [2]. The development of 
acquired resistance to HER2 targeted agents is ultimately a universal phenomenon in 
advanced disease. Therefore, an improved understanding of clinically relevant mechanisms 
of acquired resistance and the development of more drugs which are active in metastatic 
disease remain 2 important unmet goals. Whilst the MMTV-NIC model is a useful tool for 
predicting the therapeutic response of primary tumours, the low metastatic burden makes it 
unsuitable for establishing drug activity in this setting. Furthermore, the development of 
multiple mammary tumours with differing drug sensitivities is a major obstacle in experiments 
investigating the development of acquired resistance. We therefore sought to develop 
methods of using the MMTV-NIC model to generate animals with a single mammary tumour, 
which could either be exposed to cyclical drug treatment to promote acquired resistance or 
resected to enable the development of established metastases.    
 
Specific aims of this section of the project included: 
1. Development and characterisation of tumours generated from mammary fat pad 
injection of established MMTV-NIC cell lines. 
2. Development and characterisation of tumours generated from mammary fat pad 
injection of freshly harvested disassociated mammary tumours. 
3. Use of MMTV-NIC tumour fragments to generate syngeneic orthotopic tumour 
transplants. 
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5.1 Use of established MMTV-NIC PTEN
+/- 
cell lines 




 model had previously been used to generate a panel of cell lines 
(L.Balderstone). A representative cell line (MNP 145 LU) was selected, which on western 
blot had been shown to express HER2 and both cytokeratins 8 and 14, suggesting it was 
derived from a mixed epithelial cell background containing both luminal and basal 
components (L. Balderstone). Recognising the influence of the tumour microenvironment 
on tumour progression [28] and response to therapy [289], we elected to perform orthotopic 
injections of the MNP 145LU cell line in an attempt to generate single mammary tumours. 
We injected 1*10
6
 cells into the four left mammary fat pad (MFP) of 8-week old athymic mice 
(n=6). Mice were monitored twice weekly and tumour size recorded. Tumours were permitted 
to grow to a maximal diameter of 1.5 cm (in any direction).  
 
Tumourigenicity of the cell line was demonstrated with 100% of mice developing a tumour 
with a median onset 21.8 days (range 7.5 - 65.5 days) (Figure 5.1). However, 50% of 
animals (n=3) were sacrificed prematurely due to significant skin ulceration. The remaining 3 
mice were sacrificed due to tumour burden at a median interval of 42 days (range 39-56 
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Figure 5.1- Growth curves of MNP 145 LU derived tumours. Mice were inoculated with 
1*10
6 
MNP 145 LU cells and monitored twice weekly for tumour onset and 
progression. Mean volume calculated from 2 successive readings is plotted against 
time since fragment implantation. Median interval between MFP inoculation and 
tumour onset was 21.8 days (n=6). Median duration of survival post tumour 
development was 42 days (n=3).   
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Cell line derived tumours appeared phenotypically distinct compared to parental GEMM 
tumours with loss of the highly cellular nodules seen in the parental model (Figure 5.2). 
These tumours also exhibited an increased stromal content, within which irregular cellular 
palisades sat with loss of the normal cell-cell contact inhibition. We used IHC to further 
characterize tumours and to determine whether cell line derived tumours recapitulated the 
features of the parental GEMM.  Using Ki67 as a marker of cell proliferation, we showed that 
cell line derived tumours were highly proliferative as we had previously demonstrated for the 
parental GEMM tumours (see chapter 4). However, unlike the parental GEMM tumours, we 
were unable to demonstrate any significant HER2 expression (Figure 5.2). We also found no 
evidence of metastatic spread when a single section of lung tissue per mouse was 
examined. 
 
Although this technique allowed the rapid generation of mammary tumours, the striking loss 
of HER2 expression and the loss of tumour architecture in all tumours meant that this 
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 Figure 5.2- MNP 145 LU generated tumours were not representative of the parental 
GEMM from which they are derived. Ai: Representative H and E images demonstrating 
loss of cellular nodules in the cell line derived tumours. Cell line derived tumours 
contain increased stroma (a) within which sit palisades of cells with loss of contact 
inhibition (b). Main image mag x20, insert mag x40. Aii: Representative images of 
paraffin embedded sections stained with a Ki67 antibody demonstrating highly 
proliferative nature of tumours (n=5, mag x20). Aiii: Representative images of paraffin 
embedded sections stained with a HER2 antibody demonstrating loss of HER2 
expression in cell line derived tumours (n=5) and preserved HER2 expression in 
GEMM tumour from which the cell line was derived (mag x40). B: Box whisker plot 
analysis of percentage of nuclei positive for Ki67 in MNP 145 LU derived tumours 
confirming the highly proliferative nature of these tumours, as previously 
demonstrated for the parental GEMM tumours (see chapter 4). Ki67 images analysed 
using ImmunoRatio software to calculate percentage nuclei positive for Ki67 in six 
low power fields (mag x20) per tumour. 
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5.2 Use of  dissociated MMTV-NIC PTEN
+/-
 tumours 
to generate mammary tumours 
 
To try and overcome the issue of HER2 loss during in vitro culture, tumours from MMTV-NIC 
mice were harvested, dissociated using collagenase and 0.5*10
6
 cells injected into the   
fourth MFP of 3 9-week old FVB mice. As the immune system plays a critical role in tumour 
development  [27], we decided to use immune-competent FVB mice as tumour recipients in 
this experiment to enhance the physiological relevance of the model. Mice were monitored 
twice weekly for tumour onset and growth. 
 
 Tumour penetrance was defined as the percentage of mice that developed a tumour which 
resulted in the animal being sacrificed due to tumour burden. Tumour penetrance was low 
with only 1 of 3 mice developing an established tumour. This tumour was not detected until 
75 days after MFP inoculation, which is much later than the onset of tumours following 
injection of an established cell line. The animal was sacrificed 77 days after tumour onset. A 
second mouse developed an early tumour but this spontaneously regressed.        
 
Due to the poor tumour penetrance rate, we repeated this experiment using a different 
parental tumour but in this experiment we used 2*10
6 
cells to inoculate the fourth MFP of 7 
14-week old FVB mice. Again tumour penetrance rate was disappointing with only 1 of 7 
(14%) mice developing an established tumour at 63 days post inoculation. The tumour 
experienced extremely rapid growth and the animal was sacrificed 7 days later due to 
tumour burden. A further 4 mice developed early tumours but these spontaneously 
regressed after a median of 15.5 days (range 7-42 days).    
 
H and E sections of the resulting tumours demonstrated preservation of the parental 
tumour’s nodular super-structure and stromal content, which was more reflective of that seen 
in the parental model (Figure 5.3). We used IHC with a Ki67 antibody to confirm these were 
highly proliferative tumours. However, unlike the MNP 145 LU tumours, we were able to 
demonstrate continued HER2 expression using IHC. 
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 Histological examination of a single section of lung tissue revealed no evidence of lung 
metastases, although the small numbers of tumour bearing mice make it difficult to draw any 
firm conclusions about the potential of these tumours to metastasize. 
 
In summary, inoculation of freshly dissociated MMTV-NIC PTEN
+/-
 tumours generated 
tumours with similar histomorphological features to the parental GEMM. However, poor 
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Figure 5.3- Inoculation of dissociated MMTV-NIC PTEN
+/-
 tumours generated tumours 
with similar histomorphology to the parental GEMM tumours. Ai: Representative H 
and E images showing highly cellular nodules (a) in both GEMM and dissociated 
MMTV-NIC PTEN
+/-
 tumours. Main image mag x20, insert mag x40. Aii: Representative 
images of paraffin embedded sections stained with a Ki67 antibody demonstrating 
highly proliferative nature of tumours (n=5, mag x20). Aiii: Representative images of 
paraffin embedded sections stained with a HER2 antibody confirming preserved HER2 
expression in dissociated MMTV-NIC PTEN
+/-
 tumours (n=5, mag x40). B: Box whisker 
plot analysis of percentage of nuclei positive for Ki67 in dissociated MMTV-NIC 
PTEN
+/-
tumours.Ki67 images analysed using ImmunoRatio software to calculate 
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5.3 Use of MMTV-NIC PTEN
+/-
 tumour fragments to 
generate mammary tumours  
 
Although freshly harvested and dissociated MMTV-NIC PTEN
+/-
 tumours remained 
tumourigenic when transplanted into syngeneic hosts, the high frequency of spontaneous 
tumour resolution made this approach unfeasible in further experiments. To try and preserve 
the structure of the mature tumour structure without the potentially damaging effects of the 
collagenase treatment, we decided to use fragments derived from mature MMTV-NIC 
PTEN
+/- 
tumours to generate mammary tumours in syngeneic hosts. This approach has 
previously been successfully used with other GEMMs [308], [309] [69].  
  
5.3.1 Optimization of fragment cryopreservation 
 
In order to minimise the stock of recipient mice required, we opted to cryopreserve fragments 
following harvesting. Fragments were then defrosted and transplanted when a suitable 
cohort of recipient mice was available.  
 
Two separate cryopreservation protocols have previously been used in the lab. To compare 
the two protocols, a single MMTV-NIC PTEN
+/-
 tumour was harvested, washed in 70% 
ethanol and PBS and then cut into 2 mm fragments. Half the fragments (original protocol) 
were frozen at -80
0
C in freezing mix (90% FBS, 10% DMSO). The remaining 50% of 
fragments (modified protocol) were re-suspended in PBS and centrifuged at 450 x g for 1 
minute. The supernatant and any suspended material, comprising fat and fibrous tissue, 
were removed. The remaining fragments underwent step-rate freezing in 50:50 DMEM:  
freeze mix. At the time of surgery, both sets of fragments were defrosted and washed in PBS 
prior to transplantation into the fourth MFP of 6 15-week old FVB mice. Mice were monitored 
twice weekly for tumour onset and growth. Animals were sacrificed once tumours reached a 
maximum of 1.5 cm in any single direction. Tumour onset was defined as the development of 
a measurable tumour. OS was measured from the time of tumour onset to the time of 
sacrifice. Tumour penetrance rate was defined as the percentage of mice developing a 
tumour which resulted in the animal being sacrificed due to tumour burden. 
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We observed an increased tumour penetrance rate using the modified protocol. Of 6 mice 
which received fragments prepared using the modified protocol, 4 (66.6%) developed 
tumours with a median onset of 18 days following surgery. In comparison, only 1 mouse 
(16.6%) developed a tumour from a fragment prepared using the original protocol. This 
tumour did not become measurable until 153 days following surgery. The small number of 
tumours generated, particularly using the original protocol, makes it difficult to draw any firm 
conclusions regarding the impact of cryopreservation technique on subsequent tumour 
latency or growth rate. However, the results of this experiment suggest that, possibly 
unsurprisingly, once a tumour is established, further progression is not dependent on the 
method of cryopreservation (Figure 5.4). The median OS of mice bearing tumours derived 
from fragments prepared using the modified protocol was 117.5 days compared to 86 days 
for the single mouse with a fragment prepared using the original protocol.    
 
The improved penetrance rate seen with the modified protocol was likely due at least in part 
to the slower freezing rate as it reduced the risk of intracellular ice crystal formation and 
subsequent cell trauma [310]. However, despite the random allocation of fragments between 
the 2 protocols, it was not possible to exclude variations in fragment composition as an 
explanation for the differing penetrance rates. This was a relatively small study, which we 
have not repeated, making it difficult to conclusively determine that the modified protocol was 
superior to the original protocol. However, our preliminary data does strongly suggest that 
the modified protocol is at least as efficacious as the original protocol and therefore we have 
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Figure 5.4- Growth curve of fragment derived tumours following original (red data line) 
and modified cryopreservation (black data lines) protocols. The efficacy of different 
cryopreservation protocols was compared using fragments derived from the same 
mature MMTV-NIC PTEN
+/-
 tumour. Fragments from both protocols were transplanted 
into fourth MFP of 6 FVB mice. Mice were monitored twice weekly for tumour 
development and growth. Mean volume calculated from 2 successive readings is 
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5.3.2 Determining reproducibility of MMTV-NIC PTEN+/- fragment 
transplantation 
 
To determine the reproducibility of transplantation results, fragments from different parental 
tumours were transplanted into FVB recipients. 
 
We observed considerable variations in tumour penetrance rates in the different experiments 
across this series (Table 5.1). The median tumour penetrance across all experiments was 
40% (range 0-80%). Tumour latency was defined as the interval between fragment 
transplantation and the development of measurable disease. In transplanted fragments 
which successfully established a tumour, the median latency was 23.0 days (range 14-76 
days) with no statistical difference between the latency interval of tumours generated within 
different experiments (p=0.38, single way ANOVA). Transplanted tumours recapitulated the 
variable growth rate seen in the parental model with individual tumours generated from the 
same parental tumour displaying marked differences in growth rates (Figure 5.5). However, 
there was no statistical difference in the OS of mice bearing tumours generated in different 
experiments (p=0.11, single way ANOVA) and this was most likely attributable to the wide 
variations in OS observed within individual experiments. Examination of a single H and E 
section per mouse revealed limited metastatic spread to the lungs in only 2 animals (4.1%) in 
the entire experimental series (Dr. J. Loane, consultant pathologist). In this limited data 
set there did not appear to be any relationship between the presence of metastases in the 
parental GEMM and fragment recipients although using a single lung section to characterize 
metastatic spread within the entire organ is likely to have resulted in a substantial under-
estimation of the true incidence of lung metastases within both the parental GEMM and 
tumour fragment recipients. Whilst, further characterization using a greater number of lung 
sections per mouse would be informative, this initial data does suggest that, similarly to the 
parental GEMM, the growth rate of transplanted tumours was too rapid to permit the 
development of established metastatic disease prior to the time of sacrifice.  
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Table 5.1- Outcomes of a series of MMTV-NIC PTEN
+/-
 fragment transplant 
experiments. Fragments were harvested from different parental MMTV-NIC PTEN
+/- 
tumours and transplanted into FVB mice. Mice were monitored twice weekly for 
tumour onset and growth for a minimum of 150 days. Tumour penetrance was defined 
as the percentage of mice which developed a tumour, which ultimately required the 
animal to be sacrificed. Tumour latency represents the interval between tumour 
transplantation and development of measurable tumour. Median OS was measured 
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Figure 5.5- Comparison of growth curves of fragment derived tumours from different 
experiments. Fragments were harvested from different parental MMTV-NIC PTEN
+/- 
tumours and transplanted into FVB mice. Mice were monitored twice weekly for 
tumour onset and growth. Mean volume calculated from 2 successive readings is 
plotted against time since fragment implantation. Tumours derived from the same 
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5.3.3 Further characterization of fragment derived tumours 
 
Examination of H and E sections from fragment derived tumours revealed that, similarly to 
the parental GEMM, they were comprised of highly cellular nodules (Figure 5.6). 
Examination by an experienced breast pathologist confirmed the presence of highly mitotic, 
grade 3 carcinomas with frequent areas of necrosis, which were indistinguishable from 
tumours developed in the parental GEMM (Dr. J. Loane). To ensure preservation of tumour 
histomorphology during transplantation, sections of fragment derived tumours and the 
parental tumour from which they were derived were stained for both HER2 and Ki67. Both 
parental and fragment derived tumours demonstrated inter- and intra-tumoural heterogeneity 
in HER2 expression. Consistent with the frequent observation of mitotic bodies on H and E 
sections, a high percentage of nuclei stained positively for Ki67 in both parental and 
fragment derived tumours. 
 
Of the 3 methods used to generate single mammary tumours from the MMTV-NIC PTEN
+/-
 
model, fragment transplantation appeared the most promising and we therefore decided to 
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Figure 5.6- Transplantation of MMTV-NIC PTEN
+/- 
fragments generated tumours which 
were indistinguishable from the parental GEMM tumours. Ai: Representative H and E 
images demonstrating that both GEMM and fragment derived tumours were 
comprised of highly cellular nodules. Tumours were highly proliferative and contained 
multiple cells undergoing mitosis (a). Both GEMM and fragment derived tumours 
contained frequent areas of necrosis (b). Main image mag x20, insert mag x40. Aii: 
Representative images of paraffin embedded sections stained with a Ki67 antibody 
demonstrating highly proliferative nature of tumours (n=12, mag x20). Aiii: 
Representative images of paraffin embedded sections stained with a HER2 antibody 
demonstrating heterogenous nature of HER2 expression in both GEMM and fragment 
derived tumours (n=5, mag x40). B: Graph of percentage nuclei positive for Ki67 in 3 
sets of matched parental (red data point) and fragment derived tumours (black data 
points). Ki67 images analysed using ImmunoRatio software to calculate percentage 
nuclei positive for Ki67 in six low power fields (mag x20) per tumour. Series 1: p= 0.04, 
series 2: p=0.08, series 3: p=0.03 (Mann Whitney U test).    
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5.4 Exploring factors predictive of tumour 
penetrance 
 
Tumour fragment transplantation allowed the generation of tumours, which recapitulated the 
features of the parental model. However, the variability in tumour penetrance rates was a 
major limitation. Identification of factors predictive of poor penetrance would help to reduce 
the number of recipient animals needed and expedite future experiments. We therefore 
sought to explore factors which might identify a parental tumour as being unsuitable for 
generating fragments.  
 
5.4.1 Growth characteristics of parental tumour 
 
Parental tumours were arbitrarily classified as highly penetrant if ≥ 40% of transplanted 
fragments generated a viable tumour. Tumours with a penetrance rate of <40% were 
classified as poorly/non-penetrant.  
 
We initially examined the characteristics of the parental GEMM tumour from which the 
fragments were derived to determine if these influenced penetrance rates. Tumours arising 
in the first MFP were described as having a cervical origin whilst those originating in the 
second and third MFPs were described as axillary and those from the fourth and fifth MFP as 
inguinal. The site of origin of the parental tumour alone was not sufficient to predict tumour 
penetrance (Table 5.2). We then considered the latency period of the parental tumour to 
determine whether tumours which developed at a younger age conferred a more aggressive 
phenotype resulting in improved penetrance rates.  We observed no difference in the latency 
interval between highly and poorly/non- penetrant tumours. The median age of tumour onset 
in highly penetrant tumours was 78 days compared to 66.5 days in poorly/non-penetrant 
tumours (p=0.16, Mann Whitney U test). Finally, we used OS from the time of parental 
tumour development as a surrogate for growth rate. All parental animals were sacrificed at a 
maximum of 28 days following tumour onset, irrespective of the size of the tumour. When the 
maximum tumour dimension <1.5 cm at the time of sacrifice, OS was defined as > 28 days. 
The median OS in highly penetrant tumours was 28 days compared to 26 days in poorly/non 
penetrant tumours. 
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To explore whether penetrance rates could be influenced by systemic factors in the donor 
animal, we generated fragments using cervical and axillary tumour from the same animal 
(experiments 6 and 7). Fragments from the cervical tumour were poorly penetrant whilst 
those from the axillary tumour were highly penetrant suggesting that systemic features of the 
donor-animal were not responsible for the variable penetrance rates observed. This is 
consistent with previously published data using the MMTV-PyMT driven GEMM, where 
axillary and inguinal tumours from the same animal demonstrated different growth rates and 
different genetic signatures [311].  
 
To explore whether the recipient animal’s characteristics could influence fragment transplant 
outcomes, we transplanted a second set of fragments generated during experiment 3 into a 
further cohort of FVB mice.  Both experiments demonstrated similar penetrance rates (66.6% 
vs. 50%). There was also no statistical difference between the median latency interval of 
fragment derived tumours in the 2 experiments (20 vs. 33.5 days, p=0.16, Mann Whitney U 
test).  
 
In summary, these experiments suggest that the fragment transplant outcomes are primarily 
dependent on, as of yet unidentified, parental tumour characteristics and are not influenced 
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Table 5.2- Parental tumour growth characteristics did not predict for tumour fragment 
penetrance rate. Parental tumours classified as highly or poorly/non- penetrant if ≥ 
40% or <40% fragments generated a viable tumour respectively. Tumour latency 
represented the interval between tumour transplantation and development of 
measurable tumour. Median OS measured from the development of a palpable tumour 
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5.4.2 Histomorphology of parental tumours  
 
We used IHC to further explore parental factors which might influence the outcomes of 
tumour fragment transplantation. Using Ki67, we found all tumours were highly proliferative. 
There was no statistical difference in the percentage of nuclei which stained positively for 
Ki67 between poorly/non-penetrant and highly penetrant tumours (p=0.60, Mann Whitney U 
test, Figure 5.7). HER2 expression was also unchanged between highly and poorly/non-
penetrant tumours. The use of non-transplanted tumour regions to predict fragment 
phenotype is clearly a limitation of these experiments, particularly as these are such 
heterogeneous tumours. Future experiments may be improved by selection of adjacent 
tumour tissue for assessing phenotype and generation of fragments to help minimise the 
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Figure 5.7- Ki67 and HER2 expression was unaltered between poorly/non-penetrant 
and highly-penetrant tumours. Ai: Representative images of paraffin embedded 
sections from both poorly/non-penetrant and highly-penetrant tumours stained with a 
Ki67 antibody (mag x20). Aii: Representative images of poorly/non-penetrant and 
highly-penetrant paraffin embedded sections stained with a HER2 antibody (mag x40). 
Bi: Quantification of percentage nuclei positive for Ki67 in both poorly/non-penetrant 
(n=2) and highly-penetrant tumours (n=2, p=0.60, Mann Whitney U test). Ki67 images 
analysed using ImmunoRatio software to calculate percentage nuclei positive for Ki67 
in six low power fields (mag x20) per tumour. Bii: Membranous HER2 histoscore of 
poorly/non-penetrant (n=2) and highly penetrant (n=2) tumours. Histoscore 
determined by calculating the sum of the product of percentage cells stained by the 
intensity graded from 0-3, where 1 =weak, 2=moderate and 3=strong staining 
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5.4.3 Effect of vascularisation in the parental tumour on 
penetrance rate 
 
Establishment of an independent vascular supply is a critical step in tumour progression. We 
frequently identified macroscopic areas of tumour necrosis within MMTV-NIC tumours, 
suggesting regions of these tumours were under-perfused. We performed IHC using a CD31 
antibody, a marker of vasculature [285], to determine whether poor parental tumour 
vascularisation resulted in hypoxically stressed and non-viable tumour fragments. Due to the 
huge variation in the cross sectional area of individual blood vessels identified, we calculated 
the mean area occupied by blood vessels in 6 low-powered fields (mag x20). We observed 
non-statistically significant variations in the extent of vascularisation between individual 
tumours (p=0.1, one-way ANOVA) (Figure 5.8). However, no difference in the extent of 
vascularisation was identified between poorly/non-penetrant and highly penetrant tumours 
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Figure 5.8- CD31 expression was unaltered between poorly/non-penetrant and highly-
penetrant tumours. IHC was performed on formalin fixed paraffin embedded tumours 
with CD31 primary antibody. Images analysed using Image J software to calculate the 
sum of the area within blood vessel lumens as indicated by CD31 positive staining in 
6 low powered fields per tumour. A: Variation in extent of vascularisation in panel of 
parental tumours. Mean value ± SEM depicted (p=0.10, one-way ANOVA). B: Box-
whisker plot analysis of extent of vascularisation in poorly/non-penetrant (n=2) and 
highly penetrant (n=3) tumours (p=0.37, Mann Whitney U test). Ci: Negative control 
comprising of MMTV-NIC PTEN
+/-
 tumour section incubated in the absence of CD31 
antibody. Scale bar represents 100 μm. Cii: Representative image of IHC with CD31 
antibody on MMTV-NIC PTEN
+/-
 tumour (mag x20). Arrowhead denotes representative 
blood vessels. Ciii: High powered view of CD31 positive blood vessels (mag x40).  
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5.4.4 Effect of HIF1α on tumour penetrance 
 
As the extent of vascularisation was unchanged between highly and poorly/non-penetrant 
tumours, we decided to explore whether differences in the ability to adapt to hypoxia were 
responsible for the variable penetrance rates observed. In human breast cancer, hypoxia, as 
measured by Hypoxia Inducible Factor 1α (HIF1α) expression, is associated with early 
relapse, development of widespread metastases and reduced OS [312]. In addition to 
hypoxia, HIF1α expression may be increased following loss of tumour suppressor genes, 
such as PTEN, increased expression of receptor tyrosine kinases, such as EGFR, and 
hyperactivation of intracellular signalling pathways, such as Akt and Src. Following its 
activation, HIF1α translocates to the nucleus and dimerizes with HIF1β to form HIF1. HIF1 
regulates a range of pro-survival responses that select for an increasingly aggressive and 
invasive cancer phenotype [313].  
 
 Given the high expression of HER2 and hyper-activation of the Akt pathway, it was 
unsurprising that a panel of parental tumours all stained strongly for nuclear HIF1α when IHC 
was performed (Figure 5.9). However, there was no statistical difference in nuclear 
histoscore when highly and poorly/non-penetrant tumours were compared (p= 0.14, Mann 
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Figure 5.9- HIF1α expression was unaltered between penetrant and poorly/non-
penetrant tumours. IHC was performed on formalin fixed paraffin embedded tumours 
with HIF1α primary antibody. Nuclear histoscore was determined using 6 
representative high powered fields (x40 mag) and calculating the sum of the product 
of percentage cells stained by the intensity graded from 0-3 (histoscore = (% *1)+ (% 
*2) + (% *3)). A: Variation in expression of HIF1α in a panel of 5 parental tumours. 
Mean value ± SEM depicted (p=0.08, one way ANOVA). B: Box-whisker plot analysis of 
HIF-1α in poorly/non-penetrant (n=2) and highly penetrant (n=3) tumours (p=0.14, 
Mann Whitney U test). Ci: Negative control comprising of MMTV-NIC PTEN
+/-
 tumour 
section incubated in the absence of HIF1α antibody. Scale bar represents 100 μm. Cii: 
Representative image of IHC staining with HIF1α antibody on MMTV-NIC PTEN
+/-
 
tumour. (Mag x40).  
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5.4.5 The effect of the immune system on tumour penetrance 
rate 
 
In all the previously described experiments, we observed instances of spontaneous tumour 
resolution following initial growth. The MMTV-NIC model was generated on an FVB 
background and therefore fragment transplantation was classified as syngeneic. However, 
prior to transplantation, recipient animals had not been exposed to Cre-recombinase or the 
rat-derived HER2 transgene used in this model and therefore an immune response against 
epitopes on these proteins could be mounted. We hypothesised that increased 
immunogenicity might explain the low penetrance rates observed with some of these 
tumours. 
 
To determine the effect of the immune system on tumour penetrance, fragments from a 
single MMTV-NIC PTEN
+/-
 tumour were transplanted into the fourth MFP of either 6-week old 
immunocompetant FVB mice (n=5) or athymic nude mice (n=5). Tumour penetrance was 
high (80%) in both cohorts. However, the rate of tumour growth was slower in the athymic 
mice with a non-statistically significant delay in tumour onset (Figure 5.10). Median tumour 
onset was 33.5 days (range 27-44 days) in athymic mice compared to 23.0 days (range 23-
72 days) in the FVB recipients (p=0.30, Mann Whitney U test). There was also a marked 
increase in OS from 42.5 days (range 25-139 days) in FVB recipients to 108.5 days (range 
60-157 days) in athymic mice (p= 0.11, Mann Whitney U test). The lack of statistical 
significance was likely due to both the small cohort sizes used and the wide variation in OS 
seen within cohorts in this experiment.    
 
To determine whether the reduced growth rate seen in the athymic cohort was due to the 
strain of the recipient animals or a consequence of impaired immunity, we transplanted 
fragments from a second parental tumour into either FVB mice (n=6) or age matched CD-1 
nude mice (n=4). Animals were monitored twice weekly for tumour development and on 
development of established tumours FVB recipients were entered into drug-response studies 
(see section 6.1). Again tumour penetrance was high in both cohorts with 100% of the CD-1 
nude mice and 66.7% of FVB mice developing established tumours. As in the previous 
experiment, we observed a delay in tumour development in CD-1 nude 
immunocompromised recipients compared to the FVB cohort. Median tumour onset in CD-1 
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nude mice was 32.0 days (range 20-48 days) compared to 21.5 days (range 16-37 days) in 
FVB mice (p=0.31, Mann Whitney U test, Figure 5.10B).     
 
Coincidently, both parental tumours used in these experiments were highly penetrant in both 
immunocompetent and immunocompromised cohorts. It is therefore not possible to 
determine whether initiation of an early immune response against the growing tumour may 
have accounted for the low penetrance rates observed in some of our earlier experiments. 
However, the marked delay in tumour onset seen in both immunocompromised cohorts was 
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Figure 5.10- Tumour growth was delayed in athymic and CD-1 nude tumour-fragment 
recipients. Tumour fragments were transplanted into the fourth mammary fat pad of 
cohorts of FVB mice and immunodeficient mice. Mice were monitored twice weekly for 
tumour onset and progression. Mean volume calculated from 2 successive readings 
was plotted against time since fragment implantation. A: Growth curve of fragment 
derived tumours in FVB mice (solid data line) and athymic nude mice (dashed data 
line). B: Growth curve of fragment derived tumours in FVB mice (solid data line) and 
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5.4.6 The impact of PTEN status on fragment transplantation 
 
5.4.6.1 Exploring the impact of PTEN genotype on tumour fragment 
transplantation  
 
PTEN is an important tumour suppressor gene [314] and therefore its expression may 
impede successful generation of fragment-derived tumours. To explore this further, 
fragments harvested from mature MMTV-NIC PTEN 
FL/+
 tumours were transplanted into the 
fourth MFP of 7-week old FVB mice. This experiment was performed on 3 separate 
occasions using different parental tumours in each experiment. Mice were monitored twice 
weekly for tumour onset and growth for at least 180 days following fragment transplant. 
Overall, only 1 tumour was generated from 21 fragment transplants (Table 5.3). Generation 
of MMTV-NIC PTEN 
FL/+
 transplants was therefore not viable and all future experiments (see 




5.4.6.2 Determining the effect of PTEN protein expression on tumour 
penetrance rates 
 
Previous studies have demonstrated that over 50% of MMTV-NIC PTEN
+/- 
develop LOH for 
PTEN [272]. We therefore decided to explore whether MMTV-NIC PTEN
+/- 
tumours which 
had lost the second PTEN allele were more readily transplantable than those which retained 
it. Using IHC, we demonstrated that PTEN expression was not detectable in the majority of 
both highly and poorly/non-penetrant tumours. All tumours contained small foci of cells which 
had retained PTEN expression but its expression was too restricted to permit further 
quantification (Figure 5.11). This data appears to suggest that PTEN expression was not a 
critical factor in determining tumour penetrance, although the use of non-transplanted 
material to determine the phenotype of the fragments means we cannot exclude residual 
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Table 3.3- Transplantation of MMTV-NIC PTEN 
FL/+ 
fragments failed to generate viable 
tumours. Fragments from 3 MMTV-NIC PTEN 
FL/+
 tumours were transplanted into the 
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Figure 5.11- Representative images of PTEN expression in highly and poorly/non- 
penetrant tumours. IHC performed with a PTEN antibody on highly (n=3) and 
poorly/non-penetrant (n=3) tumours. Negative control consisting of MMTV-NIC PTEN
+/- 
tumour section incubated in the absence of primary antibody. Positive control 
comprising section of BT474 xenograft stained with PTEN antibody. Mag x40. Scale 
bar represents 100 μm. 
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5.5 Serial transplantation of tumour fragments  
 
As we had been unable to identify factors predictive of tumour penetrance, we decided to 
explore whether existing fragment-derived tumours could be used successfully to generate 
further fragments for transplantation.  To determine the feasibility of serial transplantation, 3 
fragment-derived tumours, each generated from a different, highly-penetrant parental 
tumour, were used to produce further fragments. Serial transplantation successfully 
recapitulated the features of first generation fragment transplantation with high penetrance 
and variable growth rates observed in all 3 experiments (Table 5.4). Furthermore, by 
comparing H and E sections and using IHC to stain for HER2 and Ki67 we demonstrated 
preservation of tumour histomorphology (Figure 5.12).  Serial transplantation is therefore 
potentially a suitable option for increasing stocks of reliably transplantable tumour material 
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Table 5.4- Serial transplantation of fragments resulted in cohorts of second 
generation fragment recipients with a high frequency of tumour development. 
Heterogeneity of growth characteristics was maintained following second generation 
transplantation. Fragment-derived tumours from highly penetrant parental tumour 
(experiments 1A, 2A and 3A) were selected at random and used to generate further 
fragments for transplant into further cohorts of FVB mice (experiments 1B, 2B and 
3B).  Animals were monitored twice weekly for tumour onset and development and 
were sacrificed when tumour burden ≥ 1.5 cm in any direction. Tumour latency was 
defined as interval between fragment transplantation and development of a 
measurable tumour. OS was defined from the development of measurable disease 
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Figure 5.12- Transplantation of second generation MMTV-NIC PTEN
+/- 
fragments 
generates tumours with preserved histomorphology of first generation transplant. i: 
Representative H and E images demonstrating preserved tumour morphology 
between first and second generation derived tumours (mag x20). ii: Representative 
images of paraffin embedded sections stained with a Ki67 antibody demonstrating 
highly proliferative nature of tumours (n=3,mag x20). iii: Representative images of 
paraffin embedded sections stained with a HER2 antibody demonstrating 
heterogenous nature of HER2 expression in both first and second generation 
fragment derived tumours (n=3, mag x40).  
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Whilst the MMTV-NIC model is a useful tool for exploring drug efficacy in primary tumours, it 
is not suitable for use in studies looking to characterise drug efficacy in metastatic disease or 
for exploring mechanisms of acquired resistance. There is currently a major unmet need to 
develop models of metastatic breast cancer as it is not possible to assume that drugs which 
are active in early breast cancer will also be efficacious in advanced disease as subsets of 
genes can be differentially regulated between primary and secondary tumours [168]. In 
addition, preclinical studies have shown that the normal tissue surrounding a tumour is 
capable of influencing both the tumour’s microenvironment and its response to therapy [289] 
suggesting that metastatic deposits within different organs may also respond differently to 
treatment. A second urgent priority is the development of physiologically relevant models 
suitable for studying mechanisms of acquired resistance. Acquired resistance to HER2 
targeted therapies is ultimately inevitable in advanced breast cancer. Whilst many different 
resistance mechanisms have been identified using in vitro approaches, very few of these 
have been successfully corroborated in clinical studies. Studying drug activity in metastatic 
disease and the development of tumours with acquired resistance to HER2 targeted agents 
could be facilitated by use of a model with a single mammary tumour, which could be either 
resected to allow development of established metastases or exposed to cyclical drug 
treatment to generate resistant tumours. We therefore decided to explore 3 different 
methods of using the MMTV-NIC model to generate single mammary tumours.   
   
5.6.1 Comparison of methods used for generating single 
mammary tumours 
 
We initially used one of a panel of established MMTV-NIC PTEN
+/-
 cell lines (MNP145 LU)   
to generate mammary tumours. We found that MFP injection of this cell line into a cohort of 
athymic mice resulted in the rapid generation of mammary tumours in all recipients. This was 
consistent with data previously obtained in the lab, which showed that both MFP and 
subcutaneous injections of MNP145LU into FVB recipients also resulted in the rapid 
development of tumours.   However, although western blot had previously been used to 
demonstrate low HER2 expression in the cell line (L. Balderstone), we were unable to 
demonstrate any HER2 expression within the resulting tumours using IHC, precluding the 
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use of this approach in further experiments using AZD8931. Loss of HER2 expression during 
in vitro culture is common, although other groups have successfully managed to develop cell 
lines which retained HER2 expression and sensitivity to HER2 directed therapies [315]. The 
loss of HER2 expression may have been caused by a combination of several factors. Firstly, 
the lines were generated from whole tumours and therefore contained mixed cell 
populations. Developing tumours in vivo are subjected to continual selection pressure 
favouring the proliferation of HER2 expressing cells. The removal of this selection pressure 
during 2D in vitro growth results in the outgrowth of cell populations which are best adapted 
to tissue culture conditions but in this case it may be that these are not the populations which 
are most reflective of the parental tumour. Secondly, MMTV promoter expression is 
frequently lost during in vitro culture, which might also contribute to the loss of HER2 
expression. This could be avoided in the future by supplementation of the media with either 
hydrocortisone or dexamethasone, which, by binding to the promoter’s steroid response 
element, enhances MMTV transcription (H. Smith, personal communication). Finally, these 
cell lines are prone to undergoing EMT, which has previously been associated with loss of 
HER2 expression [167]. Use of 3D tissue culture techniques, which more accurately 
reproduce in vivo growth conditions [316], may help in the future to generate cell lines which 
more fully recapitulate the characteristics of the original tumour. 
 
We used 2 further approaches to try and overcome the issue of HER2 loss during in vitro 
culture; firstly MMTV-NIC PTEN
+/-
 tumours were harvested and dissociated with collagenase 
prior to the resulting cell suspension being used to inoculate the MFP of recipient mice and 
secondly we used mature MMTV-NIC PTEN
+/-
 tumours to generate fragments for 
transplantation. Both methods resulted in the generation of tumours which continued to 
express HER2. A major benefit of both of these approaches over the use of established cell 
lines to generate further tumours was their ability to recapitulate the tumour 
microenvironment. Although breast cancer is classically considered to be a disease 
originating in epithelial cells, it is increasingly clear that other cell populations (including 
fibroblasts, myofibroblasts, endothelial cells and immune cells) within the tumour 
microenvironment are capable of influencing tumour progression. Comparison of normal and 
tumour associated stromal tissue has revealed multiple genetic and epigenetic changes 
affecting a wide variety of genes, including those implicated in invasion, angiogenesis and 
growth factor production. Many of these mutations develop early in tumour development and 
may predate the development of invasive disease. Furthermore, several studies have shown 
that the proliferation, survival, differentiation and invasive capacity of breast cancer cells can 
be influenced by both myoepithelial and stromal cell populations and that a healthy 
mammary microenvironment is able to induce a differentiated state in cancer cells 
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suggesting that cancer cells are dependent on the abnormal microenvironment in which they 
developed [28]. Therefore the ability of both of these approaches to recapitulate the tumour 
microenvironment is likely to result in the generation of tumours which more accurately 
reflect the behaviour and therapeutic response of the parental model. 
 
Variable tumour penetrance rates remain an issue with both these techniques. Overall 
tumour fragment transplantation resulted in a 40% penetrance rate, which was higher than 
we observed in either experiment using dissociated tumour cells. This improvement in 
tumour penetrance may be due to preserved tumour architecture following fragment 
transplantation as although major cell populations may be represented following tumour 
disassociation the tumour’s organisational structure is lost. However, the wide inter-
experimental variations in penetrance rates observed following fragment transplantation 
means that in order to directly compare the 2 approaches we would need to use the same 
tumour to generate dissociated tumour cells and fragments for transplantation. However, 
based on our preliminary data, fragment transplantation appeared to be the most promising 
technique and therefore we opted to use this approach in all further experiments.    
 
5.6.2 Use of fragment transplantation to generate tumours 
which recapitulate features of parental GEMM 
 









 [69] models has already successfully been used to test drug efficacy in metastatic 
breast cancer and to develop tumours with acquired resistance to cytotoxics. However, 
previous attempts to transplant MMTV-NIC fragments into immunocompetent hosts failed 
and it was postulated that this was due to an immune response against the rat derived HER2 
transgene [311], which shares 94% homology with the equivalent murine gene [317]. In 
addition to the lack of prior exposure to the HER2 transgene, our MMTV-NIC model was 
bred on an FVB background and therefore prior to fragment transplantation, recipients had 
not been exposed to Cre-recombinase, which therefore also had the potential to act as an 
immune response trigger.  To try and explore the contribution of the immune system to the 
variable penetrance rates observed, we transplanted fragments from the same parental 
tumour into cohorts of FVB and immunocompromised CD-1 or athymic mice. Coincidently, 
tumour penetrance was high in all cohorts in these experiments. Therefore although there 
was a small increase in penetrance when fragments were transplanted into the CD-1 nude 
cohort, it was not possible to fully determine any potential role the immune system might play 
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in determining the outcome of fragment transplantation. However, we observed a striking 
delay in tumour growth when fragments were transplanted into either of the 
immunocompromised strains. This delay may be a consequence of using unmatched 
immunocompetent and immunocompromised mouse strains, which at present is 
unavoidable. Immune-deficient FVB strains are not available and therefore to overcome this 
issue, the model would need to be re-derived on a different genetic background with a 
matched immune-deficient strain. However, the delayed growth may also be as a result of 
specific deficiencies within the immune system of the immune-deficient strains used. The 
immune system exists in a state of dynamic equilibrium and is capable of inducing both pro- 
and anti-tumorigenic states. Both the immune-compromised mouse models used in these 
experiments lacked any functioning T cells but retained B and natural killer (NK) cell activity 
[318]. Both B and NK cells have been implicated in the innate anti-tumour response whilst a 
variety of different subtypes of T cells exist, with differing effects on a growing tumour [27]. 
Loss of pro-tumourigenic T cells, specifically CD4+ Th2 cells, resulting in unopposed B and 
NK cell activity may have shifted the immune system balance in favour of tumour resolution. 
This could be further explored by fragment transplantation into the NOD-SCID IL2rɣ strain, 
which in addition to lacking functioning T cells also lacks B and NK cells. Alternatively, 
comparison of the immune-infiltrate of both highly and poorly/non-penetrant parental tumours 
may provide further evidence for the role of the immune system in moderating tumour 
development. Unfortunately, we were unable to optimise 2 antibodies to tumour associated 
macrophages on FFPE sections and would need to repeat these experiments collecting 
frozen sections for analysis. 
 
Our fragment derived tumours demonstrated considerable inter- and intra-tumoural 
heterogeneity. We observed marked differences in the growth rate of fragment derived 
tumours even amongst tumours generated from the same parental tumour. Despite their 
development from only a small amount of parental tumour, we also observed marked intra-
tumoural variation in HER2 expression. This is consistent with previously published data 




 model, where fragment derived tumours contained 
discrete epithelial and mesenchymal regions suggesting that more than 1 cancer subclone in 
the initial fragment had successfully proliferated to generate a heterogeneous tumour [69]. 
This heterogeneity is essential in enabling fragment derived tumours to mimic the diverse 
clinical behaviours of human HER2 positive breast cancer and ensuring that fragment 
derived tumours are clinically relevant models. However, it also implies that continued 
selection pressure during in vivo growth could potentially result in the generation of tumours 
which do not necessarily reflect the parental tumour from which they were derived. 
Previously published studies have used comprehensive genetic analysis to confirm that 
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fragment derived tumours are genetically similar to the parental tumours from which they are 
derived [69], [309]. Use of either systematic genetic or proteomic approaches to ensure that 
our fragment derived tumours remain representative of the tumours from which they 
originated would be beneficial in the future. 
 
One major limitation of this approach is the variability and unpredictability of tumour 
penetrance rates, potentially resulting in lengthy experiments using large numbers of 
recipient animals. Variation in tumour penetrance when using the MMTV-NIC PTEN
+/-
 model 
to generate fragments appeared to be due to tumour-specific factors rather than generalised 
features within the donor as tumours from the same donor animal had different penetrance 
rates. Similarly, transplantation of fragments generated from the same tumour into 2 different 
cohorts of FVB mice resulted in similar penetrance rates suggesting that recipient 
characteristics were not the dominant factor in determining penetrance rates.  The extremely 
low penetrance rates observed when MMTV-NIC PTEN 
FL/+ 
tumours were used to generate 
fragments suggests that PTEN expression could be a crucial factor in determining fragment 
transplant outcomes. However, when we compared PTEN expression between highly and 
poorly/non-penetrant MMTV-NIC PTEN
+/-
 tumours, we found it was unable to explain the 
differing penetrance rates. To date, we have not considered whether all or only a subset of 
tumour cells are capable of generating a further tumour and it would be interesting to explore 
specifically whether the percentage of cancer stem cells within the tumour might be 
predictive of tumour fragment penetrance. As well as helping to ensure that fragment derived 
tumours are representative of the parental model, a more comprehensive genetic or 
proteomic screening strategy may also be informative in determining the factors predictive of 
tumour penetrance. In the event we are unable to determine factors predictive of tumour 
penetrance, serial transplantation of highly-penetrant tumours would be an alternative option 
to increase our supply of reliably transplantable material. 
 
A further limitation of using fragments to generate tumours is that fragment derived tumours 
are generated from mature, end-stage tumours and therefore cannot be used to explore 
events in early disease or evolving changes during disease progression. Whilst these events 
may be more readily studied in the original GEMM, issues surrounding the timing of 
metastatic seeding may be more problematic. Metastatic seeding is frequently an early event 
in spontaneous GEMMs and may predate the onset of classically defined invasive disease 
based on light microscopy findings [290]. Animals bearing fragment derived tumours will 
develop metastases from end-stage tumour cells, which have been subject to different 
selection pressures in the MFP than cells which metastasized at an early stage and 
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showed that primary tumours and their metastases were genetically indistinguishable [69]. 
However, in human breast cancer, 15% of mutated genes show a differential mutational 
status between primary and recurrent tumours [319] suggesting that the site of metastases 
evolution may play a critical role in determining the phenotype of subsequent tumours and 
also potentially their response to therapy. If, in the future, we are able to use fragment 
derived tumours to generate established metastatic disease, it would be useful to compare 
the genetic and proteomic signatures of lung metastases from both spontaneous GEMM and 




The use of the MMTV-NIC model to produce animals bearing single mammary tumours will 
greatly facilitate our ability to explore both drug efficacy in metastatic disease and events 
involved in the development of acquired drug resistance. Of the 3 methods of developing 
isolated tumours we have explored, fragment transplantation was the most promising and 
resulted in the generation of strongly HER2 positive tumours. At present the major limitation 
of this approach appears to be the variable and unpredictable tumour penetrance rates, 
although more comprehensive genetic and/or proteomic screening is required to ensure that 
fragment derived tumours are truly representative of the parental GEMM. Serial 
transplantation of highly penetrant tumours is a viable option to overcome the unpredictability 
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fragment transplantation, we generated animals with a single 
mammary tumour, with the long-term goals of being able to study both mechanisms of 
acquired resistance and drug efficacy in metastatic disease. Previously published studies 










 [69] models have 
shown that fragment transplantation resulted in a second generation of tumours which were 





fragments displayed similar sensitivity to cytotoxic drugs as 
observed in the original GEMM. Encouragingly, fragment derived tumours displayed the 
same heterogeneity in response to cytotoxics as observed in the original model, suggesting 
that fragment derived tumours were capable of recapitulating the diverse range of tumour 
behaviour and responses seen in clinical practice.  
 
In the following experiments, we sought to determine whether tumours generated as a result 
of MMTV-NIC PTEN
+/- 
tumour fragment transplantation displayed the same response to drug 
treatment as the original model. Specific aims of this section of the project included: 
 
1. Comparison of responses of MMTV-NIC PTEN
+/-
 model and fragment derived 
tumours to paclitaxel.  
2. Comparison of responses of MMTV-NIC PTEN
+/-
 model and fragment derived 
tumours to HER2 directed therapies, using AZD8931 as an example.  
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6.1 Determination of Therapeutic response of 
Fragment Derived Tumours to Paclitaxel 
 
To explore the response of fragment-derived MMTV-NIC PTEN
+/- 
tumours to paclitaxel, 
fragments were harvested from 2 separate MMTV-NIC PTEN
+/- 
tumours and transplanted 
into FVB recipients. When tumours reached a volume ≥ 0.15 cm
3
, mice were randomized to 
either treatment with weekly intraperitoneal (IP) paclitaxel (10 mg/kg) formulated in 
Cremaphor EL and ethanol (1:1, v:v) or vehicle for a maximum of 4 doses. Randomization 
was balanced to ensure that both drug (n=3) and vehicle (n=3) treated arms contained an 
equal number of tumours derived from the different parental tumours. Animals were 
monitored twice weekly for tumour progression and sacrificed once the tumour had reached 
1.5 cm (in any direction) or at 72 hours following their final dose. OS was defined as the 
interval from commencing treatment to time of sacrifice. 
 
As we had previously observed in the original MMTV-NIC PTEN
+/-
 model (see chapter 4), 
paclitaxel treatment resulted in a statistically significant increase in OS of mice bearing 
fragment derived tumours (Figure 6.1A). Median OS was increased from only 14 days in 
vehicle treated animals (range 7-14 days) to 24 days (range 24-24 days) in drug treated 
animals (p=0.03, Gehan-Breslow Wilcoxon test). Looking at the response of individual 
tumours to treatment, we found that although paclitaxel slowed tumour growth, it did not 
result in tumour shrinkage (Figure 6.1B), again emulating our observations in the original 
model.  
 
Using IHC with an antibody to cleaved caspase 3, we confirmed that paclitaxel treatment 
resulted in a small yet statistically significant increase in apoptosis. The median percentage 
area occupied by cells undergoing apoptosis was 0.98% in paclitaxel treated tumours 
compared to 0.36% in vehicle treated tumours (p=0.002, Mann Whitney U test, Figure 6.2). 
These results were consistent with the low levels of apoptosis observed in the original 
MMTV-NIC PTEN
+/-
 model and are likely due at least in part to the very transient nature of 
apoptosis, which after completion becomes undetectable. Paclitaxel can also result in 
necrosis and again this may be the dominant mechanism of cell death in MMTV-NIC PTEN
+/- 
tumours.         
Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
 




Figure 6.1: Paclitaxel treatment slowed tumour growth and prolonged OS in fragment 
derived MMTV-NIC PTEN
+/- 
tumours mirroring the response seen in the original MMTV-
NIC PTEN
+/- 
model. A: Overall survival in vehicle (n=3) and paclitaxel (n=3) treated 
fragment derived tumours, p=0.003, Gehan-Breslow Wilcoxon test. B: Growth rate of 
vehicle and paclitaxel treated fragment derived tumours. 
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Figure 6.2:  Paclitaxel resulted in apoptosis in fragment derived MMTV-NIC PTEN
+/- 
tumours. A cleaved caspase 3 antibody was used to perform IHC on paraffin 
embedded sections of paclitaxel and vehicle treated fragment derived tumours. 
Images analysed using Image J software to calculate percentage area, which stained 
positive for cleaved caspase 3 in six low power fields (mag x20) per tumour. A: Box –
whisker plot analysis of percentage area positive for cleaved caspase 3 in vehicle 
(n=3) and paclitaxel (n=3) treated tumours. p=0.0019, Mann Whitney U test. B: 
representative images of IHC; negative control (i), vehicle (ii) and paclitaxel (iii) treated 
tumour. Negative control consists of tumour section incubated in the absence of 
primary antibody.   Scale bar 100 μm. Mag x20.    
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6.2 Determination of Therapeutic response of 
Fragment Derived Tumours to AZD8931 
 
To determine the sensitivity of fragment derived tumours to AZD8931, fragments derived 
from 2 different parental tumours were transplanted into cohorts of FVB mice. Animals with 
an established tumour of ≥ 0.06 cm
3
 were randomized to treatment with either vehicle (n=5) 
or AZD8931 (100 mg/kg, n=6) once daily by oral gavage. Treatment continued until complete 
tumour resolution, defined as an absence of measurable disease, or until the animal was 
sacrificed due to tumour burden (tumour ≥1.5 cm, in any direction). Tumours were 
randomized according to the parental tumour of origin, to ensure both vehicle and drug 
treated groups contained approximately equal numbers of tumours from each of the parental 
tumour.  
 
Similarly to our earlier observations in the MMTV-NIC PTEN
+/-
 model (see chapter 4), 
AZD8931 treatment prolonged OS in mice bearing fragment derived tumours (p=0.002, 
Gehan-Breslow Wilcoxon test, Figure 6.3). The median OS of vehicle treated animals was 
53 days (range 14-102 days). In comparison, all 6 of the fragment bearing animals treated 
with AZD8931 survived for at least 102 days. It was not possible to further clarify OS in the 
AZD8931 treated cohort as drug treatment was withdrawn following complete tumour 
resolution and restarted when the primary tumour recurred in an effort to generate tumours 
with acquired resistance to AZD8931 (see section 6.4).  
 
Comparison of the response of individual MMTV-NIC PTEN
+/- 
model tumours and fragment-
derived tumours to AZD8931 revealed a striking difference in drug sensitivity (Figure 6.4). As 
previously described, MMTV-NIC PTEN
+/-
 model tumours initially responded to AZD8931 
with 2 out of 5 tumours shrinking by at least 50% and the remaining 3 maintaining a stable 
volume (Figure 6.4A). However, they rapidly developed resistance and continued to grow 
through ongoing drug treatment (Figure 6.4B and Chapter 4 Figure 4. 11B). In contrast, 
fragment derived tumours were more sensitive to AZD8931 as all tumours fully resolved, 
albeit over varying treatment durations. The median duration of AZD8931 treatment required 
to cause tumour resolution was 25.5 days (range 10-98 days)(Figure 6.4 C and 4D). After 
AZD8931 withdrawal, 60% of tumours recurred after a median interval of 42 days (range 10-
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88 days) off treatment. The remaining animals were observed for a minimum of 152 days off 
drug treatment but did not develop tumour recurrence during this period.  
 
During our initial experiment using the MMTV-NIC model, AZD8931 treatment was 
commenced when tumours reached a volume ≥ 0.1 cm
3
. In case the increased sensitivity of 
fragment derived tumours was caused by initiating treatment at a lower starting volume (0.06 
cm
3
), we repeated this experiment in a second cohort of fragment bearing mice but started 
treatment at a volume ≥ 0.1 cm
3
. AZD8931 resulted in complete tumour eradication in drug 
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Figure 6.3: AZD8931 treatment prolonged OS in MMTV-NIC PTEN
+/-
 fragment derived 
tumours. Animals with fragment derived tumours ≥ 0.06 cm
3 
were randomized to 
treatment with vehicle (n=5) or AZD8931 (n=6). Mice were monitored twice weekly for 
tumour onset and development and sacrificed when tumour burden ≥ 1.5 cm in any 
direction. Survival was defined as interval from commencing treatment until time of 
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Figure 6.4: MMTV-NIC PTEN
+/-
 fragment derived tumours were more sensitive to 
AZD8931 than the MMTV-NIC PTEN
+/-
 model. A: Initial responses of MMTV-NIC PTEN
+/- 
model tumours to AZD8931 before all tumours became resistant and grew through 
drug treatment. B: Response of MMTV-NIC PTEN
+/- 
model to AZD8931 (n=5) and 
vehicle (n=5). C: MMTV-NIC PTEN
+/-
 fragment derived tumours fully resolved in 
response to AZD8931 when commenced at volume ≥ 0.06 cm
3
 but over varying time 
intervals. D: Response of MMTV-NIC PTEN
+/-
 fragment derived tumours to AZD8931 
(n=5) and vehicle (n=5). E: MMTV-NIC PTEN
+/-
 fragment derived tumours fully resolved 
in response to AZD8931 when commenced at volume ≥ 0.1 cm
3. 
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6.3 Exploring factors contributing to enhanced 
sensitivity of fragment derived tumours to AZD8931 
 
The increase in sensitivity of fragment derived tumours to AZD8931 compared to the original 
GEMM was surprising, particularly as we had already demonstrated that the response to 
paclitaxel was preserved following fragment transplantation. We considered 3 possible 
explanations for this; firstly changes in target receptor expression, secondly altered 
vascularisation and finally changes in the ability to adapt to hypoxia.     
 
AZD8931 resulted in complete tumour eradication amongst the fragment derived tumours. 
Therefore, these analyses have been conducted on the matched untreated parental and 
fragment derived tumours generated during our earlier experiments. 
 
 
6.3.1 Comparison of HER2 expression between parental and 
fragment derived tumours  
 
We used IHC with a HER2 antibody to demonstrate that the significant intra-tumoural 
heterogeneity of expression observed in the parental tumours was also present in fragment 
derived tumours with all tumours containing regions of strong, moderate and absent HER2 
expression (Figure 6. 5A). Comparing HER2 expression across 3 sets of matched parental 
and fragment derived tumours, we found a close agreement between each parental tumour 
and the corresponding fragment derived tumours (Figure 6.5B), suggesting that increased 
HER2 expression in fragment derived tumours was not responsible for the increased 
sensitivity to AZD8391.  
 
We also used IHC to compare expression of pTyr 1221/1222 HER2 and pTyr 1289 HER3 in 
model and fragment derived tumours but the patchy nature of expression prevented us from 
drawing any conclusions.   
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Figure 6.5: HER2 expression was consistent between matched parental and fragment 
derived MMTV-NIC PTEN
+/- 
tumours. IHC was performed on paraffin embedded 
sections of parental and fragment derived tumours with a total HER2 antibody. A: 
Representative IHC images of parental (i) and fragment derived tumours (ii). Negative 
control (iii) consists of tumour section incubated in the absence of primary antibody.  
Mag x40. Scale bar represents 100 μm. B: Immunohistochemical analysis of 
membranous HER2 expression in matched parental and fragment derived tumours. 
Red data points represent parental tumours. Black data points represent fragment 
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6.3.2 Comparison of vascularisation between parental and 
fragment derived tumours 
 
IHC with a CD31 antibody was performed to determine whether altered vascularisation 
resulting in enhanced drug delivery might contribute to the increased sensitivity of fragment 
derived tumours to AZD8931. In the 2 tumour series we examined, there was no consistent 
relationship between vascularisation in the parental and transplanted tumours (Figure 6.6). 
There was no difference in the extent of vascularisaion between parental and fragment 
derived tumours in the first tumour series we examined. However, in the second series we 
examined, the mean percentage area contained within a CD31 positive region was 
significantly higher in fragment derived tumours than the parental tumour (p=0.01, Mann 
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Figure 6.6: Comparison of vascularisation in parental and fragment derived MMTV-NIC 
PTEN
+/- 
tumours. IHC was performed on matched sections of parental and fragment 
derived formalin fixed paraffin embedded tumours with CD31 primary antibody. 
Images analysed using Image J software to calculate area encompassed in a CD31 
positive region in 6 low powered fields per tumour.  Ai: Negative control comprising of 
fragment derived tumour section incubated in the absence of CD31 antibody. Scale 
bar represents 100 μm. Aii: Representative image of IHC with CD31 antibody on 
fragment derived tumour (mag x20). Arrowhead denotes representative blood vessels. 
Aiii: High powered view of CD31 positive blood vessels (mag x40). Arrowhead denotes 
representative blood vessels.  B: Box-whisker plot analysis of extent of 
vascularisation in parental tumours (red data point) and matched fragment derived 
tumours (black data points). Horizontal line represents mean and error bar the SEM 
for each series. Asterix denotes statistically significant p value in second tumour 
series (p=0.01), calculated using Mann Whitney U test. 
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6.3.3 Comparison of HIF1α expression between parental and 
fragment derived tumours 
 
As changes in the extent of vascularisation did not account for the differential sensitivity to 
AZD8931 observed between parental and fragment derived tumours, we explored whether 
alterations in HIF1α expression might explain it. In addition to hypoxia, HIF1α expression is 
upregulated in response to PTEN loss, changes in the expression of receptor tyrosine 
kinases, such as EGFR, and hyperactivation of intracellular signalling pathways, eg Akt and 
Src [313]. HIF1α expression therefore acts as a composite biomarker for multiple factors 
which individually confer a more aggressive tumour phenotype [313]. Furthermore, 
preclinical studies also support a role for these factors in the development of resistance to 
HER2 targeted agents [147].  
 
Using IHC, we demonstrated variable HIF1α expression between different parental and to a 
lesser extent amongst different fragment derived tumours, although all specimens expressed 
moderate to high levels of the protein (Figure 6.7). Comparison of HIF1α expression 
revealed statistically significant differences between matched parental and fragment derived 
tumours in 2 out of 3 tumours series we examined. However, there was no consistency in 
the direction of change with increased expression in the parental tumour in series 2 and 
reduced expression in series 3 compared to the corresponding fragment derived tumours.    
 
In summary, MMTV-NIC PTEN
+/-
 fragment derived tumours were more sensitive to AZD8931 
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Figure 6.7: Both parental and fragment derived MMTV-NIC PTEN
+/- 
tumours strongly 
expressed HIF1α. IHC was performed on formalin fixed paraffin embedded parental 
and corresponding fragment derived tumours with HIF1α primary antibody. Nuclear 
histoscore determined using 6 representative high powered fields (x40 mag) and 
calculating the sum of the product of percentage cells stained by the intensity graded 
from 0-3 (histoscore = (% *1) + (% *2) + (% *3)). A: Representative IHC images-i: 
Negative control consisting of tumour section incubated in the absence of primary 
antibody. Scale bar represents 100 μm. ii: parental MMTV-NIC PTEN
+/- 
tumour section 
stained with HIF1α antibody. iii: fragment derived tumour section stained with CD31 
antibody. Mag x40.   
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6.4 Generation of fragment derived tumours with 
acquired resistance to AZD8931 
 
One of our major goals has been to use fragment derived tumours to study mechanisms of 
acquired resistance to HER2 targeted therapies. In order to begin exploring factors 
underpinning acquired resistance to AZD8931, we generated fragments from 3 separate 
MMTV-NIC PTEN
+/-
 tumours and transplanted them in to cohorts of FVB mice. Following the 
development of established tumours, we randomised mice to treatment with either vehicle or 
AZD8931. In the initial 2 experiments, randomization was performed once the tumour had 
reached a volume ≥ 0.06 cm
3
. Animals continued to receive daily vehicle treatment until they 
were sacrificed due to mammary tumour burden at a maximum dimension of 1.5 cm. 
AZD8931 was administered in a pulsatile manner with mice receiving daily treatment until 
the tumour was no longer measurable. Treatment was then withdrawn and the tumour 
allowed to re-grow to a sufficient size that it could be accurately measured at which point 
treatment was re-instituted. Tumours were classified as resistant when able to continue 
growing in the presence of ongoing AZD8931 treatment and were permitted to grow to a 
maximum dimension of 1.5 cm, although the animal bearing the resistant tumour in 
experiment 2 had to be culled prematurely due to the tumour’s slow growth and the animal’s 
advanced age. We observed a high rate of tumour loss within the first 2 treatment cycles in 
AZD8931 treated animals with only 1 out of 3 tumours becoming fully drug resistant in both 
experiments.  To try and reduce the incidence of tumour loss in the third experiment, we 
decided to delay starting treatment until tumours had a volume of ≥ 0.3 cm
3
 and to withdraw 
treatment when tumours had a volume ≤ 0.15 cm
3
. Treatment was not restarted until the 
tumour had re-grown to at least 0.3 cm
3
. Despite the adjustments to the treatment schedule, 
the rate of tumour loss remained high with only 1 out of 3 tumours developing resistance to 
AZD8931. All 3 of our resistant tumours required 4 cycles of AZD8931 treatment to become 
drug resistant, although the treatment duration required for individual tumours to become 
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Figure 6.8: Generation of fragment derived tumours with acquired resistance to 
AZD8931. Tumour fragments, generated from 3 different parental tumours, were 
transplanted into cohorts of FVB mice and after developing tumours, mice were 
randomised to treatment with vehicle or AZD8931. Repeated cycles of AZD8931 were 
administered to facilitate the selection of tumour cell clones with acquired resistance 
to AZD8931. Ai-iii: growth curves of vehicle treated (black lines) and AZD8931 treated 
(red lines) tumours in 3 separate experiments. Bi-iii: Growth curves of AZD8931 
resistant tumours showing timing and duration of AZD8931 treatment.   
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6.5 Initial characterisation of AZD8931 resistant 
tumours 
 
6.5.1 Histological comparison of AZD8931 sensitive and 
resistant tumours 
 
Examination of the matched AZD8931 naive and resistant tumours generated in the first 
experiment confirmed they were histologically indistinguishable from each other (Dr J. 
Loane, consultant pathologist). However, whilst the AZD8931 naive tumours generated in 
the later 2 experiments were similar in appearance, the 2 resistant tumours had a more 
pleomorphic appearance and were comprised of highly mitotic spindle cells (Figure 6.9) with 
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Figure 6.9: Representative H and E images of AZD8931 naive and resistant tumours 
showing heterogeneity in mechanisms used by tumours to develop resistance to 
AZD8931. Series 1: AZD8931 resistant tumour was phenotypically indistinguishable 
from AZD8931 sensitive tumour. Series 2 and 3: AZD8931 resistant tumours consisted 
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6.5.2 Comparison of HER2 expression between AZD8391 
naive and resistant tumours 
 
Previous preclinical studies have linked changes in the expression of HER family receptors 
to resistance to HER2 targeted therapies [147]. Furthermore, loss of HER2 expression has 
been described in up to 30% of metastases originating from a HER2 positive breast cancer 
[64] and is highly likely to contribute to acquired drug resistance. We therefore decided to 
compare HER2 expression in AZD8931 naive and resistant tumours to determine whether 
changes in HER2 expression underpinned resistance in our model. Using IHC, we 
demonstrated preserved HER2 expression in the resistant tumour generated in the first 
experiment but total loss of membranous HER2 expression in both spindle cell tumours 
(Figure 6.10). Over 90% of metaplastic breast cancers are HER2 negative [320] and 
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Figure 6.10- Acquisition of spindle cell morphology was associated with loss of 
membranous HER2 expression in AZD8931 resistant tumours. IHC was performed 
with a HER2 antibody on paraffin embedded sections of AZD8931 naive and resistant 
tumours.  Membranous histoscore determined using 6 representative high powered 
fields (x40 mag) and calculating the sum of the product of percentage cells stained by 
the intensity graded from 0-3, where 1=weak, 2=moderate and 3=strong staining 
(histoscore = (% *1) + (% *2) + (% *3)). A: Representative images of tumours stained 
with HER2 antibody. Mag x40. Scale bar represents 100 μm. B: Membranous HER2 
histoscore. Black data points represent AZD8931 sensitive tumours. Red data points 
represent AZD8931 resistant tumours. 
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6.5.3 Comparison of expression of markers of epithelial to 
mesenchymal transition (EMT) between spindle cell and 
epithelial tumours 
 
Although the origin of metaplastic breast carcinoma remains to be determined, EMT has 
been postulated as a critical event in its pathogenesis. Furthermore, previously published 
studies have linked the induction of EMT to HER2 loss and resistance to HER2 targeted 
therapies [167] in vitro. We therefore used IHC to compare expression of E-cadherin and 
vimentin between our different tumours. All of the AZD8931 naïve tumours and the resistant 
tumour generated in our first experiment showed strong E-cadherin expression but did not 
express vimentin, consistent with an epithelial phenotype. However, E-cadherin expression 
had been lost in both spindle cell carcinomas (Figure 6.11) and there was ubiquitous 
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Figure 6.11: Acquisition of spindle cell morphology is associated with loss of E-
cadherin in AZD8931 resistant tumours. IHC was performed with an E-cadherin 
antibody on paraffin embedded sections of AZD8931 naive and resistant tumours.  
Mag x40. Scale bar represents 100 μm. 
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Figure 6.12: Acquisition of spindle cell morphology is associated with vimentin 
expression. IHC was performed with a vimentin antibody on paraffin embedded 
sections of AZD8931 naive and resistant tumours.  Mag x40. Scale bar represents 100 
μm. 
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6.5.4 Comparison of proliferation between AZD8931 naïve 
and resistant tumours  
 
Alterations in cell cycle progression and apoptosis are well established strategies used by 
tumour cells to develop resistance to HER2 targeted agents in vitro. We used Ki67 to 
compare cell proliferation in our AZD8931 resistant and naive tumours.   We found there was 
no statistical difference in the percentage of Ki67 positive nuclei between our AZD8931 naive 
and resistant tumour in experiment 1 (p=0.27, Mann Whitney U test). Interestingly, although 
the resistant tumours generated in experiments 2 and 3 had both undergone EMT, the 
impact on cell proliferation was very different. The percentage of Ki67 positive nuclei in the 
resistant tumour was significantly reduced compared to the 2 vehicle treated tumours in 
experiment 2 (p<0.001, Mann Whitney U test). Conversely, in experiment 3, the resistant 
tumour had a significantly increased percentage of Ki67 positive nuclei compared to its 
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Figure 6.13:  Different resistance strategies had differing effects on cell proliferation. 
IHC performed on paraffin embedded tumour sections with a Ki67 antibody. Images 
analysed using Immunoratio software to calculate percentage of Ki67 positive nuclei 
in six low power fields (mag x20) per tumour. A: Representative images of IHC 
staining for Ki67 in AZD8931 naive and resistant tumours. Mag x20. Scale bar 
represents 100 μm. B: Box and whiskers plot of percentage Ki67 positive nuclei in 
AZD8931 naive and resistant tumours. Asterix denotes statistically significant p value. 
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6.6 Discussion  
 
6.6.1 Comparison of GEMM and fragment derived tumours to 
paclitaxel and AZD8931 
 
To further characterise our fragment derived tumours, we decided to compare their response 
to both cytotoxics and HER2 directed agents, using paclitaxel and AZD8931 as examples. 
We found that both MMTV-NIC PTEN
+/-
 mice and animals with fragment derived tumours 
responded similarly to paclitaxel. In both groups of animals, paclitaxel prolonged OS but 
failed to cause tumour shrinkage (see chapter 4 for further discussion). This preserved 
response to cytotoxics between the parental GEMM and fragment derived tumours was 




model, where a 
similar response to doxorubicin [308], docetaxel [296] and topotecan [309] has previously 
been reported.  
 
We also found that AZD8931 increased OS in both MMTV-NIC PTEN
+/-
 mice and recipients 
of fragment derived tumours. However, whilst tumours in the original GEMM rapidly became 
resistant to AZD8931, fragment derived tumours fully resolved whilst on treatment and 40% 
did not recur despite prolonged observation off treatment, suggesting the tumours had been 
completely eradicated. This difference in sensitivity remains to be explained but our 
preliminary data suggest that it is not attributable to changes in HER2 expression or HIF1α 
expression. We did observe a statistically significant increase in vascularisation in 1 series of 
fragment derived tumours, although in absolute terms this only corresponded to a 4.7% 
change, which is relatively small to account for such a profound difference in tumour 
behaviour. Our experiments did only quantify total vasculature and previous studies have 
demonstrated differences in the percentage of functional vasculature between parental and 
transplanted models of pancreatic adenocarcinoma, when the percentage total vasculature 
remained unchanged [321]. It could be in our model that differences in functional vasculature 
were more marked than changes in total vasculature although if increased vascularisation 
was responsible for the enhanced response of fragment derived tumours to AZD8931, we 
would anticipate a similar response to paclitaxel, which was not observed. An alternative 
explanation for the differential sensitivity of GEMM and fragment derived tumours to 
AZD8931 may relate to differences in the tumour microenvironment. Tumour fragments were 
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transplanted into healthy MFP whilst in the GEMM the peri-tumoural MFP was highly 
abnormal [272]. The abnormal MFP in the original GEMM may produce growth factors 
which, acting in either a paracrine or systemic fashion, promote continued tumour growth 
despite AZD8931 treatment. The absence of these growth factors might have rendered 
fragment derived tumours more susceptible to AZD8931. Although we have yet to explain 
the lack of concordance in the activity of AZD8931 between the original GEMM and fragment 
derived tumours, it is important to determine whether this is specific to AZD8931 or whether 
it is also observed with other molecularly targeted agents with either proven (e.g. lapatinib) 
or predicted (e.g Akt inhibitors) efficacy in HER2 positive breast cancer. 
 
Encouragingly, the heterogeneity of response to AZD8931 seen in the original GEMM was 
also preserved following fragment transplantation. Whilst all fragment derived tumours did 
ultimately resolve on AZD8931 treatment, we observed considerable variation in the rate of 
response, even amongst tumours derived from the same parental tumour. This preservation 













models and most importantly was 
reflective of the diverse behaviours seen in HER2 breast cancer in the clinic. 
 
6.6.2 Use of fragment transplantation to generate tumours 
with acquired resistance to AZD8931 
 
We also used fragment transplantation to generate a small panel of tumours with acquired 
resistance to AZD8931. Despite limited numbers, preliminary analysis showed that different 
tumours utilised a variety of strategies for developing drug resistance, again modelling the 
broad range of therapeutic responses seen in clinic. Specifically, we observed evidence of 
EMT in 2 of our resistant tumours, which we have also identified as being linked to the 
development of HER2 targeted therapy resistance during our in vitro studies (see chapter 7 
for further discussion). The ability to generate drug resistance in vivo is potentially a useful 
tool in preclinical drug resistance studies. To date, the majority of studies exploring 
resistance to HER2 directed therapies have used cell line based techniques and although 
numerous resistance mechanisms have been identified in vitro, clinical validation has proved 
challenging. The use of fragment-derived tumours to explore resistance mechanisms offers a 
more physiologically relevant model with tumours developing resistance whilst exposed to 
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ongoing in vivo selection pressures. Therefore any resistance strategies identified may be 
more predictive of clinically relevant resistance mechanisms and in this case helps to 
validate our in vitro findings. More comprehensive analysis of these tumours is required to 
further understand the drivers of resistance in this model. However, our preliminary data 
provides a strong rationale for basing therapeutic decisions on the biology of the individual 
resistant tumour, which may be very different from that of the primary tumour. The 
observation that 2 out of 3 of our resistant tumours no longer expressed HER2 further 
emphasises this point. To date, major advances in overcoming clinical resistance to 
trastuzumab have focussed on alternative strategies for targeting HER2 signalling, either 
through combining drugs which target different HER family receptors or through use of drug-
antibody conjugates such as trastuzumab-emtansine (T-DM1). As it is rarely mandatory to 
re-biopsy tumours at the time of entry into clinical trials, patients whose tumours no longer 
express HER2 risk being exposed to the toxicity of treatments which might not be anticipated 
to be effective. Furthermore, failure to characterise resistant tumours could also result in 
novel agents being incorrectly labelled as ineffective if the trials in which their efficacy is 
determined unknowingly contain large numbers of patients in whom the treatment would not 
be expected to be efficacious.  
 
Two major limitations of this approach are the low numbers of resistant tumours generated 
and the lengthy nature of these experiments. Further studies are required to generate a 
larger panel of resistant tumours. Although this will initially require transplantation of multiple 
fragments from different parental tumours to try and generate a tumour panel which includes 
a broad range of resistant mechanisms, we plan to streamline subsequent studies by using 
resistant tumours to generate further fragments for transplantation. Previously published 




model has shown that tumour resistance is 
preserved following transplantation of resistant material into new hosts [308]. Hopefully in the 
future this will enable the creation of cohorts of animals bearing resistant tumours, suitable 
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Transplantation of MMTV-NIC PTEN
+/- 
fragments resulted in the generation of tumours with a 
preserved response to paclitaxel and enhanced sensitivity to AZD8931. Using fragment 
transplantation, we also demonstrated the heterogeneous nature of acquired resistance to 
AZD8931 highlighting the need for repeat tumour assessment prior to starting therapy in the 
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Chapter 7: Generation and characterisation of 
cell lines with acquired resistance to HER2 
directed tyrosine kinase inhibitors (TKI) 
 
The introduction of HER2 directed therapies has arguably been one of the greatest 
advances in the management of breast cancer in recent years. Trastuzumab in combination 
with chemotherapy has been hugely successful as first line therapy in both early and 
metastatic breast cancer. However, although 50% of patients with metastatic breast cancer 
initially respond to treatment [136], the development of resistance is ultimately universal. 
Until recently the only other licensed therapeutic option was lapatinib, a HER2 and EGFR 
targeting TKI. Yet despite high initial response rates in HER2 positive tumours [138], 
resistance is also inevitable. A greater understanding of the mechanisms underpinning the 
development of resistance therefore remains a key priority. Numerous potential mechanisms 
of resistance have been identified in preclinical studies yet few of these have been tested 
clinically. One mechanism of resistance which has been explored clinically is a 
compensatory increase in the signalling of other HER family receptors.  Preclinical studies 
using trastuzumab have shown that forced over-expression of EGFR by HER2 positive 
SKBR3 cells rendered cells trastuzumab resistant [322]. However, clinical studies have failed 
to identify any consistent relationship between EGFR expression and trastuzumab sensitivity 
and the addition of gefitinib to trastuzumab failed to improve treatment efficacy [64]. Yet, 
combination therapy such as lapatinib with trastuzumab [139] [323] and pertuzumab, 
trastuzumab and docetaxel have successfully improved treatment outcomes [324] [325], 
suggesting that inhibition of multiple HER family receptors might be more efficacious than 
single target inhibition and as such may help to delay the onset of acquired resistance. 
However, despite the initial success of these complex, multi-agent regimes, resistance still 
remains ultimately inevitable. 
 
Lapatinib is classified as dual inhibitor of EGFR and HER2, but in reality it is a more potent 
inhibitor of HER2 and the extent of EGFR inhibition in vivo remains uncertain. Preclinical 
studies have suggested that incomplete inhibition of EGFR in conjunction with increased 
heregulin expression drives continued PI3K/Akt signalling and lapatinib resistance [173] and 
cell line studies have shown an inverse correlation between expression of phospho-EGFR 
and HER3 and lapatinib sensitivity [271]. AZD8931 is a novel equipotent reversible TKI of 
EGFR and HER2, which through robust inhibition of both EGFR and HER2 also reduces 
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HER3 signalling. Preclinical data suggests that AZD8931 is predominantly active in ligand 
driven HER family signalling and therefore, following preliminary evidence of its efficacy in 
phase1 trials [326], further clinical studies have focussed on its role in populations with 
mixed or low HER2 expressing tumours [145], [145]. However, given its activity in the 
MMTV-NIC model (see chapters 4 and 6) and its potential to provide more global inhibition of 
HER family signalling, we decided to compare its activity and the mechanisms  involved in 
acquired resistance in HER2 positive breast cancer cell lines with that of lapatinib. Initial 
experiments used cell lines derived from the MMTV-NIC PTEN
+/-
 model. However, due to 
lack of sensitivity and poor reproducibility, we conducted further studies in established 
human HER2 positive breast cancer cell lines.  
 
Specific aims of this section of the project included: 
 
1. Determining the sensitivity of MMTV-NIC PTEN cell lines to lapatinib and AZD8931. 
2. Determining the sensitivity of human HER2 positive cell lines to lapatinib and 
AZD8931. 
3. Development of cell lines with acquired resistance to lapatinib and AZD8931. 
4. Initial characterisation of resistant cell lines using western blotting. 
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7.1 Sensitivity of MMTV-NIC PTEN
+/- 
cell lines to 
lapatinib and AZD8931 
  
To determine the in vitro effects of lapatinib and AZD8931 on proliferation of the MMTV-NIC 
PTEN
+/-
 cells, 2 cell lines (WGH 129RM and WGH 135RM) were selected from a panel 
previously generated in the lab (L. Balderstone). Both cell lines had already been shown to 
express HER2 and CK8, confirming that they were derived from a HER2 expressing 
epithelial cell clone within MMTV-NIC PTEN
+/- 
tumours. These cell lines differed with respect 
to PTEN expression; WGH 135RM continued to express PTEN whilst WGH 129RM showed 
no residual expression by western blot (L. Balderstone). Therefore by using these 2 cell 
lines, we aimed to explore the role of PTEN expression in determining in vitro sensitivity to 
lapatinib and AZD8931.  
 
We treated cells with escalating doses of either lapatinib or AZD8931 for 72 hours before 
performing an SRB assay. The mean IC50 for WGH 129RM and WGH 135RM cells treated 
with lapatinib was 3.12 µM and >5 µM (the drug’s maximum aqueous solubility) respectively. 
Using AZD8931, we calculated mean IC50s of 4.12 µM and 2.22 µM in WGH 129RM and 
WGH 135RM cells (Figure 7.1). All these calculated IC50s were greater than the peak plasma 
concentrations recorded during phase1 clinical trials [327] [326] and therefore we considered 
both cell lines to be resistant to these drugs. The in vitro resistance of MMTV- NIC PTEN
+/- 
cell lines to AZD8391 was in marked contrast to the drug’s profound effects on proliferation 
in vivo (Chapter 4) and this loss of sensitivity was most likely due to reduced HER2 
expression during in vitro culture, which we have previously observed with another cell line in 
this panel (Chapter 5), coupled with the tendency of these cell lines to undergo EMT (H. 
Smith, personal communication). We also encountered issues with reproducibility, 
particularly when using AZD8931, as we observed wide variations in IC50 across different 
experiments (Figure 7.1). Both these cell lines contain multiple phenotypically distinct 
subpopulations, which are likely to exhibit different drug sensitivities. Whilst this 
heterogeneity may be more reflective of the multiple clones found within a tumour during in 
vivo growth, it is also likely to have contributed to the wide variations in drug response seen 
in vitro. For these reasons, we decided to conduct all further experiments on established 
human HER2 positive cell lines.     
 
 
Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
Chapter7: Generation and characterisation of cell lines with acquired resistance to HER2 directed 






Figure 7.1- MMTV-NIC PTEN
+/-
 derived cell lines were resistant to lapatinib and 
AZD8931. MMTV-NIC PTEN
+/- 
WGH 135RM and WGH 129RM cell lines were treated with 
either lapatinib or AZD8931 for 72 hours and an SRB performed. Data was analysed 
using GraphPad Prism 6 software. Ai: Mean IC50 from series of SRB assays with 
lapatinib (n=3) and AZD8931 (n=15). Error bars represent SEM. Lapatinib mean IC50 ± 
SEM: WGH 135RM 5.98 ± 0.56 µM, WGH 129 RM- 3.12 ± 0.97 µM. AZD8931 mean IC50 ± 
SEM: WGH 135RM- 4.12 ± 0.80 µM, WGH 129 RM- 2.22 ± 0.79 µM.  B: Representative 
phase images of WGH 135 RM (i) and WGH 129 (ii). Arrowheads on lower image 




Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
Chapter7: Generation and characterisation of cell lines with acquired resistance to HER2 directed 
tyrosine kinase inhibitors (TKI)     248 
 
 
7.2 Determining sensitivity of SKBR3 and BT474 cell 
to lapatinib and AZD8931. 
 
We chose to use SKBR3 and BT474 cell lines in all further experiments as whilst both cell 
lines strongly expressed HER2, they differed with respect to several other important 
characteristics. Neither cell lines expressed ER but whilst BT474 cells strongly expressed 
PR, SKBR3 cells were only weakly positive (Figure 7.2). SKBR3 has therefore been 
classified as belonging to the HER2 over-expressing molecular subgroup whilst BT474 
belongs to the luminal B subgroup [328]. The cell lines are also reported to differ with 
regards to their PI3K mutational status; SKBR3 cells express wild type PI3K whilst BT474 
cells contain an activating mutation in the catalytic domain [329]. Both cell lines, however, 
continued to express PTEN (Figure 7.2). 
  
To determine the sensitivity of both cell lines to lapatinib and AZD8931, we cultured cells in 
the presence of escalating doses of either drug for 72 hours before performing an SRB 
assay. Each experiment was performed in triplicate and the mean IC50 and SEM calculated 
(Figure 7.3). Both drugs inhibited proliferation of SKBR3 and BT474 cells. For lapatinib the 
mean IC50 was 0.07 µM in SKBR3 cells and 0.06 µM in BT474 cells. For AZD8931, the mean 
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Figure 7.2- Characterisation of SKBR3 and BT474 cell lines in terms of HR status and 
PTEN expression. SKBR3 and BT474 xenografts were generated by inoculation of the 
MFP with 5*10
6
 cells suspended in matrigel. IHC was performed on paraffin embedded 
sections of the resulting tumours. Positive controls comprise sections of human 
hormone receptor positive breast cancer stained with the appropriate antibody. Mag 
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Figure 7.3- Both lapatinib and AZD8931 inhibited proliferation of SKBR3 and BT474 
cell lines. 5000 cells were plated out into each well of a 96 well plate and 24 hours later 
treated with escalating doses of either lapatinib or AZD8931. After 72 hours an SRB 
assay was performed. Data was analysed using GraphPad Prism 6 software.  
Representative curves from a series of 3 experiments displayed. Error bars represent 
SEM across 6 wells treated at the same drug dose within 1 experiment. Lapatinib 
mean IC50 ± SEM: SKBR3- 0.07 ± 0.05 µM, BT 474- 0.06 ± 0.01 µM. AZD8931 mean IC50 ± 
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7.3 Generation of lapatinib resistant cell lines 
 
BT474 and SKBR3 cells were cultured in T25 flasks and when cells were approximately 80% 
confluent, treatment was commenced with lapatinib. We used 3 different starting 
concentrations of drug to try and encompass the active dose range observed in the previous 
proliferation assays thereby maximising the efficiency with which resistant lines were 
generated. The lowest concentration we started treatment at was 0.04 µM, which was in the 
range of the IC50 for both cell lines. In separate flasks we also commenced treatment at 0.1 
µM and 5 µM, which was the highest drug concentration achievable due to the limited 
aqueous solubility of the drug.  On reaching confluence, 50% of each flask was passaged on 
and the remainder frozen down so that the entire spectrum of resistant cells was available 
for use in future experiments if required (Figure 7.4). Cells were maintained at the same 
concentration of lapatinib for a minimum of 2 passages prior to dose escalation. All 
experiments were performed in duplicate.  
 
No cells from either cell line survived culture with the maximum concentration of lapatinib. 
However, SKBR3 cells did survive in the presence of 0.1 µM lapatinib although they initially 
failed to proliferate. After 7 weeks, cells in 1 of the 2 flasks (Lap. R-SKBR3a) started to 
develop a more mesenchymal phenotype and proliferate rapidly (Figure 7.5). After a further 
2 weeks, we observed similar changes in the second flask (Lap. R-SKBR3b). Cells 
continued to proliferate despite the rapid escalation of lapatinib concentration and were 
classified as resistant when able to proliferate in the presence of 5 µM lapatinib. Both Lap. R-
SKBR3a and b became resistant after 11 weeks of culture in the presence of lapatinib. Cells 
in the flask which commenced treatment at 0.04 µM lapatinib were surplus to requirements 
and therefore frozen down early in the dose escalation process.  
 
Despite the presence of an activating PI3K mutation, BT474 cells were less easily rendered 
resistant to lapatinib. No BT474 cells survived in the presence of lapatinib at either 5 µM or 
0.1 µM. Cells survived in culture in the presence of 0.04 µM lapatinib for approximately 17 
weeks but failed to proliferate. We therefore decided to increase the percentage of FBS 
which the cells were cultured in to 20%. After a further 2 weeks, the cells had become 
confluent and the dose was escalated. As the lapatinib dose was increased, the cells also 
developed an increasingly mesenchymal appearance with a spindle-shaped morphology and 
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instead of the close cell-cell contacts observed in the parental cell line, resistant cells only 
made contact with each other at focal points (Figure 7.5). Both Lap. R-BT474 a and b cell 
lines were classified as resistant after 27 weeks of culture in the presence of the drug, when 
they were able to survive in the presence of 5 µM lapatinib. Following the acquisition of 
resistance, all cell lines continued to be maintained in the presence of 5 µM lapatinib. 
 
We performed cell counting experiments to further quantify the difference in growth rate 
observed between both sets of parental and resistant cell lines. SKBR3 and BT474 cells 







 cells/ml). Cells were re-counted 96 hours later, when cells at the top 
concentration were approximately 80% confluent. All resistant cell lines grew extremely 
rapidly and therefore despite reducing the initial number of cells (0.03*10
6
 cells/ml and 
0.015*10
6
 cells/ml), we repeated our cell counts after only 48 hours, again when cells were 
approximately 80% confluent (Figure 7.6). All experiments were performed in triplicate. The 
doubling time of resistant SKBR3 and BT474 cells was significantly shorter than their 
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Figure 7.4- Incremental dose escalation of lapatinib to generate resistant cell lines.  
The concentration of lapatinib was kept constant for at least 2 passages prior to dose 
escalation. A flexible dose escalation strategy was used so that the magnitude of 
dose increase was adjusted according to the cells’ ability to adapt to the previous 
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Figure 7.5- Acquisition of resistance to lapatinib coincides with development of 
mesenchymal phenotype in both SKBR3 and BT474 cell lines. Both parental cell lines 
have a classical rounded epithelial appearance and form attachments to neighbouring 
cells along the entire length of the cell. Lapatinib resistant cells appear spindle 
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Figure 7.6- Proliferation of parental (A) and lapatinib resistant cell lines (B). Parental 
cells were seeded in a 12-well plate at 3 different concentrations. Each concentration 
was plated in duplicate. Proliferation was measured 96 hours later by cell counting. 
Resistant cell lines were seeded in duplicate at 2 different concentrations. White bars 
represent an initial cell count of 0.015*10
6
 and black bars represent a starting cell 
count of 0.03*10
6
 cells.  To avoid cells becoming confluent, proliferation was assessed 
in all resistant cell lines after 48 hours. Mean values with SEM displayed from a series 
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Cell Line Mean doubling time (± SEM) in hours 
Parental SKBR3 59.39 ± 3.8 
Lap. R-SKBR3a 14.90 ± 0.83  
Lap. R-SKBR3b 19.02 ± 1.78  
 
Table 7.1-Cell doubling time of parental SKBR3 cells was significantly prolonged 
compared to lapatinib resistant cell lines (p<0.001, one way ANOVA).  denotes 
statistically similar means. 
 
Cell Line Doubling time (± SEM) in hours 
Parental BT474 88.53 ± 6.99 
Lap. R-BT474a 19.91 ± 0.97  
Lap. R-BT474b 19.58 ± 0.76 
 
Table 7.2- Cell doubling time of parental BT474 cells was significantly prolonged 
compared to lapatinib resistant cell lines (p<0.001, one way ANOVA).  denotes 
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7.4 Confirmation that lapatinib resistant cell lines 
were resistant to lapatinib 
 
After cells had been maintained in 5 µM lapatinib for at least 2 passages, we rechecked their 
sensitivity to the drug. Both parental SKBR3 and BT474 cells and their resistant counterparts 
were treated with escalating doses of lapatinib for 72 hours and then an SRB assay was 
performed. All experiments were performed in triplicate.  Despite treating cells up to a 
lapatinib concentration of 5 µM, which is the maximum achievable dose, the IC50 of resistant 
cell lines was not reached. We also found that following prolonged culture, the parental 
SKBR3 cell line became less sensitive to lapatinib and therefore we opted to compare 
percentage cell kill in the resistant cell lines at the equivalent concentration to the parental 
cell line’s IC50 in each individual experiment. Even allowing for the loss of sensitivity of 
SKBR3 cells to the drug, we found that the percentage cell kill was significantly reduced in 
both Lap.R-SKBR3a and b cell lines with a mean percentage cell kill of 0.2% and 0% 
respectively (p=0.002, one way ANOVA). The percentage cell kill was also significantly 
reduced in Lap. R-BT474 a and b cells compared to their parental cell line with a mean 
percentage cell kill of only 8.13% and 7.47% respectively at the parental cell line’s IC50 dose 
(p=0.001, one way ANOVA) (Figure 7.7).  
 
To determine the long-term stability of the resistant phenotype, we seeded all resistant cell 
lines into 2 separate flasks. For each cell line, cells in the first flask continued to be cultured 
in the presence of 5 µM lapatinib whilst those in the second were grown in the absence of 
drug. After a minimum of 8 weeks, we re-checked the drug sensitivity of cells which had 
been grown in both the presence and absence of lapatinib. All experiments included a 
positive control comprising of the parental cell line treated with increasing doses of lapatinib 
to confirm continued potency of the drug. After 8 weeks of culture in the absence of drug, we 
observed a statistically significant increase in the percentage cell kill of lap. R-SKBR3a cells 
from 0.2% to 11.9%, although despite this the cell line must still be classified as lapatinib 
resistant. The percentage cell kill of lap. R-SKBR3b cells also increased from 0% to 5.13% 
but this did not reach statistical significance (p=0.001, one way ANOVA with Tukey’s test). 
No difference in the percentage kill of either of the BT474 resistant cell lines was observed, 
irrespective of whether they were cultured in the presence or absence of lapatinib (p=0.774, 
one way ANOVA) (Figure 7.8).       
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Figure 7.7- Proliferation of lapatinib resistant cell lines is not substantially inhibited by 
the parental cell line’s IC50 dose. Parental SKBR3 and BT474 cells (5000 cells/well) and 
their resistant counterparts (1250 cells/well) were seeded into 96 well plates. After 24 
hours, cells were treated with escalating doses of lapatinib for 72 hours before an 
SRB assay was performed. Data was analysed using GraphPad Prism 6 software. 
Mean percentage cell kill ± SEM for each cell line calculated from a series of 3 
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Figure 7.8- Lapatinib resistance was not reversible following drug withdrawal for 8 
weeks. Two flasks were seeded with each resistant cell line. One flask per cell line 
continued to be cultured in the presence of 5 μM lapatinib, whilst the second flask 
was cultured in the absence of drug. After an interval of at least 8 weeks, drug 
sensitivity assays were repeated in cell lines cultured both in the presence and 
absence of drug. All experiments included a positive control comprising of the 
parental cell line treated with escalating doses of lapatinib to confirm the continued 
potency of the drug. Data was analysed using GraphPad Prism 6 software. Mean 
percentage cell kill ± SEM for each cell line calculated from a series of 3 experiments 
is displayed.   
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7.5 Demonstration that lapatinib resistant cell lines 
were cross resistant to AZD8931   
 
To determine whether lapatinib resistant cells remained sensitive to AZD8931, we treated 
both lapatinib sensitive and resistant SKBR3 AND BT474 cells with escalating doses of 
AZD8391 for 72 hours prior to performing an SRB assay. All lapatinib resistant cell lines 
were significantly less sensitive to AZD8931 than the parental cell lines from which they were 
derived but there was no statistical difference in the percentage cell kill observed between 
the different resistant cell lines (Figure 7.9). At the parental SKBR3 cell line’s IC50 dose, the 
mean percentage cell kill observed in lap. R-SKBR3a and lap. R-SKBR3b was 10.4% and 
13.4% respectively (p=0.002, one way ANOVA with Tukey’s test). At the parental BT474 cell 
line’s IC50 dose, the mean percentage cell kill in lap. R-BT474a and lap. R-BT474b was 6.6% 
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Figure 7.9- Lapatinib resistant SKBR3 and BT474 cells were less sensitive to AZD8931 
than parental cell lines. Parental SKBR3 and BT474 cells (5000 cells/well) and their 
resistant counterparts (1250 cells/well) were seeded into 96 well plates. After 24 hours 
cells were treated with escalating doses of AZD8931 for 72 hours before an SRB assay 
was performed. Data was analysed using GraphPad Prism 6 software. Mean 
percentage cell kill ± SEM for each cell line calculated from a series of 3 experiments 
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7.6 Generation of AZD8931 resistant cell lines 
 
We adopted a similar dose escalation strategy to generate cell lines which were resistant to 
AZD8931. Again BT474 and SKBR3 cells were cultured in T25 flasks and commenced on 
AZD8931 when cells were approximately 80% confluent. Treatment was commenced at 1 of 
the following 3 concentrations; 0.0067 µM (the minimum concentration required to inhibit 
proliferation in previous experiments), 0.231 µM (approximates to the IC50 of both cell lines), 
or 0.670 µM, (the maximum concentration viable BT474 cells were observed at in above 
experiments). However, during our initial experiments prolonged treatment with 0.670 µM 
resulted in total cell death in both cell lines and in the BT474 cell line there were few viable 
cells at the lower 2 concentrations. Therefore, a further flask in which treatment was 
commenced at 0.0035 µM was set up. Media, containing fresh drug, was replaced twice 
weekly and on reaching confluence, 50% of each flask was passaged on and the remainder 
frozen down so that the entire spectrum of resistant cells was available for use in future 
experiments if required. Again, a constant concentration of AZD8931 was maintained for at 
least 2 passages prior to dose escalation and all experiments were performed in duplicate. 
 
Attempts to generate AZD8931 resistant BT474 cell lines were unsuccessful. The maximum 
concentration of AZD8931 which BT474 cells could be maintained in was 0.077 µM and 
despite increasing the percentage of FBS to 20%, growth at this concentration was too slow 
to generate sufficient cells for use in further experiments. After continuous culture with 
AZD8931 for approximately 1 year, this cell line was rejected as being unable to adapt to 
AZD8931 exposure.     
 
SKBR3 cells were able to adapt to culture with AZD8931. Both flasks treated at 0.0067 µM 
and 1 of the 2 flasks treated at 0.231µM AZD8931 retained viable cells after prolonged 
culture in the presence of the drug. Flasks containing cells incubated with 0.0035 µM of 
AZD8931 were therefore superfluous and frozen down early in the dose escalation process. 
Viable cells in all other flasks were incubated with incrementally increasing concentrations of 
AZD8931 (Figure 7.10). A flexible dose escalation scheme was employed so that the 
magnitude of dose escalation could be adjusted to reflect the ease with which cells had 
adapted to the previous dose level. Therefore, when the time interval spent at a dose level  
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was prolonged, the next dose escalation was more cautious than when cells rapidly grew 
through a particular AZD8931 concentration. Cells were considered resistant once they were 
able to actively proliferate in the presence of 0.670 µM AZD8931, which equates to a 
concentration of 317.5 ng/ml. This concentration is within the range of plasma concentrations 
detected at the MTD during the phase I trial [326] and therefore resistance mechanisms 
exhibited at this drug concentration were likely to be clinically relevant. Following the 
acquisition of resistance, cells continued to be constantly cultured in the presence of 0.670 
µM AZD8931.  
 
Three AZD8931 resistant SKBR3 derived cell lines were generated. Resistance was 
achieved in the first of these cell lines (8931 R-SKBR3c) after 11 weeks. Resistance was 
achieved in the final 2 cell lines in 24 weeks (8931 R-SKBR3a) and 25 weeks (8931 R-
SKBR3b). Similarly to our lapatinib resistant cell lines, development of resistance in all 3 cell 
lines coincided with acquisition of a distinct mesenchymal phenotype (Figure 7.11), 
characterized by development of a spindle-shaped cell morphology. Again, the close 
intercellular connections seen in the parental cell line were replaced by focal point 
connections in all resistant cell lines. This phenotypic change was also accompanied by an 
increase in growth rate and cell counting experiments were performed to further quantify this 
change (Figure 7.12). The cell doubling time was significantly reduced in all 3 resistant cell 
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Figure 7.10- Incremental dose escalation of AZD8931 to generate AZD8931 resistant 
cell lines.  The concentration of AZD8931 was maintained for at least 2 passages prior 
to dose escalation. A flexible dose escalation strategy was used so that the 
magnitude of dose increase was adjusted according to the cells’ ability to adapt to the 
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Figure 7.11- Development of resistance coincided with acquisition of a distinct 
mesenchymal phenotype. A: Parental cells have a rounded, epithelial appearance and 
form close cell-cell attachments along the cell’s entire length. Resistant cell lines 8931 
R-SKBR3a (B), 8931 R-SKBR3b (C) and 8931 R-SKBR3c (D) appeared spindle shaped 
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Figure 7.12- Parental cells were seeded in a 12-well plate at 3 different concentrations. 
Each concentration was plated in duplicate. Proliferation was measured 96 hours later 
by cell counting. Resistant cell lines were seeded in duplicate at 2 different 
concentrations. White bars represent an initial cell count of 0.015*10
6
 and black bars 
represent a starting cell count of 0.03*10
6
 cells.  To avoid cells becoming confluent, 
proliferation was assessed in all resistant cell lines after 48 hours. Mean values with 
SEM displayed from a series of 3 experiments.  
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Cell Line Mean doubling time (± SEM) in hours 
Parental SKBR3 59.39 ± 3.8 
8931 R-SKBR3a 14.90 ± 0.83  
8931 R-SKBR3b 19.02 ± 1.78  
8931 R-SKBR3c 13.87 ± 0.77  
 
Table 7.3: Cell doubling time of parental SKBR3 cells was significantly prolonged 
compared to AZD8931 resistant cell lines (p<0.001, one way ANOVA).  denotes 
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7.7 Confirmation that 8931 R-SKBR3 a-c cell lines 
were resistant to AZD8931 
 
Once cells had been maintained in AZD8931 0.670 µM for at least 2 passages, we re-
checked their sensitivity to the drug. Both parental and resistant SKBR3 cell lines were 
cultured in the presence of escalating doses of AZD8931 for 72 hours before SRB assays 
were conducted. All experiments were performed in triplicate. Despite increasing the 
maximum concentration of AZD8931 to 20 µM, the IC50 of resistant cell lines was not 
reached. As previously noted when checking lapatinib sensitivity, we found that following 
prolonged culture parental SKBR3 cells also became less sensitive to AZD8931. Therefore, 
in the following analysis we have again compared percentage cell kill in the resistant cell 
lines at the parental cell line’s IC50 concentration within each individual experiment. Even 
allowing for the loss of sensitivity in the parental cell line, we found that the percentage cell 
kill was significantly reduced in all 3 resistant cell lines. At the parental cell line’s IC50, the 
mean percentage cell kill was 0.1%, 0.0% and 1.1% in 8931 R-SKBR3a, 8931 R-SKBR3b 
and 8931 R-SKBR3c respectively (Figure 7.13). There was no significant difference in the 
percentage cell kill for any of the 3 resistant cell lines (p<0.001, one way ANOVA). 
 
We determined the long-term stability of the resistant phenotype by seeding all 3 resistant 
cell lines into 2 flasks. For each cell line, 1 flask continued to be cultured in the presence of 
AZD8931 0.670 μM and the second flask was cultured in the absence of drug. Sensitivity to 
AZD8931 was re-checked after all cell lines had been cultured in the absence of drug for a 
period of at least 8 weeks. No difference in the percentage cell kill of any resistant cell line 
was observed,  irrespective of whether they were cultured in the presence or absence of 
AZD8931 (p=0.01, one way ANOVA), suggesting that once established resistance was 
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Figure 7.13- Proliferation of 8931-RSKBR3 a-c was not inhibited by the dose of 
AZD8931 which inhibited proliferation of the parental cell line by 50%.  Parental 
SKBR3 cells (5000 cells/well) and 8931 R-SKBR3a-c cells (1250 cells/well) were seeded 
into 96 well plates. 24 hours later cells were treated with escalating doses of AZD8931 
for 72 hours before SRB assays were performed.  Data was analysed using GraphPad 
Prism 6 software. Mean percentage cell kill ± SEM for each cell line calculated from a 
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Figure 7.14- AZD8931 resistance was not reversible following drug withdrawal for 8 
weeks. Two flasks were seeded with each resistant cell line. One flask per cell line 
continued to be cultured in the presence of 0.670 μM AZD8931, whilst the second flask 
was cultured in the absence of drug. After an interval of at least 8 weeks, drug 
sensitivity assays were repeated in cell lines cultured both in the presence and 
absence of AZD8931. All experiments included a positive control comprising of 
parental SKBR3 cells treated with escalating doses of AZD8931 to confirm the 
continued potency of the drug. Data was analysed using GraphPad Prism 6 software. 
Mean percentage cell kill ± SEM for each cell line calculated from a series of 3 
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7.8 Demonstration that AZD8931 resistant cell lines 
were cross resistant to lapatinib 
 
To explore whether AZD8931 resistant cells remained sensitive to lapatinib, we treated both 
parental and AZD8931 resistant cells with increasing doses of lapatinib for 72 hours and 
then performed SRB assays.  All 3 AZD8931 resistant cell lines were also resistant to 
lapatinib (Figure 7.15). At the parental SKBR3 cell line’s IC50, the mean percentage cell kill in 
the resistant cell lines was 0.27%,0.93% and 0.0% in  8931R-SKBR3a, 8931R-SKBR3b and 
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Figure 7.15- AZD8931 resistant cell lines were resistant to lapatinib. 96 well plates 
were seeded with parental SKBR3 (5000 cells/well) and AZD8931 resistant cell lines 
(1250 cells/well) and 24 hours later treated with increasing doses of lapatinib for 72 
hours. SRB assays were then performed. Data was analysed using GraphPad Prism 6 
software. Mean percentage cell kill ± SEM for each cell line calculated from a series of 
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7.9 Confirmation of target inhibition at lapatinib and 
AZD8931 concentrations which inhibit 
proliferation 
 
Many existing TKIs, such as dasatinib, are classified as promiscuous drugs as although they 
potently inhibit their targets, they lack specificity. Therefore, in addition to inhibition of their 
target tyrosine kinases, many have a range of off-target effects caused by inhibition of non-
target kinases. To explore whether the effects of lapatinib and AZD8931 on proliferation 
were due to on-target effects, we performed western blots on cell lysate from parental BT474 
cells which had been treated with escalating doses of lapatinib and parental SKBR3 cells 
which had been treated with either escalating doses of lapatinib or AZD8931 for 24 hours. 
We aimed to incorporate drug concentrations in these experiments which encompassed the 
IC50 of the cell lines as calculated in the above SRB experiments. However, we found that 
the sensitivity of the SKBR3 cell line to both lapatinib and AZD8931 was reduced following 
prolonged culture. We therefore recalculated the IC50 of the SKBR3 cell line to both drugs at 
the time of performing these western blots and selected appropriate doses to encompass the 
modified IC50. The modified IC50 for the SKBR3 cells treated with lapatinib was 0.5 µM and 
for AZD8931 it was 1.5 µM. The IC50 for the parental BT474 cell line was unchanged 
following prolonged in vitro culture. 
 
As predicted, we observed dose dependent reductions in both pTyr 1248/Tyr 1173 
HER2/EGFR and pTyr 1221/1222 HER2 expression in both AZD8391 and lapatinib treated 
cells (Figure 7.16a). We also observed a reduction in pTyr 1289 HER3 expression in both 
lapatinib treated SKBR3 and BT474 cells and also in AZD8931 treated SKBR3 cells. A trend 
towards increased total HER2 expression was seen in all cell lines and HER3 expression 
also appeared to be increased, although this was most marked in lapatinib treated cells. 
Both the expression and activation of EGFR was too low in both BT474 and SKBR3 cells to 
enable us to draw any firm conclusions about the effect of these drugs on this signalling 
pathway. Akt and p44/42 MAPK are 2 important downstream readouts of HER family 
signalling. Consistent with reduced HER2 and HER3 activity, we observed dose dependent 
reductions in both Akt and p44/42 MAPK activity in both lapatinib and AZD8931 treated cells 
(Figure 7.16b).  
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In summary, this data shows that target inhibition is achieved at drug concentrations which 
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Figure 7.16- Lapatinib and AZD8931 inhibited HER family signalling (Ai, ii) resulting in 
inhibition of downstream signalling pathways (B). Parental BT474 and SKKBR3 cells 
were incubated overnight with increasing doses of lapatinib before being used to 
generate cell lysate for western blotting. Lysate was also generated from SKBR3 cells, 
which had been treated overnight with AZD8931. Aii: Lysate from untreated A431 cells 
included as a positive control for EGFR and pTyr 992 EGFR antibodies in lapatinib 
treated assays.  20 μg protein loaded in each lane, except on EGFR and pEGFR blots 
where 40 μg protein loaded. Tubulin used as loading control.  
   
 
 






Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
Chapter7: Generation and characterisation of cell lines with acquired resistance to HER2 directed 
tyrosine kinase inhibitors (TKI)     277 
 
 
7.10 Comparison of parental and resistant cell lines 
 
7.10.1 Comparison of target receptor expression and 
downstream pathway activation  
  
Altered expression of HER family proteins has previously been described as underlying 
acquired resistance to both trastuzumab and lapatinib [147]. Therefore, we used western 
blotting to compare expression of target receptors in untreated parental SKBR3 cells and in 
our AZD8391 resistant cell lines (Figure 7.17A).  We initially used tubulin as a loading control 
but despite replicating these blots, we noticed consistent variations in the signal obtained 
with this antibody across the different cell lines tested, particularly when comparing the 
parental SKBR3 cell line with AZD8931 resistant cell lines. These differences were not 
present in our initial blots comparing receptor expression within the different parental cell 
lines suggesting that these changes were related to the development of a mesenchymal 
phenotype during the development of resistance. We therefore elected to use GAPDH as an 
alternative loading control in western blots comparing expression of proteins in parental and 
resistant cell lines, which suggested loading was uniform across the tested cell lines. We 
used Image J to quantify densitometry changes in replicate blots (Tables 7.4).  We found 
statistically significant reductions in expression of both total HER2 (p<0.001, one way 
ANOVA, Table 7.4) and HER3 (p=0.002, one way ANOVA) in our resistant lines. Expression 
of pTyr 1221/1222 HER2 and pTyr 1289 HER3 was also reduced in our resistant cell lines, 
where its expression was barely detectable. However, we found that expression of total 
EGFR was up-regulated in all resistant lines, although this did not reach statistical 
significance, most likely as a consequence of the low number of blots analysed. Despite this 
up-regulation, the receptor was largely inactive, with minimal pTyr 992 EGFR expression in 
either the parental or resistant lines. Looking downstream of the HER family receptors, we 
found a statistically significant increase in expression of both total Akt (p=0.013, one way 
ANOVA) and p44/42MAPK (p<0.001, one way ANOVA Figure 7.4). We also observed a 
corresponding increase in the expression of the phosphorylated and active fractions of these 
signalling molecules, suggesting that our resistant cell lines had managed to adapt to 
reduced HER family signalling through up regulation of both Akt and p44/42 MAPK to ensure 
continued signalling through these critical pathways. The functional consequences of these 
signalling changes have been addressed in further experiments (see section 7.11). 
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To determine whether these changes were specific to AZD8931 resistant cell lines or 
reflected changes found more widely in cell lines with acquired resistance to HER2 targeted 
TKIs, we compared HER family receptor expression in parental SKBR3 cells and in 
untreated lapatinib resistant SKBR3 cell lines. We observed reductions in expression of both 
total HER2 and HER3 of approximately 95% (p= <0.001, one way ANOVA, table 7.5) and 
85% (p<0.001, one way ANOVA) respectively. Again, expression of both pTyr 1221/1222 
HER2 and pTyr 1289 HER3 was barely detectable in either resistant cell line. Unlike our 
AZD8931 resistant cell lines, we did not observe an increase in total EGFR expression in our 
lapatinib resistant SKBR3 cell lines and expression of both total EGFR and pTyr 992 EGFR 
was too low in all cell lines to permit further analysis. As in our AZD8931 resistant cell lines, 
we observed an increase in total Akt expression in both lapatinib resistant SKBR3 cell lines 
(Table 7.5). However, pSer 473 Akt was undetectable in both resistant cell lines, suggesting 
that, unlike in our AZD8931 resistant cell lines, this increase in expression was not 
accompanied by increased activation. Unlike in our AZD8931 resistant cell lines, we 
observed no increase in p44/42 MAPK expression in lapatinib resistant cell lines. However, 
expression of pThr202/Thr185, Tyr 204/187 p44/42 MAPK was reduced in both resistant cell 
line consistent with reduced signalling p44/42 MAPK signalling activity. Together, this data 
suggests that survival in our lapatinib resistant SKBR3 cell lines was independent of both Akt 
and p44/42 MAPK signalling.   
 
To explore whether these changes were specific to SKBR3 derived cell lines or whether they 
might be generalizable to other cell lines, we examined changes in HER receptor expression 
in our lapatinib resistant BT474 derived cell lines. Again, we observed significant reductions 
in expression of both total HER2 (p<0.001, one way ANOVA) and HER3 (p=0.002, one way 
ANOVA) in both lapatinib resistant BT474 cell lines. Again, expression of both pTyr 
1221/1222 HER2 and pTyr 1289 HER3 was barely detectable in either resistant cell line. 
Expression of total EGFR was too low to permit quantification in any of the cell lines. 
However, pTyr 992 EGFR was readily detectable in the parental cell line but was 
undetectable in either resistant cell line. As in our lapatinib resistant SKBR3 cell lines, the 
BT474 resistant cell lines appeared to have developed Akt and p44/42 independent 
signalling mechanisms as we did not observe an increase in expression of these signalling 
molecules (Table 7.5). Furthermore, we observed marked reductions in the expression of 
both pSer 473 Akt and pThr202/Thr185, Tyr 204/187 p44/42 MAPK.                 
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Taken together, these results suggest that reduced HER family receptor expression is a 
common mechanism employed by cells to develop resistance to HER2 targeting TKIs. 
However, the downstream consequences of this loss appears to be drug specific; our 
AZD8931 resistant SKBR3 cell lines adapted by up regulating Akt and p44/42 MAPK to 
support ongoing signalling through these critical pathways whilst both our lapatinib resistant 
SKBR3 and BT474 cell lines had developed independent, alternative signalling mechanisms 
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Figure 7.17-  Representative western blots comparing expression of target receptors 
(A) and downstream pathway activation (B) in untreated parental and AZD8931 or 
lapatinib resistant cell lines. Aii: Lysate from untreated A431 cells included as a 
positive control for EGFR and pTyr 992 EGFR antibodies. 20 μg protein loaded in each 
lane, except on EGFR and pEGFR blots where 40 μg protein loaded. Tubulin and 
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Table 7.4- Quantification of changes in total protein expression in AZD8931 resistant 
cell lines by western blot. Expression in resistant cell lines displayed relative to 
parental cell line expression (which always equalled 1). Image J software used to 
quantify changes in total protein expression in a series of 3 experiments. P values, 
comparing differences in protein expression between parental and resistant cell lines, 
calculated using one way ANOVA with Tukey’s test. Statistically similar means 
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AKT 1.30 (0.17) 1.77 (0.004) 0.010 1.01 (0.37) 0.66 (0.26) 0.315 
P44/42 
MAPK 
1.12 (0.25) 1.61 (0.07) 0.055 0.91 (0.18) 0.86 (0.29) 0.788 
 
Table 7.5- Quantification of changes in total protein expression in lapatinib resistant 
cell lines on western blot. Expression in resistant cell lines displayed relative to 
parental cell line expression (which always equalled 1). Image J software used to 
quantify changes in total protein expression in a series of 2 experiments. P values 
comparing differences in protein expression between parental and resistant cell lines 
calculated using one way ANOVA with Tukey’s test. Statistically similar means 
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7.10.2 Comparison of signaling pathway changes in 
response to lapatinib and AZD8931 in parental and 
resistant SKBR3 cells. 
 
To further explore the contribution of HER family receptor expression changes on the 
resistant phenotype, parental and resistant cell lines were incubated overnight with 
escalating doses of AZD8391 or lapatinib.  As previously described, parental cell lines 
demonstrated dose-dependent reductions in phosphorylation and activation of HER2, HER3 
and EGFR. Dose dependent reductions in both Akt and p44/42 MAPK activity were also 
observed. In all our resistant cell lines, we observed persistent Akt and p44/42 MAPK activity 
when treated with escalating doses of AZD8931 (Figure 7.18) or lapatinib (Figure 7.19, 
Figure 7.20) despite reduced HER receptor expression. Increasing the dose of lapatinib used 
to treat Lap. R-SKBR3b cells to 2 μM resulted in a substantial reduction in Akt activity. 
Resistant cell lines were maintained in the presence of 5 μM of lapatinib and this therefore 
suggests that persistent Akt activity alone was not sufficient to account for the resistant 
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Figure 7.18: AZD8931 resistance was associated with persistent Akt and p44/42 MAPK 
activity in the presence of AZD8931. Parental and resistant cell lines were treated 
overnight with escalating doses of AZD8931 before lysate was generated for western 
blotting. Optimal exposures for each individual cell line displayed and therefore 
parental and resistant cell line images not necessarily contemporaneous. 20 μg 
protein loaded in each lane except for EGFR and pTyr 992EGFR where 40 μg protein 
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Figure 7.19: Lapatinib resistance in SKBR3 cells was associated with persistent Akt 
and p44/42 MAPK activity in the presence of lapatinib. Lysate was generated from 
parental and resistant cell lines treated with escalating doses of lapatinib. Optimal 
exposures for each individual cell line displayed and therefore parental and resistant 
cell line images not necessarily contemporaneous. 20 μg protein loaded in each lane, 
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Figure 7.20: Persistent activation of Akt and p44/42 MAPK was observed in lapatinib 
resistant BT474 cells in the presence of escalating doses of lapatinib. Parental and 
resistant cell lines were treated overnight with escalating doses of lapatinib before 
lysate was generated for western blotting. Optimal exposures for each individual cell 
line displayed and therefore parental and resistant cell line images not necessarily 
contemporaneous.  20 μg protein loaded in each lane, except in EGFR blot where 40 
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7.10.3 Initial exploration of additional mechanisms of 
acquired resistance to HER2 targeted TKIs 
 
Mechanisms of acquired resistance to HER2 targeted therapies have been the focus of 
numerous previously published studies [147] [330]. Using lysate from untreated parental cell 
lines and their AZD8931 or lapatinib resistant derivatives, we used western blotting to 
explore whether any of these previously established resistance mechanisms were present in 
our cell lines. Consistent with our earlier observations that AZD8931 resistant cell lines were 
cross resistant with lapatinib resistant cell lines and vice versa (Figure 7.9 and 7.15), we 
observed considerable overlap in the resistance strategies used by AZD8391 and lapatinib 
resistant cell lines. Resistance to both AZD8931 and lapatinib was associated with loss of 
PTEN expression (Figure 7.21). Despite a reduction in total Src in all 3 AZD8931 resistant 
cell lines, we observed an increase in pTyr 416 Src expression suggesting increased Src 
activity in these cell lines. A similar increase in pTyr 416 Src expression was observed in 
lapatinib resistant SKBR3 cell lines although total Src expression was unchanged. However, 
we did not observe any consistent change in Src activity in BT474 derived lapatinib resistant 
cell lines. Using pTyr 1162 /1163 IGF1R expression, 2 key autophosphorylation sites on 
IGF1R [331], we measured IGF1R signalling activity. Again, we observed an increase in 
IGF1R activity in both AZD8931 and lapatinib resistant SKBR3 cells but saw no change in 
activity in BT474 derived lapatinib resistant cell lines. Phosphorylation of the EphA2 receptor 
tyrosine kinase receptor by Akt on serine residue 897 has been associated with increased 
cell migration [332]. We found that pSer 897 EphA2 expression was increased in all resistant 
cell lines along with total EphA2 which has also been linked to resistance 
 
In summary, we identified multiple signalling changes in all the resistant cell lines. However, 
further experiments are required in the future to identify which of these changes, if any, were 
responsible for driving resistance.    
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Figure 7.21- Key changes in signalling pathways linked to resistance in AZD8931 and 
lapatinib resistant cell lines. 20 μg protein loaded in each lane. Tubulin and GAPDH 
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7.10.4 Confirmation of induction of EMT in resistant cell lines 
 
As previously described, acquisition of both lapatinib and AZD8931 resistance was 
associated with a distinctive change in phenotype and development of a mesenchymal 
appearance. We therefore compared expression of EMT markers in parental and resistant 
cell lines. Both N-cadherin [333] and vimentin [334] expression were upregulated in all 
resistant cell lines (Figure 7.22), consistent with their mesenchymal appearance (Figures 7.5 
and 7.11). Loss of E-cadherin is considered a hallmark of EMT [333] and we observed loss 
of expression in lapatinib resistant BT474 cells. However, the SKBR3 cell line contains a 
deletion in CDH1, the E-cadherin encoding gene, and therefore does not express any E-
cadherin protein [335]. Although CDH1 mutations are not frequently reported in ductal breast 
carcinomas, reduced E-cadherin protein expression is common [336]. Therefore, EMT in a 
low E-cadherin expressing tumour is likely to be a commonly encountered scenario making 
our lapatinib and AZD8931 resistant cell lines still relevant in the wider clinical context.  
 
Cells which have undergone EMT display an increasingly migratory phenotype [337], [338]. 
Using AZD8931 resistant cell lines, we conducted random migration studies to further 
confirm that resistant cells had undergone EMT. 3000 cells were seeded in a 6 well dish and 
images acquired every 15 minutes overnight. Image J software was used to analyse the 
images and to calculate the total and the vectorial distance covered by individual cells 
(analysis by J. Main). The mean accumulated distance was significantly increased in all 3 
resistant cell lines (p<0.001, One way ANOVA, Figure 7.23). The mean distance travelled by 
parental SKBR3 cell lines was only 10.89 μm compared to 59.22 μm and 52.60 μm covered 
by 8931 R-SKBR3b and 8931 R-SKBR3c cell lines respectively.  8931 R-SKBR3a was the 
most motile of all cell lines with a mean of 73.47 μm travelled, which was significantly greater 
than the motility of parental SKBR3 and 8931 R-SKBR3b and 8931R-SKBR3c cell lines. 
Similarly, in terms of the vectorial distance covered, all 3 resistant cell lines demonstrated 
increasingly motility with 8931 R-SKBR3a being the most motile of all cell lines (p<0.001, 
one way ANOVA). Persistence of movement, defined as vectorial distance/accumulated 
distance, was not significantly different between any of the cell lines (p=0.078, One way 
ANOVA). 
 
An increase in invasion capacity is also characteristic of mesenchymal cells [337], [338]. 3D 
invasion studies through matrigel (performed by J. Main) demonstrated a non-significant 
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increase in invasive capacity of the 3 resistant cell lines (p=0.092, One way ANOVA, Figure 
7.24). When compared to the invasive capacity of the parental SKBR3 cell line at 60 μm, 
mean invasive capacity of 8931-RSKBR3a, 8931-RSKBR3b and 8931- RSKBR3c was 
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Figure 7.22-  AZD8931 and lapatinib resistant cell lines have changes in EMT markers. 
Ai: Western blots demonstrating loss of epithelial markers in BT474 resistant cell 
lines and acquisition of mesenchymal markers in SKBR3 and BT474 resistant cell 
lines. 20 μg protein loaded in each lane. Tubulin used as loading control Aii: western 
blot confirming absence of E-cadherin expression in all SKBR3 cell lines. BT474 
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Figure 7.23- 8931 R-SKBR3 cell lines demonstrated an increasingly motile phenotype. 
A 6 well dish was seeded with 3000 cells in total media and images recorded every 15 
minutes overnight using the automated Olympus Scan R-screening station. 
Experiments performed in triplicate and analysed using Image J. Ai: total cumulative 
distance travelled was statistically increased in all 3 AZD8931 resistant cell lines 
compared to the parental cell line (p<0.001, one way ANOVA). Aii: Significantly 
increased vectorial distance travelled by the 3 AZD8931 resistant cell lines (p<0.001, 
one way ANOVA). A iii: No significant difference was observed in persistence 
(vectorial distance/accumulated distance) between parental and AZD8931 resistant 
cell lines (p=0.078, one way ANOVA). Graphs depict mean value. Error bars represent 
standard deviation (data analysed and figures prepared by J. Main).  B: 
Representative cell tracks showing distance travelled by individual parental and 
resistant cells during experiment. The red line depicts migration track of cells which 
finish below the horizontal line whilst the black line represents migration of track cells 
which finish above the horizontal line. Blue dot represents median net migration 
distance of all representative cells. 
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Figure 7.24- 8931 R-SKBR3 cell lines demonstrated non-statistical increase in invasive 
capacity. A: Invasion of parental and 8931-R SKBR3 cell lines through matrigel-coated 
invasion chambers over 24 hours, where invasion of parental SKBR3 cell line was 
defined as 100%. All experiments performed in triplicate. Mean value displayed with 
error bars representing standard deviation. P=0.092 (one way ANOVA). B: Montage of 
representative confocal images taken at 10 μm intervals through the 3D matrigel 
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7.11 RPPA analysis of signalling changes associated 
with AZD8931 resistance 
 
Numerous studies have already explored mechanisms of acquired resistance to lapatinib. 
We therefore decided to focus our further studies on mechanisms of acquired resistance to 
the novel drug AZD8931. RPPA platforms use a candidate driven approach to provide 
simultaneous quantitative evaluation of changes in multiple intracellular signaling pathways. 
We performed RPPA analysis on parental and resistant AZD8931 SKBR3 cell lines (K. 
Macleod). All experiments were performed in triplicate. The signal intensity obtained with 
each antibody reflected both the antibody’s affinity for its target protein and the protein’s 
abundance. Therefore, to try and ensure the biological relevance of our results, only data for 
antibodies in which the median signal in either the parental or resistant cell lines was in 
excess of 1.5 times the signal of the secondary antibody alone were included in our dataset 
with the aim of preventing over-analysis of data derived from weak or non-specific signals 
which were not reflective of true changes in pathway activity. We retrospectively set this 
threshold after observing that the signal with the pTyr 1248/ Tyr 1173 HER2/EGFR was 
approximately 1.5 times that of the secondary antibody and having previously demonstrated 
that this level of phosphorylation with this antibody was readily detectable on western blot, 
we felt this was a practical strategy to ensure inclusion of only meaningful results. In the 
following description only values which met this arbitrary threshold have been included and 
where possible the ratio of phospho:corresponding total protein is presented to give a 
measure of changes in activity within individual pathways [206]. Where this was not possible, 
the RFI has been presented, corrected using global normalization technique [282]. The log2 
of all values in the resistant cell lines have been calculated and normalized against the log2 
of the corresponding parental cell line value. Therefore in the following figures (Figures 7.25, 
7.26, 7.27 and 7.28), any data series with a positive value on the Y-axis represents 
increased protein expression in the resistant cell lines compared to the parental cell line. Any 
data series with a negative value on the Y-axis indicates reduced protein expression in the 
resistant cell lines (for full set of results see Appendix 4). 
 
Initial inspection of results showed close agreement between the 3 resistant cell lines in 
expression patterns of individual proteins suggesting common mechanisms of resistance/ 
were present (Figure 7.25, 7.26, 7.27, 7.28). In terms of individual proteins, we wanted to 
further explore changes in HER2, HER3 and EGFR expression and activity. Consistent with 
our western blot data, we saw a dramatic reduction in total HER2 expression in all 3 of the 
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resistant cell lines using RPPA. The RFIs obtained with antibodies for other HER family 
signaling proteins were often narrowly in excess of the 1.5 fold secondary antibody threshold 
(corresponding to an RFI of 103.00, Figure 7.25B). Although we used the same pTyr 
1248/1173 HER2/EGFR antibody in both our western blotting and RPPA experiments, we 
saw no reduction in the expression of this protein using RPPA. Western blotting is still 
considered to be the gold-standard technique and the discrepancy between our results 
achieved using this technique and RPPA is likely due to low level of signal achieved with this 
antibody on this platform. This suggests that in retrospect our 1.5 fold threshold may have 
been inadequate to exclude non-specific signals and that this antibody was not suitable for 
use on this platform. Similarly, we saw no difference in expression of either total or the 
phosphorylated and active subsets of either HER3 between the parental SKBR3 and 
AZD8931 resistant cell lines and this was most likely because both these antibodies also 
lacked sensitivity on the RPPA platform. The level of EGFR expression alone was too low to 
quantify in all cell lines and therefore analysis was restricted to expression of pTyr 1173 
EGFR alone. We did not identify any significant difference in pTyr 1173 EGFR expression 
between resistant and parental cell lines, although again the generated signal was probably 
too low in all lines to permit reliable interpretation of the data. In summary, due to lack of 
sensitive antibodies, the RPPA platform was not suitable for exploring changes in expression 
of HER family signaling receptors in our resistant cell lines.   
 
We looked down stream of the HER family receptors at Akt and p44/42 MAPK signaling. The 
RFI achieved for both total and the phosphorylated and activated subsets of these proteins 
was at least 2 fold in excess of our 1.5 fold threshold. We found a significant increase in Akt 
activity as measured by both pSer473 and pTyr 308 Akt expression (Figure 7.26A). This 
increase in Akt signaling was likely due, at least in part, to loss of PTEN expression 
(p<0.001, one way ANOVA), which we demonstrated using both RPPA and western blotting 
(RPPA data not shown). Consistent with our observed increase in Akt activity, we observed 
an increase in pThr 389 p70 S6 kinase expression (p<0.001, one way ANOVA), which as an 
auto-phosphorylation site acts as a marker of this protein’s activity [339]. Similarly, we 
observed an increase in the phosphorylation of S6 ribosomal protein at 2 separate sites 
[340], (p<0.001, one way ANOVA), which again was consistent with an increase in Akt 
signaling. Furthermore, we observed a statistically significant reduction in the activity of 
GSKβ (p=0.031, one way ANOVA), again consistent with increased Akt activity. MAPKs are 
also important downstream readouts of HER family signaling. Intriguingly, on western blot, 
we identified an increase of similar magnitude in both total p44/42 MAPK and pThr 202/Thr 
185, Tyr 204/Tyr 187 p44/42 MAPK. However, using RPPA we found a statistically 
significant reduction in p44/42 MAPK activity (p=0.001, one way ANOVA, Figure 7.26B). 
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Considering total p44/42 MAPK and pThr 202/Thr 185, Tyr 204/Tyr 187 p44/42 MAPK 
separately, we found that expression of total protein was unchanged between parental and 
resistant cell lines. However, unexpectedly, we found a substantial reduction in pThr 202/Thr 
185, Tyr 204/Tyr 187 p44/42 MAPK in the resistant cell lines. We also noted a significant 
increase in activity of the SAPK/JNK MAPK (p= 0.034).      
 
During this analysis, we compared the expression of several proteins which have been 
previously implicated in resistance to HER2 targeted therapies. Increased Src activity has 
been identified as a critical player in a number of independent pathways which result in 
trastuzumab resistance [155]. We observed a statistically significant increase in Src activity 
in all 3 of our resistant cell lines (p=0.001, one way ANOVA, Figure 7.27A). The receptor 
tyrosine kinase, MET has also been shown to be upregulated following trastuzumab 
treatment and to contribute to acquired resistance by HER2 independent activation of the 
PI3K/Akt pathway [156]. We did not observe any difference in total MET expression between 
our parental and resistant cell lines, although again the RFIs achieved with this antibody 
were only just in excess of our 1.5 fold secondary antibody threshold. Unfortunately, 
expression of pTyr 1234 MET was too low to permit reliable quantification.       
 
Defects in cell cycle regulation and apoptosis have also been linked to resistance to HER2 
directed therapies [147]. We observed an increase in CDK2 expression (Figure 7.27B), 
which plays a key role in promoting passage through the G1/S check point [342]. However, 
we did not observe any difference in cyclin D1 expression, which has also been implicated in 
regulating the same checkpoint [343] and we observed a reduction in expression of pSer 216 
cdc25c in resistant cell lines (p <0.001, one way ANOVA) consistent with reduced cell cycle 
progression and specifically entry into mitosis [341]. Counter-intuitively, we observed a 
statistically significant increase in expression of the pro-apoptotic protein Bid [344] and a 
reduction in the expression of the inhibitor of apoptosis survivin [345]. No difference in 
expression of either total Bim or pSer69 Bim, which is responsible for triggering the 
degradation of this pro-apoptotic molecule [346], were observed. Taken together, these 
changes suggest that avoidance of apoptosis was not an important mechanism underpinning 
resistance to AZD8931.  
 
We also used RPPA to explore changes in expression of a number of other signaling 
pathways. We observed a statistically significant reduction in expression of total Stat3 in all 3 
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resistant cell lines (p<0.001, one way ANOVA, Figure 7.28A). We also observed a reduction 
in pTyr 783 PLCɣ: PLCɣ expression (p<0.001, one way ANOVA, Figure 7.18B), which is a 
well established target of EGFR [347]. CrkL is phosphorylated by BCR/Abl on tyrosine 
residue 207 [348] and we observed an increase in pTyr 207 CrkL expression in all 3 resistant 
cell lines (p <0.001, one way ANOVA, Figure 7.18B).  
 
In summary, this data suggests that our resistant cell lines adopted multiple different 
resistance strategies, including down regulation of HER2, development of HER2 
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Figure 7.25- A. Changes in expression of total and phosphorylated HER2, HER3 and 
EGFR associated with AZD8931 resistance. Statistically significant p values denoted 
by red asterix. Vertical lines demonstrate range between maximum and minimum 
values. Horizontal bar represents median value (n=3). Blue, green and purple lines 
represent 8931R-SKBR3a, 8931R-SKBR3b and 8931R-SKBR3c data sets respectively.  
All p values calculated using one way ANOVA.  B. Tabulated RFI values of HER family 
signaling proteins. All included values met the arbitrary threshold set at 1.5 times the 
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Figure 7.26-  A. RPPA analysis demonstrated that AZD8931 resistance was associated 
with an increase in Akt signalling and its downstream signalling pathways. B: A 
statistically significant reduction in p44/42 MAPK signalling and an increase in 
SAPK/JNK expression were observed in AZD8931 resistant cell lines. Vertical lines 
demonstrate range between maximum and minimum values. Horizontal bar represents 
median value (n=3). Blue, green and purple lines represent 8931R-SKBR3a, 8931R-
SKBR3b and 8931R-SKBR3c data sets respectively. Statistically significant p values 
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Figure 7.27- A. AZD8931 resistance was associated with a statistically significant 
increase in Src activity. B: Changes in signalling pathways regulating cell cycle 
control and apoptosis were observed in AZD8931 resistant cell lines. Vertical lines 
demonstrate range between maximum and minimum values. Horizontal bar represents 
median value (n=3). Blue, green and purple lines represent 8931R-SKBR3a, 8931R-
SKBR3b and 8931R-SKBR3c data sets respectively. Statistically significant p values 
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Figure 7.28- A. Development of AZD8931 resistance was associated with a reduction 
in total Stat3 expression. B: Reduced PLCɣ signalling activity and reduced expression 
of pCrkl was observed in AZD8931 resistant cell lines. Vertical lines demonstrate 
range between maximum and minimum values. Horizontal bar represents median 
value (n=3). Blue, green and purple lines represent 8931R-SKBR3a, 8931R-SKBR3b 
and 8931R-SKBR3c data sets respectively. Statistically significant p values denoted 
by red asterix. All p values calculated using one way ANOVA. 
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7.12 Mass spectrometry analysis of differences in 
protein expression patterns between parental 
and AZD 9831 resistant cell lines. 
 
Mass spectrometry can also be used to interrogate signalling network interactions and to 
identify both specific molecules and broader cellular processes underpinning drug 
resistance. This approach can incorporate multiplex, non-targeted measurements in a 
quantitative manner enabling a more global assessment of protein expression in our cell 
lines.  Label free mass spectrometry was therefore performed by one of our collaborators 
(Dr. Thierry Le Bihan) on both parental SKBR3 and 8931R-SKBR3c cells to provide more 
information on critical cellular processes underpinning the resistant phenotype. 
 
We classified proteins as being significantly differently expressed between the 2 cell lines if 
the following 2 criteria were met: 1. fold change in expression between the 2 cell lines, as 
measured by at least 2 peptides, was >2, 2. the calculated pair-wise p value was ≤0.05. In 
total 533 proteins were significantly differently expressed between the parental and resistant 
cell lines (Figure 7.29). Expression of 72.8% (n=388) of these proteins was reduced in 8931 
R-SKBR3c compared to the parental cell line. Expression of only 27.2% (n=145) proteins 
was increased in 8931 R-SKBR3c compared to the parental cell line. (For a full list of these 
proteins see Appendix 5). Western blotting was used to confirm the results of a selection of 
the differentially expressed proteins in all 3 resistant cell lines (Figure 7.30). As with our 
initial western blots, close agreement was observed between protein expression in all 3 
resistant cell lines again suggesting that resistance in the 3 lines was driven by common 
mechanisms.  
 
Classification of proteins according to function demonstrated that proteins affecting gene 
transcription and cytoskeletal structure, adhesion and cell migration were the most 
commonly altered representing 13.7% and 12.8% of all differentially expressed proteins 
respectively (Figure 7.30, Figure 7.31). Proteins which were up-regulated in the 8931 R-
SKBR3c cell line and were classified within the same functional group did not always have 
complementary actions, for example caldesmon, which inhibited the motility of gastric cancer 
cell in vitro  and was associated with reduced lymph node metastases in vivo [349], was up-
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regulated in the 8931 R-SKBR3c cell line.  Conversely, talin 1, which was also up-regulated 
in 8931 R-SKBR3c cell lines, enhanced the motility of glioma cells in vitro [350]. This lack of 
complementary actions between proteins in the same functional group was also evident 
amongst proteins which were down-regulated in the 8931 R-SKBR3c cell line, suggesting 
changes in complex signalling pathways had rendered some signalling pathways redundant. 
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Figure 7.29- Volcano plot demonstrating 533 differentially expressed proteins between 
parental SKBR3 and 8931R-SKBR3c cell lines. Each data point represents 1 protein. 
The difference in expression between parental and resistant cell line, expressed as lg
-2
 
fold change, is plotted on the x axis. The statistical significance of this difference 
(calculated using one way ANOVA) is plotted on the y axis. Proteins with a fold 
change > 1.5 or < 0.6667, measured by at least 2 peptides, and with a p value ≤ 0.05 
are considered statistically differently expressed between the 2 cell lines. These 
proteins are plotted in the upper, outer regions (marked by the red lines) on the above 
graph. Amongst the differentially expressed proteins, over half had reduced 
expression in the resistant cell line compared to the parental cell line resulting in the 
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Figure 7.30- Validation of proteomic data by western blot. A: Graphical depiction of 
selected proteomic data. All experiments performed in triplicate. Red data points 
represent parental SKBR3 values. Black data points represent 8931-RSKBR3 c values. 
B: Confirmation of proteomic data by western blot. 20 μg protein loaded in each lane. 
Tubulin used as a loading control (J. Main).  Note consistency of expression of 
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Figure 7.31- Classification of proteins with reduced expression in 8931R-SKBR3c cell 
line according to function. 87.9% of proteins with significantly reduced expression in 
the 8931 R-SKBR3c cell line could be classified into the above functions. Proteins 
which affected gene transcription, cytoskeletal structure, cell adhesion and migration 
were the most frequently down regulated in the resistant cell line. When proteins had 






Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
Chapter7: Generation and characterisation of cell lines with acquired resistance to HER2 directed 




Figure 7.32- Classification of proteins with increased expression in 8931R-SKBR3c 
cell line according to function. 92.4% of proteins with significantly increased 
expression in the 8931 R-SKBR3c cell line could be classified into the above 
functions. Proteins which affect gene transcription, cytoskeletal structure, cell 
adhesion and migration were the most frequently up-regulated in the resistant cell 
line. When proteins had more than 1 function, they have been classified under both 





Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
Chapter7: Generation and characterisation of cell lines with acquired resistance to HER2 directed 





In this current series of experiments we aimed to explore mechanisms of acquired resistance 
to the TKIs lapatinib and AZD8931. We found that previously established MMTV-NIC 
PTEN
+/- 
cell lines were inherently resistant to both drugs, most likely as a result of the loss of 
HER2 expression during in vitro culture, which we had previously observed with another cell 
line in this panel (see Chapter 5). We therefore decided to undertake this work in 2 widely 
used human HER2 positive cell lines; SKBR3 and BT474. Following continuous culture in 
the presence of escalating doses of lapatinib we generated 2 resistant cell lines from both 
the BT474 and SKBR3 parental cell lines, which retained their resistance even after drug 
withdrawal. After prolonged culture of the parental SKBR3 cell line in the absence of drug, 
we also observed a reduction in its sensitivity to lapatinib. Consistent with our observations 
that the resistant cell lines had undergone EMT (see below for further discussion), Lesniak 
described spontaneous induction of EMT in selected untreated SKBR3 cell clones resulting 
in these cells becoming resistant to trastuzumab [167]. It is therefore likely that in the SKBR3 
cell line, lapatinib accelerated the natural selection process favouring the growth of a pre-
existent, rapidly proliferative and inherently resistant subpopulation of cells. However, both 
our BT474 derived lapatinib resistant cell lines also developed a similar phenotype and 
histomorphology as our SKBR3 resistant cell lines suggesting that at least during in vitro 
culture this is a real mechanism through which cells are able to adapt to culture in the 
presence of lapatinib and is not only restricted to the SKBR3 cell line. Cells were classified 
as lapatinib resistant when able to proliferate in the presence of 5 µM of drug, which is its 
maximum aqueous solubility. We elected to culture cells in this maximum achievable 
concentration with the aim of amplifying any active resistant strategies to ensure their 
detection. However, the maximum drug concentration achieved in humans at the 
recommended dose of 1500 mg daily is between 1 and 2 µg/ml [327], which equates to a 
concentration of 1.72 to 3.4 µM. Although, we maintained our cells in a drug concentration in 
excess of this, we observed the characteristic morphological changes in our resistant cell 
lines when cultured at sub-maximal concentrations and therefore the mechanisms of 
resistance we have identified are likely to have been active at physiologically relevant 
concentrations. 
 
To determine whether these changes were specific to lapatinib resistant cells, we also 
generated 3 SKBR3 cell lines with acquired resistance to the novel equipotent inhibitor of 
HER2 and EGFR, AZD8931. As we had observed during generation of our lapatinib resistant 
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cell lines, we also noted a progressive loss of AZD8931 sensitivity following prolonged 
culture of our parental SKBR3 cell line, suggesting that again continuous drug exposure 
accelerated the selection of inherently drug resistant cell clones with a mesenchymal 
phenotype. This is further supported by our data showing that lapatinib resistant cells were 
cross resistant to AZD8931 and vice versa. Cells were classified as AZD8931 resistant once 
they were able to proliferate in the presence of 0.670 µM of drug. This concentration falls 
within the range of plasma concentrations observed at the MTD during the phase 1 trial [326] 
and therefore the resistance mechanisms identified are potentially clinically relevant.    
 
The BT474 cell line has an activating mutation in the PI3K catalytic domain [328]. PI3K is a 
positive regulator of Akt activity and activating mutations within its catalytic domain have 
been linked to trastuzumab and lapatinib resistance in preclinical models [147] [351] [154]. 
Although clinical data relating to the impact of PI3K mutational status on lapatinib sensitivity 
is less conclusive [352] [191] [353], it might therefore be predicted that the BT474 cell line 
would adapt to continuous culture in the presence of drug more readily than the SKBR3 cell 
line, which does not have such a mutation. However, generating lapatinib resistant BT474 
cells was challenging and required a longer period of drug exposure to achieve this than the 
development of lapatinib resistance in SKBR3 cells. Furthermore, despite prolonged efforts, 
we were unable to render BT474 cells resistant to AZD8931. Therefore, our inability to 
generate an AZD8931 resistant BT474 cell line appears to be partially drug and partially cell 
line related. In terms of drug related causes, AZD8931 robustly inhibits HER2, HER3 and 
EGFR signalling but although lapatinib potently inhibits HER2 it less potently inhibits both 
EGFR and HER3 signalling [273]. Therefore, the ability to develop lapatinib resistance in 
BT474 cells may be due to residual EGFR and HER3 signalling activity, which is not present 
when cells are treated with AZD8931. There are several possible explanations why as a cell 
line BT474 cells might be more resilient to resistance generation that the SKBR3 cell line. 
Firstly, the BT474 cell line appears to be more homogeneous as it does not display the same 
tendency to spontaneously change phenotype and lose drug sensitivity over time as the 
SKBR3 cell line. During the development of resistance in the SKBR3 cell line, drug treatment 
appears to act to speed up a naturally occurring phenomenon and it is therefore unsurprising 
that the development of lapatinib resistance in BT474 cells is a more lengthy process. 
Furthermore, the cell doubling time of BT474 cells is much longer than that of SKBR3 cells 
and this may also contribute to the longer time interval required to generate resistance.  
Finally, when the effects of PI3 kinase mutations on sensitivity to HER2 directed therapies 
have been considered in clinical trials, all mutations tend to have been considered as 1 
pooled group. However, prospective analysis of samples collected as part of the Neosphere 
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trial, comparing treatment with single agent trastuzumab versus trastuzumab with 
pertuzumab, showed that although when considered as a whole, PI3K mutations were not 
predictive of treatment outcomes, on an individual basis, certain mutations appeared to be 
associated with worse outcomes [324]. It is therefore feasible that certain PI3 kinase 
mutations could be protective against the development of resistance.  
 
In summary, through continuous culture in the presence of drug, we have generated a panel 
of cell lines with acquired resistance to either lapatinib or AZD8931.    
  
7.13.1 Loss of target receptor expression as a mechanism of 
resistance 
 
Several previous studies have shown that acquisition of resistance to HER2 targeting TKIs is 
associated with changes in expression of HER family receptors. Our data agrees with that of 
Lesniak and colleagues, who demonstrated loss of HER2 expression during induction of 
EMT in SKBR3 cells leading to lapatinib resistance [167]. Importantly our data also 
demonstrates that this mechanism of resistance is not solely restricted to the SKBR3 cell line 
but shows that BT474 cells can be rendered resistant to lapatinib through a similar 
mechanism. However, unlike our results and those of Lesniak, the majority of previously 
published studies have shown persistent HER2 signalling following the development of 
HER2 targeted therapy resistance. Loss of HER2 expression has been identified in up to a 
third of patients with metastatic breast cancer previously treated with trastuzumab ± lapatinib 
[168] suggesting that our cell lines are clinically relevant models. Furthermore, we have 
demonstrated that several mechanisms of resistance which were initially identified in cell 
lines with persistent HER2 signalling, including loss of PTEN, increased IGF1IR expression 
and enhanced Src activity, were active in our resistant cell lines suggesting that certain 
signalling pathways are activated following the development of resistance, irrespective of its 
mechanism. To date clinical approaches to overcoming resistance have predominantly 
focused on utilizing different strategies to target HER2 signalling yet this overlap between 
HER2 dependent and HER2 independent resistance strategies may explain why, although 
frequently initially effective, development of novel methods of targeting HER2 have had 
limited longer term efficacy with the development of resistance still remaining inevitable.  
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It is also interesting to note that short and long-term TKI treatment had very different effects 
on HER family receptor expression. In contrast to the loss of HER2 expression seen 
following long-term TKI treatment, we observed a dose-dependent increase in total HER2 
expression following short-term AZD8931 and lapatinib treatment. This increase in total 
HER2 has previously been noted following short-term lapatinib treatment [354] and has been 
attributed to reduced receptor ubiquitination resulting in the accumulation of the inactive 
receptor at the plasma membrane [355]. Similarly, although long-term TKI treatment resulted 
in loss of HER3, we observed a tendency towards increased total HER3 expression following 
short-term treatment with both AZD8391 and lapatinib treatment, which when observed 
following lapatinib treatment has been attributed at least in part to changes in transcriptional 
regulation [356]. As predicted, we observed a dose-dependent reduction in both pTyr 
1148/1173 HER2/EGFR and pTyr 1221/1222 HER2 expression following short-term TKI 
treatment but interestingly, we also observed a dose-dependent reduction in HER3 activity 
following treatment with either drug. AZD8931 is a more potent inhibitor of both HER2 and 
HER3 phosphorylation with IC50 values of 3 nmol/L and 4 nmol/L respectively compared to 9 
nmol/L and 13 nmol/l for lapatinib [273]. Furthermore, the duration of this inhibition is likely to 
be markedly different between the 2 drugs. Through equipotent inhibition of both HER2 and 
EGFR, AZD8931 results in robust and persistent inhibition of HER3 signalling [273]. 
However, previously published data has shown that transphosphorylation of HER3 is only 
transiently inhibited following lower doses of lapatinib with restoration of signaling after 48 
hours despite continued drug treatment. The resumption of HER3 signalling occurs due to 
persistent Akt inhibition, which normally exerts a negative regulatory effect on HER3 
expression through a combination of both transcriptional and post-transcriptional 
mechanisms [356] and ultimately also results in restoration of Akt and p44/42 MAPK activity. 
Therefore, lapatinib’s initial success in suppressing Akt drives an increase in HER3 signalling 
and subsequently enables an escape from lapatinib’s inhibitory effect on cell proliferation.   
 
A major issue we encountered during this series of experiments was our inability to replicate 
our initial western blotting findings of reduced total and phosphorylated HER2 and HER3 in 
our AZD8931 resistant cell lines using RPPA. Western blotting remains the gold standard 
technique for exploring changes in protein expression during tissue culture although its 
usefulness is limited by its low throughput nature and at best when used to determine the 
extent of changes in protein expression, it can be described as semi-quantitative. RPPA is 
an increasingly widespread technique which has been attracting considerable excitement as 
it offers may benefits including high throughput analysis of multiple samples enabling the 
precise and simultaneous analysis of expression changes in numerous proteins despite only 
requiring a small amount of primary material. However, the ability to determine changes in 
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the expression of any given protein is dependent on both the relative abundance of the 
individual protein and the affinity and specificity of the antibody being used. Previous studies 
have shown that RPPA is able to detect proteins expressed in the fentogram/ml range with 
linearity seen at the sub pictogram/ml range. However, the major limiting factor in detecting 
many phosphorylated proteins or other post-translationally modified proteins is the 
availability of highly specific antibodies as unlike in western blotting, RPPA only generates a 
single signal and it is therefore impossible to distinguish between proteins of different 
molecular weights [357]. Validation of an individual antibody for use in RPPA involves 
demonstrating that it produces a single band on western blot; the intensity of which 
correlates with the signal generated on the RPPA platform. All the antibodies used in these 
experiments have previously been validated but as this is a costly and time consuming 
process, efforts have been made within the RPPA community to share this data and thereby 
accelerate the widespread introduction of RPPA into laboratory practice. Therefore not all of 
the antibodies have been validated on the platform used in these experiments. The quality of 
antibodies can also vary over time and therefore although these antibodies have previously 
been validated this should be repeated. The data from these experiments suggest that at 
present, with the exception of the total HER2 antibody, the HER family receptor antibodies 
are not suitable for use on the RPPA platform and that our western blot data should be 
accepted as the most representative result. Furthermore, this data also illustrates the fact 
that RPPA should still be considered a screening tool rather than providing definitive data 
and therefore we should use western blotting to confirm the remainder of our results.   
 
A further issue relating to the use of RPPA is determining an appropriate threshold below 
which any signal generated is attributed to non-specific antibody binding. This threshold will 
by definition always be somewhat arbitrary in nature. In these experiments, we used the 
strength of the signal generated with the pTyr 1248/1173 HER2/EGFR antibody to set this 
threshold at 1.5 times the signal generated with the secondary antibody alone, having 
previously demonstrated that we could detect differences in expression of this protein 
between our parental and resistant cell lines with this antibody by western blotting. In 
retrospect, this was not the most appropriate criteria to determine such a threshold as the 
data obtained using RPPA was not validated using western blotting. It would have been 
more appropriate to set this threshold according to the signal generated using an antibody 
where our RPPA data was consistent with our western blotting data, such as Akt. Setting 
such a threshold is a balancing act between minimising the over-interpretation of data 
artefact and inappropriate rejection of genuine results.  The intensity of the signal generated 
using the Akt antibody was considerably higher than that obtained with the pTyr 1248/1173 
HER2/EGFR antibody and therefore adopting this as a threshold would allow a greater 
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degree of confidence that any novel targets identified using RPPA were likely to represent 
genuine results. However, it does increase the risk of novel markers of resistance identified 
using RPPA being falsely rejected as representing data artefact. With greater experience of 
this technology, determining an appropriate threshold is likely to become more 
straightforward but at present our experience further serves to highlight the importance of 
validating data obtained using RPPA by western blotting.    
 
7.13.2 Effects of lapatinib and AZD8931 resistance on Akt and 
p44/42 MAPK signaling 
 
Although we identified loss of HER family receptor expression in both AZD8931 and lapatinib 
resistant cell lines, the downstream consequence on Akt and p44/42 MAPK signaling were 
different depending on the agent used to generate resistance. Using both western blotting 
and RPPA, we identified an increase in both total and pSer473 Akt expression in all 3 
AZD8931 resistant cell lines.  Furthermore, using RPPA we showed appropriate changes in 
several signalling pathways downstream of Akt, including an increase in p70S6 kinase 
activity, which has previously been identified as a marker of resistance in lapatinib resistant 
HER2 over-expressing MCF7 cells  [160]. Although we identified an increase in p44/42 
MAPK activity on western blot, we found a reduction in its activity using RPPA. As discussed 
above, the validity of results obtained with certain antibodies on the RPPA platform, in this 
case the pThr202/Thr185, Tyr 204/Tyr 187 p 44/42 MAPK is the most likely explanation for 
our disconcordant results and therefore we have taken the increase in p44/42 MAPK activity 
identified on western blot as the most representative result. However, when looking at Akt 
and p44/42 MAPK expression in our lapatinib resistant cell lines using western blotting we 
found the activity of both signalling pathways was reduced in all cell lines. The impact of Akt 
and p44/42 MAPK signalling has been the focus of numerous studies. Several previous 
studies have causally linked persistent Akt signalling to lapatinib resistance. Yu and 
colleagues showed that the presence of an activating mutation within PI3K p110α or over-
expression of PI3K p110α culminated in increased Akt activity and lapatinib resistance. 
Furthermore, inhibition of PI3K p110α, but not p110β, inhibited cell proliferation both in vitro 
and in vivo [351]. In a separate study, persistent Akt activity in lapatinib resistant cells was 
overcome using the mTOR inhibitors rapamycin and ridaforolimus and when combined with 
lapatinib these drugs acted in a synergistic manner to reduce tumour cell proliferation both in 
vitro and in vivo [177]. Similarly, when combined with lapatinib, the mTOR1/2 and Akt 
inhibitor INK-128 inhibited HER2 and HER3 phosphorylation and not only suppressed 
PI3K/Akt/mTOR activity but also p44/42 MAPK activity resulting in sustained tumour 
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shrinkage in lapatinib resistant xenografts [178]. Wilson et al found that HGF treatment was 
able to rescue lapatinib sensitive cell lines from the drug’s cytotoxic effects and resulted in 
the outgrowth of a subset of cells with enhanced MET expression resulting in re-activation of 
both PI3K/Akt and p44/42 MAPK signaling [157]. However, another study identified RON 
tyrosine kinase, a member of the MET receptor tyrosine kinase family, as a potential 
upstream activator of Akt in lapatinib resistance and reported that treatment with the PI3 
kinase inhibitor GDC-0941 but not the MEK inhibitor PD0325901 was able to reduce cell 
proliferation in this model [185]. Whilst in a further study looking at the effects of MEK 
inhibition alone, Gayle found that failure of lapatinib to suppress p44/42 MAPK activity was 
associated with inherent resistance to the drug and that combined treatment with lapatinib 
and the same MEK inhibitor (PD0325901) resulted in a synergistic inhibition of cell growth 
and induced a G0/1 cell cycle arrest [358]. These studies suggest there is a lack of 
consensus regarding the contribution of p44/42 MAPK activity to the resistant phenotype and 
although collectively they appear to implicate persistent Akt activity in lapatinib resistance, it 
is important to note that several other signaling pathways, independent of both Akt and 
p44/42 MAPK activity, have been linked to lapatinib resistance. These include increased ER 
[183] [191] and NF-κβ (due to increased either NIPB [193] or RelA [153] expression) 
signaling, up-regulated survivin expression and an enhanced glucose deprivation response 
[166]. It is possible that one of these Akt and p44/42 MAPK independent signaling pathways, 
or an as of yet unidentified pathway, may be active within our lapatinib resistant lines. 
Together with the published literature, our data serves to emphasise that even within the 
relatively restricted parameters of cell line and xenograft assays, numerous different 
resistance mechanisms are seen within the different models used. Therefore, considering 
the vast array of different genetic and epigenetic permutations found within human breast 
cancer, the range of different resistance mechanisms active within the clinical setting is likely 
to be immense. It is therefore extremely unlikely that a single strategy that will universally 
overcome clinical resistance will ever be identified and ideally in the future clinical trials will 
need to focus on testing novel therapeutic approaches within a cohort of patients in whom a 
predetermined resistance strategy has already been identified.  
 
AZD8931 offers more robust inhibition of HER family receptors than lapatinib [273] and it 
may therefore seem counter-intuitive that AZD8931 resistant cell lines expressed increased 
Akt and p44/42 MAPK whilst lapatinib resistant cell lines developed alternative signalling 
strategies. Previous studies have identified complex cross-coupling between Akt and p44/42 
MAPK signalling with inhibition of Akt causing up-regulation of p44/42 MAPK signalling and 
vice versa [356]. It is therefore feasible that more complete inhibition of HER family signalling 
in the longer term results in a compensatory increase of both downstream signalling 
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pathways. Combinational therapy using drugs which target the PI3K/Akt and p44/42 MAPK 
pathways may therefore be an attractive option in both subsets of patients with AZD8931 
and lapatinib resistance. Combined treatment with MEK and PI3K targeting drugs has 
previously been shown to synergistically inhibit growth of both a KRAS-driven lung cancer 
model and an N-RAS mutant melanoma model [359]. However, considerable concern has 
been expressed as to whether these drugs could be used together at therapeutically relevant 
doses without incurring intolerable toxicities. Three phase 1 trials using combinations of PI3K 
and MEK inhibitors in advanced solid cancers have already been reported and several more 
are underway. In 2 of the 3 trials already reported, the combination was well tolerated with 
preliminary evidence of activity, particularly in low-grade serous ovarian cancer and 
advanced melanoma, although both of these tumour types have previously been shown to 
respond to single agent MEK inhibitors [360]. There were no documented responses in 
HER2 positive breast cancer in these trials, although they are unlikely to recruit such patients 
as there is currently no scope for continuing HER2 directed therapy within them.   
 
In summary, inhibition of PI3K/Akt and/or p44/42 MAPK pathways appears an attractive 
option to overcome HER2 TKI resistance in a proportion of cases.   
 
7.13.3 Strategies to identify mechanisms of resistance to   
HER2 targeted therapies 
 
We used 2 complementary approaches to further explore the mechanisms underpinning 
resistance in our AZD8931 resistance model; RPPA and mass spectrometry. RPPA is an 
increasingly widely available target driven technology, which is useful for detecting changes 
in expression of large groups of proteins connected to pre-specified signaling pathways, the 
activity of which might be predicted to have changed within the biological system of interest.  
However, as discussed above, the availability of good quality antibodies, particularly those 
detecting phosphorylated proteins, limits its ability to detect signaling changes within certain 
pathways. It is also an inefficient technique for discovering novel therapeutic candidate 
proteins which might be implicated in the resistant phenotype. We therefore also performed 
mass spectrometry, which is a non-targeted approach that allows global and quantitative 
assessment of protein expression and can therefore be used to both identify individual 
proteins and broader cellular processes involved in the development of resistance. Previous 
studies have tended to focus on changes in expression of phosphorylated proteins giving a 
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measure of signaling pathway activity in different models. In this series of experiments, we 
have focused on changes in total protein level, rather than focusing on post-transcriptional 
modifications, although analysis of phosphospecific proteomic changes is currently 
underway. 
 
Using these approaches, we have identified changes in the expression of a number of 
proteins which have previously been linked to resistance, including loss of HER2 receptor 
expression [167], up-regulation of p70S6 kinase expression [160] and increased Src activity 
[155]. Enhanced Src activity in particular appears a promising therapeutic target as it has 
been identified as a common downstream event in several independent pathways resulting 
in resistance to HER2 directed therapies [155]. Consistent with previous studies [361] [155], 
we demonstrated increased Src activity in all 3 AZD8931 resistant cell lines compared to the 
parental SKBR3 cell line. We also identified a similar increase in Src activity in our lapatinib 
resistant SKBR3 cell lines, suggesting this is a common mechanism of resistance to HER2 
targeting TKIs. Furthermore, looking at our data regarding the in vivo efficacy of AZD9831 in 
the MMTV-NIC model, we observed complete suppression of Src activity in the sensitive 
MMTV-NIC PTEN 
FL/+ 
model but not in the less sensitive MMTV-NIC PTEN
+/- 
model (Chapter 
4.2.6.2), suggesting the association between Src activity and AZD8931 resistance is not 
exclusively an in vitro phenomenon. Intriguingly, there have been no clinical reports on the 
efficacy of combining Src inhibitors with either trastuzumab or lapatinib, although the 
reported activity of single agent dasatinib in HER2 positive breast cancer was disappointing 
[179].  
 
Contrary to the published data, we observed reduced expression of the inhibitor of apoptosis 
(IAP) survivin [362] in our AZD8931 resistant cell lines. Previously published studies have 
shown that the expression of survivin in HER2 positive breast cancer is up-regulated by PI3K 
[363] [354] and that the anti-tumour effects of lapatinib are closely correlated with the down 
regulation of survivin [183]. It is therefore feasible that suppression of survivin could protect 
cells against an important mechanism of HER2 directed therapy cytotoxicity. However, to 
date no such association between reduced survivin expression and drug resistance has 
been described in the published literature. Indeed, several previous studies have implicated 
elevated survivin expression in both primary [165] [192] and acquired [183] [192] resistance 
to trastuzumab and lapatinib.  
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We also identified several potential novel markers of AZD8931 resistance, including reduced 
pTyr 783 PLCɣ: PLCɣ expression. The SH2 domain of PLCɣ is phosphorylated on tyrosine 
residue 783 by EGFR [364] and therefore expression of pTyr 783 PLCɣ can be used as a 
biological readout of EGFR activity. This reduction was therefore consistent with the 
reduction in pTyr 992 EGFR expression initially identified on western blot.  
 
We also observed a statistically significant reduction in STAT3 expression in our AZD8931 
resistant cell lines, although this has yet to be confirmed by western blotting. One study 
demonstrated STAT3 expression in the cytoplasm and nucleus of 69% and 23% of cases of 
node-negative breast cancer respectively and found that nuclear STAT3 expression was 
associated with improved survival [365]. However, in a separate study of 571 breast cancer, 
no association between STAT3 expression and prognosis was documented [366]. 
Furthermore, no relationship between STAT3 expression and resistance to HER2 targeted 
therapies has previously been described although prior studies have identified an 
association between Stat3 expression and HER2 gene amplification [261]. Given the 
substantial reductions in HER2 expression in our resistant cell lines, it is unsurprising that 
Stat3 expression was also reduced. Unfortunately, the signal generated with the pTyr 705 
Stat3 antibody was too low to determine whether AZD8931 resistance was associated with a 
change in specific activity of Stat3. 
 
 
During these experiments numerous potential novel proteins involved in the resistant 
phenotype, particularly using mass spectrometry, have been identified. In the first instance, 
these potential hits need validation using western blotting although to date this technique has 
successfully corroborated our results in all of the proteins tested. Once change in expression 
has been confirmed, functional studies using either gene silencing techniques, such as 
siRNA, or forced over-expression will be required to determine which of these changes have 
actively contributed to the development of the resistant phenotype and which were merely 
passenger mutations. This dataset may also prove a useful resource in identifying potential 
markers of resistance to HER2 targeting TKIs. Finally, any successfully identified driver-
mutations or putative biomarkers will need to be validated in clinical samples to ensure that 
they are clinically relevant. Our proteomics data has highlighted a number of possible 
mechanisms for further study and suggests that future efforts to overcome resistance will 
need to target multiple different signalling pathways, either by inhibition of multiple molecular 
targets individually or, if possible, inhibition of targets at critical pathway intersections. One 
particularly interesting mechanism identified on both western blotting and in our proteomic 
data set was EMT.   
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7.13.4 Association of HER2 targeted resistance with EMT 
 
We found that proteins which altered gene transcription or cytoskeletal structure, adhesion 
and cell migration were the most commonly affected groups of proteins in our proteomic data 
set. Consistent with our earlier observations that AZD8391 resistance was associated with 
loss of epithelial characteristics and acquisition of mesenchymal traits, we identified changes 
in expression of several other proteins which have been previously been established as 
hallmarkers of EMT, including loss of cytokeratin expression, up-regulation of fibronectin and 
changes in expression of several genes which regulate the expression of matrix 
metalloproteinases (MMPs) [367]. The receptor tyrosine kinase Axl has previously been 
linked to EMT within breast [334] [368] and pancreatic [369] cancers and more recently 
within non-small cell lung cancer (NSCLC) [370]. A previous study comparing the expression 
of Axl in matched primary and secondary breast cancers found up-regulation of Axl 
expression within metastatic tumours and furthermore expression within the primary tumour 
was an independent risk factor for reduced OS [368].  We have previously shown, using 
western blotting, that expression of Axl was increased in all 3 of our AZD8931 resistant cell 
lines [114]. Furthermore, using mass spectrometry we identified an increase in the 
expression of vimentin and YAP1 in our resistant cell line, both of which have previously 
been linked to Axl expression. Up-regulation of Axl expression has previously been identified 
as driving resistance in lapatinib resistant BT474 cells [186]. Further experiments are 
currently underway to explore whether inhibition of this receptor successfully inhibits growth 
in our model. Cells which have undergone EMT have been widely reported to be resistant to 
most conventional anti-cancer therapies, including chemotherapy and radiotherapy and 
therefore considerable effort has been invested in attempts to develop therapies which 
specifically target the EMT process [367]. Inhibition of Axl is amongst the most promising of 
these strategies and it has previously been shown that Axl inhibitors are able to interact 
synergistically with anti-mitotic drugs to trigger cell death amongst cancer cells which have 
undergone EMT [371]. Furthermore, it has been suggested that Axl inhibition inhibits the 
proliferation of NSCLC cells that have undergone EMT and acts to restore sensitivity to the 
EGFR inhibitor, erlotinib [370], although this has not been replicated in other studies [371]. 
Forfetinib is a multi-kinase inhibitor, which inhibits MET, VEGFR-2, RON, KIT and Axl, and 
has already been tested in phase 1 clinical trials. Initial results appeared promising with 74% 
of patients having a best response of stable disease [372]. However, pharmacodynamic 
studies did not explore whether significant inhibition of Axl was achieved at the MTD and as 
one of the most commonly experienced adverse events in this study was hypertension, a 
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well-established complication of anti-angiogenic drugs, such as VEGFR inhibitors, it is 
possible that side-effects due to inhibition of other signaling pathways may have prevented 
dose escalation to a sufficient level to achieve adequate Axl inhibition. Attempts to generate 
more specific Axl inhibitors are currently underway. 
 
Associations between HER2, EMT and trastuzumab resistance have previously been well 
documented. HER family signaling is one of the many factors to have been implicated in the 
induction of EMT [338]. Furthermore, induction of EMT has been linked to acquisition of a 
stem-cell properties and resistance to trastuzumab [373]. However, the nature of this 
association remains controversial. Ortega-Cava et al described a continuous requirement for 
HER2 kinase activity to trigger loss of epithelial cell polarity and lumen formation in a 3D in 
vitro assay. However, consistent with our data, other groups have described concomitant 
loss of HER2 expression with the induction of EMT in both in vitro [330] [167] and in vivo 
models [374], suggesting that proliferation in these transformed mesenchymal cells was 
independent of HER2 signaling. These results are also consistent with earlier observations 
that acquired resistance to AZD8931 in some MMTV-NIC PTEN
+/- 
tumours was associated 
with loss of HER2 expression and development of a mesenchymal appearance (see Chapter 
6.5). However, whilst induction of EMT has been associated with resistance to HER2 
directed therapies using both in vitro and in vivo preclinical models, this association has not 
been validated in clinical studies and so its relevance within the patient population remains 
uncertain. In fact, controversy still exists as to the relevance of EMT in human tumours as 
mesenchymal cells within human cancer are rarely more than an isolated phenomenon, 
although this has been attributed to the potentially transient and reversible nature of EMT 
[367]. Further controversy also exists about the impact of individual markers of EMT on 
prognosis; a large meta-analysis of 1107 breast cancer samples reported that tumours with 
increased gene expression of the EMT markers SNA1, TWIST1 and VIM or reduced 
expression of CDH1 had a reduced recurrence free survival [375]. However, a second study 
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Resistance to HER2 targeted therapies is a commonly encountered clinical scenario and 
overcoming this resistance has been the focus of numerous studies. We have generated 
lapatinib resistant BT474 and SKBR3 cell lines and AZD8931 resistant SKBR3 cell lines 
through continuous culture of cells in the presence of escalating drug doses. Initial 
characterization of our cell lines demonstrated that both lapatinib and AZD8931 resistant cell 
lines displayed common morphological and intracellular signaling changes and were cross-
resistant to the opposing TKI. Although functional studies have not yet been performed, 
resistance appeared to be multi-factorial in nature and was associated with loss of HER 
receptor expression and induction of EMT. Further proteomic analysis is currently being 
undertaken.     
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conclusions  
 




 and MMTV-NIC models of HER2 positive 
breast cancer, we have demonstrated that GEMMs are powerful tools in which to study 
mechanisms of tumour response and resistance in the presence of both a functioning 
immune system and an intact microenvironment. Although identical mutations are 
responsible for driving tumourigenesis in animals of the same genotype, the random 
acquisition of secondary mutations generates tumours with variable growth kinetics and 
therapeutic responses which model more accurately the huge spectrum of tumour behaviour 
observed within the clinical population. Using the MMTV-NIC model, we have generated 
tumours with acquired resistance to AZD8931 and shown that different tumours develop 
resistance via distinct mechanisms, for example loss of HER2 expression was identified in 
tumours which had undergone EMT whilst HER2 expression and an epithelial phenotype 
was preserved in another tumour, strongly suggesting that a ‘one size fits all solution’ for 
HER2 directed therapy resistance is likely to be unattainable. To better understand these 
mechanisms of resistance, we generated a panel of AZD8931 resistant cell lines and used a 
combination of RPPA and mass spectrometry to further interrogate signalling changes within 
the resistant cell lines. These resistant cell lines lacked the heterogeneity seen within our 
resistant GEMM tumours with all resistant cell lines having undergone EMT and loss of 
HER2 expression. However, the consistency of these results with those observed in a subset 
of our resistant MMTV-NIC tumours suggests that despite their well published limitations, 
traditional in vitro cell line approaches can still make an important contribution to preclinical 
drug development programmes, as long as the findings can be replicated in more 
physiologically relevant pre-clinical models. In our experience, resistant cell lines were 
relatively rapidly generated and provided an almost limitless supply of material for proteomic 
screening, enabling us to reserve our limited supply of resistant tumour material for analysis 
of the most potentially interesting hits. For example, several proteins implicated in EMT, 
initially identified by mass spectrometry, have since been demonstrated to be up-regulated in 
our resistant cell lines by western blotting and 1 of these proteins, YAP1, has also been 
shown to be up-regulated in AZD8931 resistant tumours, which had undergone EMT (M. 
Canel). Furthermore, use of publically available gene expression databases indicated that 
over-expression of several of these EMT associated proteins, such as BAG3, YAP1 and 
galectin 1, were associated with poor prognosis in HER2 positive breast cancer. Over-
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expression of all 3 genes was a better predictor of outcome than any individual gene alone 
(A. Sims) and whilst gene expression data does not necessarily translate into meaningful 
changes in protein expression, these findings suggest that our dataset could be used to 
identify a set of EMT markers associated with resistance to HER2 targeted therapies. If such 
a gene or proteomic signature could be validated within human tumour samples, it could in 
the future be used to identify a sub-set of patients in whom treatment with HER2 targeted 
therapies leads to induction of EMT who may benefit from treatments that specifically target 
cells which have undergone EMT, such as Axl inhibitors.  
 
Major technical advances in preclinical studies have led to the identification of increasing 
numbers of potential therapeutic targets, enhanced understanding of the mechanisms 
underpinning tumuorigenesis and ever growing numbers of new molecularly targeted agents. 
Gratifyingly, some of these advances have already been translated into meaningful 
improvements in the management of cancer patients. For example, crizotinib, a selective 
inhibitor of ALK and MET tyrosine kinases, showed high RR in phase 1 trials of heavily pre-
treated patients with advanced NSCLC harbouring ALK rearrangements [377] . Impressively, 
target identification, initiation of a phase 1 trial and enrollment of a phase 3 registration trial 
was all achieved within 3 years and crizotinib has subsequently been approved by both the 
Food and Drug Authority (FDA) and European Medicines Authority (EMA).  A recent meta-
analysis confirmed that crizotinib offers improved outcomes compared to previous standard 
treatments [378] and marks a significant advance in the management of this group of poor 
prognostic patients with previously few treatment options. However, for the most part 
incorporation of knowledge from preclinical studies into clinical practice has been 
frustratingly slow and arguably early phase oncological trials currently face a period of 
unprecedented technical, logistical and financial challenges.             
 
Whilst improved preclinical models have furthered our understanding of the role of several 
key proteins and targets in the pathogenesis of cancer, validating these findings in human 
tumours remains of critical importance. Several studies have highlighted discrepancies 
between the role of proteins in mouse models and human tumours, for example resistance to 
PARP inhibitors has been attributed to up-regulation of drug efflux proteins in a GEMM of 
BRCA1 deficient tumour, which has not been replicated in their human counterparts [67]. 
High throughput assays are increasingly used in preclinical studies and to a much more 
limited extent in clinical trials. More widespread introduction into clinical studies would be a 
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major undertaking involving training of large numbers of staff and standardization of 
techniques from initial sample collection and fixation to sample processing and assay 
calibration. Furthermore, analysis of human samples is likely to be complicated by the 
additional heterogeneity observed in human tumours compared to their murine counterparts, 
in part a consequence of the increased frequency of somatic mutations and structural 
rearrangements observed in human cancers [72]. Within a heterogeneous cell population, 
the proliferation of different sub-clones is likely to be regulated by a range of independent of 
driving mutations. Greater understanding of the tumorigenic potential of individual signalling 
abnormalities is required in order to establish what proportion of cells must display a given 
abnormality to benefit from a specific targeted agent. Furthermore, when multiple driving 
mutations are present throughout the tumour, consideration must be given to establishing 
some sort of hierarchy for selecting the most appropriate targets for inhibition. Given the 
restrictions of poly-pharmacology, we believe that whilst molecularly targeted agent are likely 
to play increasingly important roles in the management of human tumours in the future, more 
broad spectrum cytotoxics will continue to make a fundamental contribution to the 
management of patients with cancer allowing us to reserve targeted agents for the most 
tumorigenic mutations and chemoresistant phenotypes. Inclusion of non-epithelial elements 
in samples for analysis is likely to be a further source of tumour heterogeneity. Whilst micro-
dissection may be used to ensure samples consist purely of epithelial cells, it risks over-
simplifying the complex functional interactions found in mature tumours, where non-epithelial 
elements do not simply provide architectural support but modify tumour behaviour and 
therapeutic response. Should high throughput screening techniques be successfully 
incorporated into clinical trials, an additional factor to consider will be the need to balance the 
capacity for increasingly refined tumour molecular characterisation versus the feasibility of 
accruing sufficient patients to conduct a clinical trial within a realistic time frame. Failure to 
achieve the correct balance could unintentionally delay progress.    
 
Integral to robust characterisation of advanced cancers prior to entry into clinical studies is 
the need to perform further biopsies at the time of disease recurrence. The value of repeat 
biopsies has been well documented by numerous studies showing significant differences in 
the phenotypes of primary tumours and corresponding metastases. For example in one 
study 12% of HER2 negative primary tumours gave rise to HER2 positive metastases [379] 
and in separate studies up to a third of metastases from HER2 positive primary tumours had 
lost HER2 over-expression [168]. However, the ethics as well as the significant logistical and 
financial issues entailed in such an undertaking have led to this being a hotly debated issue 
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within the clinical setting. Clearly, the risk-benefit ratio of performing further biopsies needs 
to be well balanced on a case by case basis and individual decisions will be influenced by 
the extent and site of material available. Even if repeat biopsying at the time of disease 
recurrence is accepted as standard practice, most patients develop multiple metastatic 
deposits and therefore consideration needs to be given as to which of these heterogeneous 
lesions should be sampled. As already discussed, this is likely to be dictated to a large 
extent by the safety of biopsying lesions at certain anatomical locations, for example biopsy 
of a superficial metastatic nodal deposit is technically more straight forward and safer than 
biopsy of a liver metastases, although accurate characterisation and optimisation of 
therapeutic response of the latter is arguably more important as it is likely to have the 
greatest impact on patient morbidity and mortality.  
 
Due to the ease of access, use of circulating tumour cells (CTCs) and cell free DNA are 
potentially attractive options to avoid many of the issues involved in repeating tumour 
biopsies. The presence of CTCs at presentation of metastatic breast cancer has previously 
been demonstrated to be the strongest predictor of OS when compared to age, HR status, 
HER2 status and site of metastases [380]. Furthermore, CTCs have been shown to be better 
at predicting early response to treatment in breast cancer than traditional imaging techniques 
[381]. However, both CTCs and cell free DNA need to be validated as being representative 
of metastatic deposits prior to their use for tumour characterisation. 
 
A further factor contributing to the low success rate of novel molecularly targeted agents in 
clinical trials is the paucity of validated biomarkers. Comparison of trial outcomes for drugs 
developed alongside a companion biomarker with those lacking such a marker highlights 
their importance in streamlining drug development; the percentage of drugs with an 
accompanying biomarker successfully progressing through phase 1, 2 and 3 trials is 90%, 
69% and 85% respectively. In contrast, for drugs developed in the absence of such a 
biomarker only 74%, 47% and 51% successfully progress through phase 1, 2 and 3 clinical 
trials respectively [382]. Despite these results, 67% of non-orphan drugs in phase 1 clinical 
trials do not have a companion biomarker [383]. Numerous factors contribute to the 
challenges faced in developing biomarkers but in particular incomplete understanding of the 
biology underpinning individual biomarkers is likely to be of critical importance. For example, 
KRAS mutational status has been successfully introduced to predict benefit from treatment 
with the EGFR inhibitor cetuximab [384]. However, more recently, it has been demonstrated 
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that not all KRAS mutations have an equal impact on cetuximab sensitivity, with tumours 
possessing a mutation in codon 13 displaying similar RR to those seen in wild-type KRAS 
[385]. Further issues relate to difficulties in standardizing sample collection, sample 
processing and assay technique as exemplified by the findings that 20% of HER2 assays 
performed at primary treatment sites as part of 2 large adjuvant breast studies were 
considered incorrect on central pathological review [386] [387]. Finally, the criteria for any 
given biomarker may well be tumour type specific, for example different criteria are used to 
determine HER2 positivity in gastric [388] and breast [389] cancers thereby potentially 
dramatically increasing the number of biomarkers required.  
 
The time pressures associated with the introduction of ever more sophisticated tumour 
characterization techniques into clinical trials are also likely to be immense. Whilst in 
preclinical studies, tumour material is frequently stored and analyzed simultaneously; this is 
clearly not feasible in clinical trials. Large numbers of samples will need to be processed as 
part of later phase clinical trials and appropriate time frames for analysis will largely be 
dictated by pressures to start patients on therapy in a timely fashion as for the majority of 
patients with advanced malignancies there remains a relatively short, critical window in 
which patients are fit to consider further treatment. 
 
Finally, the huge financial expenditure associated with such developments means that the 
cost of clinical trials and drug development programmes only looks set to rise. To recuperate 
their initial expenses, the pharmaceutical industry will be forced to pass these on to the 
consumer in terms of escalating drug prices. The inescapable and uncomfortable reality is 
that in the future only a minority of patients are likely to be able to afford to access such 
innovative therapies, whether through state or private funded means. Therefore, the 
differences in treatment outcomes between patients who can and cannot afford such 
treatments only looks set to widen.  
In conclusion: 
 GEMMs are a valuable addition to preclinical drug development programmes. 
 Src plays an important role in early tumour development and the Src inhibitor 
dasatinib may be useful in preventing tumour development in high risk individuals.  
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 Distinct mechanisms lead to resistance to HER2 directed therapies within individual 
tumours and therefore a ‘one size fits all’ solution to acquired resistance is likely to 
be unobtainable. 
 PTEN loss moderates tumour sensitivity to AZD8931 in the MMTV-NIC model. 
  Induction of EMT and loss of HER2 expression may represent an important 
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Appendix 1- RPPA data Comparison of 
signalling pathways between vehicle and 
dasatinib treated BLG-6222  derived tumours.  
 
 
RPPA analysis was performed on lysate of vehicle and dasatinib treated  BLG-6222 derived 
tumours.  Where possible phosphorylated the ratio of phospho : corresponding total protein 
is presented {Tibes, 2006 #2112}. The relative fluorescence intensity (RFI) for all other 
antibodies is presented, corrected using global normalization technique {Guo, 2012 #69}.  P 
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Appendix 2- RPPA data Comparison of 
signalling pathways between MMTV-Nic PTEN 
FL/+
 and MMTV-Nic PTEN+/- models 
 
RPPA data confirming reduced expression of PTEN and increased Akt activation in MMTV-
Nic PTEN
+/-





(n=3) tumours.  Where possible the ratio of phospho : corresponding 
total protein is presented {Tibes, 2006 #35}. The relative fluorescence intensity (RFI) for all 
other antibodies is presented, corrected using global normalization technique {Guo, 2012 
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Appendix 3- RPPA data Comparison of 
signalling pathways between vehicle and AZD 






RPPA analysis was performed on lysate of vehicle and AZD 8931 treated tumours from both 
the MMTV-Nic PTEN 
FL/+
 and MMTV-Nic PTEN
+/- 
tumours.  Where possible phosphorylated 
the ratio of phospho : corresponding total protein is presented {Tibes, 2006 #35}. The 
relative fluorescence intensity (RFI) for all other antibodies is presented, corrected using 
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Appendix 4: Comparison of signalling 
pathways between parental SKBR3 and 
AZD8931 resistant cell lines 
 
RPPA analysis was performed on lysate of untreated parental SKBR3 and AZD8931 
resistant cell lines. Where possible phosphorylated the ratio of phospho : corresponding total 
protein is presented {Tibes, 2006 #35}. The relative fluorescence intensity (RFI) for all other 
antibodies is presented, corrected using global normalization technique {Guo, 2012 #34}.  P 
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Appendix 5- List of proteins differentially 
expressed between parental SKBR3 and AZD8931 
R-SKBR3c cell lines. 
 
Genes Up-regulated in RSKBR3 c  versus parental SKBR3 cell line 
 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble). 
 BCL2-associated athanogene 3. 
 COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis). 
 CTP synthase. 
 DNA (cytosine-5-)-methyltransferase 1. 
 Dan (Hsp40) homolog, subfamily A, member 1- Co-chaperone of Hsp70.  
 RAN, member RAS ontogeny family.  
 SERPINE1 mRNA binding protein 1. 
 SH3-domain GRB2-like endophilin B1. 
 Sec61 beta subunit.  
 TAR DNA binding protein. 
 Triosephosphate isomerase 1. 
 UDP-glucose pyrophosphorylase 2. 
 Y box binding protein 1. 
 Acetyl-Coenzyme A carboxylase alpha. 
 Alanyl-tRNA synthetase. 
 Annexin A1. 
 Basic transcription factor 3. 
 Block of proliferation 1. 
 Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase. 
 Cold shock domain protein A. 
 Cytochrome b5 type A (microsomal). 
 Cihydropyrimidinase-like 2.  
 Eukaryotic translation elongation factor 1 gamma. 
 Eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa.  
 Eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa. 
 Eukaryotic translation initiation factor 3, subunit A . 
 Eukaryotic translation initiation factor 3, subunit D. 
 Eukaryotic translation initiation factor 3, subunit E. 
 Eukaryotic translation initiation factor 3, subunit F. 
 Eukaryotic translation initiation factor 3, subunit L. 
 Eukaryotic translation initiation factor 4H.  
 Eukaryotic translation initiation factor 5A. 
 Fibronectin 1. 
 Filamin A, alpha (actin binding protein 280). 
 Glutamate dehydrogenase 1. 
 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2. 
 Heterogeneous nuclear ribonucleoprotein A3.  
 Retinoblastoma binding protein 4. 
 Methylthioadenosine phosphorylase. 
 Minichromosome maintenance complex component 6. 
 Myosin, heavy chain 9, non-muscle. 
 Neural precursor cell expressed, developmentally down-regulated 4. 
 Non-metastatic cells 1, protein (NM23A). 
  Non-metastatic cells 2, protein (NM23B). 
 Peroxiredoxin 4. 
 Phosphogluconate dehydrogenase. 
Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
Appendix 5     377 
 
 
 Phosphoglycerate dehydrogenase. 
 Phosphoglycerate mutase 1 (brain). 
 Poly(A) binding protein. 
 1 poly-U binding splicing factor 60KDa. 
 Polymerase I and transcript release factor. 
 Proliferating cell nuclear antigen. 
 Proteasome (prosome, macropain) 26S subunit, ATPase, 2. 
 Proteasome (prosome, macropain) 26S subunit, ATPase, 3. 
 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 4. 
 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 6.  
 Protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform. 
 Ribonucleotide reductase M1One of the 2 subunits comprising RRM1.  
 Ribosomal protein L17. 
 Ribosomal protein L18. 
 Ribosomal protein L19.  
 Ribosomal protein L27. 
 Ribosomal protein L28. 
 Ribosomal protein L35. 
 Ribosomal protein L35a.  
 Ribosomal protein L3. 
 Ribosomal protein L4. 
 Ribosomal protein L6. 
 Ribosomal protein S14.  
 Ribosomal protein S15.  
 Ribosomal protein S17. 
 Ribosomal protein S9. 
 Ribosomal protein, large, P2. 
 Sequestosome 1. 
 Serine/threonine kinase receptor associated protein (STRAP).  
 Seryl-tRNA synthetase. 
 Proteasome 26S subunit, ATPase, 4.  
 ATP-binding cassette, sub-family E (OABP), member 1. 
 Eukaryotic translation initiation factor 4A, isoform 1. 
 Similar to heat shock 70kD protein binding protein; suppression of tumorigenicity 13 (colon 
carcinoma) (Hsp70 interacting protein). 
 Spectrin, beta, non-erythrocytic 1. 
 Splicing factor 3b, subunit 3, 130kDa. 
 Thioredoxin-like 1. 
 Ubiquitin-conjugating enzyme E2 variant 1 
 Ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast). 
 Valosin-containing protein. 
 Actinin alpha 1. 
 Annexin A2. 
 Chloride intracellular channel 4. 
 Gelsolin (amyloidosis, Finnish type). 
 Heterogeneous nuclear ribonucleoprotein A/B.  
 Microtubule-associated protein, RP/EB family, member 1.  
 14-3-3 protein epsilon. 
 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 
polypeptide. 
 Vinculin. 
 EH-domain containing 2. 
 H3 histone, family 3B (H3.3B) 
 Caldesmon 1. 
 Calponin 3, acidic 
 Dynactin 1 (p150, glued homolog, Drosophila)  
 Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus). 
 Heat shock 70kDa protein 4. 
 Lamin A/C. 
 Structural maintenance of chromosomes 2. 
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 Talin 1. 
 BAI1-associated protein 2. 
 Karyopherin (importin) beta 1. 
 Septin 11. 
 Tubulin, alpha 4a. 
 EH-domain containing 1. 
 Sec61 beta subunit. 
 Clathrin, light chain (Lca). 
 Myosin, light chain 6, alkali, smooth muscle and non-muscle. 
 ADP-ribosylation factor 5. 
 NM_005347; heat shock 70kDa protein. 
 Proteasome (prosome, macropain) 26S subunit, ATPase, 4.  
 ARP1 actin-related protein 1 homolog A, centractin alpha. 
 Angio-associated, migratory cell protein. 
 Moesin.  
 Vimentin. 
 Hypoxanthine phosphoribosyltransferase 1. 
 Vesicle amine transport protein 1 homolog.  
 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1. 
 Yes-associated protein 1, 65kDa. 
 Fragile X mental retardation, autosomal homolog 1.  
 Fragile X mental retardation, autosomal homolog 2. 
 Esterase D/formylglutathione hydrolase.  
 Kinectin 1 (kinesin receptor). 
 Plectin 1, intermediate filament binding protein 500kDa. 
 Family with sequence similarity 49, member B 
 Calumenin 
 Lectin, galactoside-binding, soluble, 1 
 Poly(A) binding protein, cytoplasmic 1 
 AHNAK nucleoprotein 
 ATP-binding cassette, sub-family F (GCN20), member 2 
 CDV3 homolog (mouse) 
 COP9 constitutive photomorphogenic homolog subunit 4 (Arabidopsis) 
  S100 calcium binding protein A10 
 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1- 
 WD repeat domain 1 
 Annexin A8-like 2 
 Cold shock domain containing E1, RNA-binding.  
 Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1. 
 Myoferlin. 
 Myosin, light chain 12A, regulatory, non-sarcomeric. 
 Protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1). 
 Tetratricopeptide repeat domain 35. 
 
Genes Down-regulated in RSKBR3 c  versus parental SKBR3 cell line 
 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1. 
 ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H. 
 ATPase, Na+/K+ transporting, alpha 1 polypeptide. 
 CD3e molecule, epsilon associated protein. 
 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1.  
 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
 DEAD (Asp-Glu-Ala-Asp) box polypeptide 47 
 DEAH (Asp-Glu-Ala-His) box polypeptide 9.  
 EMG1 nucleolar protein homolog.  
 FK506 binding protein 4. 
 GNAS complex locus. 
 IMP (inosine monophosphate) dehydrogenase 1. 
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 IMP (inosine monophosphate) dehydrogenase 2. 
 MYB binding protein (P160) 1a. 
 NAD(P)H dehydrogenase, quinone 1. 
 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa.  
 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa. 
 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa. 
 NOL1/NOP2/Sun domain family, member 2. 
 NOP56 ribonucleoprotein homolog. 
 Obg-like ATPase 1. 
 PEST proteolytic signal containing nuclear protein. 
 PHD finger protein 5A. 
 PRP40 pre-mRNA processing factor 40 homolog A. 
 Parkinson disease (autosomal recessive, early onset) 7. 
 RAB6C, member RAS oncogene family. 
  RAB6A, member RAS oncogene family.  
 RAD23 homolog B. 
 RAN binding protein 2. 
 RNA binding motif protein 28. 
 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, 
member 4. 
 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, 
member 2. 
 Shwachman-Bodian-Diamond syndrome. 
 Sjogren syndrome antigen B (autoantigen La). 
 THO complex 4. 
 TNF receptor-associated protein 1. 
 Treacher Collins-Franceschetti syndrome 1. 
 Tu translation elongation factor, mitochondrial. 
 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break 
rejoining). 
 X-ray repair complementing defective repair in Chinese hamster cells 6. 
 Acetyl-Coenzyme A acyltransferase 1. 
 Acyl-CoA synthetase long-chain family member 3.  
 Acyl-Coenzyme A dehydrogenase. 
 Adenine phosphoribosyltransferase.  
 Adenosine deaminase, RNA-specific. 
 Adenosine kinase. 
 Adenylate kinase 2. 
 Aldehyde dehydrogenase 4 family, member A1.  
 Aldehyde dehydrogenase 7 family, member A1. 
 Aldo-keto reductase family 1, member A1 (aldehyde reductase). 
 Aldolase A, fructose-bisphosphate. 
 Aminoacyl tRNA synthetase complex-interacting multifunctional protein 1. 
 Argininosuccinate synthetase 1. 
 Arginyl aminopeptidase (aminopeptidase B). 
 Arginyl-tRNA synthetase. 
 asparaginyl-tRNA synthetase. 
 Calreticulin. 
 Carbamoyl-phosphate synthetase 1. 
 Carbonyl reductase 1. 
 Carnitine palmitoyltransferase 1A.  
 Catechol-O-methyltransferase. 
 Catenin (cadherin-associated protein), delta 1 
 Cathepsin D. 
 Cellular retinoic acid binding protein 2. 
 Chaperonin containing TCP1, subunit 2 (beta) . 
 Chaperonin containing TCP1, subunit 5 (epsilon). 
 Chromodomain helicase DNA binding protein 4. 
 Chromosome 1 open reading frame 25.Citrate synthase.  
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 Cleavage and polyadenylation specific factor 6, 68kDa. 
 Coatomer protein complex, subunit alpha. 
 Creatine kinase. 
 Creatine kinase, mitochondrial 1A; creatine kinase, mitochondrial 1B. 
 Cullin-associated and neddylation-dissociated 1. 
 Cytidine monophosphate (UMP-CMP) kinase 1, cytosolic. 
 Desmoplakin. 
 Dicarbonyl/L-xylulose reductase. 
 Dihydrolipoamide S-acetyltransferase. 
 Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex). 
 Dihydrolipoamide dehydrogenase. 
 Enolase 1, (alpha). 
 Enoyl Coenzyme A hydratase 1. 
 Eukaryotic translation elongation factor 1 beta 2; eukaryotic translation elongation factor 1 
beta 2-like 
 Eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein). 
 Eukaryotic translation initiation factor 3, subunit C. 
 Eukaryotic translation initiation factor 4 gamma, 1. 
 Eukaryotic translation initiation factor 4A, isoform 3. 
 Eukaryotic translation initiation factor 4E  
 Eukaryotic translation initiation factor 5B.  
 Exosome component 6. 
 Far upstream element (FUSE) binding protein 1. 
 Fatty acid synthase. 
 Fibrillarin. 
 Flap structure-specific endonuclease 1.  
 Fumarate hydratase. 
 Fusion (involved in t(12;16) in malignant liposarcoma).  
 General transcription factor II. 
 Glucose-6-phosphate dehydrogenase.  
 Glutamyl-prolyl-tRNA synthetase. 
 Glyceraldehyde-3-phosphate dehydrogenase-like 6. 
 Glycyl-tRNA synthetase.  
 Glyoxylate reductase/hydroxypyruvate reductase.  
 Guanine monphosphate synthetase. 
 Heat shock 60kDa protein 1 (chaperonin). 
 Heat shock 70kDa protein 1A; heat shock 70kDa protein 1B. 
 Heat shock 70kDa protein 8. 
 Heat shock 70kDa protein 9 (mortalin). 
 Heat shock protein 90kDa alpha (cytosolic), class A member 2; heat shock protein 90kDa 
alpha (cytosolic), class A member 1. 
 Heterogeneous nuclear ribonucleoprotein A2/B.  
 Heterogeneous nuclear ribonucleoprotein C (C1/C2).  
 Heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 
37kDa). 
 Heterogeneous nuclear ribonucleoprotein D-like. 
 Heterogeneous nuclear ribonucleoprotein F. 
 Heterogeneous nuclear ribonucleoprotein H1 (H). 
 Heterogeneous nuclear ribonucleoprotein M. 
 Heterogeneous nuclear ribonucleoprotein R. 
 Hexokinase 1. 
 Hexokinase 2. 
 High-mobility group box 1. 
 Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), alpha subunit. 
 Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), beta subunit. 
 Hydroxysteroid (17-beta) dehydrogenase 10. 
 Inosine triphosphatase. 
 Interleukin enhancer binding factor 2, 45kDa. 
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 Interleukin enhancer binding factor 3, 90kDa. 
 Isocitrate dehydrogenase 2 (NADP+), mitochondrial. 
 Isocitrate dehydrogenase 3 (NAD+) alpha. 
 Isoleucyl-tRNA synthetase. 
 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1)/ 
 Keratin 7.  
 Lactate dehydrogenase A. 
 Lactate dehydrogenase B. 
 Leucine rich repeat (in FLII) interacting protein 1.  
 Leucine rich repeat containing 47. 
 Leucine-rich PPR-motif containing.  
 Leucyl-tRNA synthetase.  
 Lysyl-tRNA synthetase.  
 Mago-nashi homolog, proliferation-associated. 
 Malate dehydrogenase 2, NAD (mitochondrial).  
 Methylcrotonoyl-Coenzyme A carboxylase 1 (alpha). 
 Methylcrotonoyl-Coenzyme A carboxylase 2 (beta). 
 Microsomal glutathione S-transferase 1.  
 Mitochondrial ribosomal protein L49. 
 Nicotinamide phosphoribosyltransferase. 
 Nucleosome assembly protein 1-like 1. 
 Oxidative-stress responsive 1. 
 Paraspeckle component 1. 
 Peroxiredoxin 1. 
 Peroxiredoxin 2.  
 Peroxiredoxin 3. 
 Peroxiredoxin 6. 
 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1. 
 Phosphofructokinase, muscle. 
 Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase. 
 Phosphorylase, glycogen; brain. 
 Poly (ADP-ribose) polymerase 1. 
 Polynucleotide kinase 3'-phosphatase. 
 Polypyrimidine tract binding protein 1. 
 Prohibitin 2. 
 Prolyl 4-hydroxylase, alpha polypeptide I. 
 Prostaglandin E synthase 3 (cytosolic). 
 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 12. 
 Proteasome (prosome, macropain) activator subunit 1 (PA28 alpha). 
 Proteasome (prosome, macropain) activator subunit 2 (PA28 beta). 
 Protein disulfide isomerase family A, member 6. 
 Protein phosphatase 1G (formerly 2C), magnesium-dependent, gamma isoform. 
 Pyridoxal-dependent decarboxylase domain containing 1. 
 Pyrophosphatase (inorganic) 1. 
 Pyruvate carboxylase. 
 Pyruvate dehydrogenase (lipoamide) beta. 
 Ribonuclease/angiogenin inhibitor 1. 
 Ribophorin II. 
 Ribosomal L1 domain containing 1. 
 Ribosomal protein L13. 
 Ribosomal protein L14. 
 Ribosomal protein L15. 
 Ribosomal protein L22. 
 Ribosomal protein L7. 
 Ribosomal protein L9. 
 Ribosomal protein S18. 
 Ribosomal protein S24. 
 Ribosomal protein S25. 
 Ribosomal protein S27a.  
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 Ribosomal protein, large, P1. 
 Ribosome binding protein 1 homolog 180kDa. 
 Scaffold attachment factor B. 
 Sepiapterin reductase. 
 Serrate RNA effector molecule homolog (Arabidopsis). 
 Signal transducer and activator of transcription 3 (acute-phase response factor). 
 Ewing sarcoma breakpoint region 1. 
 Pyruvate kinase, muscle.. 
 RNA binding motif protein, X-linked. 
 Small nuclear ribonucleoprotein 200kDa (U5). 
 Calcyclin binding protein. 
 Chaperonin containing TCP1, subunit 8 (theta). 
 Eukaryotic translation initiation factor 4A, isoform 2. 
 Heterogeneous nuclear ribonucleoprotein L. 
 Protein kinase, DNA-activated, catalytic polypeptide. 
 Small nuclear ribonucleoprotein 70kDa (U1). 
 Solute carrier family 25 (mitochondrial carrier; dicarboxylate transporter), member 10. 
 Solute carrier family 25, member 13 (citrin). 
 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5. 
 Sorbitol dehydrogenase. 
 Splicing factor proline/glutamine-rich (polypyrimidine tract binding protein associated). 
 Splicing factor, arginine/serine-rich 6.  
 Staphylococcal nuclease and tudor domain containing 1. 
 Succinate dehydrogenase complex, subunit A, flavoprotein (Fp). 
 Suppressor of Ty 16 homolog (S. cerevisiae). 
 Tankyrase 1 binding protein 1, 182kDa. 
 Thioredoxin. 
 Thioredoxin domain containing 12. 
 Thymidine kinase 1. 
 Topoisomerase (DNA) I. 
 Topoisomerase (DNA) II alpha. 
 Transaldolase 1. 
 Transducin (beta)-like 3. 
 Translocated promoter region (to activated MET oncogene). 
 Trichorhinophalangeal syndrome I. 
 Tripartite motif-containing 28. 
 Tryptophanyl-tRNA synthetase. 
 Tubulin tyrosine ligase-like family, member 12. 
 Tubulin tyrosine ligase-like family, member 3. 
 Ubiquitin specific peptidase 7.  
 Ubiquitin-like modifier activating enzyme 1. 
 HER2. 
 Within bgcn homolog. 
  2',3'-cyclic nucleotide 3' phosphodiesterase. 
 2,4-dienoyl CoA reductase 1, mitochondrial. 
 AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast). 
 ATP citrate-lyase. 
 ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit. 
 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac 
muscle. 
 APEX nuclease (multifunctional DNA repair enzyme) 1. 
 CNDP dipeptidase 2 (metallopeptidase M20 family). 
 N-ethylmaleimide-sensitive factor. 
 Acetyl-Coenzyme A acetyltransferase 2- 2 acetyl-CoA. 
 Aldehyde dehydrogenase 2 family. 
 Calpain 2, (m/II) large subunit.  
 Calpain, small subunit 1. 
 Cathepsin C. 
 Copine III.  
 Tripeptidyl peptidase II. 
Use of Genetically Engineered Mouse Models in Preclinical Drug Development 
Appendix 5     383 
 
 
 Nitrilase family, member 2. 
 Crystallin, zeta (quinone reductase). 
 Cytochrome c oxidase subunit Vib polypeptid e 1 (ubiquitous). 
  VAMP (vesicle-associated membrane protein)-associated protein B and C. 
 Complement component 1, q subcomponent binding protein. 
 Keratin 18. 
 Keratin 19  
 Keratin 8. 
 Programmed cell death 6 interacting protein.  
 Transportin 1. 
 Transferrin receptor (p90, CD71). 
 SEC22 vesicle trafficking protein homolog B (S. cerevisiae). 
 SEC24 family, member C (S. cerevisiae). 
 USO1 homolog, vesicle docking protein (yeast). 
 Archain 1. 
 Coatomer protein complex, subunit alpha. 
 Coatomer protein complex, subunit beta 2 (beta prime). 
 Coatomer protein complex, subunit epsilon. 
 Hook homolog 1 (Drosophila). 
 Vacuolar protein sorting 35 homolog (S. cerevisiae). 
 Importin 4. 
 Optic atrophy 1 (autosomal dominant). 
 Ras homolog gene family, member T2. 
 Scinderin.  
 Sec1 family domain containing 1.  
 Secernin 1.  
 Secretory carrier membrane protein 3. 
 Signal recognition particle 14kDa (homologous Alu RNA binding protein) 
 Signal recognition particle receptor (docking protein). 
 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 
6. 
 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta 
polypeptide.  
 Unc-13 homolog D (C. elegans). 
 Protein disulfide isomerase family A, member 3. 
 Transforming, acidic coiled-coil containing protein 2. 
 CAP, adenylate cyclase-associated protein 1 (yeast). 
 H2A histone family, member Y. 
 LIM domain and actin binding 1. 
 RAB5C, member RAS oncogene family. 
 USO1 homolog, vesicle docking protein (yeast). 
 Apoptotic chromatin condensation inducer 1. 
 Capping protein (actin filament) muscle Z-line, alpha 1. 
 Capping protein (actin filament) muscle Z-line, beta.  
 Coronin, actin binding protein 1A. 
 Desterin (Actin depolymerazing factor). 
 Emerin. 
 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3. 
 Histone cluster 1, H1b. 
 Histone cluster 1, H2bb. 
 Histone cluster 1, H2bi; histone cluster 1, H2bg; histone cluster 1, H2be; histone cluster 
1, H2bf; histone cluster 1, H2bc. 
 Inverted formin, FH2 and WH2 domain containing. 
 Keratin 4.  
 Metastasis associated 1 family, member 2. 
 Profilin 1. 
 Ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2). 
 Regulator of chromosome condensation 1.  
 Regulator of chromosome condensation 2. 
 ADP-ribosylation factor 4. 
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 GDP dissociation inhibitor 2. 
 RAB1B, member RAS oncogene family. 
 Myosin 1C. 
 Nucleoporin 88kDa. 
 Selenium binding protein 1. 
 Signal recognition particle 14kDa (homologous Alu RNA binding protein). 
 Signal recognition particle receptor (docking protein). 
 GTPase activating protein and VPS9 domains 1. 
 Mannose-6-phosphate receptor binding protein 1-Mannose 6-phosphate receptors.  
 Spectrin, beta, non-erythrocytic 2. 
 NDRG family member 3. 
 Peroxiredoxin 5. 
 Solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1. 
 S100 calcium binding protein A16. 
 Glutathione S-transferase mu 3 (brain). 
 Heat shock 27kDa protein 1.  
 Hypoxia up-regulated 1. 
 Protein kinase, cAMP-dependent, regulatory, type II, alpha. 
 Signal recognition particle 68kDa. 
 Tight junction protein 2 (zona occludens 2). 
 GTPase activating protein (SH3 domain) binding protein 1. 
 Anterior gradient homolog 2 (Xenopus laevis). 
 Sideroflexin 1. 
 Tumor protein D52. 
 Rho GDP dissociation inhibitor (GDI) alpha. 
 ATP citrate lyase. 
 Cysteine-rich protein 2. 
 Family with sequence similarity 62 (C2 domain containing), member A. 
 Family with sequence similarity 120A. 
 Cortactin. 
 ATPase family, AAA domain containing 3A. 
 DAZ associated protein 1. 
 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21. 
 EPS8-like 2. 
 IQ motif containing GTPase activating protein 1. 
 KIAA0664. 
 LPS-responsive vesicle trafficking, beach and anchor containing. 
 LUC7-like 2 (S. cerevisiae). 
 PDGFA associated protein 1; similar to PDGFA associated protein 1. 
 Ran GTPase activating protein 1. 
 S100 calcium binding protein A14. 
 StAR-related lipid transfer (START) domain containing 10. 
 Acetyl-Coenzyme A acetyltransferase 1. 
 Basic leucine zipper and W2 domains 2. 
 Breast carcinoma amplified sequence 1. 
 Calcyphosine. 
 Canopy 2 homolog (zebrafish). 
 Chromosome 14 open reading frame 166. 
 Chromosome 8 open reading frame 55. 
 Coiled-coil domain containing 6. 
 Coiled-coil-helix-coiled-coil-helix domain containing 2 
  Coronin, actin binding protein, 1B. 
 Cysteine and glycine-rich protein 1. 
 Cytoskeleton-associated protein 4. 
 Epiplakin 1. 
 Epithelial cell adhesion molecule. 
 Family with sequence similarity 62 (C2 domain containing), member B. 
 Family with sequence similarity 83, member H. 
 Growth factor receptor-bound protein 7: 
 Heterogeneous nuclear ribonucleoprotein U-like 2. 
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 Metastasis associated 1 family, member 3. 
 Nucleolin.  
 Ornithine aminotransferase (gyrate atrophy). 
 Periplakin. 
 Plakophilin 3 
 Progesterone receptor membrane component 1.  
 Protein kinase C substrate. 
 Regulation of nuclear pre-mRNA domain containing 1B. 
 Ring finger protein 114.  
 Stomatin (EPB72)-like 2. 
 Stress-induced-phosphoprotein 1. 
  Symplekin. 
 Testis derived transcript (3 LIM domains). 
 Thymopoietin. 
 Transketolase. 
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